camptothecin has been researched along with Colorectal Cancer in 2588 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 96 (3.71) | 18.2507 |
| 2000's | 1030 (39.80) | 29.6817 |
| 2010's | 1254 (48.45) | 24.3611 |
| 2020's | 208 (8.04) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, C; Jin, W; Li, M; Lou, L; Tang, W; You, T; Zheng, C | 1 |
| Ichikawa, D; Iino, H; Okamoto, H; Shiba, S; Sudoh, M | 1 |
| Anhut, P; Busse, D; Eckstein, M; Grützmann, R; Hartmann, A; Kersting, S; Merkel, S; Neufert, C; Neurath, MF; Ostermeier, N; Roth, JP; Schreiner, W; Siebler, J; Stoehr, R; Uder, M; Vitali, F; Wein, A; Wolff, K | 1 |
| Antonuzzo, A; Boccaccino, A; Borelli, B; Buonadonna, A; Caponnetto, S; Conca, V; Cremolini, C; Daniel, F; Falcone, A; Lonardi, S; Marmorino, F; Masi, G; Pietrantonio, F; Raimondi, A; Rossini, D; Santini, D; Sbrana, A; Tomasello, G; Zaniboni, A | 1 |
| Aktaş, Y; Benito, JM; Bilensoy, E; Bilgiç, E; Can Öztürk, S; Esendağlı, G; Korkusuz, P; Ünal, S; Yanık, H | 1 |
| Boku, N; Esaki, T; Izawa, N; Kawakami, K; Kawakami, T; Komoda, M; Makiyama, A; Masuishi, T; Mitani, S; Moriwaki, T; Nagashima, K; Nakajima, TE; Okuda, H; Tsuji, Y; Yamamoto, S; Yamamoto, Y; Yamazaki, K | 1 |
| Chen, Y; Huang, Q; Li, K; Liu, X; Shen, Y; Sui, M; Wang, H; Zhang, Q; Zhu, Q | 1 |
| Fujii, H; Kadono, T; Kimura, H; Nakatsugawa, Y; Nishimura, T; Okuyama, Y; Sato, H; Tomatsuri, N; Urata, Y; Yamada, S | 1 |
| Aoyama, T; Kazama, K; Numata, M; Oshima, T; Rino, Y; Sato, M; Sato, S; Shiozawa, M; Sugano, N; Tamagawa, H; Uchiyama, M; Yukawa, N | 1 |
| Elsamany, S; Elsisi, GH; Mohamed Hassanin, FA; Saleh, K; Tashkandi, E | 1 |
| Alsrhani, A; Farhana, A; Koh, AE; Kothandan, S; Mok, PL; Subbiah, SK | 1 |
| Jung, A; Kirchner, T; Klauschen, F; Kumbrink, J; Li, P; Pók-Udvari, A | 1 |
| Cremolini, C; Esser, R; Falcone, A; Folprecht, G; Martinelli, E; Mazard, T; Modest, DP; Tsuji, A | 1 |
| Bang, SM; Jung, EH; Kim, JH; Kim, JW; Kim, KJ; Kim, SA; Kim, SH; Kim, YJ; Lee, JH; Lee, JO; Lee, JS; Lee, JY; Lee, KW; Nam, M; Park, H; Suh, KJ; Sung, JH | 1 |
| Ahn, JB; Beom, SH; Byun, HK; Chang, JS; Kim, HS; Kim, K; Kim, MS; Koom, WS; Lee, J; Park, EJ; Shin, SJ; Yang, G | 1 |
| Bedon, L; Buonadonna, A; Cecchin, E; Dal Bo, M; Fabbiani, E; Polano, M; Toffoli, G | 1 |
| Aranda, E; Díaz, IA; Élez, E; García-Alfonso, P; Gómez-España, MA; Graña, B; Grávalos, C; Losa, F; Martínez de Castro, E; Ortiz-Morales, MJ; Polo, E; Riesco, MDC; Rodriguez-Ariza, A; Ruiz-Casado, A; Safont, MJ; Salgado, M; Salud, A; Tabernero, J; Toledano-Fonseca, M; Valladares-Ayerbes, M | 1 |
| Ito, Y; Kobuchi, S; Sakaeda, T; Sakai, S | 1 |
| Chau, I; Lau, DK; Mencel, J | 1 |
| Adam, R; Adenis, A; Aparicio, T; Assenat, E; Audemar, F; Bouché, O; Chauvenet, M; Fonck, M; Francois, E; Galais, MP; Ghiringhelli, F; Guimbaud, R; Houyau, P; Jouffroy, C; Khemissa, F; Kianmanesh, R; Lopez-Crapez, E; Mercier-Blas, A; Mineur, L; Rivoire, M; Thezenas, S; Ychou, M | 1 |
| Liu, H; Rong, X; Wang, J; Wang, Y; Yu, H; Zhao, J | 1 |
| Fujitani, K; Hata, T; Inoue, A; Kagawa, Y; Kato, T; Kawai, K; Komatsu, H; Miyazaki, Y; Motoori, M; Murata, K; Naito, A; Nishizawa, Y; Ohta, T; Takeda, Y; Tomokuni, A | 1 |
| Coburn, N; David, E; Kiss, A; Ni, T; Pugash, R; Raphael, MJ; Voizard, N | 1 |
| Deng, YX; Hou, ZL; Lin, JZ; Lu, ZH; Pan, ZZ; Peng, JH; Zhang, LJ; Zhang, WL; Zhou, C | 1 |
| Dai, WP; Jiao, XD; Li, XN; Liu, K; Qin, BD; Qin, WX; Sun, L; Wang, MM; Wang, Z; Ye, CY; Yuan, LY; Zang, YS | 1 |
| Atkins, JN; Bainter, TM; Blanke, CD; Fuchs, CS; Goldberg, RM; Hochster, HS; Innocenti, F; Lenz, HJ; Ma, C; Mayer, RJ; McCleary, NJ; Meyerhardt, JA; Ng, K; Niedzwiecki, D; O'Neil, BH; O'Reilly, EM; Ou, FS; Polite, BN; Venook, AP; Zhang, S | 1 |
| Chang, TK; Chen, PJ; Chen, YC; Huang, CW; Li, CC; Su, WC; Tsai, HL; Wang, JY; Yin, TC | 1 |
| Caramoci, A; Grigorescu, A; Ionescu, AM; Pop, M | 1 |
| Li, N; Nagasaki, Y; Nguyen-Trinh, QN; Trinh, KXT; Trinh, NT; Vo, VT; Vong, LB | 1 |
| Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Bekaii-Saab, TS | 1 |
| Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H | 1 |
| Chovancova, B; Kajsik, M; Krizanova, O; Liskova, V; Roller, L | 1 |
| Ahn, MS; Bae, BN; Baik, SH; Beom, SH; Han, SW; Jeon, SY; Jo, HJ; Kang, MH; Kim, DH; Kim, HK; Kim, JG; Kim, JH; Kim, JS; Kim, JY; Lee, MA; Lee, S; Oh, J; Park, I; Park, YS; Shin, SH; Yoon, JA; Zang, DY | 1 |
| Bekaii-Saab, T; Dakhil, SR; Faggen, M; Fuchs, CS; Heying, EN; Lipsyc-Sharf, M; Meyerhardt, JA; Ng, K; Noble, S; Ou, FS; Rubinson, DA; Schrag, D; Schuetz, SR; Stella, PJ; Weckstein, DJ; Wender, DB; Yurgelun, MB; Zemla, TJ | 1 |
| Cai, Z; Jin, L; Kagawa, Y; Makiyama, A; Satake, H; Shinozaki, E; Tanizawa, Y | 1 |
| Allegrini, G; Antoniotti, C; Boccaccino, A; Borelli, B; Buonadonna, A; Conca, V; Cremolini, C; Dell'Aquila, E; Germani, MM; Lonardi, S; Maddalena, G; Marmorino, F; Masi, G; Passardi, A; Pietrantonio, F; Randon, G; Rossini, D; Zaniboni, A | 1 |
| Al-Batran, SE; Decker, T; Denzlinger, C; Fischer, LE; Giessen-Jung, C; Heinemann, V; Heinrich, K; Heintges, T; Held, S; Jung, A; Kahl, C; Kaiser, F; Kiani, A; Kirchner, T; Kullmann, F; Lerchenmüller, C; Modest, DP; Peuser, B; Scheithauer, W; Seipelt, G; Stahler, A; Stauch, M; Stintzing, S; Uhlig, J; von Weikersthal, LF; Weiss, L | 1 |
| Alonso de Castro, B; Cameselle García, S; Carmona Campos, M; Cousillas Castiñeiras, A; De la Cámara Gómez, JC; Fernández-Montes, A; Gómez-Randulfe Rodríguez, MI; González Villarroel, P; Martínez-Lago, N; Méndez Méndez, JC; Romero Reinoso, C; Salgado Fernández, M; Vidal Insua, Y | 1 |
| Antoniotti, C; Brodskiy, P; Calegari, MA; Carullo, M; Conca, V; Corti, F; Cremolini, C; Elliott, A; Fassan, M; Intini, R; Korn, M; Lenz, HJ; Lonardi, S; Masi, G; Mauri, G; Moretto, R; Pella, N; Pietrantonio, F; Rasola, C; Rossini, D; Salati, M; Sartore-Bianchi, A; Scartozzi, M; Shields, A | 1 |
| Soulen, MC; White, SB | 1 |
| Arai, H; Battaglin, F; Heinemann, V; Jayachandran, P; Kawanishi, N; Lenz, HJ; Millstein, J; Soni, S; Stintzing, S; Wang, J; Yang, Y; Zhang, W | 1 |
| Liu, JY; Liu, X; Long, YX; Qiu, M; Zhou, YW | 1 |
| Akazawa, N; Ando, T; Hirata, K; Kagawa, Y; Kato, T; Maeda, H; Mishima, H; Nagasaka, T; Nagata, N; Oba, K; Sakamoto, J; Shiozawa, M; Watanabe, J; Yamada, T; Yokota, M | 1 |
| Arai, H; Battaglin, F; Cremolini, C; Falcone, A; Heinemann, V; Jayachandran, P; Kawanishi, N; Lenz, HJ; Liu, T; Loupakis, F; Mancao, C; Millstein, J; Shen, L; Soni, S; Stintzing, S; Wang, J; Xiao, Y; Yang, Y; Zhang, W | 1 |
| Aparicio, J; Capdevila, J; Gallego, RÁ; Galván, P; García de Albeniz, X; Hernandez-Yagüe, X; Hernando, J; Maurel, J; Muñoz Boza, F; Oliveres, H; Páez, D; Richart, P; Riesco-Martinez, MC; Serrano, S; Vera, R; Virgili Manrique, AC | 1 |
| Iwai, M; Kimura, M; Usami, E; Yoshimura, T | 1 |
| Giuliani, J | 1 |
| Auberger, B; Auclin, E; Bernard-Tessier, A; Botsen, D; Bouche, O; Bourgeois, V; Bureau, M; Darbas, T; Doat, S; Dubreuil, O; Gignoux, P; Gluszak, C; Godet, T; Goujon, G; Grados, L; Hammel, P; Jaffrelot, M; Lambert, A; Lecaille, C; Lecomte, T; Locher, C; Moulin, V; Nassif, E; Neuzillet, C; Palmieri, LJ; Pernot, S; Perret, A; Perrier, M; Randrian, V; Roth, G; Saint, A; Sefrioui, D; Stouvenot, M; Taieb, J; Torregrosa, C; Tournigand, C; Trager, S; Turpin, A; Vaflard, P | 1 |
| Banerjee, A; Chrabaszcz, S; Dhiman, A; Gamblin, TC; Johnston, FM; Klooster, B; Rajeev, R; Turaga, KK; Witmer, HDD | 1 |
| Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H | 1 |
| Almeida, A; Castro, F; Lúcio, M; Resende, C; Sarmento, B; Schwartz, S | 1 |
| Kashihara, H; Nakao, T; Nishi, M; Shimada, M; Takasu, C; Tokunaga, T; Wada, Y; Yamashita, S; Yoshikawa, K; Yoshimoto, T | 1 |
| Blaney, M; Cubillo, A; Kozloff, M; Liang, JT; Lowe, T; Matrana, M; Naumovski, L; Sahtout, M; Strickler, JH; Wainberg, ZA | 1 |
| Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schwaner, I; Stahler, A; Stintzing, S | 1 |
| D'Anastasi, M; Decker, T; Gesenhues, AB; Heinemann, V; Heintges, T; Hesse, N; Hofmann, FO; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Link, H; Modest, DP; Moehler, M; Scheithauer, W; Stintzing, S; von Weikersthal, LF | 1 |
| Barzi, A; McCombs, JS; Zheng, H | 1 |
| Afable, M; Gathirua-Mwangi, W; Khan, T; Wu, Y; Yang, T | 1 |
| García-Gil, S; Gutiérrez-Nicolás, F; Miarons, M; Riera, P | 1 |
| Chen, X; Cui, L; Meng, F; Wang, H; Xian, S; Xu, J; Zhan, C | 1 |
| Boldig, K; Ganguly, A; Kadakia, M; Rohatgi, A | 1 |
| Jiang, W; Liu, Q; Yang, D; Yang, SB | 1 |
| Kazama, H; Terazawa, T; Uetake, H; Watanabe, J; Yamane, S; Yoshino, T | 1 |
| Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S | 1 |
| Hassan, MA; Khalil, KA; Mahmoud, IA; Musallam, HS | 1 |
| Bagby, SM; Cadogan, EB; Davis, SL; Diamond, JR; Durant, ST; Hartman, SJ; Hughes, GD; Leal, AD; Lieu, CH; Messersmith, WA; Pitts, TM; Schlaepfer, M; Simmons, DM; Tse, T; Yacob, BW | 1 |
| Bassali, F; Book, A; Bruckner, HW; De Jager, R; Dusowitz, E; Gurell, D | 1 |
| Allegrini, G; Antoniotti, C; Borelli, B; Carullo, M; Citarella, F; Cremolini, C; Dell'Aquila, E; Fulgenzi, CAM; Lonardi, S; Marmorino, F; Masi, G; Nappo, F; Passardi, A; Pietrantonio, F; Rossini, D; Santini, D; Spagnoletti, A; Tamburini, E; Vetere, G; Zaniboni, A | 1 |
| Barber, PR; Forsyth, S; Gao, F; Hackett, LD; Hartley, JA; Hochhauser, D; Lopes, A; Lowe, HL; Ng, TT; Pearce, S; Propper, DJ; Sarker, D; Saunders, MP; Spanswick, VJ; Weitsman, GE; White, L | 1 |
| Betrian, S; Brac De La Perriere, C; Chaltiel, L; Delord, JP; Sarradin, V | 1 |
| Chen, B; Fu, W; Gaiddon, C; Gross, I; Han, X; Hou, L; Hou, Y; Li, L; Liang, Y; Long, B; Meng, X; Pang, W; Wang, L; Wang, Y; Xu, C; Yao, H; Zhang, X; Zhong, T; Zhou, K | 1 |
| Bendell, J; Cervantes, A; Chiu, VK; Fakih, M; Falcone, A; Fontaine, M; Grothey, A; Hitron, M; Oh, SC; Shah, MA; Tabernero, J; Taieb, J; Tebbutt, NC; Tomasek, J; Van Cutsem, E; Wu, C; Xu, B; Xu, RH; Yamaguchi, K; Yoshino, T | 1 |
| Acar, R; Akbas, S; Akinci, MB; Araz, M; Arslan, C; Artac, M; Bahceci, A; Bilgetekin, I; Bilici, A; Cakir, E; Celik, E; Cilbir, E; Cincin, I; Dede, DS; Demirkiran, A; Deniz, GI; Dogan, I; Erdem, D; Erdogan, AP; Eren, OO; Erol, C; Garbioglu, DB; Gulmez, A; Hacibekiroglu, I; Hamdard, J; Hizal, M; Inal, A; Kahraman, S; Kaya, AO; Koca, S; Kubilay, P; Kucukarda, A; Kut, E; Mandel, NM; Menekse, S; Nayir, E; Oksuzoglu, B; On, S; Oyman, A; Ozyukseler, DT; Paydas, S; Sakin, A; Sen, E; Sendur Mehmet, AN; Sevinc, A; Taskaynatan, H; Tastekin, D; Turhal, S; Uncu, D; Yalcin, B; Yildirim, ME | 1 |
| Chen, Y; Du, C; Jiang, X; Li, S; Luo, Y; Wang, Y; Wu, L; Xie, Y; Zhang, R | 1 |
| Alés Díaz, I; Aranda, E; Élez, E; García-Alfonso, P; García-Ortiz, MV; Gómez-España, MA; Graña, B; Grávalos, C; Losa, F; Polo, E; Riesco, MC; Rivera, F; Rodríguez, R; Rodríguez-Ariza, A; Ruiz-Casado, A; Safont, MJ; Salgado, M; Salud, A; Tabernero, JM; Toledano-Fonseca, M; Valladares-Ayerbes, M | 1 |
| Abad, LP; Aguilera, MJS; Bonastre, MTT; Hernández, IB; Pérez, IP; Raga, MG; Rodríguez, PL; Sosa, MM; Urtasun, JA; Veiga, RC | 1 |
| Fujimura, T; Nakura, M; Nojima, K; Sasaki, S; Takenaka, S; Takeshita, M; Watanabe, T; Yamazaki, H | 1 |
| Bergamo, F; Conca, V; Cremolini, C; Di Donato, S; Fanotto, V; Fontanini, G; Germani, MM; Giordano, M; Latiano, TP; Lonardi, S; Masi, G; Moretto, R; Niccoli, C; Passardi, A; Pietrantonio, F; Prisciandaro, M; Proietti, A; Tamburini, E; Ugolini, C; Zaniboni, A | 1 |
| Asaoka, T; Furukawa, K; Hyuga, S; Imasato, M; Iwamoto, K; Mizushima, T; Moon, J; Naito, A; Nakahara, Y; Ohashi, T; Takeda, M | 1 |
| Chang, PY; Chang, WC; Chen, PK; Chiu, SH; Hsu, TF; Ko, KH; Lin, HH | 1 |
| Antoniotti, C; Bensi, M; Bergamo, F; Boccaccino, A; Boquet, I; Catteau, A; Conca, V; Cremolini, C; Galon, J; Giordano, M; Leonetti, S; McGregor, K; Morano, F; Murgioni, S; Nielsen, TJ; Papiani, G; Passardi, A; Pietrantonio, F; Ross, DT; Rossini, D; Salvatore, L; Schweitzer, BL; Seitz, R; Tamburini, E; Varga, MG | 1 |
| Altucci, L; Anderson, A; Ciardiello, D; Ciardiello, F; Coker, O; De Falco, V; Della Corte, CM; Famiglietti, V; Fowlkes, NW; Kanikarla, P; Kopetz, S; Lee, HM; Martinelli, E; Martini, G; Morris, V; Napolitano, S; Sorokin, A; Tabernero, J; Troiani, T; Villareal, OE; Woods, M | 1 |
| Chen, JH; Huang, CI; Huang, YK; Lee, HM; Lin, PM; Su, YC | 1 |
| Cao, J; Ding, Y; Feng, X; Ji, D; Liu, L; Mao, C; Song, L; Song, W; Wu, Y; Xu, N; Zhang, J; Zhang, Y | 1 |
| Beppu, N; Hirata, M; Ikeda, M; Ikeuchi, H; Kataoka, K; Kimura, K; Kuribayashi, M; Nishimura, Y; Nomura, K; Ohashi, E; Song, J; Takenaka, Y; Uchino, M; Yanagawa, T; Yarimizu, A | 1 |
| Chorawala, MR; Patel, RS; Thakur, A | 1 |
| Azuma, K; Dote, S; Fujii, R; Fukui, R; Goto, E; Hayasaka, D; Hayashi, Y; Hirabatake, M; Hirata, T; Honda, S; Ikesue, H; Itakura, S; Ito, K; Kataoka, N; Kobayashi, A; Kobayashi, Y; Kohno, E; Makihara, K; Mashimo, K; Meguro, Y; Miyake, M; Miyata, H; Morimoto, N; Nakao, M; Nakata, Y; Negoro, Y; Nishiuma, S; Odaira, N; Shigemori, M; Shimato, A; Shiwaku, E; Suzuki, S; Takagi, M; Takahashi, K; Takahashi, M; Takahashi, Y; Tasaka, M; Tokutome, A; Watanabe, H; Yagisawa, K; Yamaguchi, D; Yamamoto, Y; Yokomizo, A; Yoshino, M | 1 |
| Boccaccino, A; Bustreo, S; Carullo, M; Clavarezza, M; Cremolini, C; Cupini, S; Daniel, F; Libertini, M; Lonardi, S; Morano, F; Niger, M; Palermo, F; Pietrantonio, F; Procaccio, L; Raimondi, A; Rossini, D; Santini, D; Tomasello, G; Zaniboni, A | 1 |
| Burkart, C; Eucker, J; Fischer von Weikersthal, L; Heinemann, V; Heinrich, K; Kahl, C; Kaiser, F; Karthaus, M; Kasper-Virchow, S; Krammer-Steiner, B; Modest, DP; Müller, C; Pihusch, R; Prager, GW; Reinacher-Schick, A; Schwaner, I; Stauch, M; Stintzing, S; Taieb, J; Tougeron, D | 1 |
| Bock, F; Cappel, ML; Frerker, B; Hildebrandt, G; Klautke, G; Kriesen, S; Manda, K | 1 |
| Chang, CK; Chiu, PF; Hsu, LC; Huang, PS; Liang, PH; Lin, CS; Lin, YY; Yang, HY; Yu, LC | 1 |
| Chin, K; Fukuda, K; Fukuoka, S; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K; Yoshino, K | 1 |
| Chang, W; Cui, Y; Ding, K; Fan, J; Feng, Q; He, G; Liang, F; Liang, L; Lin, Q; Ren, L; Tang, W; Wang, H; Wang, J; Wang, X; Wei, Y; Xu, J; Ye, F; Ye, Q; Zhao, R; Zhou, G; Zhu, D | 1 |
| Honma, T; Imai, M; Ishikawa, T; Iwanaga, A; Jimbo, R; Kobayashi, Y; Sano, T; Sato, R; Sato, T; Yokoyama, J | 1 |
| Armansyah, A; Khoe, LC; Megraini, A; Nadjib, M; Nugraha, RR; Permanasari, VY; Putri, S; Saldi, SRF; Santatiwongchai, B; Sastroasmoro, S; Setiawan, E | 1 |
| Fukuda, H; Hamaguchi, T; Hashimoto, T; Hironaka, S; Kanemitsu, Y; Kataoka, T; Mizusawa, J; Otsu, S; Takashima, A; Tsukamoto, S | 1 |
| Hansen, TF; Havelund, BM; Jensen, LH; Lindebjerg, J; Rafaelsen, SR; Raunkilde, L; Thomsen, CB | 1 |
| Anchisi, S; Bohanes, P; Derigs, HG; Geffriaud-Ricouard, C; Grünberger, B; Gueldner, M; Hofheinz, RD; Piringer, G; Scholten, F; Schwarz, L; Thaler, J; von Moos, R | 1 |
| Kim, KP; Lee, BK; Yoon, S | 1 |
| Imai, H; Ishioka, C; Kasahara, Y; Kawamura, Y; Komine, K; Ouchi, K; Saijo, K; Sasaki, K; Shirota, H; Takahashi, M; Takenaga, N; Taniguchi, SH; Yoshida, Y | 1 |
| Fuks, D; Gayet, B; Goumard, C; Okumura, S; Scatton, O | 1 |
| Doi, T; Hirotani, K; Kagari, T; Koga, Y; Koganemaru, S; Kojima, T; Kuboki, Y; Maeda, N; Matsumura, Y; Yamauchi, M; Yasunaga, M | 1 |
| Andersen, CL; Demuth, C; Johansen, AFB; Knudsen, M; Krag, SRP; Kronborg, CS; Lyskjær, I; Rasmussen, MH; Rosenkilde, M; Spindler, KG; Sørensen, BS; Vang, S | 1 |
| Bafaloukos, D; Bamia, C; Bombolaki, I; Chatzopoulos, K; Chrisafi, S; Efstratiou, I; Fountzilas, G; Kafiri, G; Koliou, GA; Kotoula, V; Kourea, HP; Makatsoris, T; Mauri, D; Mavroeidis, L; Papadopoulou, K; Papakostas, P; Papatsibas, G; Pectasides, D; Pentheroudakis, G; Petraki, K; Samantas, E | 1 |
| Arai, K; Ariyoshi, N; Ishii, I; Kaneya, N; Matsubara, H; Miyauchi, H; Ohira, G; Suzuki, T; Yamamoto, K; Yamazaki, K; Yamazaki, S | 1 |
| Baijal, S; Chau, I; Cunningham, D; Ellis, R; Harrison, M; Khakoo, S; Ograbek, A; Pedley, I; Raouf, S; Ross, P; Steward, W; Tahir, S | 1 |
| Allain, EP; Buonadonna, A; Cecchin, E; Couture, F; D'Andrea, M; De Mattia, E; Guillemette, C; Jonker, D; Labriet, A; Lévesque, É; Rouleau, M; Simonyan, D; Toffoli, G; Villeneuve, L | 1 |
| Higashijima, J; Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Takasu, C; Yamada, S | 1 |
| Allegrini, G; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Buonadonna, A; Cordio, S; Cremolini, C; Dell'Aquila, E; Falcone, A; Latiano, TP; Libertini, M; Lonardi, S; Marmorino, F; Masi, G; Moretto, R; Passardi, A; Pella, N; Randon, G; Ratti, M; Ricci, V; Ronzoni, M; Rossini, D; Tamburini, E; Urbano, F; Zucchelli, G | 1 |
| Amano, S; Aoyama, T; Ju, M; Komori, K; Maezawa, Y; Masuda, M; Morita, J; Mushiake, H; Numata, M; Oshima, T; Rino, Y; Sato, T; Sawazaki, S; Tamagawa, H; Yukawa, N | 1 |
| Artru, P; Auclin, E; Auvray, M; Coriat, R; Hammel, P; Hautefeuille, V; Lecaille, C; Lecomte, T; Locher, C; Moulin, V; Pernot, S; Sickersen, G; Taieb, J; Tougeron, D; Vernerey, D | 1 |
| Hopkins, AM; Karapetis, CS; Lim, HH; Rowland, A; Sorich, MJ; Yuen, HY | 1 |
| Alessandroni, P; Bergamo, F; Borelli, B; Catalano, V; Cremolini, C; Falcone, A; Giordani, P; Graziano, F; Intini, R; Lonardi, S; Mattioli, R; Negri, F; Rocchi, MBL; Rossini, D; Santini, D; Sarti, D; Stragliotto, S; Vincenzi, B; Zagonel, V | 1 |
| Berry, SR; Chan, KKW; Ko, YJ; Riesco-Martínez, M; Wong, WWL; Zargar, M | 1 |
| Chiron, M; Paccard, C; Tabernero, J; Van Cutsem, E | 1 |
| Antista, M; Barault, L; Corallo, S; de Braud, F; Di Bartolomeo, M; Di Maio, M; Di Nicolantonio, F; Farina, G; Fucà, G; Gori, S; Guarini, V; Lobefaro, R; Lonardi, S; Longarini, R; Macagno, M; Martinetti, A; Milione, M; Morano, F; Mosconi, S; Murgioni, S; Pagani, F; Palermo, F; Perrone, F; Petrelli, F; Pietrantonio, F; Raimondi, A; Randon, G; Rimassa, L; Sartore-Bianchi, A; Tamborini, E; Tomasello, G | 1 |
| Gao, H; Gao, M; Jiang, G; Lin, X; Su, Q; Tong, J; Yang, Z; Zhang, A; Zhang, X | 1 |
| Bouvet, M; Clary, B; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G | 1 |
| Chang, TK; Chang, YT; Huang, CW; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yeh, YS | 1 |
| Cremolini, C; Dienstmann, R; Sveen, A | 1 |
| Aderka, D; Al-Batran, S; Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Held, S; Jung, A; Kahl, C; Kaiser, F; Kiani, A; Kirchner, T; Kullmann, F; Lenz, HJ; Lerchenmüller, C; Modest, DP; Moehler, M; Neureiter, D; Scheithauer, W; Seipelt, G; Stintzing, S; Tejpar, S; Wirapati, P | 1 |
| Aucoin, N; Berry, S; Couture, F; Gillesby, B; Kavan, P; Kennecke, H; Maroun, J; Poulin-Costello, M | 1 |
| Cid, NG; Labandeira, CM; Manrique, MCA; Mata, JG; Montes, AF; Núñez, MÁ; Ron, DA; Vera, R | 1 |
| Becker, T; Boersch, K; Burmeister, G; Forster, M; Franke, A; Hendricks, A; Hinz, S; Röcken, C; Rosenstiel, P; Schafmayer, C | 1 |
| Li, J; Peng, L; Shi, Y; Tan, C; Wan, X | 1 |
| Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Held, S; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Michl, M; Moehler, M; Scheithauer, W; Stintzing, S; von Einem, JC | 1 |
| Chen, SC; Chiang, TY; Hsu, HC; Jane, SW | 1 |
| Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D | 1 |
| Alonso, V; Cabrera, JM; Escudero, P; González, B; González, E; Iranzo, P; Juez, I; López, C; Martínez, NP; Mata, E; Pericay, C; Rivera, F; Ruiz-Casado, A; Safont, MJ; Salgado, M; Vera, R | 1 |
| Cai, X; Chen, Y; Fang, H; Fang, W; Li, H; Li, Q; Lin, X; Ma, D; Nie, Y; Peng, C; Shen, L; Wang, N; Wang, W; Xu, R; Zhao, Q; Zhu, B; Zhu, L | 1 |
| Adachi, T; Eguchi, S; Enjoji, T; Hidaka, M; Inoue, Y; Ito, S; Kanetaka, K; Kobayashi, K; Kosaka, T; Kuba, S; Okada, S; Takatsuki, M; Tetsuo, H; Torashima, Y; Yamaguchi, S; Yamanouchi, K | 1 |
| Burge, M; Clarke, SJ; Feeney, K; Gibbs, P; Jones, K; Marx, G; Molloy, MP; Price, T; Reece, WHH; Segelov, E; Tebbutt, NC | 1 |
| Allen, A; Berlin, J; Das, S | 1 |
| Fukata, T; Fukuzaki, T; Hojo, S; Ito, Y; Nishida, H; Ohigashi, H; Okimura, S; Shingai, T; Takayama, O; Taniguchi, Y; Yoshioka, S | 1 |
| Hata, T; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Murakami, K; Murata, K; Naito, A; Omura, Y; Sakamoto, T; Takeda, Y; Takeno, A | 1 |
| Alvarez, R; Andel, J; Bendell, JC; Bennouna, J; Bessudo, A; Boetsch, C; Cervantes, A; Franjkovic, I; García-Alfonso, P; Gracián, AC; Heil, F; Hurwitz, H; Hussein, M; Krieter, O; Lahr, A; Lechner, K; López-López, C; Miron, ML; Montagut, C; Moons, V; Plezia, P; Rossomanno, S; Samuel, L; Sauri, T; van der Westhuizen, A; Vivas, CS | 1 |
| Glynne-Jones, R; Harrison, M | 1 |
| Becker, T; Bemelmans, M; Bruns, CJ; Denecke, T; Folprecht, G; Gebauer, B; Heinemann, V; Heinrich, K; Held, S; Lang, H; Modest, DP; Neumann, UP; Pratschke, J; Rentsch, M; Ricard, I; Seehofer, D; Stahler, A; Stintzing, S; von Einem, JC | 1 |
| Chen, S; Feng, C; Guo, C; Hua, L; Huang, H; Li, G; Lin, Z; Mo, Q; Shen, Y; Wei, M; Xu, J | 1 |
| Aranda, E; Balbín, M; Bando, I; Bellosillo, B; Calle, SG; Díaz-Rubio, E; García-Alfonso, P; Llovet, P; Lopez, C; Martínez, A; Mediero, B; Moral, VM; Orden, V; Ortiz-Morales, MJ; Palanca, S; Peligros Gomez, MI; Quintero, G; Salud, A; Sastre, J; Viéitez, JM | 1 |
| Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Hanna, DL; Heinemann, V; Lenz, HJ; Loupakis, F; Miyamoto, Y; Naseem, M; Ning, Y; Puccini, A; Schirripa, M; Soni, S; Stintzing, S; Suenaga, M; Tokunaga, R; Yang, D; Zhang, W | 1 |
| Chang, W; Cho, JY; Cho, S; Jheon, S; Kang, SB; Kim, DW; Kim, JH; Kim, JW; Kim, K; Kim, SA; Lee, KW; Oh, HK; Suh, KJ | 1 |
| Adam, R; Bouchahda, M; Innominato, PF; Levi, FA; Ulusakarya, A | 1 |
| Ahn, JB; Baek, JY; Beom, SH; Cho, SH; Chu, CW; Chun, YJ; Hong, S; Jung, M; Kim, SG; Kim, TW; Lee, KW; Park, YS; Shin, SJ | 1 |
| Atzpodien, J; Buechner-Steudel, P; Ettrich, T; Florschütz, A; Geissler, M; Greeve, J; Heinemann, V; Held, S; Kanzler, S; Kurreck, A; Martens, UM; Modest, DP; Nörenberg, D; Reinacher-Schick, AC; Riera-Knorrenschild, J; Seidensticker, M; Seufferlein, T; Stintzing, S; Tannapfel, A; Wessendorf, S | 1 |
| Aktaş, Y; Benito, JM; Bilensoy, E; Ünal, S | 1 |
| Asaro, F; Fortuna, S; Garziera, M; Geremia, S; Scarabel, L; Toffoli, G | 1 |
| Chan, LF; Kamei, Y; Miyakita, H; Ogimi, T; Okada, K; Sadahiro, S; Saito, G; Suzuki, T | 1 |
| Cheng, Q; Liao, L; Pei, F; Ye, S; Zhu, G | 1 |
| Cai, Y; Deng, Y; Hu, H; Xie, X; Zhang, J | 1 |
| Avallone, A; Giuliani, F | 1 |
| Cookson, E | 1 |
| Fujiwara, D; Hoshida, T; Mashimo, K; Morimoto, N; Nishida, S; Noda, A; Sakaguchi, K; Takeda, T; Tsubaki, M | 1 |
| Abdhaghighi, MJ; Jalali, H; Janbabaei, G; Negarandeh, R; Nosrati, A; Saghafi, F; Salehifar, E | 1 |
| Augustine, T; Chandy, C; Coffey, M; Fogel, E; Goel, S; Maitra, R; Parakrama, R; Tesfa, L | 1 |
| Aprile, G; Belfiore, A; Boccaccino, A; Brich, S; Cattaneo, L; Centonze, G; Cillo, U; Corallo, S; Cremolini, C; De Braud, F; Falcone, A; Fassan, M; Fontanini, G; Germani, MM; Lonardi, S; Loupakis, F; Marmorino, F; Milione, M; Morano, F; Morelli, L; Moretto, R; Pietrantonio, F; Prisciandaro, M; Rossini, D; Urbani, L | 1 |
| Kaci, R; Lo Dico, R; Mathonnet, M; Naneix, AL; Pocard, M; Taibi, A | 1 |
| Haihong, L; Jiamin, X; Quan, Q; Shuwen, H; Wei, W; Xi, Y; Yizhen, J; Yuefen, P | 1 |
| Kashiwa, M; Matsushita, R | 1 |
| Fischer von Weikersthal, L; Fraccaroli, A; Haas, M; Heinemann, V; Heinrich, K; Held, S; Holch, JW; Jung, A; Kullmann, F; Modest, DP; Moehler, M; Scheithauer, W; Schulz, C; Stintzing, S; von Einem, JC | 1 |
| Aljubran, A; Alzahrani, A; Badran, A; Bazarbashi, S; Eldali, A; Elshenawy, MA; Rauf, MS | 1 |
| Abgral, R; Amrane, K; le Pennec, R; Metges, JP; Schick, U | 1 |
| Ahmed, SU; Dasari, A; Eng, C; Fogelman, D; Jácome, AA; Johnson, B; Kee, B; Kopetz, S; Mehdizadeh, A; Morris, V; Overman, M; Raghav, K; Rogers, J; Rothschild, N; Shureiqi, I; Wolff, R | 1 |
| Antoniotti, C; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Brunella, DS; Corallo, S; Cremolini, C; Falcone, A; Grassi, E; Lonardi, S; Marmorino, F; Morano, F; Moretto, R; Pietrantonio, F; Racca, P; Rossini, D; Salvatore, L; Tamberi, S; Tamburini, E; Tortora, G | 1 |
| Dorcaratto, D; Garcés-Albir, M; Huerta Álvaro, M; Muñoz-Forner, E; Pérez-Santiago, L; Roselló Keranën, S; Sabater, L | 1 |
| Fujiwara, Y; Nakane, M; Yamaguchi, T | 1 |
| Aranda, E; Élez, E; Gallego, J; González, E; Safont, MJ; Salgado, M; Vera, R | 1 |
| Bates, DDB; Capanu, M; Chatila, W; Chou, J; Hersch, J; Kelsen, D; Paroder, V; Schultz, N; Tang, L; Yaeger, R | 1 |
| Chen, JB; Chen, TL; Huang, CW; Huang, HY; Ke, TW; Lin, YW; Sung, YC; Tang, HC; Tsai, CS; Tsai, HL; Wang, HM; Wang, JH; Wang, JY; Wu, CC | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Antonuzzo, L; Bergamo, F; Berselli, A; Bordonaro, R; Damato, A; Iachetta, F; Maiello, E; Nasti, G; Normanno, N; Pinto, C; Romagnani, A; Tonini, G; Zaniboni, A | 1 |
| Boige, V; Boilève, A; De Cuyper, A; Ducreux, M; Gelli, M; Larive, A; Mahjoubi, L; Malka, D; Najdawi, M; Pignon, JP; Smolenschi, C; Tazdait, M; Tselikas, L | 1 |
| Antonuzzo, L; Castiglione, F; Di Costanzo, F; Lastraioli, E; Lavacchi, D; Messerini, L; Palmieri, VE | 1 |
| Froelich, MF; Gesenhues, AB; Heinemann, V; Hesse, N; Hofmann, FO; Holch, JW; Modest, DP; Nörenberg, D; Petersen, EL; Sommer, WH; Stintzing, S | 1 |
| Aparicio, T; Caroli-Bosc, FX; Dahan, L; Desrame, J; Doat, S; Lapeyre-Prost, A; Le Malicot, K; Lecomte, T; Lepage, C; Marthey, L; Mary, F; Pernot, S; Sigrand, J; Taieb, J | 1 |
| Auman, JT; Bertagnolli, MM; Blanke, CD; Casey, G; Etheridge, AS; Furukawa, Y; Howell, SD; Innocenti, F; Jiang, C; Kubo, M; Lenz, HJ; McLeod, HL; Ou, FS; Owzar, K; Parker, JS; Patil, SA; Plummer, SJ; Ratain, MJ; Sibley, AB; Venook, AP | 1 |
| Baba, H; Denda, T; Hyodo, I; Izawa, N; Kondoh, C; Makiyama, A; Masuishi, T; Moriwaki, T; Muro, K; Nakajima, TE; Nakamura, M; Nishina, T; Okuda, H; Shitara, K; Sunakawa, Y; Yamaguchi, H; Yamanaka, T; Yamazaki, K; Yonesaka, K; Yoshino, T | 1 |
| Balachandran, VP; Boerner, T; Buisman, FE; D'Angelica, MI; Drebin, JA; Gonen, M; Jarnagin, WR; Kemeny, NE; Kingham, TP; Narayan, RR; Seier, K; Srouji, RM; Wei, A | 1 |
| Antoniotti, C; Aprile, G; Bergamo, F; Boccaccino, A; Bordonaro, R; Buonadonna, A; Caponnetto, S; Cremolini, C; Cupini, S; Falcone, A; Fea, E; Grande, R; Lonardi, S; Marmorino, F; Moretto, R; Pietrantonio, F; Rossini, D; Santini, D; Tamburini, E; Tomasello, G; Zaniboni, A; Zucchelli, G | 1 |
| Chen, K; He, L; Hu, W; Lei, L; Li, Y; Lv, Z; Xie, X; Zhou, B; Zhou, Z | 1 |
| Li, Q; Liao, W; Wang, X; Wu, Q; Zhang, M; Zhang, P | 1 |
| Chen, B; Han, G; Huang, C; Ye, J; Yu, W; Zheng, D; Zhuang, J | 1 |
| Antoniotti, C; Bergamo, F; Buonadonna, A; Caponnetto, S; Cremolini, C; Ermacora, P; Falcone, A; Germani, MM; Latiano, TP; Lonardi, S; Masi, G; Moretto, R; Pietrantonio, F; Rapisardi, S; Ricci, V; Ritorto, G; Rossini, D; Santini, D; Tomasello, G; Zaniboni, A | 1 |
| Fujiwara, T; Inukai, M; Kikuchi, T; Kobayashi, M; Kurisu, Y; Matsumoto, T; Miguchi, M; Moriyama, I; Nagano, H; Nagasaka, T; Nasu, J; Nishina, T; Nozaka, K; Shinozaki, K; Shiraishi, T; Tanioka, H; Tsuchihashi, K; Yamada, T; Yoshida, R; Yuasa, Y | 1 |
| Al-Batran, SE; Decker, T; Heinemann, V; Heintges, T; Held, S; Jung, A; Kahl, C; Kaiser, F; Kiani, A; Kirchner, T; Kullmann, F; Lerchenmüller, C; Miller-Phillips, L; Modest, DP; Moehler, M; Scheithauer, W; Seipelt, G; Stintzing, S; von Weikersthal, LF | 1 |
| Burris, H; Chen, W; Eng, C; Esser, R; Lenz, HJ; Middleton, G; Nippgen, J; Scheithauer, W; Sobrero, A | 1 |
| Carneiro, BA; El-Deiry, WS; Marks, EI; Matera, R; Olszewski, AJ; Safran, H; Yakirevich, E | 1 |
| Antoniotti, C; Bendell, JC; Boccaccino, A; Boni, L; Borelli, B; Corallo, S; Cremolini, C; de Braud, F; Di Bartolomeo, M; Falcone, A; Fucà, G; Lonardi, S; Marmorino, F; Masi, G; Morano, F; Niger, M; Pietrantonio, F; Raimondi, A; Rossini, D; Schmoll, HJ | 1 |
| Chin, K; Kamiimabeppu, D; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Sato, T; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K | 1 |
| Almuradova, E; Çakar, B; Doğanavşargil, B; Gürsoy, P; Harman, M; Karabulut, B; Karateke, M; Sezak, M | 1 |
| Baloni, P; Bergey, D; Hood, LE; Jabbari, N; Kenerson, HL; Lausted, C; Meng, C; Pillarisetty, VG; Sullivan, KM; Tian, Q; Yan, X; Yeung, RS | 1 |
| Fujii, H; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Suzuki, A; Takahashi, T; Watanabe, D; Yamada, Y; Yoshida, K | 1 |
| Köstek, O | 1 |
| Teng, HW | 1 |
| Loree, JM; Yu, IS | 1 |
| Cai, Z; Kagawa, Y; Makiyama, A; Piao, Y; Satake, H; Shinozaki, E; Tanizawa, Y | 1 |
| Chen, Z; Guo, W; Huang, M; Li, W; Qiu, L; Wang, C; Wang, Y; Yang, Y; Zhang, W; Zhang, X; Zhang, Z; Zhao, X; Zhu, X | 1 |
| Chen, X; Fang, S; Han, W; Jin, J; Li, T; Wan, J; Wang, H; Wang, Y; Xie, B; Xie, H; Yang, B; Ying, K | 1 |
| Chen, M; Ci, T; Dai, J; Ke, X; Li, H; Qiao, Y; Xu, D | 1 |
| Aranda Aguilar, E; Élez Fernández, E; Fernández Montes, A; García-Alfonso, P; González Astorga, B; González Flores, E; López Muñoz, AM; Salud Salvia, A; Salvà Ballabrera, F; Vera García, R | 1 |
| Habib, M; Jorns, C; Nilsson, PJ; Nordenvall, C; Sparrelid, E; Villard, C | 1 |
| Kang, J; Kim, SY; Kim, TW; Lee, JS; Morita, S; Muro, K; Park, YS; Sakamoto, J; Xu, RH | 1 |
| Chen, X; Fang, T; Wan, J; Wang, H; Wang, Y; Ye, Z | 1 |
| Antoniotti, C; Bergamo, F; Boccaccino, A; Borelli, B; Cremolini, C; Falcone, A; Fontana, E; Fontanini, G; Giordano, M; Lonardi, S; Maiello, E; Morano, F; Nyamundanda, G; Passardi, A; Pella, N; Pietrantonio, F; Sadanandam, A; Santini, D; Tamburini, E; Ugolini, C; Zaniboni, A; Zucchelli, G | 1 |
| Bartolini, G; Crudi, L; Donati, C; Foca, F; Frassineti, GL; Masini, C; Matteucci, L; Monti, M; Pagan, F; Passardi, A; Rapposelli, I; Ruscelli, S; Sbaffi, S; Sullo, F; Valgiusti, M | 1 |
| Ahmed, S; Bhatti, T; Chalchal, H; Gill, D; Le, D; Moser, M; Shaw, J; Souied, O; Tan, KT; Zaidi, A | 1 |
| Doki, Y; Eguchi, H; Fukunaga, M; Kim, HM; Komori, T; Matsuda, C; Miyoshi, N; Mizushima, T; Murata, K; Paku, M; Takahashi, H; Uemura, M | 1 |
| Aoki, K; Hamano, T; Makishima, M; Oki, E; Sano, F; Yamanaka, T; Yamazaki, K; Yuki, S | 1 |
| Barbolosi, D; Deyme, L; Evrard, A; Gattacceca, F; Mbatchi, LC; Tubiana-Mathieu, N; Ychou, M | 1 |
| Capanu, M; Chatila, WK; Chou, JF; Connell, LC; D'Angelica, MI; Jarnagin, WR; Kemeny, NE; Kingham, TP; Sanchez-Vega, F; Shi, H | 1 |
| Chau, I | 1 |
| Bako, E; Chung, K; Ciardiello, F; Di Bartolomeo, M; Elez, E; Esaki, T; Fakih, M; Grothey, A; Kawakami, H; Komatsu, Y; Loupakis, F; Masuishi, T; Nishina, T; Okuda, Y; Raghav, K; Rodriguez, J; Sartore-Bianchi, A; Saxena, K; Shahidi, J; Siena, S; Wainberg, Z; Yamaguchi, K; Yamamoto, E; Yoshino, T | 1 |
| Aalbers, AGJ; Bakkers, C; Boerma, D; Brandt-Kerkhof, ARM; Bremers, AJA; Buffart, TE; Burger, JWA; Creemers, GM; de Groot, DJA; de Hingh, IHJT; de Reuver, PR; Dijkgraaf, MGW; Fijneman, RJA; Hemmer, PHJ; Kok, NFM; Koopman, M; Kranenburg, O; Kruijff, S; Kusters, M; Lahaye, MJ; Los, M; Madsen, EVE; Nederend, J; Nienhuijs, SW; Punt, CJA; Rovers, KP; Snaebjornsson, P; Tanis, PJ; Thijs, AMJ; Tuynman, JB; van 't Erve, I; van Grevenstein, WMU; van Meerten, E; Verheul, HMW; Versteeg, KS; Wiezer, MJ; Witkamp, AJ | 1 |
| Chang, TK; Chen, PJ; Chen, YC; Cheng, TL; Chuang, KH; Huang, CW; Li, CC; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yin, TC | 1 |
| Kimura, M; Teramachi, H; Usami, E; Yoshimura, T | 1 |
| Baraibar, I; Cuadra-Urteaga, JL; Élez, E; Marmolejo, D; Mulet, N; Ros, J; Salvà, F; Saoudi Gonzalez, N; Tabernero, J; Valdivia, A | 1 |
| Aprile, G; Bertolini, AS; Boccaccino, A; Clavarezza, M; Conca, V; Cremolini, C; Falcone, A; Fontanini, G; Frassoldati, A; Germani, MM; Giordano, M; Granetto, C; Lonardi, S; Masi, G; Moretto, R; Passardi, A; Pietrantonio, F; Poma, AM; Tomasello, G; Ugolini, C | 1 |
| Jin, L; Shinozaki, E; Tanizawa, Y | 1 |
| Echeverry-Molina, MI; Gómez, M; Guevara-Cuellar, CA; Martínez, P; Soto-Rojas, VE | 1 |
| Armansyah, A; Endarti, D; Khoe, LC; Kristin, E; Sastroasmoro, S; Taroeno-Hariadi, KW; Trijayanti, C | 1 |
| Anami, S; Furihata, S; Ohno, R; Takamatsu, N; Yatsu, N | 1 |
| Bando, H; Iino, S; Kadowaki, S; Kageyama, R; Kawazoe, A; Masuishi, T; Muro, K; Taniguchi, H; Yoshino, T | 1 |
| Alig, AHS; Decker, T; Fischer, LE; Heinemann, V; Heinrich, K; Holch, JW; Jelas, I; Jung, A; Kaiser, F; Kiani, A; Kirchner, T; Modest, DP; Moehler, M; Schlieker, L; Stahler, A; Stintzing, S; von Einem, JC; von Weikersthal, LF; Weiss, L; Westphalen, CB | 1 |
| Ahn, JB; Bai, L; Cho, SH; Fang, WJ; Han, SW; Hong, YS; Iwasa, S; Kim, TW; Kotaka, M; Lee, KW; Matsuoka, H; Morita, S; Muro, K; Nakamura, M; Nishina, T; Park, YS; Sakamoto, J; Yamada, Y; Yuan, XL; Yuan, Y; Zhang, DS | 1 |
| Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF | 1 |
| Jiang, Z; Li, Y; Luo, W; Wang, C; Yu, C; Zhang, H; Zhang, W | 1 |
| Alvi, R; Beca, JM; Chan, KKW; Cheung, WY; Dai, WF; Dvorani, E; Earle, CC; Gavura, S; Isaranuwatchai, W; Pataky, RE; Peacock, S; Tran, D | 1 |
| Cho, DH; Kim, CW; Kim, JC; Kim, MB; Kim, TW; Roh, SA; Yoon, YS | 1 |
| Berger, MD; Cao, S; Cremolini, C; Falcone, A; Groshen, S; Hanna, DL; Heinemann, V; Lenz, HJ; Lonardi, S; Loupakis, F; Matsusaka, S; Miyamoto, Y; Ning, Y; Okazaki, S; Schirripa, M; Stintzing, S; Suenaga, M; Sunakawa, Y; Yamauchi, S; Yang, D; Zhang, W | 1 |
| Barzi, A; Berger, MD; Cao, S; Falcone, A; Gopez, RF; Hanna, D; Heinemann, V; Lenz, HJ; Loupakis, F; Miyamoto, Y; Ning, Y; Okazaki, S; Schirripa, M; Stintzing, S; Suenaga, M; West, JD; Yang, D; Zhang, W | 1 |
| Atasilp, C; Chansriwong, P; Prommas, S; Puangpetch, A; Rerkarmnuaychoke, B; Reungwetwattana, T; Sirachainan, E; Sirilerttrakul, S; Sukasem, C; Wongwaisayawan, S | 1 |
| Andersen, EC; García-González, AP; Ritter, AD; Shrestha, S; Walhout, AJM; Yilmaz, LS | 1 |
| Ferreira, FP; Leal, F; Sasse, AD | 1 |
| A Guzzetta, A; Abdelfatah, E; Ahuja, N; Azad, N; B Baylin, S; Hu, Y; Kerner, Z; Sharma, A; Singh, J; Vatapalli, R; Wyatt McMahon, K; Yerram, S; Zahnow, C | 1 |
| Al-Batran, SE; Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Held, S; Jagenburg, A; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Miller-Phillips, L; Modest, DP; Moehler, M; Scheithauer, W; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U | 1 |
| Khorrami, S; Malekzadeh, R; Mowla, SJ; Rakhshani, N; Soleimani, M; Zavaran Hosseini, A | 1 |
| Hazama, S; Nagano, H; Oka, M; Okayama, N; Tsunedomi, R | 1 |
| Dicker, DT; El-Deiry, WS; Zhang, J; Zhao, S; Zhou, L | 1 |
| Doki, Y; Fukunaga, M; Hata, T; Ikeda, M; Kato, T; Kim, HM; Kudo, T; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nishimura, J; Sueda, T; Yamamoto, H | 1 |
| Kalluri, R; Kurywchak, P | 1 |
| Colville-Ebeling, B; Jensen, BV; Larsen, FO; Markussen, A; Nielsen, D; Riis, LB | 1 |
| Barni, S; Ghidini, M; Passalacqua, R; Petrelli, F; Russo, A; Tomasello, G | 1 |
| Akihito, T; Berger, MD; Cao, S; DePaolo, RW; Gopez, R; Heinemann, V; Ichikawa, W; Lenz, HJ; Matsusaka, S; Miyamoto, Y; Ning, Y; Okazaki, S; Schirripa, M; Stintzing, S; Suenaga, M; Sunakawa, Y; West, JD; Yang, D; Zhang, W | 1 |
| Bastide, S; Cousin, C; Favier, M; Leguelinel-Blache, G; Loriot, V; Obled, S; Phouttasang, V; Thibault, V; Wolf, P | 1 |
| Crispin, A; Fischer von Weikersthal, L; Giessen-Jung, C; Haas, M; Heinemann, V; Holch, JW; Jung, A; Kirchner, T; Kruger, S; Michl, M; Modest, DP; Neumann, J; Quietzsch, D; Schalhorn, A; Stahler, A; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Einem, J | 1 |
| Allegrini, G; Antoniotti, C; Aprile, G; Boni, L; Cremolini, C; Di Donato, S; Falcone, A; Lonardi, S; Loupakis, F; Marmorino, F; Masi, G; Passardi, A; Pietrantonio, F; Ricci, V; Ronzoni, M; Salvatore, L; Santini, D; Schirripa, M; Tamburini, E; Tomasello, G; Valsuani, C; Zagonel, V | 1 |
| Andreou, A; Bahra, M; Beierle, AS; Duwe, G; Knitter, S; Lohneis, P; Öllinger, R; Pesthy, S; Pratschke, J; Raschzok, N; Sauer, IM; Schmelzle, M; Schmuck, RB; Sinn, M; Struecker, B | 1 |
| Antoniotti, C; Cascinu, S; Cremolini, C; Demurtas, L; Falcone, A; Gelsomino, F; Giampieri, R; Loretelli, C; Mandolesi, A; Masi, G; Meriggi, F; Pusceddu, V; Puzzoni, M; Scartozzi, M; Zaniboni, A; Ziranu, P | 1 |
| Atkins, JN; Benson, AB; Berry, S; Bertagnolli, MM; Blanke, C; El-Khoueiry, AB; Fruth, B; Goldberg, RM; Greene, C; Hochster, HS; Innocenti, F; Lenz, HJ; Mayer, RJ; Meyerhardt, JA; Mulkerin, DL; Niedzwiecki, D; O'Neil, BH; O'Reilly, EM; Polite, BN; Schilsky, RL; Schrag, D; Venook, AP; Watson, P | 1 |
| Abad, A; Aranda, E; Carrato, A; Dueñas, R; Escudero, P; Gallego, J; García-Paredes, B; Gómez, A; González, E; Grávalos, C; Longo-Muñoz, F; Losa, F; Manzano, JL; Massuti, B; Pericay, C; Rivera, F; Safont, MJ; Valladares-Ayerbes, M | 1 |
| Ahmad, T; Ahmed, M; Czejka, M; Fan, Y; Khan, RA; Mansoor, N; Sharib, S; Yang, DH | 1 |
| Gao, J; Li, J; Li, Y; Liu, D; Shen, L; Yang, R | 1 |
| Akimoto, S; Hasegawa, H; Ishida, T; Ishii, Y; Kitagawa, Y; Koishikawa, K; Okabayashi, K; Tsuruta, M | 1 |
| Aizawa, K; Furukawa, T; Kozakai, H; Mitsuboshi, S; Nagai, K; Yamada, H | 1 |
| Peng, CL; Shieh, MJ; Tsai, MH; Yang, SJ | 1 |
| Makihara, K; Miyagi, K; Nakamura, S; Nakata, I; Ueno, H | 1 |
| Bilancia, D; Cascinu, S; Corsi, DC; Ferraú, F; Galli, F; Giordano, M; Iaffaioli, RV; Labianca, R; Leone, F; Lonardi, S; Marchetti, P; Nasti, G; Ronzoni, M; Rosati, G; Scartozzi, M; Zagonel, V; Zaniboni, A | 1 |
| Andreatos, N; Buettner, S; Damaskos, C; Deshwar, A; Ghasebeh, MA; Kamel, IR; Margonis, GA; Pawlik, TM; Pour, MZ; Rezaee, N; Sasaki, K; Wang, J; Weiss, MJ; Wolfgang, CL | 1 |
| Gao, L; Li, J; Niu, B; Wu, X; Ye, R; Zhao, Z | 1 |
| Bettinger, J; Karhan, B; Peters, SS; Philip, J; Wrzesinski, SH | 1 |
| El-Deiry, WS; Hernandez Borrero, LJ; Richardson, C; Zhang, S | 1 |
| Chang, YJ; Chu, CM; Makondi, PT; Wei, PL | 1 |
| Chionh, F; Lau, D; Price, T; Tebbutt, N; Yeung, Y | 1 |
| Gonzaga-López, A; Muñoz-Rodriguez, J; Ruiz-Casado, A | 1 |
| Guo, B; Li, J; Luo, L; Tang, D; Wang, D; Wang, J; Yang, Z | 1 |
| Peng, S; Shan, S; Wang, J; Wang, L; Wu, J; Xiao, N; Yu, K; Yu, S; Zheng, S | 1 |
| Choi, YR; Han, JK; Hur, BY; Kim, JH; Park, SJ | 1 |
| Al Abo, M; Huang, SY; Kiselev, E; Liu, X; Plunkett, W; Pommier, Y; Rajapakse, VN; Sasanuma, H; Takeda, S | 1 |
| Akinwande, O; Dendy, M; Kim, HS; Ludwig, JM | 1 |
| Dochy, E; Lakomy, R; Macarulla, T; Magherini, E; Moiseyenko, VM; Papamichael, D; Prausova, J; Ruff, P; Soussan-Lazard, K; Van Cutsem, E; van Hazel, GA | 1 |
| Berlin, JD; Cohen, SJ; Dotan, E; Goldberg, RM; Goldenberg, DM; Govindan, SV; Guarino, MJ; Hecht, JR; Lieu, CH; Marshall, JL; Messersmith, WA; Sharkey, RM; Simpson, PS; Starodub, AN; Wegener, WA | 1 |
| Adam, R; Boige, V; Bouchahda, M; Carvalho, C; Desterke, C; Ducreux, M; Focan, C; Guimbaud, R; Hebbar, M; Innominato, P; Karaboué, A; Lemoine, A; Lévi, F; Milano, G; Saffroy, R; Smith, D; Taieb, J | 1 |
| Carvalho, T; Ferreira, MG; Figueiredo, N; Fior, R; Gomes, A; Mendes, RV; Póvoa, V | 1 |
| Funada, T; Kaiga, T; Kochi, M; Okada, S; Takayama, T; Yamazaki, S | 1 |
| Al-Batran, SE; Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Held, S; Holch, JW; Kahl, C; Kiani, A; Kullmann, F; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Seipelt, G; Stintzing, S; Vehling-Kaiser, U; von Einem, JC; Westphalen, CB | 1 |
| Avallone, A; Caraglia, M; Cassata, A; De Stefano, A; Nasti, G; Ottaiano, A | 1 |
| Brünner, N; Nielsen, DL; Palshof, JA; Stenvang, J; Viuff, BM | 1 |
| Artioli, M; Braghiroli, MI; Braghiroli, OFM; Costa, FP; Fernandes, GDS; Girardi, DDM; Gumz, BP; Hoff, PM; Paterlini, ACCR; Teixeira, MC | 1 |
| Allen, JN; Berger, D; Blaszkowsky, LS; Clark, JW; Collura, C; Deshpande, V; Ferrone, CR; Lillemoe, KD; Miller, CL; Murphy, JE; Parikh, AR; Qadan, M; Ryan, DP; Smalley, R; Tanabe, KK; Taylor, MS; Worthington, S | 1 |
| Costa, J; Duarte, GS; Marques, RP; Martins, AP; Pais, HL; Quintela, A; Sterrantino, C | 1 |
| Chalchal, H; Payette, E; Sarker, S | 1 |
| Cascinu, S; Cavanna, L; Codecà, C; Daniele, B; Ferrari, D; Germano, D; Giampieri, R; Labianca, R; Libertini, M; Lonardi, S; Pella, N; Puzzoni, M; Rosati, G; Scartozzi, M; Sozzi, P; Zagonel, V; Zampino, MG; Zaniboni, A | 1 |
| Boige, V; Malka, D; Rotolo, F | 1 |
| Biglietto, M; Bordonaro, R; Cardone, C; Ciardiello, F; Esposito Abate, R; Forgione, L; Giuliani, F; Iannaccone, A; Lambiase, M; Latiano, TP; Leo, S; Maiello, E; Martinelli, E; Normanno, N; Pisconti, S; Rachiglio, AM; Rinaldi, A; Rizzi, D; Sacco, A; Troiani, T | 1 |
| Aoki, I; Bakalova, R; Higashi, T; Nikolova, B; Shibata, S; Zhelev, Z | 1 |
| Baiocchi, M; De Angelis, ML; De Maria, R | 1 |
| Bracke, B; Chapelle, T; Driessen, A; Francque, S; Hartman, V; Huyghe, I; Morrison, S; Op de Beeck, B; Roeyen, G; Ysebaert, D | 1 |
| Azoulay, D; Esposito, F; Fuentes, L; Lahat, E; Lim, C; Moussallem, T; Osseis, M; Salloum, C | 1 |
| Amar, Y; Berger, F; Bieche, I; Cacheux, W; Canet, J; Cartier, A; de Koning, L; Guimbaud, R; Guyetant, S; Lecomte, T; Lièvre, A; Mariani, O; Ouine, B; Selves, J | 1 |
| Gao, J; Gong, J; Li, J; Li, Y; Shen, L; Wang, X; Wei, Q | 1 |
| Berger, MD; Cao, S; Falcone, A; Heinemann, V; Lenz, HJ; Loupakis, F; Matsusaka, S; Miyamoto, Y; Ning, Y; Okazaki, S; Schirripa, M; Soni, S; Stintzing, S; Suenaga, M; Sunakawa, Y; Yang, D; Zhang, W | 1 |
| Aparicio, T; Baconnier, M; Bedenne, L; Bouché, O; El Hajbi, F; Etienne, PL; Faroux, R; François, E; Genet, D; Khemissa Akouz, F; Kirscher, S; Lavau-Denes, S; Lecomte, T; Locher, C; Maillard, E; Oden-Gangloff, A; Paillaud, E; Retornaz, F; Rinaldi, Y; Taieb, J | 1 |
| Arita, S; Baba, E; Esaki, T; Kajitani, T; Makiyama, A; Oda, H; Shimokawa, H; Shirakawa, T | 1 |
| Demonty, G; Köhne, CH; Koukakis, R; Peeters, M; Prenen, H; Rivera, F; Siena, S; Taieb, J | 1 |
| Alonso, V; Asensio, E; Camps, J; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Feliu, J; Fernández-Martos, C; Gaba, L; Gallego, J; García-Albéniz, X; Horndler, C; Jares, P; Marín-Aguilera, M; Martín-Richard, M; Martínez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Méndez, JC; Méndez, M; Montironi, C; Prat, A; Reig, O; Rojo, F; Rosell, R; Rubini, M; Salud, A; Victoria, I | 1 |
| Allen, PJ; Balachandran, VP; Boucher, T; Capanu, M; Cercek, A; Chou, JF; D'Angelica, MI; DeMatteo, RP; Jarnagin, WR; Kemeny, NE; Kingham, TP; Pak, LM | 1 |
| Chen, L; Huang, L; Lin, X; Xie, Y; Zheng, Q | 1 |
| Becker, T; Bemelmans, M; Bruns, CJ; Denecke, T; Folprecht, G; Gebauer, B; Heinemann, V; Held, S; Lang, H; Modest, DP; Modest, HI; Neumann, UP; Pratschke, J; Rentsch, M; Ricard, I; Seehofer, D | 1 |
| Bodoky, G; Ciuleanu, TE; Cohn, AL; Ferry, D; Garcia-Carbonero, R; Hozak, RR; Konrad, RJ; Melemed, SA; Muro, K; Nasroulah, F; Obermannova, R; Ouyang, H; Portnoy, DC; Prausová, J; Siegel, RW; Tabernero, J; Van Cutsem, E; Yoshino, T | 1 |
| Akagi, Y; Baba, H; Emi, Y; Maehara, Y; Miyamoto, Y; Ogata, Y; Oki, E; Saeki, H; Sakamoto, Y; Shimokawa, M; Tanaka, T; Tokunaga, S | 1 |
| Fan, H; Jiang, Y; Li, G; Li, X; Song, G; Wang, F | 1 |
| Allegrini, G; Bergamo, F; Boni, L; Buonadonna, A; Chiara, S; Cremolini, C; Dell'Aquila, E; Di Donato, S; Falcone, A; Fea, E; Lonardi, S; Marmorino, F; Masi, G; Racca, P; Ronzoni, M; Santini, D; Schirripa, M; Stellato, M; Tomasello, G; Tomcikova, D; Tonini, G; Urbano, F; Zaniboni, A; Zeppola, T | 1 |
| Al-Batran, SE; Ettrich, TJ; Feustel, HP; Heeger, S; Hofheinz, RD; Homann, N; Kripp, M; Lorenzen, S; Merx, K; Ocvirk, J; Schatz, M; Schulte, N; Schulz, H; Tetyusheva, M; Trojan, J; Vlassak, S | 1 |
| Eftekhar, E; Jaberi, H; Mansouri, A; Naghibalhossaini, F; Shefaghat, M; Tatar, M | 1 |
| Dong, Q; Gao, H; Huang, A; Jiang, T; Liu, H; Shi, L; Sun, X; Sun, Y; Wang, X; Wu, X | 1 |
| Antoniotti, C; Aprile, G; Bergamo, F; Boni, L; Cardellino, GG; Coltelli, L; Corsi, DC; Cremolini, C; Dell'Aquila, E; Di Fabio, F; Falcone, A; Fontanini, G; Gemma, D; Grande, R; Lonardi, S; Lupi, C; Mancini, ML; Marcucci, L; Marmorino, F; Masi, G; Mescoli, C; Ronzoni, M; Salvatore, L; Tonini, G; Zagonel, V | 1 |
| Artru, P; Bennouna, J; Ducreux, M; Lievre, A; Lledo, G | 1 |
| Baumann, AB; D'Anastasi, M; Heinemann, V; Hesse, N; Hofmann, FO; Holch, JW; Modest, DP; Reiser, MF; Ricard, I; Sommer, WH; Stintzing, S | 1 |
| Crathorne, L; Hoyle, M; Huxley, N; Napier, M; Snowsill, T; Tikhonova, IA; Varley-Campbell, J | 1 |
| Bando, H; Emi, Y; Iwamoto, S; Kagawa, Y; Kanazawa, A; Kato, T; Kotaka, M; Muro, K; Nakamura, M; Nakayama, G; Oki, E; Sakisaka, H; Taniguchi, H; Touyama, T; Tsuji, A; Yamaguchi, T; Yamanaka, T; Yamazaki, K; Yoshino, T | 1 |
| Aprile, G; Bergamo, F; Cardellino, GG; Cremolini, C; de Braud, F; Falcone, A; Fassan, M; Fontanini, G; Lonardi, S; Marmorino, F; Mazzaferro, V; Mennitto, A; Milione, M; Morano, F; Morelli, L; Pellegrinelli, A; Pietrantonio, F; Prisciandaro, M; Rossini, D; Schirripa, M; Urbani, L; Zucchelli, G | 1 |
| Price, TJ | 2 |
| Geredeli, C; Yasar, N | 1 |
| Antoniotti, C; Aprile, G; Bordonaro, R; Ciuffreda, L; Di Bartolomeo, M; Di Costanzo, F; Fasola, G; Frassineti, GL; Iaffaioli, V; Leone, F; Maiello, E; Marchetti, P; Pastorino, A; Sobrero, A; Zaniboni, A; Zilocchi, C | 1 |
| Ariotti, R; Berardi, G; De Man, M; Geboes, K; Hoorens, A; Laurent, S; Smeets, P; Tomassini, F; Troisi, RI; van Dorpe, J; Varin, O | 1 |
| Ehara, S; Eizuka, M; Hasegawa, Y; Ishida, K; Kato, K; Nitta, H; Osakabe, M; Otsuka, K; Sasaki, A; Sugai, T; Tamura, A; Uesugi, N | 1 |
| Antoniotti, C; Astrow, SH; Berger, MD; Cremolini, C; Falcone, A; Hanna, DL; Lenz, HJ; Li, M; Loupakis, F; Matsusaka, S; Miyamoto, Y; Moran, M; Ning, Y; Salvatore, L; Schirripa, M; Yang, D; Zeger, G; Zhang, W | 1 |
| Elbadawy, M; Hazama, S; Kaneda, M; Nagano, H; Nakajima, M; Ohama, T; Sakurai, M; Sasaki, K; Sato, K; Suzuki, N; Takenouchi, H; Tsunedomi, R; Umata, K; Usui, T; Yamawaki, H | 1 |
| Aparicio, T; Ghebriou, D; Guetz, GD; Landre, T; Maillard, E; Taleb, C; Zelek, L | 1 |
| Evert, M; Fest, P; Fichtner-Feigl, S; Gerken, M; Herr, W; Klinkhammer-Schalke, M; Munker, S; Ott, C; Reng, M; Schlitt, HJ; Schnoy, E; Stroszczynski, C; Teufel, A; Vogelhuber, M; Wiggermann, P | 1 |
| Albrecht, MH; Gruber-Rouh, T; Hammerstingl, R; Lahrsow, M; Thompson, ZM; Vogl, TJ | 1 |
| Bruno, R; Claret, L; Karovic, S; Maitland, ML; Pentafragka, C; Schwartz, LH; Zhao, B | 1 |
| Chen, J; Feng, J; Huang, L; Liu, B; Peng, P; Qiu, H; Xie, C; Yu, Q; Yuan, X; Zang, A; Zhang, T | 1 |
| Bi, F; Cao, D; Chen, Y; Gou, H; Li, Z; Peng, Y; Yang, Y; Zhang, X | 1 |
| Aparicio, T; Baconnier, M; Barbier, E; Bedenne, L; Bouché, O; El Hajbi, F; Etienne, PL; Faroux, R; Francois, E; Genet, D; Khemissa Akouz, F; Kirscher, S; Lavau-Denes, S; Lecomte, T; Locher, C; Oden-Gangloff, A; Paillaud, E; Retornaz, F; Rinaldi, Y; Taieb, J | 1 |
| Barone, C; Bilancia, D; Calegari, MA; Cassata, A; Corsi, D; Damato, A; Daniele, B; Di Costanzo, F; Fenizia, F; Ferrau, F; Frassinetti, GL; Gori, S; Iaffaioli, RV; Maiello, E; Normanno, N; Orlandi, A; Pinto, C; Pisconti, S; Repetto, L; Soto Parra, H; Tamburini, E; Tonini, G; Zampino, MG; Zaniboni, A | 1 |
| Kopetz, S | 1 |
| Cao, S; Heinemann, V; Jelas, I; Lenz, HJ; McSkane, M; Naseem, M; Puccini, A; Stintzing, S | 1 |
| Chen, M; Chen, W; Dai, Z; Gao, C; Liang, X; Wang, J; Wang, S; Zhang, N; Zhao, B; Zhao, R | 1 |
| Bekaii-Saab, TS; Cohn, AL; El-Rayes, BF; Fernando, NH; Goldberg, RM; Grogan, W; Horgan, AM; Ivanova, A; Kasbari, SS; Kim, RD; Leonard, G; McCaffrey, J; McDermott, R; Moore, DT; O'Neil, BH; O'Reilly, S; Olowokure, OO; Ryan, T; Sanoff, HK; Sherrill, GB; Yacoub, GH; Zamboni, W | 1 |
| Harty, G; Jarrett, J; Jofre-Bonet, M | 1 |
| Burge, M; Dean, AP; Eastgate, M; Gibbs, P; Kosmider, S; Lee, B; Lee, M; Lok, SW; Ma, B; Semira, C; Shapiro, J; Steel, SA; Torres, J; Wong, HL; Wong, R; Zimet, AS | 1 |
| Abel, U; Apostolidis, L; Berger, AK; Dietrich, M; Freitag, A; Giesel, F; Grüllich, C; Haag, GM; Haberkorn, U; Jäger, D; Lordick, F; Lücke, S; Ose, J; Stange, A; Trierweiler, C; von Gall, C; Weber, TF | 1 |
| Carriquiriborde, M; Gentil, F; Gentili, C; Gigola, G; Martín, MJ; Zwenger, A | 1 |
| Chen, CQ; Ding, HW; Li, DD; Ren, TS; Wang, J; Wu, Q; Zhao, CH; Zhao, QC | 1 |
| Deng, W; Hu, R; Liang, L; Shen, L; Wang, Y; Yang, L; Yang, W; Yao, Y; Zhang, H; Zhang, J; Zhang, Z; Zhou, M | 1 |
| Abraham, I; Bartels, T; Eckstrom, J; Elquza, E; Hollings, J; Malangone, S; McBride, A; Patel, H; Scott, AJ | 1 |
| Chen, X; Lin, H; Shui, L; Shui, P; Sun, Q; Wu, YS | 1 |
| Atis, S; Combès, E; Del Rio, M; Gabanou, M; Gongora, C; Jarlier, M; Larbouret, C; Martineau, P; Mollevi, C; Pérez-Gracia, E; Torro, A; Tosi, D; Vié, N | 1 |
| Gaston-Mathe, Y; Grisoni, ML; Heinemann, V; Jung, A; Laurent-Puig, P; Liebaert, F; Montestruc, F; Neureiter, D; Stintzing, S; Thiébaut, R | 1 |
| Ba, Y; Bai, Y; Bi, F; Fan, N; Li, J; Lim, R; Liu, T; Ma, B; Magherini, E; Pan, H; Qin, S; Shen, L; Shi, D; Tsuji, A; Wei, V; Xu, J; Xu, R; Yeh, KH; Zhang, S | 1 |
| Ai, X; Du, H; Hou, X; Huang, Y; Jiang, J; Li, H; Liu, Y; Lu, L; Quan, X; Sun, L; Wang, P; Wei, X; Yuan, S; Zhan, M | 1 |
| Aranda, E; Benavides, M; Durán, G; Falcó, E; García-Alfonso, P; Gómez, A; López, R; López-Ladrón, A; Montagut, C; Muñoz, A; Rivera, F; Ruiz de Mena, I; Salgado, M; Sastre, J | 1 |
| Aliberti, C; Carandina, R; Felicioli, A; Fiorentini, G; Guadagni, S; Mulazzani, L; Sarti, D | 1 |
| Casadó, A; Mora, M; Sagristá, ML | 1 |
| Abdalla, KC; Bondarenko, I; Del Campo García, A; Franke, F; Huerga, C; Melo Cruz, F; Mendonça Bariani, G; Millán, S; Ostwal, V; Paravisini, A; Peredpaya, S; Rahuman, SA; Ramesh, A; Roca, E; Romera, A; Shah, P; Shparyk, Y | 1 |
| Cai, Y; Deng, R; Deng, Y; Hu, H; Li, J; Ling, J; Wu, Z; Yang, L; Zhang, J | 1 |
| Dote, S; Hira, D; Itakura, S; Kamei, K; Kobayashi, Y; Noda, S; Terada, T | 1 |
| Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Heinemann, V; Lenz, HJ; Lo, JH; Loupakis, F; Millstein, J; Naseem, M; Puccini, A; Soni, S; Stintzing, S; Tokunaga, R; Zhang, W | 1 |
| Esna-Ashari, O; Fathi-Azarbayjani, A; Kheradmand, F; Malekinejad, H; Mohammadian, M; Rasmi, Y; Zeynali-Moghaddam, S | 1 |
| Bodoky, G; Ciuleanu, T; Cohn, AL; García-Alfonso, P; Garcia-Carbonero, R; Grothey, A; Hozak, RR; Kim, TW; Lonardi, S; Muro, K; Nasroulah, F; O'Connor, J; Obermannová, R; Portnoy, DC; Prausová, J; Tabernero, J; Taieb, J; Van Cutsem, E; Wijayawardana, SR; Yamaguchi, K; Yamazaki, K; Yoshino, T | 1 |
| Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Freiberg-Richter, J; Giessen-Jung, C; Graeven, U; Heinemann, V; Held, S; Jung, A; Kirchner, T; Modest, DP; Peuser, B; Peveling Genannt Reddemann, C; Schenk, M; Schuch, G; Schwaner, I; Stahler, A; Stintzing, S; Uhlig, J; Vehling-Kaiser, U | 1 |
| Bendardaf, R; Pyrhönen, S; Sharif-Askari, FS; Sharif-Askari, NS; Syrjänen, K | 1 |
| Hsu, CW; Kuo, WT; Lin, HY | 1 |
| Adán, A; Castellà, C; Eixarch, A; Reguart, N; Saint-Jean, A; Sainz-de-la-Maza, M; Sánchez-Dalmau, B | 1 |
| Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Holch, JW; Jelas, I; Kahl, C; Kiani, A; Kullmann, F; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Vehling-Kaiser, U; von Einem, JC; Westphalen, CB | 1 |
| Beck, JT; Berlin, JD; Cubillo Gracian, A; Deming, DA; Elez Fernandez, E; Garcia-Alfonso, P; Gorbunova, V; Hofheinz, RD; Luo, Y; Mangel, L; Nechaeva, M; Ramanathan, RK; Sullivan, D; Torres, AH | 1 |
| Borelli, B; Masi, G | 1 |
| Burt, A; Chen, EY; Donovan, J; Kampa-Schittenhelm, KM; Kearney, MR; Lopez, CD; Strother, J; Todd, K; Vaccaro, GM | 1 |
| Aikawa, T; Akashi, K; Ariyama, H; Baba, E; Doi, Y; Esaki, T; Ito, M; Kobayashi, K; Kusaba, H; Makiyama, A; Mitsugi, K; Shimokawa, H; Takayoshi, K; Tsuchihashi, K; Uenomachi, M; Yoshihiro, T | 1 |
| Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O | 2 |
| Cai, J; Li, N; Sui, Y; Sun, H; Wei, X; Xu, C; Zhang, G; Zheng, B; Zhuang, J | 1 |
| Akbulut, H; Dost Gunay, FS; Ensari, A; İcli, F; Kırmızı, BA | 1 |
| Bjorklof, K; Buchler, T; Csoszi, T; Demonty, G; Hebart, H; Kafatos, G; Kiehl, M; Koukakis, R; Kuhn, A; Tomasek, J | 1 |
| Covela Rúa, M; de la Cámara Gómez, J; Fernández Montes, A; García Gómez, J; González Villaroel, P; Graña Suárez, B; Jorge Fernández, M; Luz Pellón Augusto, M; Martínez Lago, N; Méndez Méndez, JC; Quintero Aldana, G; Reboredo López, M; Salgado Fernández, M | 1 |
| Ahmed, A; Kozma, K; Patel, S; Rezkallah, KNM | 1 |
| Auby, D; Azzedine, A; Borget, I; Bouché, O; Denis, B; Ducreux, M; Etienne, PL; Gargot, D; Gasmi, M; Geoffroy, P; Lacas, B; Lepage, C; Lombard-Bohas, C; Michel, P; Pignon, JP; Texereau, P | 1 |
| Dai, G; Gou, M; Jia, J; Qian, N; Yang, F; Zhang, P | 1 |
| Aranda, E; Azuara, D; Bugés, C; Capellá, G; Durán, G; Élez, E; Falcó, E; García-Alfonso, P; López-López, C; Navarro, V; Páez, D; Robles-Díaz, L; Salazar, R; Salud, A; Santos, C; Valladares, M; Viéitez, JM | 1 |
| Arai, H; Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Heinemann, V; Lenz, HJ; Liang, G; Lo, JH; Loupakis, F; Mancao, C; Millstein, J; Mumenthaler, SM; Naseem, M; Puccini, A; Salhia, B; Soni, S; Stintzing, S; Tokunaga, R; Weisenberger, DJ; Zhang, W | 1 |
| Abbati, F; Brandi, G; Brocchi, S; De Lorenzo, S; Frega, G; Palloni, A; Rizzo, A | 1 |
| Gallego, I; García, G; García-Alfonso, P; Lloansí, A; Muñoz, A; Ortega, L; Sandoval, C; Torres, G | 1 |
| Çiçin, I; Demircan, NC; Erdoğan, B; Eslame, H; Gökyer, A; Hacıoğlu, MB; Köstek, O; Küçükarda, A; Solak, S; Sunal, BS; Tunçbilek, N; Uzunoğlu, S; Yılmaz, E | 1 |
| Chin, K; Ichimura, T; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Ota, Y; Shinozaki, E; Suenaga, M; Suzuki, T; Takahari, D; Wakatsuki, T; Yamaguchi, K | 1 |
| Haratani, K; Hayashi, H; Kato, R; Kawakami, H; Maenishi, O; Nakagawa, K; Nonagase, Y; Takeda, M; Takegawa, N; Tsurutani, J; Yonesaka, K | 1 |
| Aparicio, T; Barbier, E; Ben Abdelghani, M; Bennouna, J; Boige, V; Borel, C; Bouché, O; Desseigne, F; Dohan, A; Faroux, R; François, E; Gallix, B; Genet, D; Ghiringhelli, F; Guiu, B; Hoeffel, C; Jacquot, S; Jouve, JL; Khemissa-Akouz, F; Le Malicot, K; Lepage, C; Phelip, JM; Reinhold, C; Rinaldi, Y; Seitz, JF; Soyer, P; Suc, E; Taieb, J; Texereau, P | 1 |
| Argilés Martínez, G; Carmona-Bayonas, A; Castañón López, C; Fernández Montes, A; Gallego Plazas, J; García Paredes, B; Gutiérrez Abad, D; Jiménez Fonseca, P; Juez Martel, I; Llorente Ayala, B; López Doldán, MC; López Flores, M; López López, C; López Muñoz, AM; Martínez de Castro, E; Páez López, D; Sánchez Cánovas, M; Tobeña Puyal, M | 1 |
| Ahmad, SM; Chakraborty, S; Dinesh Kumar, L; Faheem, MM; Gandhi, SG; Golani, A; Goswami, A; Jamwal, VL; Jose, J; Katoch, A; Kumar, A; Kumar, R; Nayak, D; Rasool, RU | 1 |
| Block, C; Gorsuch, K; Gupta, D; Hill, D; Vashi, PG; Wan, L | 1 |
| Aparicio, J; Bordonaro, R; Bury, D; Chau, I; Cicin, I; Di Bartolomeo, M; Drea, E; Fedyanin, MY; García-Alfonso, P; Heinemann, V; Karthaus, M; Kavan, P; Ko, YJ; Maiello, E; Martos, CF; Peeters, M; Picard, P; Riechelmann, RP; Sobrero, A; Srimuninnimit, V; Ter-Ovanesov, M; Yalcin, S | 1 |
| Han, Y; Li, YH; Liang, JY; Liu, W; Wang, K; Xing, BC | 1 |
| Berkhout, M; Gallego, J; Hofheinz, RD; Karthaus, M; Köhne, CH; Koukakis, R; Mineur, L; Thaler, J; Van den Eynde, M | 1 |
| Beckert, S; Horvath, P; Königsrainer, A; Königsrainer, I; Nadalin, S | 1 |
| Kanno, M; Kichikawa, K; Koyama, F; Marugami, N; Masada, T; Nishiofuku, H; Otsuji, T; Sato, T; Sho, M; Tanaka, T; Tatsumoto, S | 1 |
| Baranyai, ZS; Besznyák, I; Bursics, A; Dede, K; Jakab, F; Landherr, L; Mersich, T; Salamon, F; Zaránd, A | 1 |
| Gong, C; Liu, L; Ma, X; Qian, Z; Wei, Y; Wu, Q; Xiong, D; Zhao, X | 1 |
| Berlin, J; Chan, E; Ciombor, KK | 1 |
| Amptoulach, S; Gritzapis, AD; Karadima, ML; Kosmas, C; Skopelitis, E; Tsavaris, N; Voutsas, IF; Xynos, ID | 1 |
| Aparicio, T; Bouché, O; Breysacher, G; Charneau, J; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Le Brun-Ly, V; Lecomte, T; Locher, C; Mitry, E; Ramdani, M; Seitz, JF; Stefani, L; Subtil, F; Teillet, L | 1 |
| Arnold, D; Dietrich, G; Freier, W; Geißler, M; Graeven, U; Hegewisch-Becker, S; Hinke, A; Kubicka, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schmoll, HJ; Tannapfel, A | 1 |
| Fischer von Weikersthal, L; Giessen, C; Haas, M; Heinemann, V; Laubender, RP; Mansmann, UR; Modest, DP; Schalhorn, A; Stintzing, S | 1 |
| Grillo, E; Jaén, P; Longo, F; Vañó-Galván, S | 1 |
| Auby, D; Bouché, O; Ducreux, M; Etienne, PL; Michiels, S; Pénichoux, J; Pignon, JP; Rougier, P; Texereau, P | 1 |
| Boix, O; Ehrenberg, R; Fischer, R; Folprecht, G; Hacker, UT; Hamann, S; Köhne, CH; Kornacker, M; Krauss, J; Kuhlmann, J; Lettieri, J; Mross, KB; Schultheis, B; Strumberg, D | 1 |
| Burge, M; Clarke, S; Cordwell, C; Gibbs, P; Reece, W; Tebbutt, N | 1 |
| Choo, SP; Chuah, BYS; Cohn, AL; Cottrell, S; Dubey, S; Galimi, F; Hei, YJ; Kopp, MV; Loberg, R; Maurel, J; McCaffery, I; Mitchell, EP; Nowara, E; Pan, Y; Sakaeva, DD; Sastre, J; Suzuki, S; Tabernero, J | 1 |
| Andersen, RF; Havelund, BM; Jakobsen, AK; Lassen, U; Pallisgaard, N; Ploen, J; Sorensen, MM; Spindler, KL | 1 |
| Cheng, D; Kuang, Q; Liu, G; Liu, X; Xu, W | 2 |
| Koopman, M; Mol, L; Ottevanger, PB; Punt, CJ; van Gils, CW | 1 |
| Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J | 1 |
| Bellet, D; Bièche, I; Cottu, P; Dangles-Marie, V; Guinebretière, JM; Laurendeau, I; Marangoni, E; Massonnet, G; Nemati, F; Richon, S; Vacher, S; Validire, P; Weiswald, LB | 1 |
| El-Rayes, B; Gao, H; Landry, J; Shelton, JW; Shu, HK; Wang, L; Waxweiler, TV; Xu, Y | 1 |
| Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohnishi, T; Ohue, M; Ota, H; Sekimoto, M; Takemasa, I; Tanaka, N; Uemura, Y; Yamamoto, H | 1 |
| Cortejoso, L; Escolar, F; García, MI; García-Alfonso, P; González-Haba, E; López-Fernández, LA; Sanjurjo, M | 1 |
| Bastian, G; Escargueil, AE; Guérin, E; Larsen, AK; Ouaret, D; Petitprez, A; Poindessous, V; Regairaz, M | 1 |
| Albino, V; Aloj, L; Caracò, C; Daniele, G; de Lutio di Castelguidone, E; Delrio, P; Giordano, P; Iaffaioli, RV; Izzo, F; Lastoria, S; Nasti, G; Ottaiano, A; Palaia, R; Piccirillo, MC; Romano, C; Romano, G | 1 |
| Cattan, S; Desauw, C; Hebbar, M; Piessen, G; Pruvot, FR; Sergent-Baudson, G; Truant, S | 1 |
| Alcindor, T; Moreau, LC; Rajan, R; Thirlwell, MP | 1 |
| Boxberger, F; Dörje, F; Harich, HD; Hohenberger, W; Koch, S; Neurath, MF; Siebler, J; Wein, A | 1 |
| Liu, TS; Qin, XY; Ren, L; Wei, Y; Xu, B; Xu, J; Ye, LC; Ye, QH; Yu, Y; Zai, SY; Zhu, DX | 1 |
| Hendel, HW; Jensen, BV; Nielsen, D; Skougaard, K | 1 |
| Cassidy, J; Hochster, H | 1 |
| Cervantes, A; de Gramont, A; Schmoll, HJ; Tournigand, C | 1 |
| Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG; Sym, SJ | 1 |
| Goel, S; Mani, S; Swami, U | 1 |
| Fukami, K; Hasegawa, J; Hirose, K; Kaneda, N; Kitamura, M; Maeda, Y; Maruo, E; Takada, H; Yamashita, K | 1 |
| Allen, TM; Anantha, M; Bally, MB; Dos Santos, N; Harasym, N; Hare, JI; Neijzen, RW; Waterhouse, DN; Webb, MS | 1 |
| Filip, S; Grim, J; Paulík, A | 1 |
| Ceelen, W; De Bruyne, S; Geboes, K; Goethals, I; Laurent, S; Mertens, J; Peeters, M; Smeets, P; Troisi, R; Van Damme, N; Van de Wiele, C | 1 |
| Jiao, SC; Li, JY; Wen, XY; Wu, LL; Zhang, GQ; Zhao, H | 1 |
| Arora, G; Barbery, K; Guerrero, G; Narayanan, G; Suthar, R | 1 |
| Akiyoshi, K; Furuta, K; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Shimada, Y; Taniguchi, H; Yamada, Y | 1 |
| Bruno, R; Claret, L; Gupta, M; Han, K; He, J; Joshi, A; Powell, B; Sarapa, N | 1 |
| Aprile, G; Bergamo, F; Bracarda, S; Cremolini, C; Falcone, A; Fontanini, G; Fornaro, L; Lonardi, S; Loupakis, F; Lupi, C; Masi, G; Morvillo, M; Salvatore, L; Schirripa, M; Sensi, E; Vivaldi, C; Zagonel, V; Zaniboni, A | 1 |
| Huppert, P; Wenzel, T; Wietholtz, H | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX | 1 |
| André, T; Bennamoun, M; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Pruvot, FR; Smith, D | 1 |
| Gao, J; Jia, R; Li, Y; Lu, M; Shen, L; Zhou, J | 1 |
| Antoniotti, C; Caparello, C; Cremolini, C; Falcone, A; Funel, N; Loupakis, F; Marmorino, F; Masi, G; Morvillo, M; Pollina, L; Salvatore, L; Schirripa, M; Vasile, E | 1 |
| Graham, J; Lindsay, CR; Roxburgh, P | 1 |
| Asada, K; Hamaguchi, T; Ito, Y; Iwasa, S; Kato, K; Shimada, Y; Ushijima, T; Yamada, Y | 1 |
| Aksu, G; Bilici, A; Cabuk, D; Gumus, M; Kaya, S; Oven Ustaalioglu, BB; Seker, M; Temiz, S; Uygun, K; Yildiz, R | 1 |
| Eng, C | 3 |
| Benstead, K; Brown, SR; Chambers, P; Chau, I; Dawson, L; Falk, S; Gwyther, S; Hill, M; Lowe, C; Maisey, N; Marshall, H; Maughan, T; Middleton, G; Napp, V; O'Callaghan, A; Oliver, A; Quirke, P; Richman, S; Seligmann, JF; Seymour, MT; Wadsley, J | 1 |
| de Gramont, A; Green, E; Haller, DG; McCleary, NJ; Meyerhardt, JA; O'Connell, M; Saltz, LB; Sargent, DJ; Twelves, CJ; Van Cutsem, E; Yothers, G | 1 |
| Chen, Q; Du, L; Hao, JJ; Jin, HJ; Li, BW; Liu, HM; Rao, GH; Wang, J; Wang, MR; Wang, XH; Yang, YL | 1 |
| Arrowsmith, ER; Bajetta, E; Del Prete, SA; Fuchs, CS; Hwang, J; Jin, J; Malek, K; Ng, K; Ryan, DP; Sedova, M; Sharma, S; Tabernero, J | 1 |
| Carr, DF; Fenwick, SW; Ghaneh, P; Greensmith, RM; Hamlett, J; Jenkins, R; Jones, RP; Kitteringham, NR; Malik, HZ; O'Grady, E; Park, BK; Poston, GJ; Rowe, C; Santoyo-Castelazo, A; Sutton, P; Terlizzo, M | 1 |
| Barni, S; Beretta, GD; Borgonovo, K; Cabiddu, M; Ghilardi, M; Lonati, V; Maspero, F; Petrelli, F; Sauta, MG | 1 |
| Biasco, G; Brandi, G; de Rosa, F; Derenzini, E; Di Girolamo, S; Ercolani, G; Falcone, A; Grazi, GL; Loupakis, F; Masi, G; Pantaleo, MA; Pietrabissa, A; Pinna, AD | 1 |
| Alvarez Suarez, S; Blanco Codeidido, M; García Alfonso, P; López Martín, P; Martin, M; Mondejar Solis, R; Muñoz Martin, A; Tapia Rico, G | 1 |
| Boers-Sonderen, MJ; Desar, IM; Koopman, M; Punt, CJ; van Herpen, CM | 1 |
| Ashkenazi, A; Beachler, C; El-Deiry, WS; Gusani, N; Lim, B; Portera, C; Sarwani, N; Scicchitano, A; Staveley-O'Carroll, K; Yang, Z | 1 |
| El-Deiry, WS; Lamparella, NE; Saroya, BS; Sarwani, NE; Yang, Z | 1 |
| Thomas, AL; Walter, H | 1 |
| Dang, YZ; Gao, J; Li, J; Li, YY; Shen, L; Sun, ZW; Wang, XC | 1 |
| Antoniotti, C; Basolo, F; Bocci, G; Canu, B; Cremolini, C; Danesi, R; Di Desidero, T; Di Paolo, A; Falcone, A; Faviana, P; Fioravanti, A; Fontanini, G; Loupakis, F; Lupi, C; Masi, G; Orlandi, P; Salvatore, L; Schirripa, M; Sensi, E | 1 |
| Dufas, T; Eichler, K; Gruber-Rouh, T; Hammerstingl, R; Vogl, TJ; Zangos, S | 1 |
| Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Dréanic, J; Goldwasser, F; Maillet, M; Mir, O | 2 |
| Barni, S; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F; Zaniboni, A | 1 |
| Antoniotti, C; Aprile, G; Benhaim, L; Bohanes, P; Cremolini, C; De Vita, F; Falcone, A; Graziano, F; Lenz, HJ; Lonardi, S; Loupakis, F; Lucchesi, S; Ronzoni, M; Ruzzo, A; Salvatore, L; Schirripa, M; Tonini, G; Wakatsuki, T; Yang, D; Zhang, W | 1 |
| Abe, H; Abe, M; Hirata, T; Mafune, K; Minamimura, K; Umemura, A | 1 |
| Akatsuka, S; Arioka, H; Azuma, T; Egawa, M; Hibi, K; Ito, T; Kenmochi, T; Koizumi, W; Nagashima, A; Nemoto, H; Sasaki, T; Shimada, K; Soda, H; Takinishi, Y | 1 |
| Lam, VW; Laurence, JM; Richardson, AJ | 1 |
| Cai, X; Cao, W; Ding, H; Liu, T; Wang, L; Wang, M; Xu, Q; Zhao, Z; Zhong, M; Zhou, X | 1 |
| Chen, JS; Chou, WC; Hsu, HC; Liau, CT; Lin, YC; Shen, WC; Wu, CE; Yang, TS | 1 |
| Araki, A; Eto, R; Hazama, S; Hinoda, Y; Kanekiyo, S; Kondo, H; Nagashima, A; Oka, M; Okayama, N; Shimizu, R; Uchiyama, T; Yamamoto, T; Yoshida, S; Yoshino, S | 1 |
| Doi, T; Feng, HP; Fuse, N; Muro, K; Noguchi, K; Ohtsu, A; Shimamoto, T; Takahari, D; Ura, T; Yoshino, T | 1 |
| Andersen, RF; Christensen, Rd; Hansen, TF; Jakobsen, A; Johnsson, A; Sørensen, FB | 1 |
| Dunne, DF; Fenwick, SW; Jones, RP; Malik, HZ; O'Grady, E; Poston, GJ; Smethurst, A; Stättner, S; Terlizzo, M | 1 |
| Chiou, YC; Lee, PC; Peng, CL; Shieh, MJ; Wong, JM | 1 |
| Blake, D; Bridgewater, J; Brown, S; Chau, I; Gollins, S; Gwyther, S; Hill, M; Lowe, C; Maisey, N; Marshall, H; Maughan, T; Middleton, G; Myint, S; Napp, V; Oliver, A; Richman, S; Seymour, M; Slater, S; Wadsley, J; Wagstaff, J | 1 |
| Baiget, M; Barnadas, A; Berenguer-Llergo, A; Del Río, E; Lasa, A; Martín-Richard, M; Páez, D; Paré-Brunet, L; Salazar, J; Sebio, A; Tobeña, M | 1 |
| Assenat, E; Causse, A; Del Rio, M; Evrard, A; Gongora, C; Jarlier, M; Leconet, W; Martineau, P; Mazard, T; Robert, B; Simony, J; Torro, A; Vezzio-Vie, N; Ychou, M | 1 |
| Fischer von Weikersthal, L; Giessen, C; Heinemann, V; Laubender, RP; Modest, DP; Schalhorn, A; Schulz, C; Stintzing, S | 1 |
| Baek, JY; Jung, KH; K Shim, E; Kim, SY; Kong, SY; S Hong, Y; Shin, A | 1 |
| Bray, C; Celik, I; Chang, SC; Denne, J; Green, G; Harbison, C; Horak, C; Khambata-Ford, S; Van Cutsem, E; Zhao, L | 1 |
| Hong, YS; Jung, KH; Kim, SY; Kong, SY; Lim, HS; Park, SR; Park, YI; Seong, MW | 1 |
| Xu, JM | 1 |
| Fu, YL; Ge, FJ; Li, SS; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Yao, K; Zhao, CH | 1 |
| Burtness, B; Chun, YS; Cohen, SJ; Hall, MJ; Nagorney, DM; Sigurdson, ER; Thomay, AA; Truty, MJ | 1 |
| Chen, CP; Chen, HH; Chen, JS; Hsieh, RK; Huang, CC; Huang, JS; Huang, WT; Hwang, WS; Jeng, HH; Kao, RH; Lee, YC; Lin, CJ; Lin, PC; Lu, YC; Uen, WC; Wang, HM; Wu, HC; Yeh, CH | 1 |
| Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Mattia, E; Dreussi, E; Polesel, J; Toffoli, G; Zagonel, V | 1 |
| Korovina, IaV; Nasyrov, AR; Pirtskhalava, TL | 2 |
| Ando, H; Fujita, Y; Hamamoto, Y; Hazama, S; Hinoda, Y; Inoue, Y; Kanekiyo, S; Kato, T; Kobayashi, M; Mishima, H; Nagata, N; Nozawa, H; Oba, K; Oka, M; Okayama, N; Okuyama, Y; Sakamoto, J; Takahashi, K; Takemoto, H; Tsunedomi, R | 1 |
| Boige, V; Borget, I; Caramella, C; Dromain, C; Ducreux, M; Dumont, F; Elias, D; Farron, M; Goéré, D; Honoré, C; Malka, D; Pottier, E | 1 |
| Capussotti, L; De Rosa, G; De Saussure, WO; Mentha, G; Rubbia-Brandt, L; Viganò, L | 1 |
| Allegra, C; Hoyle, M; Iqbal, SU; Joulain, F; Proskorovsky, I; Tabernero, J; Van Cutsem, E | 1 |
| André, T; Chibaudel, B | 1 |
| Saif, MW | 2 |
| Akiyama, Y; Aoki, T; Fujii, M; Hagiwara, K; Hironaka, K; Kochi, M; Nakajima, T; Osuka, F; Takahashi, T; Takeuchi, M; Teranishi, F | 1 |
| Alvarez, E; Campos, B; Candamio, S; Casal, J; Gallardo, E; Grande, C; Mel, JR; París Bouzas, L; Quintero, G; Villanueva, MJ | 1 |
| Alameddine, R; Mukherji, D; Shamseddine, A; Temraz, S | 1 |
| Beeke, C; Bishnoi, S; Karapetis, CS; Maddern, G; Padbury, R; Padman, S; Price, TJ; Townsend, AR | 1 |
| Bekaii-Saab, TS; Buchbinder, A; Clive, S; Fisher, GA; Garrett, CR; Goldberg, RM; Kavan, P; Ryan, T; Shacham-Shmueli, E | 1 |
| Cereda, V; di Bari, MG; Ferroni, P; Formica, V; Grenga, I; Guadagni, F; Raffaele, P; Roselli, M; Tesauro, M | 1 |
| Guren, T; Ikdahl, T; Kjersem, JB; Kure, EH; Lingjaerde, OC; Tveit, KM | 1 |
| Baba, H; Chika, N; Fukuchi, M; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Mochiki, E; Okada, N; Tajima, Y; Yokoyama, M | 1 |
| Bellister, S; Bhattacharya, R; Bollu, LR; Dupre, E; Ellis, LM; Fan, F; Gao, G; Lu, J; Tozzi, F; Weihua, Z; Xia, L; Ye, X; Zhou, Y | 1 |
| Antoniotti, C; Bergamo, F; Brunetti, I; Cremolini, C; Falcone, A; Fontanini, G; Lonardi, S; Loupakis, F; Lupi, C; Masi, G; Michelucci, A; Pfanner, E; Salvatore, L; Schirripa, M; Sensi, E; Simi, P; Zagonel, V | 1 |
| Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA | 1 |
| Cai, J; Chen, J; Dai, J; Feng, J; Ge, S; Huang, L; Li, M; Liao, X; Ma, H; Qin, K; Wang, Q; Xie, C; Yu, Q; Yuan, X; Zang, A; Zhang, T | 1 |
| Arimoto, A; Iwamoto, S; Kanazawa, A; Kataoka, K; Kato, T; Nakajima, A | 1 |
| Ba, Y; Bai, YX; Deng, T; Han, Y; Li, YH; Liu, XJ; Wang, Y; Xu, JM; Zhang, L | 1 |
| Albert-Mari, A; Jimenez-Torres, NV; Ruiz-Millo, O; Sendra-Garcia, A | 1 |
| Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA | 1 |
| Chen, X; He, D; Huang, T; Luo, W; Tan, X; Wang, C; Wang, R; Wu, X; Yu, Y; Zeng, X | 1 |
| Barbier, O; Bigo, C; Chen, S; Karin, M; Nguyen, N; Tukey, RH; Wang, K; Yueh, MF | 1 |
| Giessen, C; Heinemann, V; Laubender, RP; Modest, DP; Quietzsch, D; Schalhorn, A; Schulz, C; Stintzing, S; Vehling-Kaiser, U; von Einem, JC; von Weikersthal, LF | 1 |
| Ford, JM; McPherson, LA; Shen, Y | 1 |
| Ahn, JB; Baik, SH; Choi, GH; Choi, JS; Jung, M; Kim, H; Kim, NK; Min, BS; Shin, SJ; Yi, JH | 1 |
| Lenz, HJ; Stintzing, S | 1 |
| Bruera, G; Cannita, K; Ficorella, C; Giordano, AV; Ricevuto, E; Vicentini, R | 2 |
| Brünner, N; Christensen, IJ; Nielsen, HJ; Nielsen, SL; Nygård, SB; Spindler, KL | 1 |
| Andersen, RF; Appelt, AL; Jakobsen, A; Pallisgaard, N; Spindler, KG | 1 |
| Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Hiraki, M; Isohashi, F; Mizushima, T; Mori, M; Nishimura, J; Ogawa, K; Ohtsuka, M; Shiomi, H; Takemasa, I; Uemura, M; Yamamoto, H; Yoshioka, Y | 1 |
| Ferry, D; Fournier, M; Gebski, V; Gordon, S; Karapetis, CS; Price, TJ; Ransom, D; Simes, RJ; Tebbutt, N; Wilson, K; Yip, D | 1 |
| Bécouarn, Y; Bénichou, J; Bernard, O; Fourrier-Réglat, A; Guimbaud, R; Moore, N; Noize, P; Ravaud, A; Rouyer, M; Smith, D | 1 |
| Choi, ZS; Kim, DY; Kim, YB; Lee, JH; Lee, MY; Oh, SY; Paek, TY; Suh, KW | 1 |
| Besznyák, I; Bursics, A; Dede, K; Fekete, A; Kőszegi, G; Láng, I; Mersich, T; Mester, G; Pörneczi, B | 1 |
| Elias, D; Eveno, C; Gayat, E; Glehen, O; Goéré, D; Passot, G; Pocard, M; Soyer, P | 1 |
| Hyodo, I; Komatsu, Y; Machida, N; Ohtsu, A; Onuma, H; Sasaki, T; Yachi, Y; Yamazaki, K; Yoshino, T; Yuki, S | 1 |
| Cai, S; Li, W; Sun, M; Yu, Q; Zhang, W; Zhang, Z; Zhao, J; Zhu, D | 1 |
| Adams, R; Becker, M; Bhargava, A; Ellinghaus, P; Hoffmann, J; Kahmann, N; Müller, T; Rosenthal, A; Schmieder, R; Scholz, A; Thierauch, KH; Wilhelm, SM; Zopf, D | 1 |
| Chang, SC; Chen, WS; Chiou, SH; Jiang, JK; Lan, YT; Lin, CC; Lin, JK; Lin, TC; Wang, HS; Yang, SH | 1 |
| André, T; Cervantes, A; Chan, E; Ciuleanu, TE; Ducreux, M; Hotko, Y; Lordick, F; Peeters, M; Price, TJ; Punt, CJ; Roman, L; Sidhu, R; Sobrero, AF; Strickland, AH; Tian, Y; Van Cutsem, E; Wilson, G | 1 |
| Jiang, W; Li, Y; Liu, J; Ma, D; Yang, D | 1 |
| Bakrin, N; Cotte, E; Gilly, FN; Glehen, O; Passot, G; Roux, AS; Vaudoyer, D | 1 |
| Borg, C; Cléau, D; Curtit, E; Demarchi, M; Dobi, E; Fratte, S; Guiu, B; Heyd, B; Jary, M; Kim, S; Lakkis, Z; Lamfichekh, N; Monnien, F; Nerich, V; Nguyen, T | 1 |
| Doi, T; Fuse, N; Hamamoto, Y; Hatake, K; Iwasaki, J; Matsumoto, H; Mizunuma, N; Motomura, S; Ohtsu, A; Suenaga, M; Yamaguchi, T; Yamanaka, Y | 1 |
| Andoh, H; Hazama, S; Hirata, K; Kato, T; Mishima, H; Nagata, N; Oba, K; Okuyama, Y; Sakamoto, J; Takahashi, K | 1 |
| Adenis, A; Assenat, E; Bennouna, J; Bibeau, F; Boissière, F; Bouché, O; Conroy, T; Crapez, E; Desseigne, F; Francois, E; Galais, MP; Laurent-Puig, P; Mazard, T; Poujol, S; Samalin, E; Seitz, JF; Taieb, J; Thézenas, S; Ychou, M | 1 |
| Cho, YB; Chun, HK; Huh, JW; Kim, HC; Lee, WY; Park, YA; Yun, SH | 1 |
| Berthou, J; Bichard, D; Borg, C; Facy, O; Ghiringhelli, F; Heyd, B; Ladoire, S; Lakkis, Z; Limat, S; Lorgis, V; Nerich, V; Orry, D; Ortega-Deballon, P; Rat, P; Vincent, J | 1 |
| Chen, XW; Ju, YL; Ou Yang, MZ; Wang, JZ; Zhang, WJ; Zhu, DJ | 1 |
| Chen, X; Li, J; Ouyang, XN; Peng, YH; Wang, WW; Xie, FW; Yu, ZY | 2 |
| Beachler, C; El-Deiry, WS; Harvey, HA; Kline, CL; Mackley, HB; McKenna, K; Messaris, E; Poritz, L; Schiccitano, A; Sheikh, H; Sivik, J; Staveley-O'Carroll, K; Stewart, D; Zhu, J | 1 |
| Guo, Y; Shen, X; Shi, M; Yang, C; Yang, L; Zhang, J | 1 |
| Chang, SF; Hu, HM; Huang, CM; Huang, CW; Huang, ML; Huang, MY; Lu, CY; Tsai, HL; Wang, JY; Yu, FJ | 1 |
| Kim, JH; Kim, SE; Ku, KH; Moon, W; Park, MI; Park, SJ; Song, SE | 1 |
| Cho, YB; Do, IG; Han, SW; Hong, JY; Hong, YS; Kang, HJ; Kang, WK; Kim, HC; Kim, KM; Kim, KP; Kim, SH; Kim, TW; Kim, TY; Lee, J; Lee, WY; Lim, HY; Park, JO; Park, SH; Park, YS; Sohn, I; Yun, SH | 1 |
| Akashi, K; Ariyama, H; Baba, E; Ijichi, K; Komoda, M; Kubo, N; Kusaba, H; Tamura, S; Tsuchihashi, K; Uchino, K | 1 |
| Buonadonna, A; Caggiari, L; Cecchin, E; D' Andrea, M; De Re, V; De Zorzi, M; Innocenti, F; Racanelli, V; Talamini, R; Toffoli, G; Zagonel, V | 1 |
| Furuse, J; Kishiki, T; Masaki, T; Ohkura, Y; Ohnishi, H; Ohtsuka, K; Sugiyama, M; Watanabe, T | 2 |
| Böning, L; Jehn, CF; Kröning, H; Lüftner, D; Pezzutto, A | 1 |
| Goel, G; Lee, JJ | 1 |
| Akiyoshi, K; Hamaguchi, T; Hashimoto, H; Iwasa, S; Kato, K; Nakajima, TE; Nishitani, H; Shimada, Y; Terazawa, T; Yamada, Y | 1 |
| Abrams, TA; Fuchs, CS; Meyer, G; Meyerhardt, JA; Moloney, J; Schrag, D | 1 |
| Antoniotti, C; Benhaim, L; Bohanes, P; Cremolini, C; El-Khoueiry, R; Falcone, A; Graziano, F; Lenz, HJ; Loupakis, F; Marmorino, F; Masi, G; Ning, Y; Ricci, V; Ruzzo, A; Salvatore, L; Schirripa, M; Wakatsuki, T; Yang, D; Zhang, W | 1 |
| Andrade, AC; Barrios, CH; Chinen, RN; Correa, M; Coutinho, AK; del Giglio, A; Dutra, C; Forones, NM; Hoff, PM; Passos, VQ; Portella, Mdo S; Saragiotto, DF; van Eyll, B | 1 |
| Álvarez, R; Cubillo, A; de Vicente, E; García, E; Hernando, O; Hidalgo, M; López-Ríos, F; Perea, S; Plaza, C; Quijano, Y; Rodriguez-Pascual, J; Rubio, C; Sanchez, G | 1 |
| Ando, M; Fujii, H; Ooki, A; Sakamoto, J; Sato, A; Yamaguchi, K | 1 |
| Arita, J; Inoue, Y; Ono, Y; Saiura, A; Takahashi, M; Takahashi, Y | 1 |
| Ando, Y; Fujii, T; Fujiwara, M; Hayashi, N; Kanda, M; Kobayashi, D; Kodera, Y; Koike, M; Mashita, N; Nakayama, G; Nomoto, S; Sugimoto, H; Tanaka, C; Uehara, K; Yamada, S | 1 |
| Hiotis, S; Jibara, G; Labow, DM; Romanoff, A; Sarpel, U; Shrager, B; Tabrizian, P; Yang, MJ | 1 |
| Aliberti, C; de Baere, T; Garcia-Monaco, R; Lencioni, R; Martin, RC; Narayanan, G; O'Grady, E; Rilling, WS; Walker, D | 1 |
| Bechstein, W; Folprecht, G; Gruenberger, T; Hartmann, JT; Jaeger, D; Köhne, CH; Lang, H; Liersch, T; Lordick, F; Ockert, D; Raab, HR; Rentsch, A; Steger, U; Stoehlmacher-Williams, J; Suedhoff, T; Trarbach, T; Weitz, J | 1 |
| Bertaut, A; Ghiringhelli, F; Ladoire, S; Lorgis, V; Rambach, L; Vincent, J | 1 |
| Abbara, C; Bonhomme-Faivre, L; Chu, C; Farinotti, R; Gonin, P; Polrot, M; Tandia, M | 1 |
| Aksun, S; Alacacioglu, A; Bayoglu, IV; Coban, E; Demir, L; Dirican, A; Kucukzeybek, Y; Sutcu, R; Tarhan, MO; Varol, U | 1 |
| Chen, Q; Ha, MW; Li, P; Wang, YD | 1 |
| Büchler, MW; Jäger, D; Koch, M; Rahbari, NN; Reissfelder, C; Schulze-Bergkamen, H; Weitz, J | 1 |
| Smith, MA | 1 |
| Gongora, C | 1 |
| Mukherji, D; Shamseddine, A; Temraz, S | 1 |
| Laurent-Puig, P; Tougeron, D; Zaanan, A | 1 |
| Andersen, RF; Jakobsen, A; Pallisgaard, N; Spindler, KL | 1 |
| Caravatta, L; Cilla, S; Deodato, F; Macchia, G; Massaccesi, M; Mignogna, S; Morganti, AG; Picardi, V; Plantamura, NM; Valentini, V | 1 |
| Baba, H; Baba, Y; Etoh, K; Ishimoto, T; Iwagami, S; Iwatsuki, M; Miyamoto, Y; Murata, A; Sakamoto, Y; Shigaki, H; Sugihara, H; Watanabe, M; Yoshida, N | 1 |
| Allard, MA; Malka, D | 1 |
| Chang, SF; Chen, CF; Hu, HM; Huang, ML; Wang, JY; Yeh, YS | 1 |
| Allen, PJ; Capanu, M; Cercek, A; Chou, JF; Correa-Gallego, C; DeMatteo, RP; DʼAngelica, MI; Fong, Y; Gewirtz, AN; Jarnagin, WR; Kemeny, N; Kingham, TP; Paty, PB | 1 |
| Boschetti, G; Cotte, E; Decullier, E; Fontaine, J; Gilly, FN; Glehen, O; Isaac, S; Maurice, C; Passot, G; Vaudoyer, D; You, B | 1 |
| Ahn, JB; Baek, SJ; Baik, SH; Cho, MS; Chung, M; Hur, H; Kim, CW; Kim, MS; Kim, NK; Min, BS; Shin, SJ | 1 |
| Bi, F; Cao, D; Chen, Y; Li, Q; Qiu, M | 1 |
| Bendell, JC; Berlin, JD; El-Rayes, BF; George, TJ; Hart, LL; Kingsley, CD; Lenz, HJ; Marshall, JL; Modiano, MR; Nakashima, D; Ryan, T | 1 |
| Bando, H; Fukunaga, M; Hazama, S; Iwamoto, S; Kato, T; Matsuda, C; Mishima, H; Miyake, Y; Oba, K; Sakamoto, J | 1 |
| Arai, T; Goto, A; Hamaguchi, T; Muro, K; Sasaki, Y; Shimada, Y; Shirao, K; Ura, T; Yamada, Y | 1 |
| Antoun, S; Barret, M; Dalban, C; Latko, E; Malka, D; Mansourbakht, T; Taieb, J; Zaanan, A | 1 |
| Bowers, M; Bridgewater, J; Butler, R; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Little, L; Maughan, T; O'Reilly, D; Peterson, M; Primrose, J; Pugh, S; Rees, M; Siriwardena, A; Stanton, L; Valle, J | 1 |
| Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P | 1 |
| Doherty, GA; Lee, CS; Ryan, EJ | 1 |
| Abal, M; Barbazán, J; Candamio, S; Cano, A; Casares de Cal, Mde L; Díaz-López, A; Gómez-Tato, A; López-López, R; Muinelo-Romay, L; Vieito, M | 1 |
| Choi, PR; Kim, JH; Kim, SE; Lee, GW; Moon, W; Park, MI; Park, SJ | 1 |
| Bolonesi, RM; Rogers, JE; Shureiqi, I | 1 |
| Aitouferoukh, S; Béchade, D; Bécouarn, Y; Beyssac, R; Brunet, R; Cany, L; Fonck, M; Lalet, C; Le Morvan, V; Mathoulin-Pélissier, S; Pulido, M; Robert, J; Texereau, P | 1 |
| Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ | 2 |
| Chu, E; Lee, JJ | 2 |
| Hu, AP; Li, SL; Liang, HL; Liu, JY | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Augustine, TA; Coffey, MC; Goel, S; Klampfer, L; Maitra, R; Mariadason, JM; Seetharam, R; Tesfa, L | 1 |
| Büchert, M; Burkholder, I; Jaehde, U; Kanefendt, F; Kuhlmann, J; Moritz, B; Mross, K; Scheulen, M; Sörgel, F; Strumberg, D | 1 |
| Arao, T; Hamaguchi, T; Hayashi, H; Hirashima, Y; Honma, Y; Horita, Y; Iwasa, S; Kato, K; Kimura, H; Matsumoto, K; Nakagawa, K; Nishio, K; Okita, NT; Shimada, Y; Takashima, A; Togashi, Y; Yamada, Y | 1 |
| Akazawa, K; Funakoshi, K; Hasegawa, J; Hatakeyama, K; Maruyama, S; Okada, T; Takii, Y; Tani, T; Yamazaki, T | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Shimada, Y; Takahashi, N; Taniguchi, H; Yamada, Y | 1 |
| Li, R; Liu, WT; Song, JR; Sun, K; Wei, LX; Wu, MC; Zhang, JW; Zhang, SS; Zhao, QD; Zong, C | 1 |
| Barni, S; Borgonovo, K; Coinu, A; Ghidini, A; Petrelli, F | 1 |
| Bergamo, F; De Paoli, A; De Salvo, GL; Di Grazia, L; Esposito, G; Griguolo, G; Indraccolo, S; Lonardi, S; Mescoli, C; Nardin, M; Rugge, M; Zagonel, V; Zulato, E | 1 |
| Fan, Z; Han, G; He, L; Qin, Z; Xie, S; Xu, W | 1 |
| Chen, WS; Jiang, JK; Lan, YT; Lin, CC; Lin, JK; Lin, TC; Teng, HW; Tzeng, CH; Yang, SH; Yang, YH; Yen, CC | 1 |
| Delorenzi, M; Høgdall, E; Jensen, BV; Johansen, JS; Kruhøffer, M; Nielsen, DL; Pfeiffer, P; Rossi, S; Schou, JV; Tejpar, S; Yilmaz, M | 1 |
| Hendel, HW; Høgdall, EV; Jensen, BV; Johannesen, HH; Nielsen, D; Schou, JV; Skougaard, K | 1 |
| Barone, C; Bordonaro, R; Botti, G; Cartenì, G; Ciardiello, F; Cinieri, S; Colucci, G; De Vita, F; Febbraro, A; Fenizia, F; Giuliani, F; Lambiase, M; Maiello, E; Martinelli, E; Montesarchio, V; Normanno, N; Orditura, M; Pisconti, S; Rachiglio, AM; Rinaldi, A; Rizzi, D; Tatangelo, F; Tonini, G; Troiani, T | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY | 1 |
| Cai, SJ; Huang, LY; Li, XX; Liang, L; Peng, JJ; Shi, DB; Zheng, HT | 1 |
| Amagai, K; Ando, H; Gamoh, M; Ishioka, C; Isobe, H; Kakudo, Y; Kato, S; Mori, T; Shimodaira, H; Soeda, H; Suto, T; Takahashi, S; Watanabe, M; Yamaguchi, T | 1 |
| Chen, Q; Chen, S; Huang, C; Li, J; Liao, J; Liu, F; Su, G; Tang, W; Ye, Y | 1 |
| Bouquié, R; Boyer, JC; Broly, F; Etienne-Grimaldi, MC; Gagnieu, MC; Gaub, MP; Ged, C; Ghiringhelli, F; Le Guellec, C; Le Morvan, V; Loriot, MA; Philibert, L; Picard, N; Poncet, D; Quaranta, S; Thomas, F | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, IV; Can, A; Coban, E; Demir, L; Dirican, A; Erten, C; Koyuncu, B; Kucukzeybek, Y; Somali, I; Tarhan, MO; Varol, U; Yildiz, Y | 1 |
| Chaix, M; Ghiringhelli, F; Lorgis, V; Vincent, J | 1 |
| Bayraktar, S; Broome, P; de Queiroz Marques Junior, E; Leslie, M; Nowacki, M; Rocha-Lima, CM; Susnerwala, S; Weissman, C | 1 |
| Baba, H; Miyamoto, Y; Sakamoto, Y; Yoshida, N | 1 |
| Ehninger, G; Folprecht, G; Hamann, S; Schütte, K; Stoehlmacher-Williams, J; Trarbach, T | 1 |
| Blackmon, SH; Correa, AM; Eng, C; Kee, B; Subbiah, IM; Swisher, SG; Vaporciyan, AA | 1 |
| Aprile, G; Barsevick, A; Bonaventura, A; Elting, LS; Grunberg, SM; Keefe, DM; Koczwara, B; Nguyen, HT; Selva-Nayagam, S; Sonis, ST | 1 |
| Carter, GC; Johnson, BH; Landsman-Blumberg, PB; Li, L; Nicol, SJ; Sedgley, R; Shankaran, V | 1 |
| Cremolini, C; El-Khoueiry, RE; Falcone, A; Kardosh, A; Lenz, HJ; Li, JE; Loupakis, F; Ning, Y; Scherer, SJ; Stintzing, S; Volz, NB; Wakatsuki, T; Yang, D; Zhang, W | 1 |
| Agarwal, S; Dasari, A; Eng, C; Fogelman, D; Garrett, C; Jiang, ZQ; Kee, B; Kopetz, S; Maru, D; Morris, V; Overman, MJ; Wolff, R | 1 |
| Abe, S; Egawa, Y; Futami, K; Higashi, D; Hirano, K; Hirano, Y; Inoue, R; Maekawa, T; Mikami, K; Miyake, T; Miyazaki, M; Takahashi, H; Uwatoko, S; Yamamoto, S | 1 |
| Cao, J; Huang, XE; Qian, ZY; Shi, L; Wu, XY; Xu, X | 1 |
| Billard, V; Blot, F; Cloutier, AS; Dartigues, P; Ducreux, M; Dumont, F; Elias, D; Goéré, D; Honoré, C; Mariani, A | 1 |
| Al-Batran, SE; Decker, T; Heinemann, V; Heintges, T; Hielscher, J; Höffkes, HG; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerchenmüller, C; Lindig, RU; Link, H; Modest, DP; Moehler, M; Müller, S; Niederle, N; Rossius, L; Rost, A; Scheithauer, W; Scholz, M; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF | 1 |
| Cunningham, D; Sclafani, F | 1 |
| Hu, Y; Liu, X; Song, S; Tian, L; Wang, Y; Xu, J; Xu, X | 1 |
| Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H | 1 |
| Hirakawa, K; Ikeya, T; Maeda, K; Nagahara, H; Ohtani, H; Shibutani, M; Sugano, K | 1 |
| Baba, H; Chika, N; Haga, N; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Okada, N; Sano, M; Tajima, Y | 1 |
| Melichar, B; Mohelnikova-Duchonova, B; Soucek, P | 1 |
| Hutchinson, L | 1 |
| Abad, A; Echave, M; Frías, C; Giménez, E; Joulain, F; Lamas, MJ; Naoshy, S; Oyagüez, I; Pericay, C; Rubio, M | 1 |
| Liu, X; Xu, W | 1 |
| Bridgewater, J; Chau, I; Iqbal, SU; Joulain, F | 1 |
| Bišof, V; Dedić Plavetić, N; Krpan, AM; Ozretić, D; Rakušić, Z; Simetić, L | 1 |
| Cereda, V; Cunningham, D; Ferroni, P; Formica, V; Guadagni, F; Luccchetti, J; Nardecchia, A; Roselli, M; Smyth, EC; Tesauro, M | 1 |
| Kasperczyk, S; Malinowska-Borowska, J; Nowak, P; Rogalska, A; Świętochowska, E; Słomian, G | 1 |
| Crocenzi, T; Esparaz, B; Fisch, MJ; Glover, K; Jones, D; Kee, BK; Morris, JS; Overman, M; Slack, RS; Wen, S; Wong, L | 1 |
| Chen, L; Ju, HX; Liu, BX; Liu, LY; Luo, C; Xu, Q; Yang, YS; Ying, JE; Zhao, YZ; Zhong, HJ; Zhu, LM | 1 |
| Fujita, Y; Hamamoto, Y; Hazama, S; Inoue, Y; Kanekiyo, S; Mishima, H; Oba, K; Oka, M; Okayama, N; Sakamoto, J; Suehiro, Y; Tsunedomi, R; Yamasaki, T; Yoshino, S | 1 |
| Tong, Y; Zheng, Y; Zhou, J | 1 |
| Brunetti, AE; Lorusso, V; Maiello, E; Mangia, A; Paradiso, A; Partipilo, G; Scarpi, E; Silvestris, N; Simone, G | 1 |
| Elvin, P; Gallick, G; Jiang, ZQ; Kopetz, S; Maru, D; Morris, VK; Overman, MJ; Parikh, N | 1 |
| Baniyash, M; Biton, M; Goldshtein, A; Hubert, A; Ish-Shalom, E; Kanterman, J; Lasry, A; Sade-Feldman, M | 1 |
| Bennouna, J; Botbyl, J; de Labareyre, C; Delord, JP; Deslandres, M; Ruiz-Soto, R; Senellart, H; Suttle, AB; Wixon, C | 1 |
| Bauer, S; Formentini, A; Galle, PR; Hoffman, A; Kittner, JM; Kornmann, M; Link, KH; Maderer, A; Moehler, M; Neumann, W; Rey, JW; Schad, A; Schwarz, M; Thomaidis, T; Trautmann, M; Weinmann, A | 1 |
| Goto, A; Hamamoto, Y; Morita, S; Nakajima, T; Nakayama, N; Nishina, T; Sakamoto, J; Shimada, K; Ura, T; Yamada, Y; Yamaguchi, T; Yamazaki, K | 1 |
| Fay, F; Greene, MK; Jarvis, GE; Johnston, PG; Kissenpfennig, A; Longley, DB; Majkut, J; McCloskey, KD; McLaughlin, KM; Schmid, D; Scott, CJ; Small, DM; Spence, S | 1 |
| Arnold, D; Boxberger, F; Herrenberger, J; Hinke, A; Hoeffkes, HG; Kutscheidt, A; Leutgeb, B; Petersen, V; Schroeder, J; Schulze, M; Seraphin, J; Stein, A; Valdix, AR | 1 |
| Aichler, M; Buck, A; Feuchtinger, A; Halbritter, S; Janssen, KP; Späth, C; Walch, A; Zitzelsberger, H | 1 |
| Bokemeyer, C; Bruns, R; Csőszi, T; Élez, E; Höhler, T; Kocáková, I; Martens, UM; Melichar, B; Orlova, R; Quaratino, S; Rivera, F; Smakal, M; Straub, J; Tabernero, J; Tjulandin, S; Topuzov, E; Van Cutsem, E | 1 |
| Ba, Y; Chen, Y; Deng, T; He, Y; Li, W; Liu, R; Ren, L; Wang, X; Ying, G; Zhou, L; Zuo, D | 1 |
| Cohen, D; Cohen, S; Denlinger, C; Gold, PJ; Hochster, HS; Leichman, CG; Leichman, L; Lenz, HJ; Messersmith, W; ONeil, BH; Uboha, N | 1 |
| Graf, A; Gruenberger, B; Gruenberger, T; Singh, J; Starlinger, P; Stift, J; Stremitzer, S; Tamandl, D | 1 |
| Kirstein, MM; Kubicka, S; Lange, A; Manns, MP; Prenzler, A; Vogel, A | 1 |
| Chen, HM; Chen, WS; Jiang, JK; Lan, YT; Lin, CC; Lin, JK; Teng, HW; Yang, SH | 1 |
| Allegrini, G; Amoroso, D; Boni, C; Boni, L; Buonadonna, A; Carlomagno, C; Chiara, S; Cortesi, E; Cremolini, C; Falcone, A; Lonardi, S; Loupakis, F; Masi, G; Ronzoni, M; Salvatore, L; Spadi, R; Tomasello, G; Tonini, G; Zagonel, V; Zaniboni, A | 1 |
| Goldberg, RM; Gray, E; Karrison, TG; Sargent, DJ; Sharma, MR | 1 |
| Battat, E; Bitterman, H; Brenner, B; Feldhamer, I; Greenberg-Dotan, S; Hammerman, A | 1 |
| Gerken, M; Glockzin, G; Klinkhammer-Schalke, M; Lang, SA; Piso, P; Schlitt, HJ | 1 |
| Errico, A | 1 |
| Bosch, LJ; Haan, JC; Israeli, D; Kabbarah, O; Koopman, M; Labots, M; Meijer, GA; Mekenkamp, LJ; Nagtegaal, ID; Punt, CJ; Qu, X; Rausch, C; Tol, J; van de Wiel, MA; van Essen, HF; van Grieken, NC; Verheul, HM; Voorham, QJ; Ylstra, B | 1 |
| Goldberg, RM; Nordlinger, B; Poston, GJ | 1 |
| André, T; Auby, D; Bonnetain, F; Brucker, P; Brusquant, D; Carola, E; Chibaudel, B; Dalban, C; de Gramont, A; Dutel, JL; Faroux, R; Flesch, M; Gayet, B; Hadengue, A; Hebbar, M; Khalil, A; Landi, B; Legoux, JL; Louvet, C; Mabro, M; Martin, P; Mineur, L; Paye, F; Pruvot, FR; Smith, D; Taieb, J; Truant, S; Vaillant, E; Ychou, M | 1 |
| Brunner, S; Camenisch Gross, U; Cathomas, R; Freyholdt, T; Mey, U; von Moos, R | 1 |
| Bae, KS; Hong, YS; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG | 1 |
| Adam, R; Allard, MA; Baillie, G; Boige, V; Dartigues, P; Elias, D; Faitot, F; Faron, M; Goéré, D; Lemoine, A; Sa Cunha, A; Sebagh, M; Vibert, E; Vitadello, F | 1 |
| de Braud, F; Di Bartolomeo, M; Iacovelli, R; Pietrantonio, F | 1 |
| Barni, S; Coinu, A; Petrelli, F | 1 |
| Peeters, M; Price, TJ; Townsend, AR | 1 |
| Heinemann, V; Stintzing, S | 1 |
| Arnold, D; Bhargava, P; Chevalier, S; Cunningham, D; Ferry, DR; Hoff, PM; Lakomỳ, R; Macarulla, T; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Ten Tije, AJ; Van Cutsem, E; Van Hazel, GA; Vishwanath, RL | 1 |
| Cao, R; Hu, L; Ma, D; Zhang, S | 1 |
| Rahman, A | 1 |
| Akinwande, O; Hayes, D; Martin, RC; Miller, A; O'Hara, R; Tomalty, D | 1 |
| Borrero-Palacios, A; Cebrian, A; del Puerto-Nevado, L; Fernandez-Aceñero, MJ; Garcia-Foncillas, J; Gomez del Pulgar, T; Martinez-Useros, J; Moreno, I; Perez, N; Puime-Otin, A; Rodriguez-Remirez, M; Rojo, F; Senin, C; Soengas, MS; Vega-Bravo, R; Zazo, S | 1 |
| Chalmers, A; El-Khamisy, SF; Gilbert, DC; Gollins, S; Haley, V; Meisenberg, C; Ward, SE | 1 |
| Chen, Z; Guo, W; Li, J; Li, W; Liu, T; Shen, L; Xu, J; Zhang, W; Zhu, X | 1 |
| Cao, J; Ding, HH; Ji, ZY; Jiang, T; Jin, JH; Song, WF; Wang, JJ; Wang, LW; Wu, WD | 1 |
| Adam, R; Bridgewater, J; Chau, I; García Alfonso, P; Gruenberger, T; Hermann, F; Lasserre, S; Mudan, S; Rivoire, M; Waterkamp, D | 1 |
| Bernard, AC; Coqueret, O; De Carné Trécesson, S; Gamelin, E; Guette, C; Henry, C; Jonchère, B; Juin, P; Lam, D; Toutain, B; Vétillard, A | 1 |
| Gastman, BR; Pfannenstiel, LW | 1 |
| Furuhata, T; Hayashi, T; Hirakawa, M; Hirata, K; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Miyanishi, K; Mizuguchi, T; Murase, K; Ohnuma, H; Okagawa, Y; Okita, K; Osuga, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takimoto, R | 1 |
| Cremolini, C; Falcone, A; Loupakis, F | 1 |
| Haines, IE | 1 |
| Ando, Y; Maeda, O; Matsuoka, A | 1 |
| Kamijo, A; Okada, K; Sadahiro, S; Saito, G; Suzuki, T; Tanaka, A | 1 |
| Anchisi, S; Baertschi, D; Betticher, DC; Borner, M; Brauchli, P; Dietrich, D; Frueh, M; Herrmann, R; Hess, V; Koeberle, D; Kollar, A; Kueng, M; Matter, K; Moosmann, P; Popescu, RA; Roth, A; Saletti, P; Schacher, S; von Moos, R; Winterhalder, R | 1 |
| Beier, F; Ciardiello, F; Heinemann, V; Köhne, CH; Lenz, HJ; Melezínek, I; Rougier, P; Stroh, C; Tejpar, S; Van Cutsem, E; van Krieken, JH | 1 |
| Brünner, N; Christensen, IJ; Jakobsen, A; Nielsen, HJ; Spindler, KL | 1 |
| Nygren, P | 1 |
| Choi, YH; Kim, RB; Lenehan, J; Parfitt, J; Teft, WA; Welch, S; Winquist, E | 1 |
| Duarte, A; Duffy, S; Rodriguez-Lopez, R; Simmonds, M; Spackman, E; Wade, R; Woolacott, N | 1 |
| Chan, E; de La Bourdonnaye, G; Heiskala, M; Hwang, J; Kwak, EL; Mita, M | 1 |
| Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY | 1 |
| Aitini, E; Bajetta, E; Barni, S; Bertolini, A; Ciarlo, A; Di Bartolomeo, M; Dotti, KF; Iacovelli, R; Maggi, C; Perrone, F; Pietrantonio, F; Verusio, C | 1 |
| Fox, JL; Storey, A | 1 |
| Nipp, RD; Ryan, DP | 1 |
| Aparicio, T; Bedenne, L; Ben Abdelghani, M; Boige, V; Bouché, O; Dahan, L; Faroux, R; François, E; Ghiringhelli, F; Le Malicot, K; Legoux, JL; Linot, B; Phelip, JM; Taieb, J | 1 |
| Ashcroft, L; Backen, A; Beech, J; Chau, I; Dive, C; Gollins, S; Hasan, J; Krebs, MG; Morris, K; Renehan, AG; Saunders, MP; Valle, JW | 1 |
| El-Deiry, WS; Marks, E; Rizvi, SM; Sarwani, N; Yang, Z | 1 |
| Bonetti, A; Giuliani, J; Martelli, S; Piacentini, P | 1 |
| Berry, DP; Byrne, B; Cameron, IC; Davidson, B; Helmy, S; Khan, AZ; Malik, H; Pope, I; Pulfer, A; Sherlock, D; Thompson, M | 1 |
| Bossi, I; Cappelletti, V; Daidone, MG; de Braud, F; Di Bartolomeo, M; Di Buduo, E; Iacovelli, R; Maggi, C; Martinetti, A; Musella, V; Pietrantonio, F; Sottotetti, E | 1 |
| Antoniotti, C; Barone, C; Bonetti, A; Boni, L; Cortesi, E; Cremolini, C; D'Amico, M; Di Donato, S; Falcone, A; Granetto, C; Lonardi, S; Longarini, R; Loupakis, F; Masi, G; Salvatore, L; Spadi, R; Tomasello, G; Tonini, G; Vitello, S; Zaniboni, A | 1 |
| Atasoy, A; Babacan, NA; Cihan, S; Kos, TF; Yildirim, Y | 1 |
| Ansieau, S; Collin, G | 1 |
| Amadori, D; Cavanna, L; Fontana, A; Frassineti, GL; Lorusso, V; Mucciarini, C; Nanni, O; Passardi, A; Ragazzini, A; Ruscelli, S; Tassinari, D; Turci, D | 1 |
| Nakagawa, F; Nukatsuka, M; Saito, H; Sakata, M; Takechi, T; Uchida, J | 1 |
| Beck, JT; Brandt, U; Davidson, SJ; Garrett, CR; Hecht, JR; Mackenzie, MJ; Reid, TR; Rizvi, S; Sharma, S | 1 |
| Andersen, CL; Beck, MK; Belling, KC; Bosman, F; Brünner, N; Budinská, E; Delorenzi, M; Do, KN; Gupta, R; Hanáková, B; Hansen, TP; Jensen, NF; Moreira, JM; Nygård, SB; Pfeiffer, P; Rasmussen, MH; Roth, A; Rømer, MU; Stenvang, J; Tarpgaard, LS; Tejpar, S; Viuff, B | 1 |
| Kang, MH; Kim, JH; Kim, JW; Lee, HS; Lee, JS; Lee, KW; Moon, SU; Sung, JH | 1 |
| Burris, HA; Chen, L; Goldstein, D; Hsu, CP; Hurwitz, H; Kotasek, D; Schwartzberg, LS; Stephenson, J; Tebbutt, N; Warner, DJ | 1 |
| Cecchin, E; Chen, S; Court, MH; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Laverdiere, I; Lévesque, E; Toffoli, G; Tourancheau, A; Villeneuve, L | 1 |
| Bossi, I; Cheli, S; Clementi, E; de Braud, F; Di Bartolomeo, M; Falvella, FS; Gariboldi, M; Iacovelli, R; Maggi, C; Martinetti, A; Mazzali, C; Mennitto, R; Pierotti, MA; Pietrantonio, F; Sottotetti, E | 1 |
| Barone, C; Basso, M; Bonomo, L; Cassano, A; Cerchiaro, E; Devicienti, E; Guerra, A; Iezzi, R; Marsico, VA; Rodolfino, E | 1 |
| Hicklin, DJ | 1 |
| Chin, K; Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M; Yamaguchi, T | 1 |
| Christie, M; Desai, J; Diaz, LA; Gibbs, P; Karapetis, CS; Kinde, I; Kinzler, KW; Papadopoulos, N; Roebert, J; Singh, M; Strausberg, RL; Tacey, M; Tie, J; Tran, B; Vogelstein, B; Wang, Y; Wong, HL; Wong, R | 1 |
| Botti, G; Ciardiello, F; Colucci, G; Esposito, C; Fenizia, F; Lambiase, M; Maiello, E; Martinelli, E; Normanno, N; Rachiglio, AM; Rizzi, D; Roma, C; Tatangelo, F; Troiani, T | 1 |
| Berk, V; Bozkurt, O; Duran, AO; Elmali, F; Inanc, M; Karaca, H; Ozaslan, E; Ozkan, M; Ucar, M | 1 |
| Barni, S; Bozzarelli, S; Carnaghi, C; Destro, A; Floriani, I; Galli, F; Gerardi, C; Labianca, R; Personeni, N; Raschioni, C; Rimassa, L; Rubino, L; Santoro, A; Tronconi, MC; Verusio, C; Villa, E | 1 |
| Gruenberger, B; Gruenberger, T; Singh, J; Starlinger, P; Stift, J; Stremitzer, S; Tamandl, D | 1 |
| Ananda, S; Chapman, M; Field, K; Gibbs, P; Guerrieri, M; Jones, I; Kosmider, S; Skinner, I; Tran, B | 1 |
| Hu, XL; Li, BL; Sun, HG; Zhang, Y; Zhao, XH; Zhou, CY | 1 |
| Bodoky, G; Chang, SC; Ciuleanu, TE; Clingan, PR; Cohn, AL; Garcia-Alfonso, P; Garcia-Carbonero, R; Grothey, A; Kim, TW; Lonardi, S; Nasroulah, F; Obermannova, R; Portnoy, DC; Prausová, J; Simms, L; Tabernero, J; Van Cutsem, E; Yamazaki, K; Yoshino, T | 1 |
| Ando, Y; Fujita, K; Ichikawa, W; Minamimura, K; Miyauchi, H; Morita, S; Moriwaki, T; Nakamura, M; Ohashi, Y; Okutani, Y; Sadahiro, S; Sakata, Y; Shinozaki, K; Sugihara, M; Sugiyama, T; Takahashi, T; Takii, Y; Tanaka, C; Tsuji, A; Uehara, K | 1 |
| Almeida, GS; deSouza, NM; Jamin, Y; Papaevangelou, E; Robinson, SP | 1 |
| Denda, T; Esaki, T; Ikeda, J; Mizunuma, N; Muro, K; Nishina, T; Nishisaki, H; Suenaga, M; Sugiyama, Y; Takano, Y; Ura, T; Yasui, H | 1 |
| Bencsikova, B; Bortlicek, Z; Dusek, L; Halamkova, J; Kiss, I; Melichar, B; Ostrizkova, L; Pavlik, T; Valik, D; Vyzula, R; Zdrazilova-Dubska, L | 1 |
| Baba, H; Denda, T; Hata, T; Ina, K; Inukai, M; Iwamoto, S; Kato, T; Kunieda, K; Kurachi, K; Mishima, H; Morita, Y; Munemoto, Y; Nagata, N; Nakamura, M; Oba, K; Ooshiro, M; Sakamoto, J; Shimoyama, T; Takahashi, T; Tamagawa, H | 1 |
| Bellevicine, C; Bianco, A; Cacciola, NA; Calabrese, C; Carlomagno, C; De Stefano, A; Federico, A; Fusco, A; Malapelle, U; Milone, F; Milone, M; Pallante, P; Pellino, G; Quintavalle, C; Selvaggi, F; Sepe, R; Sgariglia, R; Troncone, G; Uchimura Bastos, A | 1 |
| Aranda, E; Chaves, M; Garcia-Alfonso, P; García-Gonzalez, M; Gómez, MJ; González-Flores, E; Grávalos, C; López-Ladrón, A; Losa, F; Massuti, B; Muñoz, A; Oltra, A; Queralt, B; Salud, A | 1 |
| Adachi, Y; Doi, K; Furumoto, K; Furuyama, H; Hasegawa, S; Hatano, E; Hirose, T; Horimatsu, T; Inoue, N; Ishii, T; Kaihara, S; Kanazawa, A; Manaka, D; Matsumoto, S; Nakamura, K; Okuno, M; Sakai, Y; Seo, S; Taura, K; Terajima, H; Tokka, A; Uemoto, S; Yasuchika, K; Yazawa, T; Zaima, M | 1 |
| Del Rio, M; Gongora, C; Jin, C; Lam, H; Li, F; Ling, X; Wani, M; Welch, J; Westover, D | 1 |
| Cui, Y; Dong, N; Meng, F; Wang, M; Wu, Y; Zhang, S | 1 |
| Killock, D | 2 |
| Abouelkhair, KM; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Ibrahim, EM; Loretelli, C; Mandolesi, A; Maristella, B; Scarpelli, M; Scartozzi, M | 1 |
| de Jong, KP; de Wilt, JH; Dejong, KH; Engelbrecht, MR; Huiskens, J; Kazemier, G; Keijser, A; Meijer, GA; Mol, L; Molenaar, IQ; Punt, CJ; Ruers, TM; Schriek, J; van Grieken, NC; van Gulik, TM; van Lienden, KP; van Tinteren, H; Verhoef, C | 1 |
| Cheng, LW; Cheng, Y; Chi, ZC; Li, Z; Liu, XW; Sun, BS | 1 |
| Bijman-Lagcher, W; de Bruin, RW; Huisman, SA; IJzermans, JN; Smits, R | 1 |
| Azvolinsky, A | 1 |
| Hsu, WH; Huang, CW; Kuo, CH; Lin, CH; Tsai, HL; Tseng, FY; Wang, JY; Wu, JY; Yang, IP; Yeh, YS | 1 |
| Cho, YB; Choi, SH; Hong, HK; Lee, WY; Yoo, HY | 1 |
| Ayez, N; Eggermont, AM; Grünhagen, DJ; Rothbarth, J; van der Stok, EP; van Meerten, E; Verhoef, C | 1 |
| Brünner, N; Bunch, L; Christensen, S; Jensen, AA; Jensen, NF; Pedersen, SF; Pedraz-Cuesta, E; Romer, MU; Stenvang, J | 1 |
| Azuma, Y; Hanashiro, K; Nakachi, A; Nishiki, T; Ota, M; Shimabuku, M; Shimabukuro, N; Shiroma, H; Teruya, T; Toritsuka, D | 1 |
| Cline-Burkhardt, M; Cohn, A; Dakhil, S; Go, WY; Hecht, JR; Piperdi, B; Saleh, M; Tian, Y | 1 |
| Aoyama, T; Kataoka, M; Kono, T; Matsuda, C; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Oshiro, M; Sakamoto, J | 1 |
| Cervantes, A; Ciardiello, F; Jego, V; Laffranchi, B; Macarulla, T; Martinelli, E; Prenen, H; Roselló, S; Tabernero, J; Tejpar, S; Troiani, T; Van Cutsem, E; von Richter, O | 1 |
| Andersen, CL; Belling, K; Bolund, L; Brünner, N; Jensen, NF; Li, J; Lin, X; Rasmussen, MH; Stenvang, J; Tarpgaard, LS; Yang, G; Zhu, S | 1 |
| Acuna, SA; Angarita, FA; McCart, JA; Ottolino-Perry, K; Sellers, C; Tang, N; Zerhouni, S | 1 |
| Danciu, M; Negru, SM; Scripcariu, V; Volovat, C; Volovat, SR | 1 |
| Bianco, R; Cardone, C; Ciardiello, D; Ciardiello, F; Fenizia, F; Formisano, L; Lambiase, M; Martinelli, E; Martini, G; Morgillo, F; Napolitano, S; Normanno, N; Troiani, T; Vitagliano, D | 1 |
| Bortlicek, Z; Büchler, T; Dusek, L; Finek, J; Kocak, I; Kocakova, I; Kohoutek, M; Melichar, B; Mohelnikova-Duchonova, B; Petruzelka, L; Prausová, J; Vyzula, R | 1 |
| Akagi, Y; Emi, Y; Higashi, H; Ishikawa, H; Kusumoto, T; Maehara, Y; Matsuda, H; Miwa, K; Ogata, Y; Oki, E; Saeki, H; Samura, H; Sueyoshi, S; Tanaka, T; Tokunaga, S; Touyama, T | 1 |
| Ayadi, M; Bouygues, A; Chouaib, S; Ferrand, N; Larsen, AK; Muchardt, C; Ouaret, D; Sabbah, M; Thiery, JP | 1 |
| Abu-Amna, M; Bar-Sela, G; Hadad, S; Haim, N; Hassoun, G | 1 |
| Díaz de Corcuera, I; García de la Torre, M; Pérez Hoyos, MT; Salgado Fernández, M; Vidal Arbués, A | 1 |
| Abramova, NA; Dvadnenko, KV; Kit, OI; Vladimirova, LY; Vodolazhskiy, DI | 1 |
| Kang, JH; Kim, B; Kim, HM; Kim, JJ; Lee, SJ; Oh, SH; Park, BH; Shin, KJ; Song, SW; Woo, JK | 1 |
| Butzke, B; Giessen-Jung, C; Heinemann, V; Oduncu, FS; Pfeufer, A; Rogowski, WH; Severin, F; Stollenwerk, B | 1 |
| Aparicio, T; Des Guetz, G; Landre, T; Mary, F; Nicolas, P; Taleb, C; Uzzan, B; Zelek, L | 1 |
| Bowman, KJ; Jones, GD; Smith, AJ; Thomas, AL; Wood, JP | 1 |
| Bai, L; Han, C; Jiao, S; Li, J; Su, D; Wang, Y; Zhang, T | 1 |
| Fausti, V; Gallo, P; Imperatori, M; Picardi, A; Santini, D; Spalato Ceruso, M; Tonini, G; Vespasiani Gentilucci, U; Vincenzi, B | 1 |
| Gao, L; Gotoh, M; Nasroulah, F; Ohtsu, A; Yamazaki, K; Yoshino, T; Yoshizuka, N | 1 |
| Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M; Yamaguchi, T | 1 |
| Artru, P; Chalabreysse, P; Desramé, J; Lledo, G; Marsot, J; Mithieux, F; Pellerin, O; Pernot, S; Taieb, J; Watkin, E | 1 |
| Crocenzi, TS; Garcia-Monaco, RD; Kelly, LR; Laing, CJ; Martin, RC; Rilling, WS; Schreeder, M; Scoggins, CR; Sharma, VR; Strasberg, SM; Tatum, CM | 1 |
| Boku, N; Doi, T; Fuse, N; Koizumi, W; Ohtsu, A; Shimada, K; Takinishi, Y; Yamazaki, K; Yoshino, T | 1 |
| Asao, T; Fujii, T; Kato, T; Kuwano, H; Morita, H; Suto, T; Tsutsumi, S; Yajima, R; Yamaguchi, S | 1 |
| Cao, J; Gao, Y; Nie, F; Ran, Z; Tong, J; Zhu, M | 1 |
| Chan, MT; Li, Z; Wu, WK; Yu, J; Yu, X | 1 |
| Cremolini, C; Falcone, A; Folwaczny, M; Heinemann, V; Jung, A; Kemmerling, R; Kirchner, T; Lenz, HJ; Loupakis, F; Matsusaka, S; Neureiter, D; Ning, Y; Sebio, A; Stintzing, S; Stremitzer, S; Sunakawa, Y; Yamauchi, S; Yang, D; Zhang, W | 1 |
| Aljubran, A; Alzahrani, A; Bazarbashi, S; Mohieldin, A; Shoukri, M; Soudy, H | 1 |
| Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H | 1 |
| Barretta, ML; Cassata, A; De Divitiis, C; Iaffaioli, RV; Nappi, A; Nasti, G; Ottaiano, A | 1 |
| André, T; Bennouna, J; Borg, C; Bouché, O; Jary, M; Kim, S | 1 |
| Al-Batran, SE; Decker, T; Heinemann, V; Heintges, T; Held, S; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerchenmüller, C; Modest, DP; Möhler, M; Scheithauer, W; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF | 1 |
| El-Rayes, BF; Goldstein, DA | 1 |
| Chen, YH; Hwang, WL; Lin, CH; Teng, CL; Wang, CY | 1 |
| Chan, DL; Karapetis, CS; Pavlakis, N; Price, TJ; Segelov, E; Shapiro, J; Tebbutt, NC | 1 |
| Crispin, A; Fischer von Weikersthal, L; Giessen-Jung, C; Heinemann, V; Held, S; Holch, J; Jung, A; Kirchner, T; Modest, DP; Neumann, J; Quietzsch, D; Schalhorn, A; Stahler, A; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Einem, JC | 1 |
| Dicker, DT; El-Deiry, WS; Hong, B; Kline, CL; Kopelovich, L; Prabhu, VV; van den Heuvel, AP; Warfel, NA; Zhang, S; Zhou, L | 1 |
| Balestra, A; Becouarn, Y; Fourrier-Réglat, A; Guimbaud, R; Jové, J; Laurent, C; Michel, P; Moore, N; Noize, P; Ravaud, A; Robinson, P; Rouyer, M; Smith, D; Tubiana-Mathieu, N | 1 |
| Ágoston, EI; Baranyai, Z; Bodoky, G; Bursics, A; Dede, K; Harsányi, L; Kulka, J; Szász, AM | 1 |
| Gandhi, A; Ghose, R; Mallick, P; Shah, P | 1 |
| Atanackovic, D; Bluemner, E; Bokemeyer, C; Brugger, W; Hapke, G; Hildebrandt, B; Illerhaus, G; Steffens, CC; Stein, A; Stöhlmacher, J; Stübs, P | 1 |
| Allegrini, G; Antoniotti, C; Boni, L; Carlomagno, C; Cazzaniga, M; Chiara, S; Cremolini, C; D'Amico, M; Falcone, A; Fontanini, G; Granetto, C; Lonardi, S; Loupakis, F; Lupi, C; Mezi, S; Ronzoni, M; Sensi, E; Tomasello, G; Tonini, G; Zaniboni, A | 1 |
| André, T; Cervantes, A; Chan, E; Ciuleanu, TE; Ducreux, M; He, P; Hotko, Y; Jung, AS; Koukakis, R; Lordick, F; Oliner, KS; Patterson, SD; Peeters, M; Price, TJ; Punt, CJ; Roman, L; Sidhu, R; Sobrero, AF; Strickland, AH; Terwey, JH; Van Cutsem, E; Wilson, G; Yu, H | 1 |
| Ciuffreda, L; Fanchini, L; Mecca, C; Pinta, F; Ponzetti, A; Racca, P; Spadi, R; Zanini, M | 1 |
| Cecchin, E; Chen, S; Couture, F; Guillemette, C; Innocenti, F; Jonker, D; Laverdière, I; Lévesque, E; Toffoli, G; Villeneuve, L | 1 |
| Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S | 1 |
| Daoud, J; Essa, S; Lafleur, M; Martel, S; Tabrizian, M | 1 |
| Leung, WW; Ng, SS; To, KK | 1 |
| Dahan-Farkas, N; Harmse, L; Panayides, JL; Penny, C; van Otterlo, W | 1 |
| De Haan, AF; Dijkstra, JR; Faber, C; Koopman, M; Mekenkamp, LJ; Nagtegaal, ID; Punt, CJ; Simmer, F; Venderbosch, S; Vink-Börger, EM | 1 |
| Ayers, M; Clarke, SJ; Cunningham, D; Ferry, D; Frödin, JE; Guren, TK; Hawkes, E; Kim, SY; Kim, TW; Kim, TY; Loboda, A; Mauro, DJ; Nebozhyn, M; Park, YS; Peckitt, C; Roh, JK; Schmoll, HJ; Sclafani, F; Tabernero, J; Watkins, DJ | 1 |
| Aravantinos, G; Gazouli, M; Isaakidou, A; Karantanos, T; Pektasides, D; Sioziou, A; Theodoropoulos, GE | 1 |
| Aprile, G; Bonotto, M; Fasola, G; Fontanella, C; Giuliani, F; Lutrino, SE; Rihawi, K | 1 |
| Canon, JL; Carrasco, J; Chapaux, X; Danse, E; Gigot, JF; Gizzi, M; Hubert, C; Humblet, Y; Jouret-Mourin, A; Lannoy, V; Lefesvre, P; Navez, B; Pairet, G; Sempoux, C; Tinton, N; Van den Eynde, M | 1 |
| Ahn, TJ; Do, IG; Kang, WK; Kim, HC; Kim, SH; Kim, ST; Lee, E; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Adhoute, X; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Breysacher, G; Charneau, J; Chone, L; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Khemissa, F; Lavau-Denes, S; Lecomte, T; Legoux, JL; Lepère, C; Locher, C; Maillard, E; Michel, P; Mitry, E; Phelip, JM; Provençal, J; Sobhani, I | 1 |
| Beltjens, F; Bengrine, L; Ghiringhelli, F; Ladoire, S; Vincent, J | 1 |
| Aparicio, T; Bedenne, L; Bouché, O; Breysacher, G; Dahan, L; Etienne, PL; Khemissa, F; Lafargue, JP; Le Malicot, K; Lécaille, C; Lecomte, T; Legoux, JL; Loriot, MA; Maillard, E; Manfredi, S; Michel, P; Mitry, E; Rougier, P | 1 |
| Hu, M; Huang, P; Su, Y; Wang, Y; Yan, D; Zhou, L; Zhu, X | 1 |
| Kim, SH; Ku, JL; Moon, HH | 1 |
| Fry, AM; Jones, GD; Sabir, SR; Sahota, NK | 1 |
| Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A | 1 |
| Han, SW; Hong, YS; Hwang, IG; Jung, SH; Kang, HJ; Kang, WK; Kim, HS; Kim, ST; Kim, TW; Lee, J; Lee, JY; Lee, KH; Lim, HY; Lim, SH; Park, JO; Park, SH; Park, YS | 1 |
| Grapsa, D; Saif, MW; Syrigos, K | 1 |
| Andersen, RF; Appelt, AL; Hoegdall, EV; Jakobsen, A; Jensen, BV; Johansen, JS; Nielsen, D; Pallisgaard, N; Pfeiffer, P; Schou, JV; Spindler, KL; Yilmaz, M | 1 |
| Ao, L; Cai, H; Chi, P; Guan, Q; Guo, Y; Guo, Z; Li, M; Li, X; Lu, X; Tong, M; Yan, H; Zheng, W | 1 |
| Azadeh, P; Hosseini Kamal, F; Mortazavi, N; Novin, K; Tahmasebi, A | 1 |
| Aglietta, M; Alabiso, I; Alabiso, O; Baratelli, C; Berruti, A; Bertona, E; Bitossi, R; Brizzi, MP; Forti, L; Leone, F; Mecca, C; Ottone, A; Polverari, RS; Racca, P; Scagliotti, GV; Tampellini, M | 1 |
| Bartnik, CM; Flowers, CR; Goldstein, DA; Neustadter, E; Zeichner, SB | 1 |
| Argiles, G; Elez, ME; Grasselli, J; Sanz-Garcia, E; Tabernero, J | 1 |
| Barbuti, R; Cerone, A; Danesi, R; Del Re, M; Milazzo, P; Sameen, S | 1 |
| Amato, DM; Avallone, A; Catalano, O; Filice, S; Fusco, R; Granata, V; Izzo, F; Nasti, G; Petrillo, A | 1 |
| Adam, R; Afshar, M; Ajavon, Y; Boige, V; Bouchahda, M; Carvalho, C; Castaing, D; De Baere, T; Ducreux, M; Focan, C; Guimbaud, R; Hebbar, M; Innominato, P; Karaboué, A; Kunstlinger, F; Lepère, C; Lévi, FA; Rougier, P; Smith, D; Truant, S; Tumolo, S | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| Fujita, K; Ishida, H; Kubota, Y; Sasaki, Y | 1 |
| Esin, E; Yalcin, S | 1 |
| Azzopardi, N; Boisdron-Celle, M; Gamelin, E; Gouilleux-Gruart, V; Gruel, Y; Lecomte, T; Morel, A; Paintaud, G; Payancé, A; Rollin, J; Watier, H | 1 |
| Dasari, A; Donehower, RC; He, P; Hidalgo, M; Jimeno, A; Jin, R; Laheru, D; Messersmith, WA; Purcell, WT; Rudek, MA; Taylor, GE; Walker, R | 1 |
| Kuppusamy, G; Praveen, TK; Satish Kumar, MN; Tummala, S; Wadhwani, A | 1 |
| Annaratone, L; Bonin, S; Bussolati, G; Capella, C; Chiaravalli, AM; Donada, M; Hoefler, G; Nardon, E; Pichler, M; Stanta, G | 1 |
| Fukushima, M; Nukatsuka, M; Shimamoto, Y; Takechi, T | 1 |
| Andria, M; Arnold, D; Cunningham, D; Dochy, E; Grávalos, C; Hoff, PM; Humblet, Y; Joulain, F; Kröning, H; Lakomý, R; Le-Guennec, S; Macarulla, T; McKendrick, J; Mitchell, E; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Tabernero, J; Ten Tije, AJ; Van Cutsem, E; van Hazel, G; Vishwanath, RL | 1 |
| Kusumi, T; Manabe, M; Miyata, Y; Mizunuma, N; Morita, Y; Taniguchi, F; Touyama, T | 1 |
| Akinwande, O; Bhutiani, N; Martin, RC | 1 |
| Amitesh, R; Beeke, C; Karapetis, C; Lo, L; Maddern, G; Moore, J; Padbury, R; Price, TJ; Roder, D; Townsend, AR | 1 |
| Ikeda, S; Ikegami, N; Murayama, JI; Sakamaki, H; Shimizu, H; Yajima, S | 1 |
| Buc, E; Chatelut, E; De la Fouchardière, C; Mendoza, C; Mineur, L; Pezet, D; Phelip, JM; Quesada, JL; Rivoire, M; Roblin, X | 1 |
| Akagi, Y; Baba, H; Emi, Y; Kawanaka, H; Kitazono, M; Maehara, Y; Maekawa, S; Miyamoto, Y; Murakami, H; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Shimokawa, M; Tanioka, H; Tsuji, A | 1 |
| Andoh, M; Kadowaki, S; Kimura, K; Kinoshita, T; Komori, A; Komori, K; Muro, K; Narita, Y; Taniguchi, H; Ura, T; Yatabe, Y | 1 |
| Doi, T; Hatake, K; Ishihara, Y; Shirao, K; Takahashi, Y; Uetake, H | 1 |
| Fujiwara, H; Ikai, A; Kishimoto, M; Otsuji, E; Sakai, T; Sowa, Y; Watanabe, M; Yanagisawa, A | 1 |
| André, T; Arbaud, C; Bachet, JB; Bennamoun, M; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Dupuis, O; Garcia, ML; Hammel, P; Khalil, A; Larsen, AK; Louvet, C; Maindrault-Gœbel, F; Tournigand, C; Wang, YW; Yeh, CG | 1 |
| Cheong, PF; Fan, L; Goh, BC; Hee, KH; Lee, LS; Lee, SC; Sapari, NS; Seng, KY; Soh, TI; Soo, R; Soong, R; Wang, LZ; Wong, A; Yong, WP | 1 |
| Autorino, R; Balducci, M; Buwenge, M; Caravatta, L; Cellini, F; Cilla, S; Deodato, F; Di Lullo, L; Gambacorta, MA; Macchia, G; Mattiucci, GC; Mignogna, S; Morganti, AG; Padula, GD; Picardi, V; Valentini, V | 1 |
| Atasilp, C; Chamnanphon, M; Chansriwong, P; Puangpetch, A; Reungwetwattana, T; Sirachainan, E; Sukasem, C; Wongwaisayawan, S | 1 |
| Allen, PJ; Boucher, TM; Capanu, M; Cercek, A; Chou, JF; D'Angelica, MI; DeMatteo, RP; Fong, YC; Jarnagin, WR; Kemeny, NE | 1 |
| Berger, MD; Cao, S; Hanna, DL; Lenz, HJ; Loupakis, F; Matsusaka, S; Miyamato, Y; Ning, Y; Okazaki, S; Parekh, A; Stintzing, S; Sunakawa, Y; Yang, D; Zhang, W | 1 |
| Lenz, HJ; Schirripa, M; Sunakawa, Y | 1 |
| Allegrini, G; Barbara, C; Bergamo, F; Boni, L; Buonadonna, A; Bustreo, S; Chiara, S; Cremolini, C; Falcone, A; Granetto, C; Lonardi, S; Loupakis, F; Mancini, ML; Masi, G; Moretto, R; Ronzoni, M; Rossini, D; Tomasello, G; Tonini, G; Vitello, S | 1 |
| Chang, W; Chen, J; Ding, J; Feng, Q; Lin, Q; Qin, X; Ren, L; Wei, Y; Xu, J; Yang, L; Ye, Q; Yu, Y; Zheng, P; Zhong, Y; Zhu, D | 1 |
| Fritzmann, J; Rahbari, NN; Reissfelder, C; Volk, AM; Weber, GF; Weitz, J | 1 |
| Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N | 1 |
| Barni, S; Bendell, JC; Bessudo, A; Bolotin, E; Eng, C; Gladkov, O; Hart, LL; Hsu, C; Kopp, MV; Kotiv, B; Langdon, R; Müller, L; Schwartz, B; Severtsev, A; Vladimirov, V; von Roemeling, R | 1 |
| Chen, KC; Lee, SY; Peng, CL; Shieh, MJ; Wei, MF; Yang, CY; Yao, CJ | 1 |
| Albayrak, D; Cicin, I; Erdogan, B; Hacibekiroglu, I; Kodaz, H; Tozkir, H; Turkmen, E; Uzunoglu, S | 1 |
| Bendell, JC; Boccia, R; Earwood, C; Gian, V; Lane, CM; Lipman, A; LoCicero, R; Meluch, A; Moskowitz, M; Peyton, JD; Waterhouse, D; Zakari, A | 1 |
| Edenfield, WJ; Koch, MD; Ramirez, KG | 1 |
| Abdallah, EA; Abdon Lopes de Mello, C; Alves, Vda S; Araújo, DV; Buim, ME; Chinen, LT; Dettino, AL; Fanelli, MF; Gasparini Junior, JL; Machado Netto, MC; Ocea, LM; Piana de Andrade, V; Souza E Silva, V; Tariki, MS | 1 |
| Franken, MD; Koopman, M; van Oijen, MG | 1 |
| Bekaii-Saab, T; Stintzing, S; Sunakawa, Y | 1 |
| Abdullah, NM; Sharial, MM; Yusof, MM; Zaatar, A | 1 |
| He, MM; Jin, Y; Li, YH; Li, ZZ; Luo, HY; Pan, ZZ; Qiu, MZ; Ren, C; Ren, J; Shao, JY; Wang, DS; Wang, F; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS; Zhang, ZC; Zhao, Q | 1 |
| Akinwande, O; Hahl, M; Kelly, L; Martin, RC; McMasters, KM; Philips, P; Scoggins, CR; Tatum, C | 1 |
| Endo, T; Hasegawa, H; Ishii, Y; Kitagawa, Y; Kondo, T; Ochiai, H; Okabayashi, K; Shigeta, K; Tsuruta, M | 1 |
| Arcaroli, JJ; Bagby, S; Blatchford, P; Capasso, A; Eckhardt, SG; Gao, D; Greene, J; Kim, J; Messersmith, WA; Nguyen, A; Pitts, TM; Purkey, A; Quackenbush, KS; Schreiber, A; Schuller, AG; Tai, WM; Wang, G | 1 |
| Chen, EX; Hagerman, L; Jonker, DJ; Keller, D; McKeever, K; Seymour, L; Siu, LL; Wells, J | 1 |
| Chong, DQ; Choo, SP; Chua, C; Imperial, M; Manalo, M; Ng, M; Tan, IB; Teo, P; Yong, G | 1 |
| Arihara, Y; Hayashi, T; Hirakawa, M; Iyama, S; Kato, J; Kobune, M; Miyanishi, K; Okagawa, Y; Ono, M; Osuga, T; Sato, T; Sato, Y; Takada, K; Takimoto, R; Tamura, F; Uemura, N; Yoshida, M | 2 |
| Atherton, PJ; Grothey, A; Loprinzi, CL; Novotny, PJ; Sloan, JA; Thanarajasingam, G | 1 |
| Becouarn, Y; Fourrier-Réglat, A; Grelaud, A; Guimbaud, R; Jové, J; Moore, N; Noize, P; Ravaud, A; Robinson, P; Rouyer, M; Smith, D; Tubiana-Mathieu, N | 1 |
| Chai, CY; Chien, TM; Huang, CN; Lin, CH; Lu, YM | 1 |
| Chantrill, LA; Ciardiello, F; Desai, J; Elez, E; Gebski, VJ; Haydon, A; Jefford, M; Karapetis, CS; Khasraw, M; Lunke, S; Nott, LM; Pavlakis, N; Price, TJ; Robledo, KP; Segelov, E; Shapiro, JD; Simes, J; Thavaneswaran, S; Underhill, C; van Hazel, G; Waring, PM; Wasan, H; Wilson, K | 1 |
| Boyer, JC; Del Rio, M; Evrard, A; Gassiot, M; Mbatchi, LC; Robert, J; Thomas, F; Tubiana, N; Ychou, M | 1 |
| Bosch, LJ; Carvalho, B; Grady, WM; Herman, JG; Koopman, M; Lao, VV; Luo, Y; Meijer, GA; Mongera, S; Monnat, RJ; Nagtegaal, ID; Punt, CJ; Snaebjornsson, P; Tang, W; Trooskens, G; van Criekinge, W; Vlassenbroeck, I; Welcsh, P | 1 |
| Hu, GY; Huang, L; Li, QX; Li, ZH; Liao, X; Liu, B; Qiu, H; Yu, QQ; Yuan, XL; Zhang, MS | 1 |
| Artaç, M; Avcı, N; Çabuk, D; Coşkun, HŞ; Dane, F; Doruk, H; Faruk Aykan, N; Karaağaç, M; Karabulut, B; Karabulut, S; Korkmaz, L; Turhal, NS | 1 |
| Bardelli, A; Bonaldi, T; Cancelliere, C; Conte, A; Cuomo, A; Di Fiore, PP; Magni, E; Penna, G; Pozzi, C; Ravenda, PS; Rescigno, M; Sigismund, S; Silvola, A; Spadoni, I; Zampino, MG | 1 |
| Berry, SR; Chan, KK; Giotis, A; Ko, YJ; Lien, K; Mittmann, N; Riesco-Martínez, MC; Wong, WW | 1 |
| Carmeli, B; Farkash, A; Katzir, I; Lomnicky, Y; Parush-Shear-Yashuv, N; Rotem Rabinovich, H; Siegelmann-Danieli, N; Vesterman Landes, J | 1 |
| Diaz-Serrano, A; Garcia-Carbonero, R; Riesco-Martinez, MC | 1 |
| Bennouna, J; Cabart, M; Campion, L; Douillard, JY; Dupuis, O; Frénel, JS; Hiret, S; Ramée, JF; Senellart, H | 1 |
| Cai, Y; Chen, J; Feng, J; Fu, Q; Fu, S; Hong, Q; Huang, L; Li, J; Liu, S; Xie, C; Xu, M; Yu, Q; Yuan, X; Zang, A; Zhang, M; Zhang, T | 1 |
| Ando, M; Baba, E; Boku, N; Denda, T; Eguchi Nakajima, T; Esaki, T; Fujikawa, K; Funai, S; Hara, H; Hirashima, T; Hosokawa, A; Hyodo, I; Kawakami, K; Kurimoto, T; Morita, S; Moriwaki, T; Murata, K; Muro, K; Nagase, M; Nakashima, K; Nishina, T; Okabe, M; Okuno, T; Otsuji, T; Sato, M; Seki, N; Shibata, Y; Shimura, T; Shinozaki, E; Shinozaki, K; Sugimoto, N; Suyama, K; Suzuki, K; Taira, K; Takayama, T; Taku, K; Tamagawa, H; Tamura, F; Tamura, T; Tsuda, M; Tsuji, A; Tsuji, Y; Tsushima, T; Ueda, S; Umeki, M; Yamashita, H; Yamazaki, K; Yoshida, M | 1 |
| Jensen, HA; Krogh, M; Pfeiffer, P; Qvortrup, C; Sorbye, H; Vestermark, LW; Winther, SB; Zubcevic, K | 1 |
| Chang-Claude, J; Kap, EJ; Popanda, O | 1 |
| Bocci, G; Kerbel, RS | 1 |
| Abdullah, S; Abi-Jaoudeh, N; Anderson, V; Duffy, AG; Figg, WD; Fioravanti, S; Greten, TF; Lee, S; Levy, E; MacLeod, AR; Makarova-Rusher, OV; Peer, CJ; Raffeld, M; Rahma, OE; Revenko, AS; Steinberg, SM; Tomita, Y; Trepel, JB; Ulahannan, SV; Walker, M; Wood, BJ | 1 |
| Ardito, F; Barone, C; Basso, M; Cassano, A; Cerchiaro, E; Dadduzio, V; Giuliante, F; Lombardi, P; Orlandi, A; Rossi, S; Strippoli, A; Vellone, M | 1 |
| Berger, MD; Cao, S; Cremolini, C; DePaolo, RW; Falcone, A; Heinemann, V; Lenz, HJ; Loupakis, F; Matsusaka, S; Miyamoto, Y; Ning, Y; Okazaki, S; Parekh, A; Schirripa, M; Stintzing, S; Stremitzer, S; Suenaga, M; Sunakawa, Y; West, JD; Yang, D; Zhang, W | 1 |
| Hu, J; Tan, X | 1 |
| Hanaka, J; Nakayama, H; Takahashi, M; Terashima, T | 1 |
| Keyoumu, S; Qu, Y; Tang, X; Tang, Y; Xu, C; Zhou, N | 1 |
| Al-Batran, SE; Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Hielscher, J; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerch, MM; Lerchenmueller, C; Michl, M; Modest, DP; Mueller, S; Scheithauer, W; Scholz, M; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U | 1 |
| Agostini, M; Calandra, E; Crotti, S; Giodini, L; Marangon, E; Nitti, D; Posocco, B; Toffoli, G; Traldi, P | 1 |
| Chantrill, L; Ciardiello, F; Day, F; Desai, J; Elez, E; Gebski, V; Haydon, A; Jefford, M; Joubert, W; Karapetis, C; Khasraw, M; Nott, L; Pavlakis, N; Price, T; Segelov, E; Shapiro, J; Tebbutt, N; Tejpar, S; Thavaneswaran, S; Underhill, C; van Hazel, G; Waring, P; Wasan, H; Wilson, K | 1 |
| Folprecht, G | 1 |
| Barreto, R; Bonetto, A; Gao, H; Liu, Y; Waning, DL; Zimmers, TA | 1 |
| Biffoni, M; Buccarelli, M; Cappellari, M; De Luca, G; Fanciulli, M; Goeman, F; Melucci, E; Pilozzi, E; Ricci-Vitiani, L; Signore, M | 1 |
| André, T; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Garcia-Larnicol, ML; Hamidou, Z; Hebbar, M; Hug de Larauze, M; Louvet, C | 1 |
| Gao, Q; Ma, J; Shen, H; Zeng, S | 1 |
| Goda, F; Goji, T; Kawamoto, S; Kimura, M; Kimura, T; Kitamura, S; Miyamoto, H; Muguruma, N; Negoro, Y; Niitsu, Y; Okahisa, T; Okamoto, K; Sakamoto, K; Shimoyama, R; Takaoka, T; Takayama, T; Tsuji, A; Yano, H; Yoshizaki, K | 1 |
| Lee, PC; Lee, SY; Lin, CY; Lin, SY; Luo, TY; Ning, ST; Peng, CL; Shieh, MJ; Shih, YH; Tsai, MH; Wei, MF | 1 |
| Ammari, S; Antoun, S; Bayar, MA; Chemama, S; Elias, D; Goéré, D; Lanoy, E; Raynard, B; Stoclin, A | 1 |
| Akinwande, O; Martin, RC; Scoggins, C | 1 |
| Aliberti, C; Carandina, R; Catalano, V; Coschiera, P; Felicioli, A; Fiorentini, G; Mulazzani, L; Sarti, D | 1 |
| Hamaguchi, T; Honma, Y; Ikezawa, N; Iwasa, S; Kato, K; Nagashima, K; Okita, N; Shimada, Y; Shoji, H; Takashima, A; Yamada, Y; Yamaguchi, T | 1 |
| Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Murono, K; Nishikawa, T; Nozawa, H; Otani, K; Tanaka, T; Watanabe, T; Yasuda, K | 1 |
| Cohen, SJ; Dotan, E; Hall, MJ; Li, T; Vijayvergia, N; Wong, YN | 1 |
| Antoniotti, C; Battaglin, F; Berenato, R; Bergamo, F; Borelli, B; Caporale, M; Cremolini, C; De Braud, F; Falcone, A; Fontanini, G; Lonardi, S; Loupakis, F; Marmorino, F; Marsico, VA; Masi, G; Mennitto, A; Moretto, R; Pietrantonio, F; Rossini, D; Salvatore, L | 1 |
| Arcaroli, JJ; Bagby, SM; Bradshaw-Pierce, EL; Capasso, A; Davis, SL; Diamond, JR; Eckhardt, SG; Ecsedy, JA; Hyatt, SL; Klauck, PJ; McPhillips, K; Messersmith, WA; Pitts, TM; Purkey, A; Selby, HM; Spreafico, A; Tan, AC; Tentler, JJ | 1 |
| Bouchahda, M; Chatelut, E; Etienne-Grimaldi, MC; Focan, C; Innominato, P; Karaboué, A; Lévi, F; Milano, G; Paintaud, G | 1 |
| Bahary, N; Bartlett, DL; Choudry, MH; Clifford, AK; Dhir, M; Hogg, ME; Holtzman, MP; Jones, HL; Perkins, S; Pingpank, JF; Shuai, Y; Steve, J; Zeh, HJ; Zureikat, AH | 1 |
| Garg, S; Song, Y; Wang, T; Xiao, Y; Yang, S; Zhang, B; Zhang, N | 1 |
| Ball, A; Bowers, M; Bridgewater, JA; Corkhill, A; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Maishman, T; Maughan, TS; O'Reilly, DA; Primrose, JN; Pugh, SA; Radford, M; Rees, C; Rees, M; Siriwardena, AK; Stanton, L; Valle, JW | 1 |
| Inoue, M; Ishioka, C; Komine, K; Ouchi, K; Shimodaira, H; Soeda, H; Takahashi, H; Takahashi, M; Takahashi, S; Zhang, X | 1 |
| Boku, N; Fukahori, M; Hamaguchi, T; Honda, K; Honma, Y; Iwasa, S; Okita, NT; Sasaki, Y; Shimada, Y; Shoji, H; Sudo, K; Takahashi, N; Takashima, A; Yamada, T; Yamada, Y | 1 |
| Bajenova, O; Danilova, A; Koshkin, S; O'Brien, SJ; Petrov, N; Raskin, G; Tolkunova, E; Tomilin, A | 1 |
| Brünner, N; Guo, J; Huang, X; Li, L; Liu, S; Pan, Q; Ren, Y; Ren, Z; Stenvang, J; Wen, B; Wu, L; Xu, S; Zhang, C; Zhou, R; Zi, J | 1 |
| Bartlett, DL; Dhir, M; Magge, D; Novak, S; Zureikat, AH | 1 |
| Adam, R; Albiol, M; Awad, S; Fenwick, SW; Figueras, J; Gruenberger, T; Jones, RP; Malik, HZ; O'Grady, E; Plant, G; Poston, GJ; Rees, M; Stremitzer, S; Terlizzo, M | 1 |
| Koopman, M; Mol, L; Ottevanger, PB; Punt, CJ | 1 |
| Bodoky, G; Ciuleanu, T; Clingan, P; Cohn, A; Garcia Alfonso, P; Garcia-Carbonero, R; Kim, TW; Lonardi, S; Nasroulah, F; Obermannová, R; Portnoy, D; Prausová, J; Tabernero, J; Van Cutsem, E; Yamazaki, K; Yang, L; Yoshino, T | 1 |
| Al-Batran, SE; Decker, T; Giessen-Jung, C; Heinemann, V; Heintges, T; Held, S; Jagenburg, A; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerch, MM; Lerchenmüller, C; Modest, DP; Moehler, M; Rossius, L; Scheithauer, W; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF | 1 |
| Beier, F; Ciardiello, F; Folprecht, G; Köhne, CH; Poston, G; Ronga, P; Van Cutsem, E | 1 |
| Crea, F; Danesi, R; De Gregorio, V; Falcone, A; Fornaro, L; Graziano, F; Loupakis, F; Masi, G; Paolicchi, E; Ricci, V; Ronzoni, M; Vivaldi, C | 1 |
| Chen, Y; Cui, Y; Liang, L; Liu, T; Wang, Y; Wang, Z; Yu, Y; Zhou, Y; Zhuang, R | 1 |
| Arbez-Gindre, F; Borg, C; Cayre, A; Fein, F; Jacquin, M; Jary, M; Kim, S; Lakkis, Z; Nguyen, T | 1 |
| Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS | 1 |
| Saltz, LB | 5 |
| Ahn, SJ; Han, JK; Kim, JH; Park, SJ | 1 |
| Ayers, M; Clarke, SJ; Cunningham, D; Ferry, D; Frodin, JE; Guren, TK; Hawkes, E; Kim, SY; Kim, TW; Kim, TY; Loboda, A; Nebozhyn, M; Park, YS; Peckitt, C; Roh, JK; Schmoll, HJ; Sclafani, F; Tabernero, J; Watkins, DJ | 1 |
| Boku, N; Denda, T; Hyodo, I; Moriwaki, T; Muro, K; Nishina, T; Nishio, K; Okuda, H; Sakai, K; Shitara, K; Takano, T; Tokunaga, S; Tsuda, M; Yamanaka, T; Yamazaki, K; Yonesaka, K | 1 |
| Artaç, M; Börüban, MC; Bozcuk, H; Er, Z; Güler, T; Karaağaç, M; Korkmaz, L; Uysal, M | 1 |
| Alcaide, J; Díez de Corcuera, I; Feliu, J; García García, T; Manzano, JL; Sastre, J; Valladares-Ayerbes, M; Vera, R | 1 |
| Atkins, J; Bellido, J; El Osta, B; Fogelman, D; Fu, S; Hong, DS; Huang, H; Janku, F; Kee, B; Kopetz, S; Lanman, R; Meric-Bernstam, F; Morris, VK; Overman, MJ; Piha-Paul, S; Shureiqi, I; Sommer, N; Sorokin, AV; Subbiah, V; Tarcic, G; Tsimberidou, AM | 1 |
| Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K | 1 |
| Pellerin, O; Pernot, S; Pointet, AL; Sueur, B; Taieb, J; Voron, T | 1 |
| Chen, HJ; Fang, S; Huang, ZH; Lin, XH; Yu, JL; Zou, ZW | 1 |
| Boedigheimer, M; Demonty, G; Fernebro, E; Greil, R; Hofheinz, RD; Karthaus, M; Köhne, CH; Letocha, H; Mineur, L; Oliner, KS; Thaler, J; Twomey, B; Zhang, Y | 1 |
| Andersen, CL; Lyskjær, I; Rasmussen, MH | 1 |
| Castillo, C; Collet-Benzaquen, D; Combemale, P; de la Fouchardière, A; Desseigne, F; Fattouh, K; Provensal, AM | 1 |
| Beier, F; Chatterjee, S; Cheng, AL; Chung, IJ; Cornelio, G; Dai, GH; Doval, DC; Gibbs, P; Gorospe, C; Guan, Z; Hill, A; Lim, R; Lin, JK; Ma, B; Masood, N; Oh, ST; Price, T; Sharma, A; Shen, L; Shim, BY; Sirachainan, E; Srimuninnimit, V; Suh, KW; Wang, HM; Wang, X; Yang, TS; Yau, T; Yeh, KH; Zaatar, A | 1 |
| Jia, J; Liu, C; Shen, L; Sun, Z; Wang, X; Zhang, X | 1 |
| Flint, S; Galvin, S; Nestor, LA | 1 |
| Aparicio, T; Auby, D; Bachet, JB; Bouché, O; Boulat, O; Breysacher, G; Cretin, J; Faroux, R; Gargot, D; Gasmi, M; Genet, D; Jouve, JL; Khemissa, F; Lecomte, T; Lepère, C; Locher, C; Maillard, E; Mitry, E; Ramdani, M; Seitz, JF; Sobhani, I; Stefani, L; Teillet, L | 1 |
| Alvarez, R; Cubillo, A; de la Varga, LU; Garralda, E; Hidalgo, M; Lopéz-Casas, PP; López-Ríos, F; Pascual, JR; Perea, S; Prieto, SH; Sánchez, G; Sarno, F; Toledo, RA; Vega, E | 1 |
| Chen, K; Gong, Y; Shen, Y; Zhang, Q; Zhou, T | 1 |
| Ålgars, A; Carpen, O; Jokilehto, T; Kaare, M; Kytölä, S; Lintunen, M; Orpana, A; Österlund, P; Ristamäki, R; Ristimäki, A; Sundström, J; Vainionpää, R | 1 |
| Chong, Z; Feng, B; Meng, Q; Mengyi, Z; Ming, L; Qiulin, T; Ruihua, H; Xin, M | 1 |
| Amoreo, CA; Benarroch-Popivker, D; Biroccio, A; Capolupo, A; Cosconati, S; D'Angelo, C; Del Gaudio, F; Di Maro, S; Gilson, E; Iachettini, S; Maresca, C; Merlino, F; Mottolese, M; Novellino, E; Rizzo, A; Salvati, E; Sperduti, I; Zizza, P | 1 |
| Cheng, TL; Hu, HM; Huang, CW; Ma, CJ; Tsai, HL; Wang, JY; Wu, IC; Yeh, YS | 1 |
| Chen, Q; Cheng, M; Wang, Z; Zhao, S | 1 |
| Allegrini, G; Aprile, G; Bergamo, F; Casagrande, M; Cillo, U; Cremolini, C; Falcone, A; Ferrari, L; Fontanini, G; Granetto, C; Loupakis, F; Marmorino, F; Masi, G; Milione, M; Moretto R, R; Pellegrinelli, A; Pietrantonio, F; Pilati, P; Sensi, E; Tomasello, G; Tonini, G; Urbani, L; Zucchelli, G | 1 |
| Benahim, E; Boige, V; de Baere, T; Deschamps, F; Ducreux, M; Goéré, D; Malka, D; Tselikas, L | 1 |
| Adams, R; Brown, S; Cheadle, J; Elliott, F; Fisher, D; Maughan, T; Middleton, G; Quirke, P; Richman, SD; Seligmann, JF; Seymour, M; Smith, CG | 1 |
| Zaniboni, A | 1 |
| Hu, Y; Lin, A; Ma, C; Niu, Y; Shi, L; Su, Y; Zhang, C; Zhou, L; Zhu, X | 1 |
| D'Souza, D; Flanagan, S; Golzarian, J; Young, S | 1 |
| Khan, SA; Paty, PB; Shia, J; Zeng, Z | 1 |
| Du, XL; Lairson, DR; Parikh, RC; Robert, MO | 1 |
| Aroldi, F; Beretta, GD; Bertocchi, P; Meriggi, F; Prochilo, T; Zaniboni, A | 1 |
| Al-Batran, SE; Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Held, S; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerchenmüller, C; Modest, DP; Moehler, M; Scheithauer, W; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Einem, JC | 1 |
| Blanke, C; Cesas, A; Choi, MR; Croitoru, A; Decaestecker, J; Gibbs, P; Hotko, Y; Jassem, J; Klippel, Z; Kurteva, G; Morrow, PK; Novotny, J; O'Reilly, S; Pinter, T; Reiner, M; Salek, T; Whittaker, S | 1 |
| Atreya, C; Korn, WM; Parikh, A; Venook, AP | 1 |
| Alexander, C; Ashford, MB; Barnes, J; Barry, ST; England, RM; Hare, JI; Kemmitt, PD; Smith, A; Strittmatter, N; Waring, MJ; Wilson, J | 1 |
| Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Murono, K; Nakajima, J; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Tanaka, T; Watanabe, T; Yasuda, K | 1 |
| Buonadonna, A; Cecchin, E; De Mattia, E; Giodini, L; Innocenti, F; Montico, M; Roncato, R; Solfrini, V; Toffoli, G | 1 |
| Hazama, S; Iida, M; Inoue, Y; Kanekiyo, S; Nagano, H; Sakamoto, K; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Tomochika, S; Tsunedomi, R; Ueno, T; Yoshino, S | 1 |
| Brünner, N; Høgdall, EV; Jensen, BV; Linnemann, D; Nielsen, DL; Palshof, JA; Pfeiffer, P; Poulsen, TS; Stenvang, J; Tarpgaard, LS; Yilmaz, M | 1 |
| Modest, DP; Neumann, UP; Pratschke, J | 1 |
| Ando, M; Beier, F; Guenther, S; Ooki, A; Van Cutsem, E; von Hohnhorst, P; Yamaguchi, K | 1 |
| Baretta, Z; Bonfill Cosp, X; Hallum, S; Martin-Richard, M; Mocellin, S; Roqué I Figuls, M; Solà, I | 1 |
| Chang, H; Chen, P; Li, B; Luo, X; Nie, P; Shi, X; Wu, B; Xu, W; Yu, X; Zou, Z | 1 |
| Ando, M; Hasegawa, H; Kadowaki, S; Komori, A; Masuishi, T; Mitani, S; Muro, K; Narita, Y; Taniguchi, H; Ura, T; Yatabe, Y | 1 |
| Loreni, G; Miele, V; Ramponi, S; Rastelli, M; Scevola, G; Sposato, S | 1 |
| Caroen, S; Carter, C; Cho-Phan, C; Fanger, G; Fisher, G; Knox, S; Kunz, P; Ning, S; Oronsky, B; Parker, C; Reid, T; Scicinski, J | 1 |
| Ashour, ME; Downs, JA; El-Khamisy, SF; El-Shafie, L; Hodgson, A; Khurram, SA; Liao, C; Meisenberg, C; Pilborough, A; Ward, SE | 1 |
| Boller, E; Dingeldein, G; Ehscheidt, P; Flohr, T; Galle, PR; Geer, T; Göhler, T; Hebart, H; Heike, M; Indorf, M; Josten, KM; Karthaus, M; Lang, C; Moehler, M; Neise, M; Rudi, J; Schimanski, CC; Schmittel, A; Staib, F; Wierecky, J; Wörns, MA | 1 |
| Cho, SH; Chung, IJ; Han, HS; Hong, YS; Kang, HJ; Kang, JH; Kim, JE; Kim, JH; Kim, JW; Kim, KP; Kim, SY; Kim, TW; Lee, JH; Lee, KT; Lee, KW; Lee, MA; Nam, BH; Oh, HS; Park, SR; Park, YI; Park, YS; Shin, DB; Song, EK; Zang, DY | 1 |
| Ando, M; Araida, T; Hamano, M; Hayashi, K; Hirai, E; Itabashi, M; Kameoka, S; Kawakami, K; Kuramochi, H; Nakajima, G; Okuyama, R; Yokomizo, H; Yoshimatsu, K | 1 |
| Berry, S; Chan, KK; Earle, C; Jerzak, KJ; Ko, YJ | 1 |
| André, T; Asselain, B; Bennouna, J; Ducreux, M; Phelip, JM | 1 |
| Alles, EJ; Bamber, JC; Cox, TR; Elyas, E; Erler, JT; Papaevangelou, E; Robinson, SP | 1 |
| Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M | 1 |
| Adlard, JW; Barrett, JH; Braun, MS; Daly, C; Elliott, F; Meade, AM; Parmar, MK; Quirke, P; Richman, SD; Selby, P; Seymour, MT; Stephens, RJ | 1 |
| Colbeck, M; Hewett, P; Luke, C; Maddern, G; Patterson, W; Pittman, K; Price, T; Rieger, N; Rodda, D; Roder, D; Townsend, A | 1 |
| Boige, V; Ducreux, M; Marti, P; Merrouche, Y; Raoul, JL; Rebischung, C; Tigaud, JM | 1 |
| Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B | 1 |
| Ayadi, M; Bertucci, F; Birnbaum, D; Borg, JP; Delpero, JR; Esterni, B; Esteyries, S; Gonçalves, A; Lagarde, A; Lelong, B; Monges, G; Olschwang, S; Taylor-Smedra, B; Turrini, O; Viens, P; Viret, F | 1 |
| Amarantidis, K; Ardavanis, A; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Polyzos, A; Souglakos, J; Tsousis, S; Vamvakas, L; Vardakis, N; Varthalitis, I; Ziras, N | 1 |
| Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL | 1 |
| Aguilar, J; Beviglia, L; Chartier, C; Clarke, MF; Dylla, SJ; Gurney, AL; Hoey, T; Lazetic, S; Lewicki, J; Ngan, L; Park, IK; Pickell, K; Raval, J; Smith-Berdan, S | 1 |
| Georgiades, CC; Geschwind, JF; Hong, K; Lee, KH; Liapi, E | 1 |
| Alvarez Z, M; González D, R; Jarufe C, N; Martínez C, J | 1 |
| Adamo, V; Battistoni, F; Dicuonzo, G; Fulfaro, F; Galluzzo, S; Rocci, L; Russo, A; Santini, D; Silletta, M; Tonini, G; Vincenzi, B; Zobel, BB | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T | 1 |
| Bearz, A; Berretta, M; Berretta, S; Fisichella, R; Lleshi, A; Nasti, G; Simonelli, C; Tirelli, U; Zanet, E | 1 |
| Banzi, C; Biasco, G; Bonetti, F; Boni, C; Brandes, A; Calandri, C; Carandina, I; Cataldo, S; DI Fabio, F; Lelli, G; Marzola, M; Nanni, O; Negri, F; Panetta, A; Pantaleo, MA; Ravaioli, E; Turci, D; Urbini, B | 1 |
| Berger, MR; Ehrenberg, R; Galle, PR; Heeger, S; Hickmann, L; Moehler, M; Schad, A; Schimanski, CC; Schulze-Bergkamen, H; Urbanik, T; Vick, B; Weber, A | 1 |
| Chu, E | 4 |
| Sharma, RI; Smith, TA | 1 |
| Chen, P; Lin, F; Sun, Y; Tang, L; Yao, Y; Zhao, H | 1 |
| Healey-Bird, BR; Kemeny, NE; Power, DG | 1 |
| Cianci, G; Cortesi, E; D'Auria, G; Gamucci, T; Grassi, G; Moscetti, L; Nelli, F; Pollera, CF; Sperduti, I; Zeuli, M | 1 |
| Anthony, L | 1 |
| Bosch, A; Cervantes, A; Chirivella, I; Martín-Martorell, P; Rodríguez-Braun, E; Roselló, S | 1 |
| Bocci, G; Danesi, R; Del Tacca, M; Di Paolo, A | 1 |
| Carnaghi, C; Comandone, A; Granetti, C; Lorusso, V; Mari, E; Oliva, C; Pressiani, T; Rimassa, L; Ronzoni, M; Santoro, A; Siena, S; Zuradelli, M | 1 |
| Benson, AB; Berinstein, NL; Caterini, J; Conry, RM; Cripps, C; Dalfen, R; Debenedette, M; Elias, I; Garett, C; Heim, WJ; Kaufman, HL; Kim-Schulze, S; Lenz, HJ; Marshall, J; Moore, M; Salha, D; Singh, D; Urba, WJ; Vogel, T; von Mehren, M; Yu, M | 1 |
| Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Waddell, T; Wilson, G | 1 |
| Barbas, AS; Bendell, JC; Broadwater, G; Clary, BM; Hurwitz, HI; Morse, MA; Niedzwiecki, D; Reddy, SK | 1 |
| Frei, CR; Greene, RE; Koeller, JM; Kwan, P; McKibbin, T; Simon, J | 1 |
| Hama, T; Hatake, K; Hirata, Y; Imada, H; Kamisugi, K; Kawakami, K; Matsusaka, S; Mizunuma, N; Nakamoto, E; Nawano, K; Ogawa, M; Shinozaki, E; Shoji, D; Suenaga, M; Yokokawa, T | 1 |
| Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM | 1 |
| Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M | 1 |
| Deeken, JF; Marshall, JL; Slack, R | 1 |
| Díaz-Rubio, E; García-Saenz, JA; Puente, J; Sastre, J | 1 |
| Fakih, M | 2 |
| McBride, D | 1 |
| Cella, D; Holmgren, E; Hurwitz, HI; Kabbinavar, FF; Wallace, JF; Yi, J; Yost, KJ | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Koopman, M; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T | 1 |
| Choi, HS; Hong, CW; Hong, YS; Jeong, SY; Jung, KH; Kim, BC; Kim, DY; Kim, SY; Park, JW; Sohn, DK | 1 |
| Grothey, A; Sargent, DJ | 1 |
| Bodoky, G; Garay, C; Habboubi, N; Haller, DG; Koralewski, PM; Miller, WH; Olivatto, LO; Rothenberg, ML; Wong, AO | 1 |
| Arai, T; Boku, N; Inaba, Y; Komatsu, Y; Mizunuma, N; Nishina, T; Sakata, Y; Satoh, T; Shirao, K; Tahara, M; Takiuchi, H; Yamaguchi, K | 1 |
| Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E | 1 |
| Berardi, R; Cascinu, S; Chiorrini, S; Galizia, E; Giampieri, R; Pierantoni, C; Scartozzi, M | 1 |
| Asaka, M; Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F | 1 |
| Hurwitz, H; Irl, C; Kabbinavar, F; Zurlo, A | 1 |
| Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J | 1 |
| Aapro, MS; Adenis, A; Aguilar, EA; Esser, R; Glynne-Jones, R; Loos, AH; Preusser, P; Siena, S; Thaler, J; Wilke, H | 2 |
| Allen, WL; Coyle, VM; Fenning, C; Gordon, M; Jithesh, PV; Johnston, PG; Lenz, HJ; Longley, DB; Proutski, I; Stevenson, L; Wilson, RH | 1 |
| Fukazawa, A; Hayashi, T; Konno, H; Kurachi, K; Nakajima, A; Nakamura, K; Nakamura, T; Suzuki, S | 1 |
| Adachi, K; Arimoto, Y; Kanamiya, Y; Nakamura, R; Nishio, K; Oba, H; Ohtani, H; Shintani, M; Yui, S | 1 |
| Abdalla, EK; Blazer, DG; Chang, DZ; Chun, YS; Curley, SA; Ellis, LM; Eng, C; Fogelman, D; Glover, KY; Kishi, Y; Kopetz, S; Maru, DM; Overman, MJ; Ribero, D; Vauthey, JN; Wang, H; Wolff, RA; Zorzi, D | 1 |
| Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P | 1 |
| Arribas, J; Balmaña, J; Baselga, J; Guzman, M; Saura, C; Scaltriti, M; Tabernero, J; Vilar, E | 1 |
| Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Sugimasa, Y; Tsuchida, K | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Matsunaga, M; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W; Yamashita, K | 1 |
| Dintinjana, M; Dintinjana, RD; Guina, T; Krznarić, Z; Radić, M | 1 |
| Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE | 1 |
| Lam, MG; Nijsen, JF; van den Bosch, MA; van der Tweel, I; van Het Schip, AD; Vente, MA; Wondergem, M; Zonnenberg, BA | 1 |
| Campbell, ME; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sanoff, HK; Sargent, DJ; Williamson, SK | 1 |
| Boige, V; Ducreux, M; Laurent-Puig, P; Malka, D | 1 |
| Ducreux, M; Laurent-Puig, P; Lièvre, A; Loriot, MA | 1 |
| Chin, K; Hatake, K; Matsusaka, S; Mizunuma, N; Muto, T; Oya, M; Shinozaki, E; Shouji, D; Suenaga, M; Yamaguchi, T | 1 |
| al-shammaa Hassan, AH; Li, Y; Liu, SY; Lu, YL; Yang, GL; Yang, XJ; Yonemura, Y; Zhang, JW | 1 |
| Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S | 1 |
| Arnold, D; Hacker, U; Kubicka, S; Schmoll, HJ; Siewczynski, R | 1 |
| Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S | 1 |
| Algeciras-Schimnich, A; O'Kane, DJ; Snozek, CL | 1 |
| Brown, TJ; Cinc, E; Fox, RM; Gibbs, P; Jennens, R; Michael, M; Ng, R; Pho, M | 1 |
| Hurwitz, HI; Kabbinavar, FF; Rosen, O; Sarkar, S; Yi, J | 1 |
| Aderka, D; Ben-Haim, M; Figer, A; Klausner, JM; Lubezky, N; Nakache, R; Shmueli, E; Small, RM | 1 |
| Baki, M | 1 |
| Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S | 1 |
| Huang, S; Okumura, K; Sinicrope, FA | 1 |
| Jover, R; Sempere, L | 1 |
| Balzer, JO; Eichler, K; Gruber, T; Hammerstingl, R; Vogl, TJ; Zangos, S | 1 |
| Khan, AZ; Makuuchi, M; Morris-Stiff, G | 1 |
| Mitry, E | 1 |
| Barone, C; Pozzo, C | 1 |
| Bonastre, J; Brouquet, A; Chevalier, J; Classe, JM; Elias, D; Ferron, G; Goéré, D; Guilloit, JM; Lefevre, JH; Marchal, F; Meeus, P | 1 |
| Doi, T; Hoshi, M; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Oshima, S | 1 |
| Fujimoto, T; Nakamura, Y; Ogawa, K; Osawa, G; Otani, T; Tsunoda, T; Yokomizo, H; Yoshimatsu, K | 1 |
| Inoue, N; Ishibashi, K; Ishida, H; Ishiguro, T; Matsuki, M; Mitsuhashi, T; Miyazaki, T; Okada, N; Okita, T; Sano, M; Yokoyama, M | 1 |
| Augé, JM; Carcereny, E; Codony-Servat, J; Gallego, R; García-Albéniz, X; Gascón, P; Longarón, R; Maurel, J; Oliveras, A; Tosca, M | 1 |
| Amado, RG; Chidiac, T; Cohn, A; Deeter, R; Hagenstad, C; Hecht, JR; Marshall, J; McCollum, D; Mitchell, E; Scroggin, C; Shahin, S; Spigel, D; Stella, P | 1 |
| Hsu, CW; King, TM; Lin, CH; Ou, WC; Wang, HT; Wang, JH | 1 |
| Bradley, LA; Dotson, WD; Douglas, MP; Kolor, K; Palomaki, GE | 1 |
| Davies, JM; Goldberg, RM | 1 |
| Hurwitz, HI; Ince, W; Novotny, WF; Rosen, O; Yi, J | 1 |
| Hendlisz, A; Van den Eynde, M | 1 |
| Buffart, TE; Carvalho, B; Eijk, PP; Koopman, M; Meijer, GA; Peters, GJ; Postma, C; Punt, CJ; van Krieken, JH; Ylstra, B | 1 |
| Abdelfattah, M; Adami, B; Flieger, D; Galle, PR; Godderz, W; Hoehler, T; Kanzler, S; Majer, K; Moehler, M; Schimanski, CC; Siebler, J; Sprinzl, MF; Teufel, A | 1 |
| André, T; Bengrine-Lefevre, L; Bidard, FC; Cervantes, A; de Gramont, A; Figer, A; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C | 1 |
| Bibeau, F; Blanchard, F; Boissière-Michot, F; Di Fiore, F; Frébourg, T; Lamy, A; Lopez-Crapez, E; Michel, P; Penault-Llorca, F; Sabourin, JC; Thezenas, S; Ychou, M | 1 |
| Berglund, A; Byström, P; Frödin, JE; Garske, U; Glimelius, B; Jacobsson, H; Nygren, P; Sundin, A | 1 |
| Antonini, NF; Hoogerbrugge, N; Koopman, M; Kortman, GA; Ligtenberg, MJ; Mekenkamp, L; Punt, CJ; van Krieken, JH | 1 |
| Faissner, R; Gasimova, L; Keese, M; Lewis, A; Löhr, M; Samel, S; Schwenke, K; Shang, E; Yagublu, V | 1 |
| Ahn, JB; Byun, JH; Hong, YS; Im, SA; Jung, KH; Kang, WK; Kim, TW; Lee, J; Lee, N; Lim, HY; Oh, DY; Park, JO; Park, SH; Park, YS; Shin, DB; Shin, SJ | 1 |
| Andersen, RF; Crüger, D; Garm Spindler, KL; Jakobsen, A; Lindebjerg, J; Pallisgaard, N; Rasmussen, AA | 1 |
| Ahn, KD; Cho, YB; Choi, SH; Chun, HK; Kim, HC; Lee, JM; Lee, WY; Shin, HJ; Song, SY; Yun, SH | 1 |
| Boesler, B; Czock, D; Keller, F; Rasche, FM; Shipkova, M | 1 |
| Flowers, C; Kauh, J; Moore, SG; Shenoy, PJ; Tumeh, JW | 1 |
| Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M | 1 |
| Fakih, MG; Rustum, YM | 1 |
| Bhushan, S; McLeod, H; Walko, CM | 1 |
| Ambrosi, A; Calise, S; Costantino, E; Esposito, F; Fersini, A; Landriscina, M; Maddalena, F; Neri, V; Piscazzi, A; Tirino, V | 1 |
| Bachet, JB; Lièvre, A; Mitry, E; Rougier, P | 1 |
| Ben-Haim, M; Figer, A; Geva, R; Klausner, JM; Lubezky, N; Nakache, R; Shmueli, E | 1 |
| Milicević, M; Popov, I; Radosević-Jelić, Lj | 1 |
| Andreuccetti, M; Baldi, G; Brunetti, IM; Cupini, S; Falcone, A; Ferraldeschi, R; Filipponi, F; Fornaro, L; Goletti, O; Loupakis, F; Masi, G; Naso, G; Pietrabissa, A; Pollina, L; Ricci, S; Vasile, E | 1 |
| Koopman, M; Punt, CJ; Seymour, MT | 1 |
| Kawabata, Y; Nakagawa, A; Tamiya, Y; Uchikoshi, H | 1 |
| Alessandroni, P; Baldelli, AM; Bisonni, R; Catalano, V; D'Emidio, S; Falcone, A; Fedeli, SL; Fornaro, L; Giordani, P; Giustini, L; Graziano, F; Loupakis, F; Mari, D; Rossi, D; Silva, RR; Torresi, U | 1 |
| Cohen, MH; Giusti, RM; Keegan, P; Pazdur, R | 1 |
| Cohen, SJ; Doyle, GV; Gabrail, NY; Iannotti, N; Meropol, NJ; Miller, MC; Mitchell, E; Morse, MA; Picus, J; Punt, CJ; Sabbath, KD; Saidman, BH; Terstappen, LW; Tissing, H | 1 |
| Asahi, D; Doi, T; Hamamoto, Y; Muro, K; Shirao, K; Takiuchi, H; Watanabe, H; Yang, BB; Yoshino, T | 1 |
| Nadai, M; Palù, G; Palumbo, M; Richter, SN | 1 |
| Adachi, M; Iida, A; Mori, K; Sakakibara, T; Sugawara, S; Sugiura, M; Takimoto, N; Yamamura, K | 1 |
| Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, A | 1 |
| Dugan, U; Heimbrook, D; Higgins, B; Kolinsky, K; Packman, K; Zhang, YE | 1 |
| Ding, W; Hakoshima, M; Hattori, Y; Kawano, K; Koga, K; Maitani, Y; Shi, L | 1 |
| Castillo, C; Cendoya, I; Fernández, E; Fernández, JL; Gil, A; Gómez Martínez de Lecea, C; Gómez Portilla, A; Guede, N; Kvadatze, M; Larrabide, I; Lirola, A; Magrach, L; Martín, E; Martínez de Lecea, C; Moraza, N; Muriel, J; Olabarría, I; Romero, E; Rua, O; Ruiz de Alegría, N; Ulibarrena, MA; Valdovinos, M | 1 |
| Bodoky, G; Chang Chien, CR; D'Haens, G; Folprecht, G; Hitre, E; Köhne, CH; Lim, R; Makhson, A; Nippgen, J; Pintér, T; Roh, JK; Rougier, P; Ruff, P; Schlichting, M; Stroh, C; Tejpar, S; Van Cutsem, E; Zaluski, J | 1 |
| Hasmann, M; Klein-Scory, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schoeneck, A; Schulmann, K; Schwarte-Waldhoff, I; Stricker, I; Tannapfel, A | 1 |
| Ducreux, M; Hebbar, M; Ychou, M | 1 |
| Gurney, H; Mathijssen, RH | 1 |
| Chen, P; Das, S; Dolan, ME; Innocenti, F; Kroetz, DL; Ramírez, J; Ratain, MJ; Relling, M; Rosner, GL; Schuetz, E | 1 |
| Carloni, F; Nicoletti, S; Ravaioli, A; Tamburini, E; Tassinari, D | 1 |
| Fazzone, W; Gordon, M; Iqbal, S; Ladner, RD; Lenz, HJ; Lurje, G; Press, OA; Rhodes, KE; Schultheis, AM; Vallböhmer, D; Yang, D; Zhang, W | 1 |
| Italiano, A; Sablin, MP; Spano, JP | 1 |
| Aussilhou, B; Belghiti, J; Dokmak, S; Faivre, S; Paradis, V; Vilgrain, V | 1 |
| Hoskins, JM; McLeod, HL | 1 |
| Biason, P; Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Mattia, E; Innocenti, F; Toffoli, G | 1 |
| Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL | 1 |
| Biesmans, B; Claes, B; De Roock, W; De Schutter, J; Jacobs, B; Lambrechts, D; Prenen, H; Tejpar, S; Van Cutsem, E | 1 |
| Bonfill Cosp, X; López, JJ; Martin-Richard, M; Roqué I Figuls, M; Solà, I | 1 |
| Alberts, SR; Fitch, TR; Goldberg, RM; Kim, GP; Mahoney, MR; Mathews, AP; Mitchell, E; Philip, PA; Pitot, HC; Rowland, KM; Sargent, DJ | 1 |
| Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X | 1 |
| Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E | 1 |
| Sobrero, A | 1 |
| Campani, D; Canestrari, E; Cascinu, S; Cremolini, C; Falcone, A; Floriani, I; Funel, N; Graziano, F; Loupakis, F; Magnani, M; Masi, G; Petrini, I; Pollina, L; Rulli, E; Ruzzo, A; Santini, D; Scartozzi, M; Schiavon, G; Stasi, I; Tonini, G | 1 |
| Baracos, VE; Dieleman, LA; Field, CJ; Sawyer, MB; Xue, H | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Berry, S; Bridgewater, J; Canon, JL; Cunningham, D; DiBartolomeo, M; Georgoulias, V; Kretzschmar, A; Mazier, MA; Michael, M; Peeters, M; Rivera, F; Van Cutsem, E | 1 |
| Caplen, NJ; Jones, TL; Martin, SE; Pommier, Y; Zhang, YW | 1 |
| Hamada, A; Saito, H; Sasaki, Y; Tazoe, K; Yokoo, K | 1 |
| Amoroso, D; Andreuccetti, M; Antonuzzo, A; Brunetti, IM; Bursi, S; Chiara, S; Cupini, S; Di Donato, S; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Petrini, I; Ricci, S; Vasile, E | 1 |
| Blackhall, FH; Ferraldeschi, R; Hadfield, KD; Minchell, LJ; Mullamitha, S; Newman, WG; Roberts, SA; Saunders, M; Tobi, S; Valle, J; Wilson, G | 1 |
| Polansky, M; Ross, AC | 1 |
| Bathe, OF; Bigam, D; Butts, C; Dixon, E; Dowden, S; Ernst, S; Holland, D; Koppel, J; Porter, GA; Sutherland, FR | 1 |
| Koopman, M; Ligtenberg, MJ; Nagtegaal, I; Punt, CJ; Van Krieken, JH; van Tinteren, H; Venderbosch, S | 1 |
| Buyse, M; De Roock, W; Piessevaux, H; Prenen, H; Schlichting, M; Tejpar, S; Van Cutsem, E | 1 |
| García-López, JL; Jaén, P; Medina, J; Moreno, C; Pérez-García, B; Vano-Galvan, S | 1 |
| Capanu, M; D'Angelica, M; Fong, Y; Jarnagin, WR; Kemeny, NE; Melendez, FD; Patel, D; Paty, PB; Schwartz, LH | 1 |
| Koopman, M; Nagtegaal, ID; Punt, CJ; van Krieken, JH; Venderbosch, S | 1 |
| Kannerup, AS; Knudsen, AR; Mortensen, FV; Nielsen, DT | 1 |
| Blinder, V; Gold, HT; Hall, MJ; Schackman, BR | 1 |
| Kocák, I; Kocáková, I; Nemecek, R; Rehák, Z; Standara, M; Svoboda, M | 1 |
| Cortesi, F; Crea, F; Danesi, R; Del Tacca, M; Gallegos Ruiz, MI; Giovannetti, E; Mey, V; Nannizzi, S; Peters, GJ; Ricciardi, S | 1 |
| Kocák, I; Kocáková, I; Lakomý, R; Nēmecek, R; Poprach, A; Svoboda, M; Vyskocil, J; Vyzula, R | 1 |
| Addeo, R; Baldi, GG; Del Prete, S; Di Fabio, F; Falcone, A; Loupakis, F; Pinto, C; Rojas Llimpe, FL; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Fukunaga, M; Furukawa, H; Ishida, H; Kato, T; Miyake, Y; Takemoto, H; Watanabe, Y | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ | 1 |
| Johnstone, E; Kerr, D; Midgley, R; Swanton, C; Tomlinson, I; Walther, A | 1 |
| Bando, H; Doi, T; Fukushima, H; Fuse, N; Kadowaki, S; Ohtsu, A; Okano, S; Tahara, M; Yoda, Y; Yoshino, T | 1 |
| Chang, YT; Chen, CW; Chu, KS; Lin, SR; Lu, CY; Tsai, HL; Wang, HM; Wang, JY; Yeh, YS; Yen, LC | 1 |
| Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Nakajima, T; Shimada, Y; Yamada, Y | 1 |
| Gill, S; Goldberg, RM | 3 |
| Bokemeyer, C; Hohenberger, W; Kwok-Keung Choi, C; Maurel, J; Navarro, M; Rivera, F; Santoro, A; Shacham-Shmueli, E; Thezenas, S; Ychou, M | 1 |
| Landherr, L; Nagykálnai, T | 2 |
| Chang, HJ; Han, HS; Hong, YS; Jung, KH; Kim, SY; Lee, KS | 1 |
| Chen, B; Chen, JZ; Cui, F; Luo, RC; Wan, C; Zheng, H | 1 |
| Basolo, F; Bencardino, K; Canestrari, E; Catalano, V; Cremolini, C; Falcone, A; Floriani, I; Fontanini, G; Galluccio, N; Graziano, F; Loupakis, F; Magnani, M; Masi, G; Rulli, E; Ruzzo, A; Salvatore, L; Santini, D; Stasi, I; Tonini, G; Vincenzi, B | 1 |
| Fukuoka, T; Hatano, N; Imamura, Y; Morita, Y; Usui, H; Yokoyama, S | 1 |
| Bai, CM; Chen, SC; Cheng, YJ; Jia, N; Shao, YJ; Zhou, JF | 1 |
| Ackland, S; Chiara, S; Clarke, S; Gapski, J; Langer, B; Mainwaring, P; Perez-Carrión, R; Sobrero, A; Young, S | 1 |
| Koopman, M; Mol, L; Ottevanger, PB; Punt, CJA | 1 |
| Goldberg, RM; Green, EM; McLeod, HL; Sanoff, HK; Sargent, DJ | 1 |
| Ishizuka, M; Kubota, K; Nagata, H; Takagi, K | 1 |
| Fukumitsu, H; Hirakawa, H; Hoshikawa, T; Makuuchi, H; Mukai, M; Ogoshi, K; Okada, K; Tajima, T; Yazawa, N | 1 |
| Cunningham, D; Okines, A | 1 |
| Kuebler, JP | 1 |
| Bower, GD; Briggs, GM; George, J; Goldstein, D; Olver, IN; Pavlakis, N; Price, D; Rossleigh, MA; Tapner, MJ; Taylor, DJ; van Hazel, GA | 1 |
| Huang, YT; Liao, WJ; Luo, W; Ma, L; Shi, M; Wang, XN; Wen, Q | 1 |
| Ho, YH; Lam, AK; Sebesan, S; Weekes, J | 1 |
| Del Monte, G; Formica, V; Guadagni, F; Ludovici, G; Palmirotta, R; Roselli, M; Savonarola, A | 1 |
| Schmidt, C | 1 |
| Beauchet, A; Brouquet, A; Julie, C; Lot, AS; Nordlinger, B; Penna, C; Prevost, G; Taleb, P | 1 |
| Bodnar, L; Stec, R; Szczylik, C | 1 |
| Alì, G; Allegrini, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Emmenegger, U; Falcone, A; Fioravanti, A; Fontanini, G; Orlandi, P | 1 |
| Chin, K; Fujiwara, Y; Hatake, K; Ichimura, T; Kobayashi, K; Konishi, F; Kuboki, Y; Matsueda, K; Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M | 1 |
| Fournier, P; Hebbar, M; Romano, O | 1 |
| Al-Kasspooles, MF; Broward, M; Cohen, MS; Henry, D; Roby, KF; Williamson, SK | 1 |
| Bearzi, I; Berardi, R; Biscotti, T; Cascinu, S; Falcone, A; Galizia, E; Labianca, R; Loupakis, F; Mandolesi, A; Masi, G; Negri, F; Pierantoni, C; Quadri, A; Scartozzi, M; Zaniboni, A; Zorzi, F | 1 |
| Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G | 1 |
| Goldberg, RM; O'Neil, BH | 1 |
| Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Karampeazis, A; Kouroussis, Ch; Polyzos, A; Souglakos, J; Vamvakas, L; Ziras, N | 1 |
| Del Vecchio Blanco, G; Fiaschetti, V; Formica, V; Grenga, I; Massara, MC; Pallone, F; Portarena, I; Roselli, M; Sileri, P; Skoulidis, F; Tosetto, L | 1 |
| Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N | 1 |
| Kemeny, NE; Power, DG | 2 |
| de Gramont, A; Hebbar, M; Pruvot, FR; Romano, O; Triboulet, JP | 1 |
| Biesmans, B; De Hertogh, G; De Roock, W; De Schutter, J; Fieuws, S; Humblet, Y; Jacobs, B; Laurent-Puig, P; Peeters, M; Pénault-Llorca, F; Piessevaux, H; Tejpar, S; Van Cutsem, E; Van Laethem, JL; Van Oirbeek, R; Vandesompele, J | 1 |
| Chang, HM; Jang, SJ; Kang, YK; Kim, JC; Kim, TW; Lee, JL; Lee, JS; Na, YS; Park, HS; Ryu, MH; Sohn, BS | 1 |
| Garcia-Alfonso, P; Gonzalez-Flores, E; Mendez-Ureña, M; Muñoz-Martin, A; Perez-Manga, G; Quiben-Pereira, R | 1 |
| Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S | 1 |
| Furuta, R; Hibi, S; Ina, K; Kataoka, T; Kawai, M; Kojima, S | 1 |
| Boostrom, SY; Donohue, JH; Harmsen, S; Kendrick, M; Nagorney, DM; Que, F; Reid-Lombardo, KM; Thomsen, K | 1 |
| Boeck, S; Heinemann, V; Schulz, C; Stemmler, HJ | 1 |
| Cai, J; Ji, X; Li, Q; Tucker, S; Wan, F; Wang, D; Zhao, R; Zhong, B; Zhu, J | 1 |
| Bobos, M; Fountzilas, G; Kafiri, G; Karavasilis, V; Karina, M; Kostopoulos, I; Papakostas, P; Pentheroudakis, G; Vrettou, E; Xiros, N | 1 |
| Koopman, M; Punt, CJ | 2 |
| Habbema, JD; Kuipers, EJ; Lansdorp-Vogelaar, I; van Ballegooijen, M; Zauber, AG | 1 |
| Venook, AP | 2 |
| Assenat, E; Bachet, JB; Boyer-Gestin, C; Lepère, C; Lièvre, A; Mitry, E; Portales, F; Rougier, P; Samalin, E; Vaillant, JN; Ychou, M | 1 |
| Cunningham, D; Yim, KL | 1 |
| Burd, R; Daskalakis, C; Dicker, AP; Ryan, A; Wachsberger, P | 1 |
| Hwang, J; Nguyen, HL | 1 |
| Heymanns, J; Kleboth, K; Köppler, H; Thomalla, J; Weide, R | 1 |
| Adlard, JW; Allan, JM; Braun, MS; Daly, CL; Meade, AM; Parmar, MK; Quirke, P; Richman, SD; Seymour, MT; Thompson, L | 1 |
| Boeck, S; Giessen, C; Heinemann, V; Moosmann, N; Schalhorn, A; Schulz, C; Stemmler, HJ; Zwingers, T | 1 |
| Barbachano, Y; Chau, I; Cunningham, D; Mikropoulos, C; Petkar, I; Strimpakos, AS | 1 |
| Adam, R; Bonhomme-Faivre, L; Castagne, V; Farinotti, R; Guettier, C; Paule, B; Picard, V; Saffroy, R | 1 |
| Barrett, JH; Chambers, P; Daly, CL; Elliott, F; Meade, AM; Quirke, P; Richman, SD; Seymour, MT; Taylor, G | 1 |
| Bosnjakovic, P; Martin, RC; O'Hara, R; Padr, R; Robbins, K; Rocek, M; Scupchenko, A; Slauf, F; Tatum, C; Tomalty, D | 1 |
| Akcan, S; Artac, M; Bozcuk, H; Ozdogan, M; Pehlivan, M; Pehlivan, S; Savas, B; Sever, T | 1 |
| Ciardiello, F; Papamichael, D; Tejpar, S | 1 |
| Chiba, N; Gamoh, M; Ishioka, C; Kakudo, Y; Kato, S; Otsuka, K; Sakayori, N; Shibata, H; Shimodaira, H; Suzuki, T; Takahashi, S; Yoshioka, T | 1 |
| Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE | 1 |
| Feilchenfeldt, J; Power, DG | 1 |
| Baselga, J; Cervantes, A; Ciardiello, F; Kisker, O; Liebscher, S; Macarulla, T; Martinelli, E; Ramos, FJ; Rivera, F; Rodriguez-Braun, E; Roselló, S; Tabernero, J; Vega-Villegas, ME | 1 |
| Bechstein, WO; Folprecht, G; Frilling, A; Goekkurt, E; Gruenberger, T; Hartmann, JT; Herrmann, T; Köhne, CH; Konopke, R; Lang, H; Liersch, T; Lordick, F; Ockert, D; Parisi, F; Raab, HR; Stoehlmacher, J; Stroszczynski, C; Weitz, J | 1 |
| Adam, R; Tejpar, S; Van Cutsem, E | 1 |
| Ardizzoni, A; Bonasoni, MP; Bozzetti, C; Camisa, R; Crafa, P; Lagrasta, CA; Negri, FV; Pedrazzi, G | 1 |
| Hashiguchi, K; Hiraki, M; Kitajima, Y; Miyazaki, K; Nakafusa, Y; Nakamura, J; Noshiro, H; Sumi, K | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Vasile, E | 1 |
| Dohn, LH; Jensen, BV; Larsen, FO | 1 |
| Abbruzzese, JL; Adinin, R; Ellis, LM; Eng, C; Glover, KY; Heymach, JV; Hoff, PM; Kopetz, S; Lieu, C; Morris, JS; Overman, MJ; Tran, HT; Valero, V; Wen, S; Wolff, RA; Yan, S | 1 |
| Lin, SR; Lu, CY; Uen, YH; Wang, JY; Wu, DC; Wu, IC; Yen, LC; Yu, FJ | 1 |
| Ho, YH; Lam, AK; Ong, K; Sebesan, S; Weekes, J | 1 |
| Prewett, M; Steiner, P; Surguladze, D; Tonra, JR | 1 |
| Brouquet, A; de Chaisemartin, C; Goasguen, N; Julié, C; Laurent-Puig, P; Penna, C; Prevost, GP | 1 |
| Araki, A; Hazama, S; Hinoda, Y; Kondo, H; Nagashima, A; Oka, M; Okayama, N; Shimizu, R; Yoshida, S; Yoshino, S | 1 |
| Bosacki, C; Merrouche, Y; Smith, D | 1 |
| Chika, N; Hatano, S; Hokama, N; Ishibashi, K; Ishida, H; Ishiguro, T; Ishii, M; Kubota, S; Kuwabara, K; Miyazaki, T; Okada, N; Tajima, Y | 1 |
| Amano, R; Hirakawa, K; Inoue, T; Ishikawa, T; Kubo, N; Maeda, K; Muguruma, K; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sawada, T; Tanaka, H; Yamada, N; Yashiro, M | 1 |
| Ide, Y; Mikami, K; Murata, K | 1 |
| Iida, A; Kaneko, T; Mishima, T; Miyazaki, M; Muto, T; Shimizu, K; Yoshidome, H | 1 |
| Azzarello, G; Basso, U; Buonadonna, A; Cecchin, E; D'Andrea, M; De Mattia, E; De Paoli, P; Gasparini, G; Innocenti, F; Lo Re, G; Mini, E; Nobili, S; Pessa, S; Toffoli, G | 1 |
| Brady, J; Corrie, PG; Margison, GP; Middleton, MR; Midgley, RS; Mortimer, P; Palmer, C; Sabharwal, A; Watson, AJ | 1 |
| Adam, R; Azoulay, D; Castaing, D; de Haas, RJ; Ducreux, M; Flores, E; Lemoine, A; Lévi, F; Paule, B; Wicherts, DA | 1 |
| Creemers, GJ; de Jong, FA; Friberg, LE; Loos, WJ; Mathijssen, RH; Planting, AS; Sparreboom, A; van der Bol, JM; Verweij, J; Wiemer, EA | 1 |
| Chiriatti, A; Fiorentini, G; Francini, G; Montagnani, F; Turrisi, G | 1 |
| Kopper, L; Tímár, J | 1 |
| Inaba, Y; Kawai, H; Muro, K; Najima, M; Sato, Y; Sawaki, A; Shibata, T; Shitara, K; Tajika, M; Takahari, D; Ura, T; Utsunomiya, S; Yamaura, H; Yatabe, Y; Yokota, T | 1 |
| Barbier, A; Bellanger, A; Capron, F; Domont, J; Genestie, C; Goldmard, JL; Hannoun, C; Khayat, D; Magné, N; Spano, JP; Vaillant, JC | 1 |
| Hoshino, S; Matsuo, K; Naito, M; Nakano, M; Noda, N; Shinohara, T; Tanaka, S; Yamashita, Y; Yamauchi, Y | 1 |
| Abe, T; Fujii, K; Goto, A; Hasegawa, Y; Nishimura, S; Shinomura, Y; Sukawa, Y; Suzuki, K; Yonezawa, K | 1 |
| Bearzi, I; Berardi, R; Biagetti, S; Bisonni, R; Cascinu, S; Falcone, A; Galizia, E; Giampieri, R; Giustini, L; Loupakis, F; Mandolesi, A; Menzo, S; Pierantoni, C; Scartozzi, M; Silva, RR; Zaniboni, A | 1 |
| Akagi, Y; Ishibashi, N; Mori, S; Ogata, Y; Sasatomi, T; Shirouzu, K | 1 |
| Akase, T; Arakawa, I; Harada, T; Inoue, T; Miyazaki, Y | 1 |
| An, X; Ding, PR; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH | 1 |
| DeLisle, S; Mullins, CD; Obeidat, NA; Pradel, FG; Zuckerman, IH | 1 |
| Chan, JM; Ho, SH; Tai, IT | 1 |
| André, T; Baumgaertner, I; Hannoun, L; Poynard, T; Ratziu, V; Vaillant, JC | 1 |
| Berglund, A; Berglund, M; Byström, P; Fredriksson, LA; Garmo, H; Glimelius, B; Kohnke, H; Sørbye, H; Wadelius, M | 1 |
| Canestrari, E; Catalano, V; Cremolini, C; D'Emidio, S; Falcone, A; Galluccio, N; Giordani, P; Graziano, F; Loupakis, F; Magnani, M; Rocchi, M; Ruzzo, A; Salvatore, L; Santini, D; Spoto, C; Tonini, G; Vincenzi, B | 1 |
| Coche, E; Gala, JL; Humblet, Y; Marot, L; Sempoux, C; Seront, E | 1 |
| Bonnans, C; Breuker, C; Brouillet, JP; Evrard, A; Hollande, F; Joubert, D; Kantar, J; Lallemant, B; Leguelinel, G; Lumbroso, S; Pascussi, JM; Poujol, S; Raynal, C | 1 |
| Akashi, I; Ashizawa, T; Hama, K; Hirano, T; Iwahori, T; Iwamoto, H; Jyojima, Y; Kihara, Y; Konnno, O; Nagao, T; Nakamura, Y; Segawa, M; Takeuchi, H; Yokoyama, T | 1 |
| Fang, H; Feng, FY; Wang, JW; Wang, XY | 1 |
| Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R | 1 |
| Bao, HY; Chen, J; Deng, J; Fang, WJ; Huang, S; Mou, HB; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC | 1 |
| Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Miyagishima, T; Sakata, Y; Tateyama, M; Wakahama, O; Watanabe, M; Yuuki, S | 1 |
| Heye, S; Maleux, G; Oyen, R; van Cutsem, E; Vaninbroukx, J | 1 |
| Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Tsunoda, Y; Watanabe, M; Yasuda, N | 1 |
| Choi, SK; Ha, CY; Ju, YT; Kang, JH; Kim, HG; Kwon, HC; Lee, GW; Lee, WS; Oh, SY | 1 |
| Komatsu, Y; Muro, K; Shibata, T; Shitara, K; Takahari, D; Takiuchi, H; Ura, T; Utsunomiya, S; Yatabe, Y; Yokota, T; Yoshida, M; Yuki, S | 1 |
| Doi, T; Fuse, N; Joh, T; Minashi, K; Ohtsu, A; Shimura, T; Tahara, M; Yoshino, T | 1 |
| Ciardiello, F; Normanno, N; Tejpar, S | 1 |
| Brown, TJ; Clavant, SP; Clingan, PR; Fox, RM; Ganju, V; Gibbs, P; Leung, J; Pho, M; Strickland, AH; Tebbutt, NC; Underhill, CR; Wong, SS | 1 |
| Falcone, A; Loupakis, F | 1 |
| Arango, D; Armengol, M; Bazzocco, S; Carreras, MJ; Dopeso, H; Elez, E; Espín, E; Hernández-Losa, J; Landolfi, S; Mariadason, JM; Mateo-Lozano, S; Mazzolini, R; Ramon Y Cajal, S; Ramos Pascual, FJ; Rodrigues, P; Schwartz, S; Tabernero, J; Wilson, AJ | 1 |
| Kawabata, Y; Nakagawa, A | 1 |
| Boehm, KA; Cartwright, T; McCollum, D | 1 |
| Dreiling, L; Gollard, R; Hecht, JR; Heim, W; Malik, I; Mo, M; Patel, R; Pillai, M; Swan, F | 1 |
| Ajmi, S; Ben Ahmed, S; Ben Fatma, L; Ben Hadj Hamida, R; Braham, A; Chabchoub, I; Gahbiche, S; Gharbi, O; Hochlef, M; Landolsi, A; Letaief, R; Limam, S; Mokni, M | 1 |
| Barrois, M; Beaune, P; Boige, V; Bouché, O; Castaing, M; Ducreux, M; Laurent-Puig, P; Le Corre, D; Loriot, MA; Malka, D; Mendiboure, J; Miran, I; Mulot, C; Pignon, JP; Trégouët, DA | 1 |
| Adam, R; Bouchahda, M; Giacchetti, S; Gorden, L; Guettier, C; Hauteville, D; Innominato, PF; Karaboué, A; Lévi, F; Saffroy, R | 1 |
| Andres, A; Gervaz, P; Majno, P; Mentha, G; Morel, P; Roth, A; Rubbia-Brandt, L | 1 |
| Alonso, V; Antón, I; Arrivi, A; Cirera, L; Constenla, M; Escudero, P; García, P; Grande, C; Guasch, I; López, LJ; Losa, F; Martin, C; Méndez, M; Moreno, I; Pericay, C; Quintero-Aldana, G; Roca, JM; Salud, A; Vicente, P; Yubero, A | 1 |
| Caron, J; Chalbos, P; Dereure, O; Duffour, J; Fiess, C; Garcin, A; Gestin-Boyer, C; Guillot, B; Portales, F; Samalin, E; Thézenas, S; Ychou, M | 1 |
| Gallinger, S; Guindi, M; Moore, M; Moulton, CA; Nanji, S; Pollett, A; Ryan, P | 1 |
| Liao, WJ; Luo, RC; Shen, P; Shi, M; Wu, Wy | 1 |
| Hashimoto, T; Inoue, K; Kokudo, N; Makuuchi, M; Maruyama, Y; Ogata, S; Sano, K; Takamoto, T; Takemura, T | 1 |
| Bruera, G; Calista, F; Cannita, K; De Galitiis, F; Ficorella, C; Gebbia, N; Guglielmi, F; Iacobelli, S; Lanfiuti Baldi, P; Mancini, M; Marchetti, P; Martella, F; Morelli, MF; Pelliccione, M; Porzio, G; Ricevuto, E; Russo, A; Santomaggio, A; Tudini, M | 1 |
| Doi, T; Fuse, N; Ikematsu, H; Kaneko, K; Koike, K; Kojima, T; Minashi, K; Mochizuki, S; Ohtsu, A; Tahara, M; Yano, T; Yoshino, T | 1 |
| Amemiya, T; Aoki, M; Hosoda, K; Kamoshida, T; Kido, H; Kojima, M; Natsu, K; Tamura, H | 1 |
| Andrasina, T; Boudný, J; Bower, M; Martin, RC; Metzger, T; Robbins, K; Tatum, C; Tomalty, D; Válek, V | 1 |
| Bouganim, N; Chaudhury, P; Hassanain, M; Kavan, P; Metrakos, P; Salman, A | 1 |
| Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M | 1 |
| Chua, TC; Esquivel, J; Koong, HN; Liauw, W | 1 |
| Audrain, O; Boucher, E; Kerjouan, M; Le Roux, C; Pracht, M; Raoul, JL | 1 |
| Goldberg, RM | 4 |
| Cathomas, R; Köberle, D; Lanz, D; Popescu, R; Roth, A; Ruhstaller, T; Simcock, M; Uhlmann, C; von Moos, R; Widmer, L | 1 |
| Bai, J; Chen, J; Duanmu, Z; Gong, Y; Huang, H; Tang, C; Yang, J; Zhou, B; Zhuang, L | 1 |
| Muro, K | 1 |
| Abou-Alfa, GK; Al-Olayan, A; Kelsen, D; Lowery, M; Naghy, M; Power, D; Saliba, T; Shah, MA; Shamseddine, A; Smyth, E | 1 |
| Baiget, M; Barnadas, A; del Rio, E; Espinosa, I; Marcuello, E; Paez, D; Paré, L; Salazar, J | 1 |
| Awatsu, A; Gasa, F; Hakamada, K; Kimura, N; Kimura, Y; Koyama, M; Morohashi, H; Murata, A; Sakamoto, Y; Sato, J; Terui, K | 1 |
| Geng, Y; Gong, W; Jiang, B; Peng, L; Qing, H; Wang, X; Zhang, H; Zhang, Y | 1 |
| Chau, GY; Chen, WS; Hsieh, YY; Hsu, YN; King, KL; Lin, JK; Lin, TC; Liu, JH; Teng, HW; Tzeng, CH | 1 |
| Chang, HJ; Choi, HS; Jeong, SY; Kim, DY; Kim, SY; Oh, JH; Park, JW; Seo, GJ; Shin, A; Yoo, SB | 1 |
| Aranda, E; Bandrés, E; Boni, V; Garcia-Foncillas, J; Gomez, MA; Maiello, E; Villa, JC; Zarate, R | 1 |
| Ajima, H; Fujita, K; Ishida, H; Kawara, K; Miwa, K; Mizuno, K; Nakayama, H; Ogata, H; Sasaki, Y; Sunakawa, Y; Takahashi, H; Yamashita, K | 1 |
| Beslija, S; Brodowicz, T; Ciuleanu, TE; Esser, R; Faluhelyi, Z; Koza, I; Kurteva, G; Messinger, D; Mrsic-Krmpotic, Z; Ocvirk, J; Pápai, Z; Papamichael, D; Scheithauer, W; Shacham-Shmueli, E; Vrbanec, D; Wenczl, M; Wrba, F; Yalcin, S; Yilmaz, U; Zielinski, CC | 1 |
| Bjerregaard, JK; Jensen, BV; Jorgensen, TL; Nielsen, D; Pfeiffer, P; Qvortrup, C | 1 |
| Oostendorp, LJ; Ottevanger, PB; Pasker-de Jong, PC; Stalmeier, PF; Van der Graaf, WT | 1 |
| Allegrini, G; Baldi, GG; Canestrari, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Graziano, F; Loupakis, F; Magnani, M; Masi, G; Ruzzo, A; Salvatore, L; Santini, D; Stasi, I; Tonini, G; Vasile, E; Vincenzi, B | 1 |
| Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Tsuchida, K; Yamamoto, N | 1 |
| Abad, A; Aranda, E; Benavides, M; Carrato, A; Ginés, A; Layos, L; Manzano, JL; Marcuello, E; Martinez-Balibrea, E; Martínez-Cardús, A; Massutí, B; Moreno, V; Navarro, M; Valladares, M | 1 |
| Astier, A | 1 |
| Akaike, M; Imada, T; Masuda, M; Matsukawa, H; Ozawa, Y; Rino, Y; Shiozawa, M; Shiraishi, R; Suzuki, H; Takahashi, M; Tamura, I; Yamamoto, N; Yamamoto, Y; Yukawa, N | 1 |
| Czejka, M; Farkouh, A; Gruenberger, B; Kiss, A; Schueller, J | 1 |
| Bachellier, P; Chenard, MP; Jaeck, D; Pessaux, P | 1 |
| Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW | 1 |
| Bosnjakovic, PM; Howard, J; Martin, RC; Padr, R; Robbins, K; Tatum, C; Tomalty, D | 1 |
| de Jong, FA; Loos, WJ; Mathijssen, RH; Planting, AS; Schellens, JH; van Aken, MO; van der Bol, JM; Verweij, J; Visser, TJ; Wiemer, EA | 1 |
| Chen, Y; Liu, Q; Luo, J; Wang, J; Wang, X; Yan, Z | 2 |
| Sartori, S; Tassinari, D; Tombesi, P | 1 |
| Bussom, S; Cheng, YC; Chu, E; Dutschman, GE; Jiang, Z; Lam, W; Li, X; Saif, MW; Ye, M; Zhang, W | 1 |
| Abdalla, EK; Agarwal, A; Boonsirikamchai, P; Charnsangavej, C; Chun, YS; Kaur, H; Kopetz, S; Loyer, EM; Maru, DM; Vauthey, JN; Wang, H | 1 |
| Goldberg, RM; McLeod, H; Sargent, DJ | 1 |
| Amoroso, D; Andreuccetti, M; Ciarlo, A; Cortesi, E; Cremolini, C; Cupini, S; Del Monte, F; Falcone, A; Fontanini, G; Fornaro, L; Granetto, C; Loupakis, F; Lupi, C; Masi, G; Salvatore, L; Sensi, E | 1 |
| Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K | 1 |
| Díaz-Rubio, E; García-Foncillas, J | 1 |
| Hull, R; Ntwasa, MM | 1 |
| Charles, KA; Chua, W; Clarke, SJ; Kho, PS; Moore, MM | 1 |
| Bosnjakovik, P; Derner, M; Joshi, J; Martin, RC; Padr, R; Robbins, K; Rocek, M; Scupchenko, A; Tatum, C; Tomalty, D | 1 |
| Armakolas, A; Batzios, S; Batziou, C; Koutantos, J; Legakis, J; Stathopoulos, GP; Stathopoulos, J; Trafalis, D | 1 |
| Baxevanis, CN; Gritzapis, AD; Kosmas, C; Tsavaris, N; Voutsas, IF | 1 |
| Jaitner, S; Jung, A; Kirchner, T; Schäffauer, AJ | 1 |
| Bruns, H; Büchler, MW; Hoffmann, K; Longerich, T; Mikalauskas, S; Mikalauskiene, L; Nickkholgh, A; Schemmer, P; Strupas, K | 1 |
| Khattak, A; Price, TJ; Townsend, AR | 1 |
| Biondo, S; Dominguez, J; Escalante, E; Frago, R; Kreisler, E; Salazar, R | 1 |
| Kim, HJ; Kim, HS; Kim, SG; Kim, TG; Oh, ST; Park, HM; Park, JS; Sohn, HJ | 1 |
| Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F | 1 |
| Grothey, A | 1 |
| André, T; Cervantes, A; Chan, E; Ciuleanu, TE; Collins, S; Ducreux, M; Gansert, J; Hotko, Y; Lordick, F; Oliner, KS; Peeters, M; Price, TJ; Punt, CJ; Roman, L; Rong, A; Sobrero, AF; Strickland, AH; Tzekova, V; Van Cutsem, E; Wilson, G | 1 |
| Fan, J; Ling, W; Ma, Y; Wang, H | 1 |
| Abajo, A; Bandres, E; Bitarte, N; Boni, V; Chopitea, A; Garcia-Foncillas, J; Ponz, M; Rodriguez, J; Zarate, R | 1 |
| Candamio, S; de la Cámara, J; Grande, C; Jorge, M; López, R; Méndez, JC; Quintero, G; Reboredo, M; Romero, C; Salgado, M | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Antonucci, A; Baldi, PL; Bruera, G; Cannita, K; De Galitiis, F; Ficorella, C; Mancini, M; Marchetti, P; Ricevuto, E; Santomaggio, A; Tudini, M | 1 |
| Campanella, C; Cognetti, F; Ettorre, GM; Garufi, C; Mottolese, M; Sperduti, I; Torsello, A; Tumolo, S; Vennarecci, G; Zeuli, M | 1 |
| Akiyama, Y; Ando, M; Ando, Y; Endo, H; Fujita, K; Kawara, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W; Yamashita, K | 1 |
| Amat, CG; Bermejo, E; Gómez-Ramírez, J; Larrañaga, E; Martín-Pérez, E; Rodríguez, A; Sanz, IG | 1 |
| Adam, R; Azoulay, D; Castaing, D; Ciacio, O; de Haas, RJ; Giacchetti, S; Guettier, C; Lévi, F; Paule, B; Sebagh, M; Wicherts, DA | 1 |
| Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M | 1 |
| Azuma, M; Bohanes, P; Danenberg, KD; Gerger, A; Gordon, MA; Hollywood, E; Lenz, HJ; Lurje, G; Ning, Y; Pohl, A; Saltz, L; Winder, T; Yang, D; Zhang, W | 1 |
| Aravantinos, G; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Linardou, H; Makatsoris, T; Papadimitriou, C; Papakostas, P; Papamichael, D; Pectasides, D; Pentheroudakis, G; Samelis, G; Skondra, M; Stavropoulos, M; Syrigos, KN; Varthalitis, I; Vourli, G; Xanthakis, I; Xiros, N | 1 |
| Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S; Vincent, J | 1 |
| Ananda, S; Gibbs, P; Heong, V; Tie, J | 1 |
| Jakab, F | 1 |
| Akashi, K; Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Futami, K; Kinugawa, N; Kusaba, H; Mibu, R; Mitsugi, K; Nakano, S; Sakai, K; Tanaka, R; Tanaka, S; Ueki, T | 1 |
| Aglietta, M; Barni, S; Beretta, GD; Corsi, D; Cortesi, E; Dapretto, E; Floriani, I; Fornarini, G; Isa, L; Labianca, R; Lonardi, S; Nicolella, D; Sobrero, A; Turci, D; Zaniboni, A | 1 |
| Furuse, J; Hosokawa, Y; Iwamoto, N; Kase, Y; Kitagawa, N; Miyazawa, T; Motoori, S; Saisho, H | 1 |
| Heinemann, V; Hoff, PM | 1 |
| Alonso, V; Alonso-Espinaco, V; Castellví-Bel, S; Escudero, P; Fernández-Martos, C; Gallego, R; Garcia-Albeniz, X; Gascón, P; Maurel, J; Pericay, C | 1 |
| Jatoi, A; Ramiscal, JA | 1 |
| Goubely, Y; Kirscher, S; Mineur, L; Molinari, N; Plat, F; Sabatier, R | 1 |
| Ghandehari, H; Goldberg, DS; Swaan, PW; Vijayalakshmi, N | 1 |
| Addeo, R; Correale, P; Dicuonzo, G; Falcone, A; Francini, G; Galluzzo, S; Graziano, F; Loupakis, F; Napolitano, A; Rocci, L; Ruzzo, A; Santini, D; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Kang, WK; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, SY | 1 |
| Allegra, C; George, T; Yothers, G | 1 |
| Allegrini, G; Andreuccetti, M; Baldi, G; Brunetti, I; Chiara, S; Cremolini, C; Crinò, L; Cupini, S; Fabbri, MA; Falcone, A; Fioretto, L; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Puglisi, M; Salvatore, L; Stasi, I; Trenta, P; Vasile, E | 1 |
| Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K | 1 |
| Barber, B; Gregory, C; Long, SR; Song, X; Wang, PF; Zhao, Z | 1 |
| Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S | 1 |
| Hou, SH; Li, YP; Liang, XB; Wang, LC; Yang, J; Zhang, X | 1 |
| Nirmala, P; Ramanathan, M | 1 |
| Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S | 1 |
| Chua, TC; Doerfer, J; Esquivel, J; Germer, CT; Kerscher, AG; Maeder, U; Morris, DL; Pelz, JO; Stojadinovic, A | 1 |
| Arends, J; Büchert, M; Fasol, U; Fischer, R; Hense, J; Jaehde, U; Kanefendt, F; Moritz, B; Mross, K; Scheulen, ME; Strumberg, D | 1 |
| De Marchis, ML; Del Monte, G; Formica, V; Grenga, I; Guadagni, F; Ludovici, G; Palmirotta, R; Roselli, M; Savonarola, A; Schirru, M | 1 |
| Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Fischer, M; Gurney, A; Hoey, T; Kapoun, AM; Lewicki, J; O'Young, G; Wang, M; Yen, WC | 1 |
| Faybik, P; Fleischmann, E; Gruenberger, T; Herberger, B; Krieger, PM; Maresch, J; Tamandl, D | 1 |
| Buzaid, AC; Esser, R; Fein, L; Hidalgo, J; Lerzo, G; Mathias, Cde C; Murad, AM; Perazzo, F; Senger, S; Simon, SD | 1 |
| Lou, H; Lu, X; Luo, G; Wang, X; Zhou, G | 1 |
| Bearzi, I; Berardi, R; Biagetti, S; Biscotti, T; Bisonni, R; Bittoni, A; Cascinu, S; Galizia, E; Giampieri, R; Giustini, L; Mandolesi, A; Pierantoni, C; Scartozzi, M; Silva, RR; Zaniboni, A | 1 |
| Fujimoto, T; Itagaki, H; Matsumoto, A; Ogawa, K; Osawa, G; Otani, T; Umehara, A; Yano, Y; Yokomizo, H; Yoshimatsu, K | 1 |
| Akiyama, H; Endo, I; Ichikawa, Y; Kumamoto, T; Matsuyama, R; Mori, R; Nojiri, K; Ota, M; Takeda, K; Tanaka, K | 1 |
| Aritake, N; Endoh, A; Katsumoto, Y | 1 |
| Ide, Y; Murata, K; Nishigaki, T | 1 |
| Aoyagi, H; Hamada, S; Hasegawa, K; Isogai, J; Kaneko, J; Katsuta, E; Maejima, S; Saguchi, M; Someno, Y; Takahata, T | 1 |
| Arai, K; Funahashi, K; Kaneko, H; Koike, J; Kubota, Y; Kurihara, A; Maeda, T; Otsuka, Y; Shimada, H; Shiokawa, H; Suzuki, T; Tamura, A; Tsuchiya, M; Watanabe, M | 1 |
| Ng, S; O'bichere, A; Platell, C; Tebbutt, N | 1 |
| Huang, YT; Liao, WJ; Luo, W; Ma, L; Shi, M; Wen, Q; Zhang, Y; Zhou, MQ | 1 |
| Arai, T; Kobayashi, S; Koike, J; Koizumi, S; Makizumi, R; Miura, K; Miyajima, N; Nakano, H; Otsubo, T; Sakurai, J; Shimamura, T; Yamada, K | 1 |
| Hori, S; Seki, A | 1 |
| Chatelut, E; Delord, JP; Duret, A; Etienne, MC; Falandry, C; Freyer, G; Lledo, G; Merrouche, Y; Milano, G; Rebischung, C | 1 |
| Endo, I; Kumamoto, T; Nojiri, K; Takeda, K; Tanaka, K | 1 |
| Barnett-Griness, O; Cohen, I; Gruber, SB; Kuten, A; Lejbkowicz, F; Rennert, G; Shulman, K | 1 |
| Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Ryu, MH | 1 |
| Abenhardt, W; Decker, T; Dietzfelbinger, H; Haberl, C; Hass, HG; Heinemann, V; Jung, A; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schalhorn, A; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF; Zellmann, K | 1 |
| Fujikawa, K; Hazama, S; Kato, T; Kimura, H; Kobayashi, M; Mishima, H; Nagata, N; Nozawa, H; Oba, K; Okuyama, Y; Sakamoto, J; Takahashi, K | 1 |
| Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S | 1 |
| Furushima, K; Ishihara, T; Katou, Y; Tanai, C; Tanaka, Y; Usui, K | 1 |
| Akiyama, Y; Ando, Y; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Mizuno, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K | 1 |
| Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW | 1 |
| Arai, Y; Asami, S; Endo, H; Idani, H; Iguchi, T; Inaba, Y; Kanazawa, S | 1 |
| Bocci, G; Canu, B; Cremolini, C; Danesi, R; Di Desidero, T; Di Paolo, A; Falcone, A; Fioravanti, A; Frumento, P; Loupakis, F; Masi, G; Orlandi, P; Salvatore, L; Schirripa, M | 1 |
| Akutsu, N; Fujii, H; Hamamoto, Y; Miyamoto, J; Nagase, M; Nishi, T; Warita, E; Yamanaka, Y | 1 |
| Bakrin, N; Cotte, E; Gilly, FN; Glehen, O; Mohamed, F; Passot, G; Steghens, A; Tod, M | 1 |
| Inaba, Y; Kato, M; Kondo, C; Mizota, A; Muro, K; Nomura, M; Sato, Y; Shitara, K; Takahari, D; Ura, T; Yamaura, H; Yokota, T | 1 |
| Frifeldt, SK; Jakobsen, A; Lindebjerg, J; Pallisgaard, N; Spindler, KL | 1 |
| Abdalla, EK; Andreou, A; Brouquet, A; Cooper, A; Curley, SA; Garrett, CR; Kopetz, S; Loyer, EM; Maru, DM; Overman, MJ; Vauthey, JN | 1 |
| Aranda, E; Carrato, A; Chau, I; Countouriotis, AM; Cunningham, D; Guillen-Ponce, C; Iveson, TJ; Ramos, FJ; Ruiz-Garcia, A; Saunders, MP; Starling, N; Tabernero, J; Tursi, JM; Vázquez-Mazón, F; Wei, G | 1 |
| Barriuso, J; Belda, C; Caldés, T; Castro, J; Cuadrado, E; Díaz-Rubio, E; Feliu Batlle, J; González-Barón, M; Martínez Marín, V; Sastre, J | 1 |
| Boot, H; Hompes, D; van Tinteren, H; Verwaal, V | 1 |
| Andreola, F; Campisi, M; Mercuri, L; Moroni, N; Pierimarchi, P; Psaila, R; Renier, D; Secchieri, C; Serafino, A; Zonfrillo, M | 1 |
| Blasco, H; Bourgoin, H; Le Guellec, C; Le Louarn, A; Lecomte, T; Pichereau, S | 1 |
| Cascinu, S; Celik, I; Ciardiello, F; Cunningham, D; Folprecht, G; Köhne, CH; Láng, I; Maurel, J; Nowacki, MP; Rougier, P; Schlichting, M; Shchepotin, I; Tejpar, S; Van Cutsem, E; Zubel, A | 1 |
| Advani, S; Bonaventura, A; Cheirsilpa, A; Esser, R; Hsieh, RK; Im, SA; Lim, R; Mueser, M; Sun, Y; Yau, TK | 1 |
| Bjerregaard, JK; Fromm, AL; Hoegdall, E; Jensen, BV; Jørgensen, TL; Larsen, FO; Nielsen, D; Pfeiffer, P; Qvortrup, C; Skougaard, K; Vistisen, K | 1 |
| Van Loon, K; Venook, AP | 1 |
| Gelderblom, H; Slingerland, M | 1 |
| Eng, C; Garrett, CR | 1 |
| Bearzi, I; Biscotti, T; Cascinu, S; Falcone, A; Faloppi, L; Galizia, E; Giampieri, R; Labianca, R; Loupakis, F; Mandolesi, A; Scartozzi, M; Zaniboni, A; Zorzi, F | 1 |
| Des Groseilliers, S; Ferland, É; Garant, A; Martin, L; Vuong, T | 1 |
| Arimochi, H; Itoh, M; Kashiwagi, M; Morita, K; Nishibori, N | 1 |
| Ahn, JB; Hong, YS; Kim, SH; Kim, SY; Kim, TW; Lee, KH; Lee, SH; Park, SH; Park, YS; Shin, SJ | 1 |
| Bubenzer, J; do O, N; Fuchs, R; Luedde, T; Roderburg, C; Spannbauer, M; Tischendorf, JJ; Trautwein, C | 1 |
| Barbato, E; Barberis, G; Comella, P; Condemi, G; Filippelli, G; Ionta, MT; Massidda, B; Natale, D; Palmeri, S; Putzu, C; Sandomenico, C; Tafuto, S; Vessia, G | 1 |
| Boc, M; Ocvirk, J; Rebersek, M | 1 |
| Deb, J; Dibra, H; Kankipati, CS; Manneh, J; Nicholl, ID; Perry, CJ; Rajan, S; Shan, S | 1 |
| Auzanneau, C; Causse, A; Collod-Beroud, G; Coquelle, A; Del Rio, M; Denis, V; Gongora, C; Martineau, P; Pasero, P; Pourquier, P; Tuduri, S; Vezzio-Vie, N | 1 |
| Branda, ME; Goldberg, RM; Grothey, A; Heun, JM; Sargent, DJ | 1 |
| Asseburg, C; Frank, M; Griebsch, I; Hartmann, JT; Köhne, CH; Mittendorf, T; Mohr, A; Osowski, U; Schulten, J | 1 |
| Bi, F; Chen, X; Chen, Y; Ge, J; Gong, FM; Hou, JM; Liu, JY; Peng, XC; Tan, BX; Xu, F | 1 |
| Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM | 1 |
| Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Matsuo, K; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Ura, T; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S | 1 |
| Baiget, M; del Rio, E; Marcuello, E; Páez, D; Paré, L; Salazar, J; Sebio, A | 1 |
| Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S | 1 |
| Boland, A; Brown, C; Buck, M; Clarke, SJ; Gebski, V; Goldstein, D; Jeffrey, GM; Lowenthal, RM; Ransom, DT; Simes, RJ; Tebbutt, NC; van Hazel, GA; Yip, S; Zalcberg, J | 1 |
| Bencardino, K; Canestrari, E; Catalano, V; Cremolini, C; Danova, M; Falcone, A; Frumento, P; Galluccio, N; Graziano, F; Loupakis, F; Magnani, M; Manzoni, M; Masi, G; Ricci, V; Ruzzo, A; Salvatore, L; Santini, D; Schirripa, M; Tonini, G; Vincenzi, B | 1 |
| Chang, SC; Lan, YT; Li, AF; Lin, AJ; Lin, CC; Lin, JK; Yang, SH | 1 |
| Kabbinavar, F; Kozloff, M | 1 |
| Boisen, MK; Jensen, BV; Johansen, JS; Larsen, O | 1 |
| Kawakami, H; Nakagawa, K; Satoh, T; Shimomura, Y; Sugioka, K; Yonesaka, K | 1 |
| Baek, JY; Chang, HJ; Chang, HM; Hong, YS; Kang, MJ; Kang, YK; Kim, KP; Kim, MJ; Kim, SY; Kim, TW; Lee, JL; Ryu, MH | 1 |
| Ankerst, DP; Giessen, C; Heinemann, V; Laubender, RP; Modest, DP; Moosmann, N; Schalhorn, A; Schulz, C; Stintzing, S; von Weikersthal, LF | 1 |
| Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Matsuda, K; Nozawa, K; Watanabe, T; Yamamoto, Y | 1 |
| Amatulli, M; Bassi, R; Deevi, D; Li, H; Paz, K; Prewett, M; Samakoglu, S; Tonra, JR; Wang, S; Witte, L | 1 |
| Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K | 1 |
| Holt, K | 1 |
| Abasolo, I; Botella, P; Corma, A; Fernández, Y; Miranda, S; Muniesa, C; Quesada, M; Ruiz, J; Schwartz, S | 1 |
| Geh, JI; Ma, YT | 1 |
| Dahan, L; Gasmi, M; Gaudart, J; Norguet, E; Ouafik, L; Seitz, JF | 1 |
| Afonso, S; Afonso, V; Stefano, E; Viani, G | 1 |
| Rocha, JA | 1 |
| Aprile, G; Avallone, A; Bordonaro, R; Butera, A; Cordio, S; De Pauli, F; Di Lucca, G; Parra, HS; Reggiardo, G; Rosati, G | 1 |
| Bethke, A; Kühne, K; Platzek, I; Stroszczynski, C | 1 |
| Matsueda, S; Sasaki, H; Tokunaga, Y | 1 |
| Dumont, F; Elias, D; Goéré, D; Hessissen, M; Mehta, SS; Quenet, F; Roca, L; Saint-Aubert, B | 1 |
| Hatake, K; Matsusaka, S; Mizunuma, N; Shinozaki, E; Suenaga, M; Ueno, M; Yamaguchi, T; Yamamoto, N | 1 |
| Akiyoshi, K; Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Miyake, M; Nakajima, T; Okita, N; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Tateishi, U; Yamada, Y | 1 |
| Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T | 1 |
| Bocci, G; Danesi, R; Del Re, M; Di Desidero, T; Di Paolo, A; Lastella, M; Polillo, M | 1 |
| Giaccone, G; Giovannetti, E; Hanauske, AR; Leon, LG; Peters, GJ; Smid, K; van Houte, BP | 1 |
| Bennouna, J; Borg, C; Bouché, O; Delord, JP; Douillard, JY; Faroux, R; François, E; Goldwasser, F; Husseini, F; Kraemer, S; Senellart, H; Trillet-Lenoir, V; Ychou, M | 1 |
| Derleyn, VA; Koopman, M; Mol, L; Muller, EW; Punt, CJ; Simkens, LH; Teerenstra, S; Ten Bokkel Huinink, D; Veldhuis, GJ | 1 |
| Abe, S; Horinouchi, Y; Kawazoe, K; Kujime, T; Minakuchi, K; Nakamura, T; Nishisako, H; Sakurada, T; Tajima, S; Teraoka, K | 1 |
| Bahary, N; Carneiro, BA; Crandall, TL; Fakih, MG; Krishnamurthi, SS; Lancaster, SL; Lembersky, BC; Pinkerton, RA; Potter, DM; Ramanathan, RK; Schmotzer, AR; Stoller, RG | 1 |
| Adenis, A; Boige, V; Boucher, E; Chauffert, B; Conroy, T; Cvitkovic, F; Ducreux, M; Farace, F; François, E; Galais, MP; Guichard, P; Jacques, N; Malka, D; Pierga, JY; Vimond, N | 1 |
| Asai, H; Chin, K; Hatake, K; Matuzaka, S; Mizunuma, N; Nozaki, A; Shinozaki, E; Suenaga, M; Watanabe, T; Yasukawa, M | 1 |
| Berglund, Å; Blomqvist, L; Byström, P; Glimelius, B; Jacobsson, H; Nygren, P; Sundin, A; Suzuki, C | 1 |
| Inoue, N; Ishibashi, K; Ishida, H; Kishino, T; Kumamoto, K; Okada, N; Sano, M | 1 |
| Fujiwara, K; Kiura, K; Kudo, K; Matsuo, K; Mizuta, M; Rai, K; Sato, T; Tsushima, M; Yamadori, I; Yonei, T | 1 |
| Ebata, T; Hiramatsu, K; Ishiguro, S; Muro, K; Nagino, M; Nishio, H; Takahari, D; Takahashi, Y; Takeuchi, E; Uehara, K; Yoshimura, K; Yoshioka, Y | 1 |
| Antonacopoulou, AG; Bafaloukos, D; Bompolaki, I; Bournakis, E; Briasoulis, E; Dimitrakopoulos, FI; Eleftheraki, AG; Fostira, F; Fountzilas, G; Galani, E; Kalofonos, HP; Kalogeras, KT; Koumarianou, A; Koutras, AK; Pectasides, D; Sgouros, J; Varthalitis, I | 1 |
| Abbott, DH; Ayanian, JZ; Catalano, P; Fouad, MN; Ganz, PA; Grambow, SC; Kahn, KL; Kolimaga, JT; Malin, JL; Provenzale, D; Schrag, D; Wallace, R; Weeks, JC; West, DW; Zafar, SY; Zullig, LL | 1 |
| Ariyoshi, Y; Fukuoka, M; Kakihata, K; Masatani, S; Sakata, Y; Shimazaki, M; Shiozawa, T; Tadokoro, J; Yamaguchi, F | 1 |
| Cohn, AL; Khandelwal, P; Mehta, N; Neubauer, MA; Richards, D; Shumaker, GC; Smith, DA; Watkins, DL; Yassine, MR; Zhang, K | 1 |
| Agarwal, A; Ferrarotto, R; Hoff, PM; Kopetz, S; Maru, D; Overman, M; Pathak, P | 1 |
| Critchfield, GC; Hamilton, SA; Kaldate, RR; Roa, BB; Saam, J; Wenstrup, RJ | 1 |
| Brenckman, W; Cheng, YC; Chu, E; Copur, MS; Jiang, Z; Kummar, S; Liu, SH; O'Rourke, M; Rose, M; Stephenson, J; Su, T; Tilton, R; Wadler, S | 1 |
| André, T; Artru, P; Bengrine-Lefevre, L; Bonnetain, F; Chibaudel, B; de Gramont, A; Desramé, J; Larsen, AK; Louvet, C; Teixeira, L; Tournigand, C | 1 |
| Farma, JM; Matteotti, RS; Nitzkorski, JR; Sigurdson, ER; Siripurapu, V; Watson, JC; Zhu, F | 1 |
| Aubele, P; Bangerter, M; Denzlinger, C; Freiberg-Richter, J; Giessen, C; Heinemann, V; Hinke, A; Kullmann, F; Mayerle, J; Modest, DP; Moosmann, N; Schulz, C; Sieber, M; Stintzing, S; Teschendorf, C; Vehling-Kaiser, U; von Weikersthal, LF | 1 |
| Arai, Y; Ashida, K; Ikeguchi, M; Katano, K; Maeta, Y; Wakatsuki, T | 1 |
| Arbitrio, M; Cannataro, M; Caraglia, M; Ciliberto, D; Di Martino, MT; Doldo, P; Fabiani, F; Guzzi, PH; Leone, E; Rotundo, MS; Sperlongano, P; Tagliaferri, P; Talarico, D; Tassone, P; Tomaino, V | 1 |
| Goto, A; Hamaguchi, T; Ichikawa, Y; Kato, K; Matsumoto, H; Shimada, Y; Yamada, Y; Yamaguchi, T | 1 |
| Burden, RE; Gazdoiu, M; Gormley, JA; Jaquin, TJ; Johnston, JA; Kuehn, D; Kwok, HF; McClurg, A; Olwill, SA; Scott, CJ; Ward, C | 1 |
| Efrusy, MB; Göke, B; Goldberg, RM; Kirchner, T; Santas, CC; Vijayaraghavan, A | 1 |
| Peeters, M; Price, T | 1 |
| Seymour, M | 1 |
| Abbas, M; Auby, D; Azzedine, A; Bedenne, L; Bouché, O; Castaing, M; Denis, B; Ducreux, M; Etienne, PL; Gargot, D; Gasmi, M; Geoffroy, P; Lombard-Bohas, C; Malka, D; Mendiboure, J; Michel, P; Pignon, JP; Rougier, P; Texereau, P | 1 |
| Allegrini, G; Baldi, GG; Brunetti, IM; Cortesi, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Ricci, S; Salvatore, L; Tuzi, A; Vasile, E | 1 |
| Fayad, W; Felth, J; Fryknäs, M; Glimelius, B; Graf, W; Gullbo, J; Hassan, S; Larsson, R; Laryea, D; Linder, S; Mahteme, H; Nygren, P; Påhlman, L; Rickardson, L | 1 |
| Hattori, M; Hayashi, T; Kawase, Y; Kozaki, K; Mizuno, A; Okochi, O; Sasada, Y; Sato, Y; Takami, Y; Takamura, S; Takeda, S; Tsuboi, K; Uno, Y | 1 |
| Crea, F; Cremolini, C; Danesi, R; Falcone, A; Farrar, WL; Fornaro, L; Frumento, P; Graziano, F; Loupakis, F; Masi, G; Paolicchi, E; Ricci, V; Ronzoni, M; Salvatore, L; Schirripa, M | 1 |
| Beachler, C; El-Deiry, WS; Finnberg, NK; Gingrich, R; Kline, CL; Liao, J; Scicchitano, A; Sheikh, HS; Sivik, J | 1 |
| Dai, M; Fu, S; Gou, M; Luo, F; Qian, Z; Song, J; Xu, X | 1 |
| Capussotti, L; Mellano, A; Muratore, A; Ribero, D; Viganò, L; Zimmitti, G | 1 |
| Crea, F; Danesi, R; Landini, I; Mini, E; Napoli, C; Nobili, S; Paolicchi, E; Perrone, G | 1 |
| Ba, Y; Feng, FY; Guan, ZZ; He, J; Liang, J; Luo, RC; Qi, C; Qin, SK; Shen, L; Wang, D; Wang, JJ; Wang, LW; Xu, JM; Xu, RH; Yu, SY | 1 |
| Decosta, L; Fernebro, E; Gamelin, E; Greil, R; Hofheinz, R; Karthaus, M; Köhne, CH; Letocha, H; Mineur, L; Thaler, J | 1 |
| Czejka, M; Ettlinger, D; Kiss, A; Koessner, C; Schueller, J; Terkola, R | 1 |
| Chen, MJ; Chuang, SC; Hou, MF; Huang, MY; Kuo, CH; Lin, SR; Ma, CJ; Tsai, HL; Wang, JY | 1 |
| Allegra, CJ; Bonnetain, F; Buyse, M; Chibaudel, B; de Gramont, A; Goldberg, RM; Sargent, DJ; Shi, Q; Tournigand, C | 1 |
| Allen, PJ; Blumgart, LH; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; House, MG; Jarnagin, WR; Kemeny, NE; Paty, PB | 1 |
| Bosnjak, SM; Hesketh, PJ; Nikolic, V; Rapoport, B | 1 |
| Ackerstaff, E; Chen, JH; Darpolor, MM; Kennealey, PT; Koutcher, JA; Le, HC; Rizwan, A; Sambol, EB; Schwartz, GK; Singer, S; Zakian, KL | 1 |
| Lewis, MR | 1 |
| Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M | 1 |
| Akiyoshi, K; Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Nagashima, K; Nakajima, T; Shimada, Y; Yamada, Y | 1 |
| Assenat, E; Bibeau, F; Bleuse, JP; Crapez-Lopez, E; Desseigne, F; Kramar, A; Mineur, L; Portales, F; Samalin, E; Thezenas, S; Viret, F; Ychou, M | 1 |
| Allen, WL; Carson, G; Coyle, VM; Gordon, MA; Jithesh, PV; Johnston, PG; Lenz, HJ; Longley, DB; Proutski, I; Stevenson, L; Van Schaeybroeck, S | 1 |
| Bechstein, WO; Folprecht, G | 1 |
| Ishikawa, K; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M | 1 |
| Adleff, V; Budai, B; Hitre, E; Komlósi, V; Kralovánszky, J; Láng, I; Nagy, T; Pap, É; Réti, A | 1 |
| Pauwels, P; Peeters, M; Reutelingsperger, CP; Staelens, S; Van Damme, N; Van de Wiele, C; Vangestel, C | 1 |
| Barroso, E; Carvalho, C; Choti, MA; de Jong, MC; Nobre, AM; Pawlik, TM; Pinto Marques, H; Ribeiro, V | 1 |
| Berger, F; Biau, J; Bousquet, G; Devun, F; Dutreix, M; Herbette, A; Robine, S; Roulin, C; Sun, JS | 1 |
| Caroli-Bosc, FX; Czerucka, D; Fenouille, N; Grosso, S; Imbert, V; Lagadec, P; Mary, D; Peyron, JF; Pontier-Bres, R; Yunchao, S | 1 |
| Chen, A; Chirmule, N; Gupta, S; Kaliyaperumal, A; Pennucci, JJ; Pérez-Ruixo, JJ; Starcevic, M; Swanson, SJ; Weeraratne, D; Wright, J; Wu, CY; Yang, BB; Zhang, K | 1 |
| Baba, H; Beppu, T; Hayashi, N; Sawayama, H; Takamori, H; Watanabe, M | 1 |
| Bearzi, I; Biagetti, S; Biscotti, T; Cascinu, S; Falcone, A; Galizia, E; Giampieri, R; Giustini, L; Loupakis, F; Maccaroni, E; Mandolesi, A; Scartozzi, M; Silva, R; Zaniboni, A | 1 |
| Alberts, SR; Franko, J; Goldberg, RM; Goldman, CD; Grothey, A; Nelson, GD; Pitot, HC; Pockaj, BA; Sargent, DJ; Shi, Q | 1 |
| Bukofzer, G; Chakravartty, A; Cole, TB; Day, M; Donawho, CK; Fox, GB; Holich, KD; Luo, Y; Mudd, SR; Palma, JP; Reuter, DR; Tapang, P; Voorbach, MJ | 1 |
| Hyodo, I; Maehara, Y; Mishima, H; Muro, K; Oba, K; Sakamoto, J; Yoshino, T | 1 |
| Barber, B; Bhosle, M; Gao, S; Klingman, D; Pelletier, E; Wang, S; Zhao, Z | 1 |
| Brünner, N; Jensen, NF; Müller, S; Nielsen, HJ; Nielsen, KV; Nielsen, SL; Rømer, MU | 1 |
| Bollag, G; Bradley, WD; Heimbrook, D; Higgins, B; Kolinsky, K; Kopetz, S; Lee, RJ; Lestini, B; Packman, K; Schostack, K; Simcox, ME; Su, F; Yang, H | 1 |
| Brünner, N; Jensen, NF; Nielsen, KV; Nygård, SB; Rømer, MU; Smith, DH | 1 |
| Benhaim, L; Labonte, MJ; Lenz, HJ | 1 |
| Ciccolini, J; Dahan, L; Evrard, A; Iliadis, A; Lacarelle, B; Mbatchi, L; Mercier, C; Norguet, E; Ouafik, L; Ries, P; Seitz, JF; Tibbitts, J | 1 |
| Bellot, GL; Koh, D; Tan, WH; Tay, LL; Wang, X | 1 |
| Fu, Y; Li, Q; Liu, C; Meng, X; Yao, L; Zhao, X; Zu, B; Zu, Y | 1 |
| Aliberti, C; Benea, G; Dallara, S; Fiorentini, G; Muzzio, PC; Pomerri, F; Tilli, M | 1 |
| Akiyama, Y; Fujita, K; Ishida, H; Kawara, K; Miwa, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K | 1 |
| Chang-Yun, L; Elnemr, A; Hirano, M; Ichinose, M; Ishibashi, H; Kitai, T; Li, Y; Matsuda, N; Mizumoto, A; Ozamto, Y; Sako, S; Takao, N; Togawa, T; Xiao-Jun, Y; Yonemura, Y | 1 |
| Chan, KM; Chen, JS; Chiang, JM; Lee, CF; Lee, WC; Wang, JY; Yu, MC | 1 |
| Baba, E; Bando, H; Boku, N; Esaki, T; Fukunaga, M; Hyodo, I; Kato, S; Katsumata, K; Miyake, Y; Moriwaki, T; Ozeki, M; Satoh, T; Takashima, A; Yamashita, K; Yamazaki, K; Yoshida, S | 1 |
| Fadlalla, K; Katkoori, V; Manne, U; Mosley, L; Samuel, T; Turner, T | 1 |
| Munakata, M; Sakata, Y | 1 |
| Hazama, S; Oka, M | 1 |
| Kawakami, H; Nakagawa, K; Satoh, T | 1 |
| Kato, K | 1 |
| Hamamoto, Y; Komaki, T; Nishi, T | 1 |
| Ikenaga, M; Mishima, H; Yasui, M | 1 |
| Decker, T; Fischer von Weikersthal, L; Giessen, C; Heinemann, V; Heintges, T; Jäger, E; Jung, A; Kirchner, T; Modest, DP; Neumann, J; Scheithauer, W; Stintzing, S; Stoll, C; Vehling-Kaiser, U | 1 |
| Jakobsen, A; Pallisgaard, N; Spindler, KL; Vogelius, I | 1 |
| Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, Ch; Makrantonakis, P; Polyzos, A; Souglakos, J; Vamvakas, L; Xynogalos, S; Ziras, N | 1 |
| Carpenter, W; Li, L; Meyerhardt, JA; Sanoff, HK; Schrag, D | 1 |
| Chu, F; Chua, TC; Liauw, W; Morris, DL | 1 |
| Capussotti, L; Ferrero, A; Langella, S; Lo Tesoriere, R; Russolillo, N; Vigano', L | 1 |
| Gaya, A; Tse, V | 1 |
| Asseburg, C; Bravo Vergel, Y; Manca, A; Meade, A; Parmar, M; Sculpher, MJ; Seymour, MT; Stephens, R | 1 |
| Atreya, CE; Bergsland, EK; Ducker, GS; Feldman, ME; Shokat, KM; Warren, RS | 1 |
| Cacciatore, I; Cornacchia, C; Feliciani, F; Mollica, A; Pinnen, F; Stefanucci, A | 1 |
| Ahn, YC; Chang, HM; Hong, YS; Jin, DH; Kang, YK; Kim, JC; Kim, KP; Kim, TW; Lee, JL; Na, YS; Park, SJ; Ryu, MH; Yu, CS | 1 |
| Brunet, R; Evrard, S; Kauffmann, A; Laroche-Clary, A; Laurand-Quancard, A; Le Morvan, V; Robert, J; Smith, D | 1 |
| Chen, E; Feld, R; Knox, J; Krzyzanowska, MK; Liu, G; MacKay, H; Moore, MJ; Petronis, J; Renouf, DJ; Wang, L; Welch, S | 1 |
| Asada, M; Kusano, K; Owa, T; Ozawa, Y; Yokoi, A; Yoshimatsu, K | 1 |
| Akashi, K; Baba, E; Esaki, T; Fujishima, H; Kusaba, H; Makiyama, A; Mitsugi, K; Nakano, S; Tanaka, R; Uchino, K | 1 |
| Gibbs, P; Tie, J | 1 |
| Crea, F; Cremolini, C; Danesi, R; Falcone, A; Fornaro, L; Graziano, F; Loupakis, F; Masi, G; Paolicchi, E; Ricci, V; Ronzoni, M; Salvatore, L; Schirripa, M | 1 |
| Assy, N; Basher, W; Chetver, L; Shnaider, J; Zidan, J | 1 |
| Bachellier, P; Chenard, MP; Fuchshuber, P; Jaeck, D; Narita, M; Nobili, C; Oussoultzoglou, E; Pessaux, P; Rosso, E | 1 |
| Addeo, R; Bronte, G; Cascinu, S; Cicero, G; Falcone, A; Frezza, AM; Garufi, C; Imperatori, M; Maiello, E; Mancuso, A; Masi, G; Recine, F; Russo, A; Santini, D; Scartozzi, M; Schiavon, G; Tonini, G; Venditti, O; Vincenzi, B | 1 |
| Hiyoshi, M; Hongo, K; Kaneko, M; Kawai, K; Kitayama, J; Murono, K; Nirei, T; Sasaki, K; Sunami, E; Tada, N; Takahashi, K; Tsuno, NH | 1 |
| Addeo, P; Bachellier, P; Chenard, MP; Fuchshuber, P; Jaeck, D; Narita, M; Oussoultzoglou, E; Rather, M; Rosso, E | 1 |
| da Costa Lima, AB; Macedo, LT; Sasse, AD | 1 |
| Baek, JH; Choi, YJ; Kang, MJ; Kim, YS; Kwon, HC; Lee, HS; Oh, SY; Park, LC; Park, MI; Park, SJ; Shin, SH | 1 |
| Coco, C; Ferlini, C; Mariani, M; Martinelli, E; Martino, C; Scambia, G; Shahabi, S; Sieber, S; Sioletic, S; Zannoni, GF | 1 |
| Brodowicz, T; Giessen, C; Heinemann, V; Knittelfelder, R; Laubender, RP; Modest, DP; Reinacher-Schick, A; Schmiegel, W; Stintzing, S; Tannapfel, A; Vrbanec, D; Zielinski, CC | 1 |
| Calway, T; Du, GJ; Du, W; He, TC; Somogyi, J; Wang, CZ; Wen, XD; Yuan, CS; Zhang, ZY | 1 |
| Conibear, J; Raouf, S; Tarver, K | 1 |
| Allen, PJ; Bao, F; D'Angelica, MI; DeMatteo, RP; Fong, Y; Hernandez-Boussard, T; Jarnagin, WR; Kemeny, NE; Klimstra, DS; Poultsides, GA; Saltz, LB; Servais, EL; Shia, J | 1 |
| Bennouna, J; Chatelut, E; Douillard, JY; El Hannani, C; Etienne-Grimaldi, MC; Faroux, R; Formento, JL; Francois, E; Francoual, M; Hennebelle, I; Jacob, JH; Milano, G | 1 |
| Chandrakumaran, K; John, TG; Knowles, B; Rees, M; Welsh, FK | 1 |
| Alfonsi, S; Bearzi, I; Biagetti, S; Bianconi, M; Bittoni, A; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Giustini, L; Loretelli, C; Maccaroni, E; Mandolesi, A; Scartozzi, M | 1 |
| Alessandroni, P; Aliberti, C; Catalano, V; Coschiera, P; Fiorentini, G; Giordani, P; Graziano, F; Mambrini, A; Montagnani, F; Mulazzani, L; Tilli, M | 1 |
| Akiyama, Y; Araki, K; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Nagashima, F; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Fukushima, M; Hareyama, M; Kai, M; Matsumoto, Y; Sakata, K; Someya, M; Tauchi, H | 1 |
| Arcaroli, JJ; Dasari, A; Gao, D; McManus, M; Messersmith, WA; Pitts, TM; Powell, RW; Quackenbush, KS; Spreafico, A; Tan, AC; Touban, BM; Varella-Garcia, M | 1 |
| Bo, X; Dexiang, Z; Haifu, W; Haohao, L; Jia, F; Jianmin, X; Lechi, Y; Li, L; Li, R; Qinghai, Y; Shenyong, Z; Tianshu, L; Xiangou, P; Xinyu, Q; Ye, W; Yunshi, Z | 1 |
| Martin, RC; Metzger, T; Schreeder, M; Scoggins, CR; Sharma, V; Tatum, C; Tomalty, D | 1 |
| Balboa, E; Barros, F; Bernardez, B; Candamio, S; Carracedo, A; Duran, G; Giraldez, JM; Lamas, MJ; Lopez, R; Mosquera, A; Vidal, Y | 1 |
| Denda, T; Hashigaki, S; Kato, T; Komatsu, Y; Lechuga, MJ; Miyata, Y; Mizutani, N; Muro, K; Nagase, M; Nishina, T; Satoh, T; Tsuji, A; Tsuji, Y; Yoshida, M | 1 |
| Abdelhay, ES; Bastos, LG; de-Freitas-Junior, JC; Freire-Neto, CA; Morgado-Díaz, JA; Rocher, BD | 1 |
| Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S | 1 |
| Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, SS; Ryoo, BY; Ryu, MH; Shin, JG | 1 |
| Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P | 1 |
| Abbruzzese, A; Apollinari, S; Bestoso, E; Botta, C; Caraglia, M; Correale, P; Cusi, MG; Misso, G; Pastina, P; Sperlongano, P; Tagliaferri, P; Tassone, P | 1 |
| Asao, T; Fujii, T; Fukasawa, T; Kigure, W; Kuwano, H; Tabe, Y; Tsutsumi, S | 1 |
| Shimada, Y | 1 |
| Broadbridge, VT; Karapetis, CS; Price, TJ | 1 |
| Ceelen, W; De Bruyne, S; Ferdinande, L; Geboes, K; Laurent, S; Libbrecht, L; Mertens, J; Peeters, M; Smeets, P; Troisi, R; Van Damme, N; Van de Wiele, C | 1 |
| Arcaroli, J; Azad, N; Carducci, MA; Dasari, A; Diaz, LA; Donehower, RC; Hidalgo, M; Laheru, DA; McManus, M; Messersmith, WA; Quackenbush, K; Rudek, MA; Taylor, GE; Wright, JJ; Zhao, M | 1 |
| Adam, R; Barroso, E; Capussotti, L; Elias, D; Figueras, J; Gigot, JF; Gruenberger, T; Herrera, J; Ijzermans, JN; Isoniemi, H; Laurent, C; Letoublon, C; Lucidi, V; Mirza, DF; Nuzzo, G; Pardo, F; Popescu, I; Poston, G; Sousa, FC; Viganò, L | 1 |
| Andersson, R; Norman, P; Spelt, L; Tingstedt, B; Törnqvist, L | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Cetin, B; Coskun, U; Isıkdogan, A; Kaplan, MA; Ozkan, M; Ozturk, SC | 1 |
| Benoist, S; Goyer, P; Hajjam, ME; Julié, C; Nordlinger, B; Penna, C | 1 |
| Gamoh, M; Ishioka, C; Iwama, N; Kato, S; Komine, K; Mori, T; Shimodaira, H; Soeda, H; Suzuki, T; Watanabe, M | 1 |
| Cakar, B; Karabulut, B; Karaca, B; Sezgin, C; Uslu, R; Varol, U | 1 |
| Barot, TC; Gulec, SA; Hall, M; Pennington, K; Schwartzentruber, D; Suthar, RR; Wheeler, J | 1 |
| Giessen, C; Heinemann, V; Jung, A; Kapaun, C; Kirchner, T; Laubender, RP; Modest, DP; Moosmann, N; Neumann, J; Stintzing, S; Wollenberg, A | 1 |
| Bae, EJ; Kang, MJ; Kwon, JM; Lee, EK; Lee, MA; Lee, NS; Lister, J; Ngoh, CA; Park, MH; Park, SJ; Park, YS; Revil, C; Shin, SJ; Zang, DY | 1 |
| Allen, WL; Carson, G; Coyle, VM; Dunne, P; Hector, S; Johnston, PG; Longley, DB; Stevenson, L; Turkington, RC; Van Schaeybroeck, S | 1 |
| Colson, YL; Grinstaff, MW; Herrera, VL; Yohe, ST | 1 |
| Akay, OM; Bal, C; Gulbas, Z; Keskin, M; Kuş, E; Ustuner, Z | 1 |
| de Lima Lopes, G; Haaland, BA; Ku, GY | 1 |
| Abajo, A; Bandres, E; Bitarte, N; Boni, V; Garcia-Foncillas, J; Gonzalez-Huarriz, M; Lopez, I; Rodriguez, J; Zarate, R | 1 |
| Abrams, TA; Ancukiewicz, M; Blaszkowsky, L; Chan, JA; Duda, DG; Elliott, M; Enzinger, PC; Goldstein, M; Jain, RK; Kulke, MH; Meyerhardt, JA; Regan, E; Schrag, D; Wolpin, BM; Zhu, AX | 1 |
| Alkis, N; Benekli, M; Berk, V; Buyukberber, S; Ciltas, A; Coskun, U; Dane, F; Dikilitas, M; Dogu, GG; Durnali, AG; Kaplan, MA; Karaca, H; Ozkan, M; Sevinc, A; Yetisyigit, T; Yildiz, R | 1 |
| Pua, U | 1 |
| Bafaloukos, D; Economopoulos, T; Eleftheraki, AG; Fountzilas, G; Kalogeras, KT; Klouvas, G; Koutras, A; Makatsoris, T; Nikitas, N; Papakostas, P; Papandreou, CN; Papaxoinis, G; Pectasides, D; Pentheroudakis, G; Samantas, E; Sgouros, J; Syrigos, KN; Timotheadou, E; Varthalitis, I; Xanthakis, I | 1 |
| Cats, A; Ciardiello, F; Gallerani, E; Gelderblom, H; Glimelius, B; Hendlisz, A; Humblet, Y; Moehler, M; Peeters, M; Sagaert, X; Schlichting, M; Tejpar, S; Van Cutsem, E; Vanbeckevoort, D; Vermorken, JB; Viret, F; Vlassak, S | 1 |
| Akiyama, S; Andoh, H; Gamoh, M; Ishioka, C; Kato, S; Maeda, S; Mori, T; Murakawa, Y; Ohori, H; Sasaki, Y; Shimodaira, H; Suzuki, T; Takahashi, S; Yamaguchi, T; Yoshioka, T | 1 |
| Alagoz, M; Chalmers, AJ; El-Khamisy, S; Gilbert, DC | 1 |
| Doornebal, J; Koopman, M; Lemmens, W; Punt, CJ; Teerenstra, S; Venderbosch, S | 1 |
| Blazer, DG; Hsu, D; Papalezova, K; Stinnett, S; Tyler, D; Zani, S | 1 |
| Berthet, C; Bigot, L; Bruno, A; Calvet, L; Dangles-Marie, V; Dartigues, P; De Thé, H; Demers, B; Dessen, P; Duchamp, O; Goéré, D; Gonin, P; Job, B; Julien, S; Lacroix, L; Landron, S; Lantuas, D; Lardier, G; Mariani, P; Merino-Trigo, A; Morgand, L; Nemati, F; Nunes, M; Pham, E; Pierré, A; Pocard, M; Prévost, G; Roman-Roman, S; Soliman, H; Vrignaud, P; Weiswald, LB | 1 |
| Eichler, K; Gallus, C; Gruber-Rouh, T; Hammerstingl, R; Mack, MG; Vogl, TJ; Zangos, S | 1 |
| Chen, X; Cheng, L; Dai, L; Deng, H; Fan, P; Li, C; Li, Y; Shi, G; Tian, H; Wei, Y; Yan, N; Yang, Y; Zhang, S; Zhang, X | 1 |
| de Braud, F; Garassino, MC; Pietrantonio, F; Torri, V | 1 |
| Ando, Y; Eguchi, T; Fujii, T; Fujiwara, M; Ishigure, K; Ishiyama, A; Kodera, Y; Koike, M; Nakayama, G; Ohashi, N; Sugimoto, H; Tsuboi, K; Uehara, K; Yokoyama, H | 1 |
| Asao, T; Hosouchi, Y; Ishibashi, K; Ishida, H; Kigure, W; Kuwano, H; Ojima, H; Tsutsumi, S; Uchida, N; Yamauchi, S; Yashuda, N | 1 |
| Gore, JC; Guo, J; Guo, N; Manning, HC; Wang, C; Xie, J | 1 |
| Arnold, D; Edelmann, T; Glockzin, G; Hildebrandt, B; Hollerbach, S; Illerhaus, G; Königsrainer, A; Richter, M; Schlitt, HJ; Schmoll, HJ; Stein, A; Wienke, A | 1 |
| Cervinka, M; John, S; Rudolf, E | 1 |
| Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M | 1 |
| Bodnar, L; Charkiewicz, R; Chyczewski, L; Ciechowicz, M; Korniluk, J; Kozłowski, W; Nikliński, J; Rokita, M; Smoter, M; Stec, R; Szczylik, C | 1 |
| Arai, Y; Aramaki, T; Boku, N; Hamada, M; Inaba, Y; Kato, K; Morita, S; Muro, K; Ohtsu, A; Satake, M; Sato, Y; Shimada, Y; Takeuchi, Y; Yamada, Y | 1 |
| Araki, T; Hashimoto, K; Inoue, Y; Kawamura, M; Kusunoki, M; Matsushita, K; Mizoguchi, A; Mohri, Y; Morimoto, Y; Okigami, M; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Uchida, K | 1 |
| Carlsson, G; Holmberg, C; Pettersson, K; Sporrong, SK | 1 |
| Brodowicz, T; Heinemann, V; Jung, A; Kirchner, T; Knittelfelder, R; Kurteva, G; Laubender, RP; Modest, DP; Neumann, J; Ocvirk, J; Papai, Z; Stintzing, S; Zielinski, CC | 1 |
| Allegra, C; Castan, R; Ferry, D; Lakomy, R; Macarulla, T; McKendrick, J; Moiseyenko, V; Polikoff, J; Prausová, J; Prenen, H; Ruff, P; Tabernero, J; Tellier, A; Van Cutsem, E; van Hazel, GA | 1 |
| Fu, FF; Jiang, HP; Jiang, WQ; Li, YX; Teng, LS; Wang, HH; Wang, WB | 1 |
| Budai, B; Hitre, E; Láng, I; Nagy, T | 1 |
| Berglund, Å; Byström, P; Glimelius, B; Johansson, B; Larsson, A; Nygren, P; Wernroth, L | 1 |
| Goto, A; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Shimada, Y; Yamada, Y | 1 |
| Akiyoshi, K; Hamaguchi, T; Hosokawa, A; Iwasa, S; Kato, K; Nakajima, TE; Nishitani, H; Ogawa, K; Shimada, Y; Sugiyama, T; Ueno, T; Yamada, Y | 1 |
| Lieberman, R | 1 |
| Ahmad, FJ; Ahmad, MZ; Akhter, S; Anwar, M; Kumar, A; Rahman, M; Talasaz, AH | 1 |
| Bekaii-Saab, TS; Bendell, JC; Cohn, AL; Dalal, D; Fish, S; Flick, ED; Grothey, A; Hurwitz, HI; Kozloff, M; Mun, Y; Roach, N; Tezcan, H | 1 |
| Bretagne, JF; Desgrippes, R; Leconte, B; Manfredi, S; Tchoundeu, B; Uguen, T | 1 |
| Baños, A; Fernebro, E; Gamelin, E; Greil, R; Hofheinz, R; Karthaus, M; Köhne, CH; Letocha, H; Mineur, L; Thaler, J | 1 |
| Asghar, U; Barbachano, Y; Chau, I; Constantinidou, A; Cunningham, D; Khan, A; Mudan, S; Rao, S; Shurmahi, F | 1 |
| Adua, D; Barucca, V; Colonna, M; Di Seri, M; Giannarelli, D; Longo, F; Mottolese, M; Romiti, A; Rossi, L; Ruco, L; Tomao, S; Veltri, E; Zoratto, F; Zullo, A | 1 |
| Allen, PJ; Bao, F; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; Jarnagin, WR; Kemeny, N; Kingham, TP; Park, JO; Shia, J; Wolf, PS | 1 |
| Aissat, N; André, T; Artru, P; Bachet, JB; Bennamoun, M; Blons, H; Cayre, A; Chibaudel, B; de Gramont, A; Ebenezer, C; Laurent-Puig, P; Mabro, M; Nguyen, S; Penault-Llorca, F; Tournigand, C | 1 |
| Hashimoto, T; Hotta, T; Iwamoto, H; Matsuda, K; Oku, Y; Takifuji, K; Yamaue, H; Yokoyama, S | 1 |
| Aloia, TA; Tzeng, CW | 1 |
| Lyseng-Williamson, KA | 1 |
| Bando, H; Fujii, S; Kadowaki, S; Kajiura, S; Nishina, T; Ohtsu, A; Shinozaki, E; Tsuchihara, K; Yamanaka, T; Yamazaki, K; Yoshino, T; Yuki, S | 1 |
| Bendell, JC; Berlin, J; Bray, GL; Firdaus, I; Gore, I; Graham, RA; Hart, LL; Hermann, RC; Low, JA; Mackey, HM; Mulcahy, MF; Yauch, RL; Zalupski, MM | 1 |
| Adotevi, O; Borg, C; Degano, SV; Demarchi, M; Dobi, E; Godet, Y; Ivanaj, A; Jary, M; Kantelip, B; Kim, S; Monnien, F; N'Guyen, T; Pivot, X; Thierry-Vuillemin, A | 1 |
| Adam, R; Andres, A; Barroso, E; Capussotti, L; Gerstel, E; Hubert, C; Majno, PE; Mentha, G; Roth, A; Toso, C | 1 |
| Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N | 1 |
| Curran, D; Folprecht, G; Griebsch, I; Hitre, E; Köhne, CH; Láng, I; Rougier, P; Sartorius, U; Van Cutsem, E | 1 |
| Fujibuchi, W; Miura, K; Unno, M | 1 |
| Kontek, R; Nowicka, H | 1 |
| Kamata, H; Koisumi, J; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A | 1 |
| Albiol, M; Alsina, M; Codina-Barreras, A; Figueras, J; Guardeño, R; Hernandez-Yagüe, X; Lopez-Ben, S; Queralt, B; Soriano, J | 1 |
| Aloia, TA; Boonsirikamchai, P; Charnsangavej, C; Chun, YS; Curley, SA; Kopetz, S; Loyer, EM; Maru, DM; Shindoh, J; Vauthey, JN; Zimmitti, G | 1 |
| Androulakis, N; Georgoulias, V; Hatzidaki, D; Kabouraki, E; Kalbakis, K; Mavroudis, D; Saridaki, Z; Souglakos, J; Vamvakas, L; Vardakis, N; Voutsina, A | 1 |
| Baba, H; Baba, Y; Beppu, T; Chikamoto, A; Iwatsuki, M; Miyamoto, Y; Okabe, H; Sakamoto, Y; Watanabe, M | 1 |
| Asayama, M; Boku, N; Doi, T; Fujino, T; Machida, N; Ohtsu, A; Onozawa, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T | 1 |
| Bertarelli, G; Biondani, P; Cortinovis, D; de Braud, F; Di Bartolomeo, M; Fanetti, G; Mariani, L; Melotti, F; Milione, M; Perrone, F; Pietrantonio, F | 1 |
| Douillard, JY; Peeters, M; Siena, S; Van Cutsem, E; Wiezorek, J; Williams, R; Zhang, K | 1 |
| Prenen, H; Van Cutsem, E | 1 |
| Dunne, D; Fenwick, SW; Gruenberger, T; Jones, RP; Koelblinger, C; Malik, HZ; O'Grady, E; Poston, GJ; Stättner, S; Stremitzer, S; Sutton, P; Terlizzo, M | 1 |
| Dvorák, J; Krajina, A; Malírová, E; Melichar, B; Nová, M; Ryska, A; Voboril, Z; Weiner, P | 1 |
| Akashi, K; Arita, S; Baba, E; Esaki, T; Kishimoto, J; Kumagai, H; Kusaba, H; Mitsugi, K; Uchino, K | 1 |
| Gou, L; Kang, T; Su, X; Wang, Y; Xie, Y; Yang, J; Yao, Y; Yi, C | 1 |
| Benhaim, L; Boige, V; Bonnet, S; De Baere, T; Deschamps, F; Dromain, C; Ducreux, M; Dumont, F; Elias, D; Faron, M; Goéré, D; Lefèvre, JH; Malka, D | 1 |
| Jiao, SC; Liu, ZY; Shen, L; Wang, JW; Wang, Y; Xu, JM; Xu, N | 1 |
| Giessen, C; Haas, M; Heinemann, V; Laubender, RP; Mansmann, U; Modest, DP; Schulz, C; Stintzing, S | 1 |
| Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S | 1 |
| Amano, K; Baba, H; Haga, N; Hatano, S; Ishibashi, K; Ishida, H; Ishiguro, T; Kumagai, Y; Kumamoto, K; Kuwabara, K; Ohsawa, T; Okada, N; Sobajima, J; Tajima, Y; Tsuji, Y | 1 |
| Blough, D; Koepl, L; Mummy, D; Ramsey, S; Shankaran, V; Yim, YM; Yu, E | 1 |
| Baek, JY; Hong, YS; Kim, HJ; Kim, JC; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Lim, SB; Park, JH; Park, SJ; Yu, CS | 1 |
| Ben-Haim, M; Geva, R; Klausner, J; Lahat, G; Lubezky, N; Nakache, R; Papoulas, M; Shacham-Shmueli, E; Winograd, E | 1 |
| Fakih, MG; Fora, AA; Groman, A; Ma, WW; McMahon, JA; Romano, KS; Wilding, G | 1 |
| Alonso, V; Codony-Servat, J; Escudero, P; Fernández-Martos, C; Gallego, R; Garcia-Albeniz, X; Martinez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Pericay, C | 1 |
| Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M | 1 |
| Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA | 1 |
| Antón, A; Aparicio, J; Aranda, E; Carrato, A; Chaves, M; Constenla, M; Dueñas, R; Escudero, P; Gallego, J; Gómez, A; González, E; Grávalos, C; Losa, F; Manzano, JL; Marcuello, E; Massuti, B; Maurel, J; Rivera, F | 1 |
| Huang, X; Jain, R; Lichinitser, M; Manikhas, G; Peeters, M; Rogowski, W; Shapiro, J; Strickland, AH; Suresh, AV; Tebbutt, NC; Warner, D; Wu, B | 1 |
| Bélanger, AS; Cecchin, E; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Lévesque, E; Toffoli, G | 1 |
| Akagi, Y; Baba, H; Emi, Y; Kakeji, Y; Maehara, Y; Natsugoe, S; Nishimaki, T; Ogata, Y; Oki, E; Sadanaga, N; Saeki, H; Shirouzu, K; Tanaka, T; Tokunaga, S | 1 |
| Barni, S; Beretta, GD; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F; Squadroni, M; Stinco, S | 1 |
| Descos, L; Freyer, G; Kraft, D; Ligneau, B; Trillet-Lenoir, V | 1 |
| de Bruijn, P; Kehrer, DF; Mathijssen, RH; Sparreboom, A; Verweij, J | 1 |
| Buzzi, F; Comella, P; Crucitta, E; De Cataldis, G; De Lucia, L; De Vita, F; Del Gaizo, F; Farris, A; Lannelli, A; Maiorino, L; Mancarella, S; Palmeri, S; Tafuto, S | 1 |
| Agrawal, S; Lindsey, JR; Nan, L; Wang, H; Yu, D; Zhang, R | 1 |
| Dolan, ME; Humerickhouse, R; Wu, MH; Yan, B | 1 |
| Aparicio, J; de las Peñas, R; Farrés, J; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM; Yuste, AL | 1 |
| Carnaghi, C; Fallini, M; Garassino, I; Masci, G; Morenghi, E; Rimassa, L; Santoro, A; Zucali, PA | 1 |
| Di Lauro, C; Gonen, M; Graham, MA; Kemeny, N; Price, C; Saltz, L; Sharma, S; Stockman, J; Teitcher, J; Tong, W; White, P | 1 |
| Berlin, JD | 1 |
| Depisch, D; Fiebiger, W; Kornek, GV; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H | 1 |
| Höffken, K; Kliche, KO; Kubsch, K; Masri-Zada, R; Raida, M | 1 |
| Allegrini, G; Brunetti, IM; Conte, P; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G; Pfanner, E | 1 |
| Adams, AL; Brady, D; Engstrom, PF; Gallo, JM; Kilpatrick, D; Lewis, NL; Litwin, S; Meropol, NJ; Scher, R; Szarka, CE; Weiner, LM | 1 |
| Bennouna, J; Ducreux, M; Hua, A; Lepille, D; Marre, A; Méry-Mignard, D; Mignot, L; Rougier, P | 1 |
| Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE | 1 |
| Ang, P; Ang, PT; Au, E; Koo, WH; See, HT | 1 |
| Schmoll, HJ | 2 |
| Needle, MN | 1 |
| Cats, A; van Ruth, S; Zoetmulder, FA | 1 |
| Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F | 1 |
| Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT | 1 |
| Fisher, MD | 3 |
| Mitry, E; Rougier, P | 3 |
| D'Orazio, AI; Gambill, BD | 1 |
| Fishman, AD; Wadler, S | 1 |
| Bilchik, AJ; Chawla, SP; Chung, MH; Foshag, LJ; Ramming, KP; Rose, DM; Stern, SS; Wood, TF | 1 |
| Erlichman, C; Hobday, TJ | 1 |
| Fisher, MD; Maung, K | 1 |
| Cvitkovic, E; Sutherland, W; Wasserman, E | 1 |
| Feld, R; Fields, A; Goel, R; Hedley, D; Jolivet, J; Lee, IM; Maroun, J; Michael, M; Moore, MJ; Oza, A; Pintilie, M | 1 |
| Danesi, R; Di Paolo, A | 1 |
| Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; García-Foncillas, J; Martín-Algarra, S; Martínez-Monge, R; Rebollo, J; Rodríguez, J | 1 |
| Chico, IM; Pazdur, R | 1 |
| Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM | 1 |
| Avallone, A; Casaretti, R; Comella, G; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Lapenta, L | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Panopoulos, C; Papadouris, S; Sarra, E; Souglakos, J; Vardakis, N | 1 |
| Chu, E; Copur, S; DeGrendele, HC; Jain, VK; Lee, D; Maung, K; Schilsky, R | 1 |
| Goldberg, RM; Hobday, TJ | 1 |
| Calvo, E | 1 |
| Randal, J | 1 |
| Kerr, D | 1 |
| Rothenberg, ML | 6 |
| Gotoh, M; Katsu, K; Kawabe, S; Ohta, S; Takiuchi, H | 1 |
| Akbulut, H; Akbulut, KG; Altuntas, F; Cindoruk, M; Icli, F; Ozturk, G; Unal, E | 1 |
| Adami, B; Baldus, M; Burg, H; Ehscheid, P; Galle, PR; Heike, M; Hoffmann, T; Hohl, H; Klein, O; Moehler, M; Schroeder, M; Schwindt, P; Zanke, C | 1 |
| Bilchik, AJ; Cabot, MC; Litvak, DA | 1 |
| Galle, PR; Heike, M; Hildner, K; Hoffmann, T; Moehler, M; Siebler, J | 1 |
| Evans, JF; Kargman, S; Kelly, CR; Kwong, E; Lam, EC; Luk, P; Wolfe, MM; Yao, M; Zheng, Y | 1 |
| Hochster, H | 1 |
| Bonetti, A | 1 |
| Fuchs, CS; Harker, G; Hecht, JR; Moore, MR; Rinaldi, D; Villa, L | 1 |
| Ishikawa, T; Ouchi, KF; Tanaka, Y; Yanagisawa, M | 1 |
| Farrell, MP; Kummar, S | 1 |
| Dong, YB; McMasters, KM; Yang, HL | 1 |
| Comte, S; Lebrun, T; Selke, B | 1 |
| Ballesteros, P; Bohn, U; Cassinello, J; Dorta, J; Fernández, JL; Huidobro, G; Jorge, M; López, R; López-Alvarez, P; Martínez-Guisado, A; Pérez-Carrión, R; Sevilla, I; Valladares, M | 1 |
| Funahashi, K; Goto, T; Koike, J; Matsumoto, H; Miki, T; Ryu, M; Shibata, Y; Shiokawa, H; Teramoto, T; Tokuyama, T; Washizawa, N | 1 |
| Malinovskiĭ, NN; Severtsev, AN; Smirnova, NB | 1 |
| Alimonti, A; Burattini, E; Pavese, I; Satta, F; Vecchione, A; Zoffoli, V | 1 |
| Glimelius, B | 2 |
| Lièvre, A; Mitry, E | 1 |
| Alvarez, E; Buesa, JM; Carrasco, J; Esteban, E; Fra, J; Jiménez Lacave, A; Muñiz, I; Sala, M; Viéitez, JM | 1 |
| Berlin, JD; Bigelow, RH; Burger, BG; Garay, CA; Gupta, S; Haller, DG; Hart, LL; Le Bail, N; Marshall, JL; Oza, AM; Ramanathan, RK; Rothenberg, ML | 1 |
| Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y | 1 |
| André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M | 1 |
| Friedman, HS; Gilbert, M; Powell, JB; Reardon, DA; Yung, WK | 1 |
| Benson, AB; Goldberg, RM | 1 |
| Carnaghi, C; Comella, P; Díaz-Rubio, E; Douillard, JY; Santoro, A; Sobrero, A; Van Cutsem, E | 1 |
| Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U | 1 |
| Cascinu, S; Georgoulias, V; Kerr, D; Labianca, R; Maughan, T; Ychou, M | 1 |
| Van Cutsem, E; Wilke, HJ | 1 |
| Jin, ML; Li, J; Li, Y; Shen, L; Yang, BQ; Zhang, XD | 1 |
| Aparicio, J; Borrega, P; de la Puente, CG; Lorenzo, A; Moreno-Nogueira, JA; Pica, JM; Reina, JJ; Rueda, A; Salvador, J | 1 |
| Aparicio, J; Bosch, C; Busquier, I; Díaz, R; Fernández-Martos, C; Galán, A; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM | 1 |
| Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J | 1 |
| Cummings, J; Hayward, RL; Jodrell, DI; Macpherson, JS; Monia, BP; Smyth, JF | 1 |
| Bamias, A; Papamichael, D; Pavlidis, N; Syrigos, K | 1 |
| Cohen, Y; Geffen, DB; Gluzman, A; Lavrenkov, K; Man, S | 1 |
| Dvorák, J; Kohout, P; Melichar, B; Melicharová, K; Solichová, D; Zadák, Z | 1 |
| Bailey, SM; Campbell, S; Cunningham, D; Glasspool, R; Hill, M; Macham, MA; Mackay, HJ; Martin, C; Massey, A; Price, T; Twelves, C; Uzzel, M | 1 |
| Lenz, HJ; Park, DJ; Stoehlmacher, J | 1 |
| Breda, M; Britto, MR; James, CA; Jannuzzo, M; Mahteme, H; Nygren, P; Porro, M; Rocchetti, M; Sarapa, N; Speed, W; Wanders, A | 1 |
| Ferns, H | 1 |
| Barceló, R; Ferreiro, J; López-Vivanco, G; Mañé, JM; Muñoz, A; Rubio, I | 1 |
| de Gramont, A; Louvet, C | 2 |
| Blumgart, L; Fong, Y; Gonen, M; Hummer, A; Jarnagin, W; Kemeny, N; Sperber, D; Stockman, J | 1 |
| Achterrath, W; Frings, S; Harstrick, A; Rustum, YM; Schleucher, N; Seeber, S; Tewes, M; Vanhoefer, U; Wilke, HJ | 1 |
| Alfonso, R; Díaz-Rubio, E; Flores, L; Macías, JA; Manrique, I; Sastre, J | 1 |
| Berlin, JD; Rothenberg, ML | 1 |
| Buzzi, F; Comella, P; De Lucia, L; De Vita, F; Farris, A; Gambardella, A; Lorusso, V; Maiorino, L; Mancarella, S; Palmeri, S | 1 |
| Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L | 1 |
| Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N | 1 |
| Fuchs, CS | 1 |
| Diasio, R | 1 |
| Gill, S; Goldberg, RM; Thomas, RR | 1 |
| Sato, A; Shimada, K; Taguchi, S | 1 |
| Boige, V; Borrini, F; Ducreux, M; Fallik, D; Jacob, S; Miquel, C; Praz, F; Sabourin, JC; Viguier, J | 1 |
| de Gramont, A; Kuebler, JP | 1 |
| Bittorf, B; Brueckl, V; Brueckl, WM; Hahn, EG; Hegewald, J; Hohenberger, W; Jüngert, B; Männlein, G; Mühldorfer, S; Schirner, I; Stickel, F; Wein, A | 1 |
| Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L | 1 |
| Iwai, T; Ohtsukasa, S; Okabe, S; Sugihara, K; Yamashita, H | 1 |
| Enomoto, K; Maruyama, K; Matsui, A; Okuda, M; Tsujitsuka, K | 1 |
| de Witte, JH; Keizer, HJ; Peters, WG; ten Bokkel Huinink, WW; van Groeningen, CJ; Voest, EE | 1 |
| Ajani, JA | 1 |
| Eisenberg, SG; Hwang, JJ; Marshall, JL | 1 |
| Hazama, S; Hinoda, Y; Oka, M | 1 |
| Nagao, M; Nakajima, Y | 1 |
| Hirata, K; Nishikawa, N; Sasaki, K; Takasaka, H; Yoshikawa, T | 1 |
| Kataoka, M; Kondo, K; Shimoyama, S | 1 |
| Motomura, S | 1 |
| Doi, T; Ohtsu, A | 1 |
| Shirao, K; Ura, T | 1 |
| Tsunoda, T | 1 |
| Akazawa, S; Murakami, T; Nakazima, T; Sakurai, T; Yamashina, T | 1 |
| Astre, C; Bressolle, F; Culine, S; Malosse, F; Pinguet, F; Poujol, S; Ychou, M | 1 |
| Omura, K | 1 |
| O'Neil, BH | 1 |
| Bria, E; Garufi, C; Sperduti, I; Terzoli, E; Vanni, B; Zappalà, AM | 1 |
| Kanzawa, F; Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T; Tsukiyama, S; Ueda, Y | 1 |
| Enomoto, M; Higuchi, T; Sugihara, K; Uetake, H | 1 |
| Achille, E; André, T; Buyse, M; Colin, P; Couteau, C; de Gramont, A; Flesh, M; Ganem, G; Landi, B; Lledo, G; Louvet, C; Mery-Mignard, D; Quinaux, E; Tournigand, C | 1 |
| Alberts, SR; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK | 1 |
| Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J | 1 |
| de Greve, J; Giaccone, G; Gruia, G; Pinedo, HM; van Groeningen, CJ; van Riel, JM | 1 |
| Lewis, NL; Meropol, NJ | 1 |
| Arizcun, A; Cruz, JJ; de la Torre, A; Diz, P; Duarte, I; España, P; García López, MJ; García-Girón, C; Martínez del Prado, P; Méndez, M; Navalon, M; Pujol, E; Salut, A | 1 |
| Comella, P | 1 |
| Vanhoefer, U | 1 |
| Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G | 1 |
| Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G | 1 |
| Bafaloukos, D; Bamias, A; Economopulos, T; Fountzilas, G; Janinis, J; Kalofonos, HP; Kouvatseas, G; Papakostas, P; Skarlos, D; Stavropoulos, M; Timotheadou, E | 1 |
| Cats, A | 1 |
| Cohen, MH; Griebel, DJ; Hirschfeld, S; Ibrahim, A; Pazdur, R; Williams, GA | 1 |
| Kitakata, H; Mai, M; Minamoto, T; Omote, K; Takahashi, Y; Yamashita, K; Yasumoto, K | 1 |
| Barni, S; Cazzaniga, M; Cremonesi, M; Ferretti, G; Ghilardi, M; Mandalà, M; Mary, C; Rezzani, C | 1 |
| Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G | 1 |
| Folprecht, G; Köhne, CH | 4 |
| Algars, A; Bendardaf, R; Collan, Y; Lamlum, H; Pyrhönen, S; Ristamäki, R | 1 |
| Bleiberg, H; Buyse, M; Di Leo, A | 1 |
| Abad, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Gómez, MA; Marcuello, E; Masutti, B; Pronk, L; Ribera, F; Sastre, J | 1 |
| Aroori, S; Boyer, J; Carey, PD; Johnston, PG; Longley, DB; McCulla, A; McLean, EG; Wilson, P | 1 |
| Goldberg, RM; Grothey, A; Sargent, D; Schmoll, HJ | 1 |
| Barón, MG; Castañón, C; de Tejada, MR; Escudero, P; Feliu, J; López-Gómez, L; Martín, MS; Martínez, MP; Pericay, C; Rodríguez-García, JM; Salud, A; Sánchez, JJ | 1 |
| Fuchs, CS; Kwok, A; McGovren, JP; Meyerhardt, JA; Ratain, MJ | 1 |
| Baba, E; Fujishima, H; Harada, M; Kikuchi, I; Mitsugi, K; Miyanaga, O; Nakano, S; Ueda, A | 1 |
| Abbruzzese, JL; Bogaard, KR; Hoff, PM; Lassere, Y; Pazdur, R; Saad, ED; Wolff, R | 1 |
| Bajetta, E; Beretta, E; Buzzoni, R; Cortinovis, D; Di Bartolomeo, M; Dognini, G; Ferrario, E; Toffolatti, L | 1 |
| Alliot, C; Barrios, M | 1 |
| Ansari, RH; Eng, C; Kasza, K; Kindler, HL; Nattam, S; Vokes, EE; Wade-Oliver, K | 1 |
| Barone, C; Basso, M; Cassano, A; Giuliante, F; Nuzzo, G; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N; Vellone, M | 1 |
| Chen, VM; Flower, RL; Jackson, D; Morel-Kopp, MC; Thrift, KM; Ward, CM | 1 |
| Abad, A; Antón, A; Carrato, A; Diaz-Rubio, E; Gallego, J; Manzano, JL; Marfa, X; Massutí, B; Yuste, AL | 1 |
| Batran, SA; Bokemeyer, C; Büchele, T; Haag, C; Hartmann, JT; Hofheinz, RD; Jäger, E; Kanz, L; Niederle, N; Oechsle, K; Pflüger, KH; Reis, HE; Wilke, HJ | 1 |
| Adam, R; Bastian, G; Bismuth, H; Castaing, D; Gil-Delgado, MA; Guinet, F; Khayat, D; Rocher, MA; Spano, JP; Taillibert, S; Urien, S | 1 |
| Aiba, K | 2 |
| Baron, A; Berlin, J; Cartwright, T; Fehrenbacher, L; Ferrara, N; Fyfe, G; Griffing, S; Hainsworth, J; Heim, W; Holmgren, E; Hurwitz, H; Kabbinavar, F; Novotny, W; Rogers, B; Ross, R | 1 |
| Punt, CJ; van Laarhoven, HW | 1 |
| Chiriatti, A; Colucci, G; Giuliani, F; Maiello, E; Mangia, A; Montemurro, S; Paradiso, A; Simone, G; Xu, J; Zito, A | 1 |
| Awad, L; Cunningham, D; Douillard, JY; Magherini, E; Mery-Mignard, D; Mitry, E; Rougier, P; Van Cutsem, E | 1 |
| Bereder, JM; Bernardini, D; Cals, L; Deplanque, G; Favre, R; François, E; Herait, P; Juin, P; Laadem, A; Merad, L; Rixe, O | 1 |
| Liu, WM; Propper, DJ; Scott, KA; Shahin, S | 1 |
| Humblet, Y | 1 |
| Hoff, PM; Pazdur, R | 1 |
| Goldberg, RM; Penland, SK | 1 |
| O'Connell, MJ | 2 |
| Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M | 1 |
| Gürkan, A; Kaçar, S; Kahya, M; Karaca, C; Uslu, A; Varilsüha, C | 1 |
| Bathe, OF; Bigam, D; Butts, C; Dixon, E; Dowden, S; Ernst, S; Ruether, D; Sutherland, F; Walley, B | 1 |
| Adam, R | 1 |
| Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J | 1 |
| Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C | 1 |
| Schrag, D | 1 |
| Bets, D; Bleiberg, H; Chau, I; Cunningham, D; Harstrick, A; Humblet, Y; Khayat, D; Mueser, M; Santoro, A; Siena, S; Van Cutsem, E; Verslype, C | 1 |
| Erlichman, C; Sargent, DJ | 1 |
| Goetz, MP; Grothey, A | 1 |
| Akbulut, H; Buyukcelik, A; Demirkazik, A; Icli, F; Onur, H; Utkan, G; Yalcin, B | 1 |
| Altés, A; Baiget, M; Del Rio, E; Gómez-Pardo, M; Marcuello, E; Menoyo, A | 1 |
| Bearss, D; Manikumar, G; Von Hoff, DD; Wadkins, RM; Wall, ME; Wani, MC | 1 |
| Carlo, WF; Fong, Y; Gonen, M; Hummer, AJ; Jarnagin, W; Kemeny, N; Schwartz, L; Sullivan, D | 1 |
| Chau, I; Cunningham, D; Dickson, J; Hill, M; Lal, R; Middleton, G; Norman, AR; Oates, J; Ross, PJ; Topham, C | 1 |
| Abad, A; Martinez-Balibrea, E; Plasencia, C; Taron, M | 1 |
| Aliustaoglu, M; Aydin, SZ; Dane, F; Ekenel, M; Gumus, M; Karamanoglu, A; Sengoz, M; Turhal, SN; Yumuk, PF | 1 |
| Boisdron-Celle, M; Dumont, A; Gamelin, E; Guérin, O; Morel, A; Rouits, E | 1 |
| Iqbal, S; Lenz, HJ | 2 |
| Alimonti, A; Cognetti, F; Di Palma, M; Ferretti, G; Gelibter, A; Pavese, I; Rasio, D; Satta, F; Vecchione, A | 1 |
| Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB | 1 |
| Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A | 1 |
| Chau, I; Cunningham, D; Hill, M; Katopodis, R; Middleton, G; Norman, AR; Oates, JR; Ross, PJ; Stewart, G; Topham, C; Waters, JS | 1 |
| Punt, CJ | 4 |
| Liu, JH | 1 |
| Damjanovic, D; Findlay, MP; Thompson, P | 1 |
| Beijnen, JH; Bertelsen, K; Fennelly, D; Garin, A; Glimelius, B; Gruia, G; Kjaer, M; Kuppens, IE; Lefebvre, P; Moiseyenko, V; Mourier, A; Norum, J; Poulsen, JP; Richel, DJ; Schellens, JH; Schoemaker, NE; Sibaud, D; Smaaland, R; Starkhammer, H; ten Bokkel Huinink, WW; Tveit, KM; Voznyi, E | 1 |
| Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Kubo, Y; Kurita, A; Masumoto, T; Moriwaki, T; Nasu, J; Nishina, T; Tsuzuki, T; Tubouchi, E | 1 |
| Allen, J; Beech, J; Carrington, B; Hogg, M; Saunders, MP; Sjursen, AM; Swindell, R; Valle, JW | 1 |
| Scheithauer, W | 1 |
| Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E | 1 |
| Acusa, A; Antón, I; Batiste-Alentorn, E; Campos, JM; Guasch, I; Losa, F; Manzano, H; Saigi, E; Salut, A; Vélez de Mendizabal, E | 1 |
| Cesta, A; Lalli, A; Lullo, LD; Nuzzo, A; Rea, S; Recchia, F; Saggio, G | 1 |
| Delaunoit, T; Findlay, BP; Fuchs, CS; Goldberg, RM; Green, E; Mailliard, JA; Morton, RF; Salim, M; Sargent, DJ; Schaefer, PL; Stella, PJ; Thomas, SP | 1 |
| Martin, MJ | 1 |
| Costa, AF; Picon, PD; Sander, GB | 1 |
| Donehower, RC; Grouleff, P; Hidalgo, M; Kelley, SK; Laheru, DA; Lum, BL; Messersmith, WA; Ramies, DA; Rogers, T; Senzer, NN | 1 |
| Bally, MB; Harasym, N; Mayer, LD; Messerer, CL; Ng, R; Ramsay, EC; Simms, EM; Tardi, P; Waterhouse, D | 1 |
| Sharieff, W | 1 |
| Brittain, M; Feld, R; Hedley, D; Michael, M; Moore, MJ; Nagai, J; Oza, A; Siu, L | 1 |
| Hiro, J; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Mori, K; Shirane, M; Tanaka, K; Yanagi, H | 1 |
| Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y | 1 |
| Allegrini, G; Andreuccetti, M; Brunetti, I; Cerri, E; Cupini, S; Falcone, A; Fontana, E; Marcucci, L; Masi, G; Ricci, S | 1 |
| Hayashi, N; Koshiishi, H; Koshiishi, Y; Okamura, T; Takahashi, E; Tamamoto, F; Yoshimura, T | 1 |
| Geffen, DB; Gluzman, A; Idelevich, E; Lavrenkov, K; Man, S; Shani, A | 1 |
| Adam, R; Azoulay, D; Bismuth, H; Castaing, D; Delvart, V; Levi, F; Pascal, G; Paule, B | 1 |
| Doggrell, SA | 1 |
| Andre, N; Graeven, U; Schmiegel, W | 1 |
| Babic, DR; Grbic, B; Jelic, SB; Matijasevic, MM; Popov, IP | 1 |
| Hadj Tahar, A | 1 |
| Cortés-Funes, H; García-Velasco, A; Gonzalez, E; Gravalos, C; Quintela-Fandino, M | 1 |
| Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A | 1 |
| Brufsky, A; Chen, HX; Day, R; Earle, M; Evans, T; Finkelstein, S; Hwang, JJ; Ramanathan, RK; Safran, H; Sinicrope, FA; Troetschel, M; Walko, C; Wong, MK; Zamboni, WC | 1 |
| Jacob, S; Miquel, C; Praz, F; Sarasin, A | 1 |
| Carvalho, LP; Fleshman, JW; Glasgow, SC; McLeod, HL; Shannon, WD; Yu, J | 1 |
| Hitre, E; Láng, I | 1 |
| André, T; Artru, P; de Gramont, A; Gayet, B; Goebel, FM; Hebbar, M; Louvet, C; Parc, R; Paye, F; Perez, N; Taïeb, J; Tournigand, C | 1 |
| Gourgou-Bourgade, S; Kramar, A; Ychou, M | 1 |
| Bernhard, J; Borner, MM; Brauchli, P; Dietrich, D; Herrmann, R; Honegger, H; Koeberle, D; Lanz, D; Popescu, R; Rauch, D; Roth, AD; Saletti, P; Wernli, M | 1 |
| Enomoto, M; Higuchi, T; Iida, S; Sugihara, K; Tsunozaki, H; Uetake, H; Yasuno, M | 1 |
| Alberts, SR; Delaunoit, T; Findlay, BP; Fuchs, C; Goldberg, RM; Green, E; Krook, J; Morton, RF; Ramanathan, RK; Sargent, DJ; Williamson, SK | 1 |
| Chung, KY; Fridman, D; Hamilton, A; Kelsen, DP; Kemeny, NE; Klimstra, DS; Pan, D; Saltz, LB; Schrag, D; Schwartz, GK; Schwartz, L; Shah, M; Shia, J; Tse, A | 1 |
| Hwang, JJ | 1 |
| Mayer, RJ; Meyerhardt, JA | 1 |
| Akita, H; Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Meguro, T; Miyagishima, T; Ohizumi, H; Sakata, Y; Takei, M; Tateyama, M; Wakahama, O; Watanabe, M; Yuuki, S | 1 |
| Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H | 1 |
| Aoyama, N; Hamano, K; Hirohata, S; Horita, K; Ishii, A; Kamigaki, T; Kasuga, M; Nakashima, T; Nishisaki, H; Shirasaka, D; Tamura, T; Yasutake, K | 1 |
| Boucher, E; Boudjema, K; de Guibert, S; Egreteau, J; Jacquelinet, C; Meunier, B; Raoul, JL | 1 |
| Tejpar, S; Van Cutsem, E; Verslype, C | 1 |
| Haller, DG; Sun, W | 1 |
| McLeod, HL; Tan, BR | 1 |
| Grem, JL | 1 |
| Lentz, F; Pons, G; Rey, E; Tran, A; Tréluyer, JM | 1 |
| Cai, X; Guo, YW; Lin, F; Sun, YJ; Tang, XC; Yao, Y; Zhao, H | 2 |
| Hamm, JT; Hecht, JR; Kabbinavar, FF; Mass, R; McCleod, M; Nelson, B; Novotny, WF; Patel, T; Perrou, B; Schulz, J | 1 |
| Albert, A; Chang, AJ; Liu, TC; Sangha, S; Wolfe, MM; Yao, M; Zhou, W | 1 |
| McLeod, HL; Shannon, WD; Watson, MA; Yu, J | 1 |
| Bleiberg, H; Borner, M; Dirix, L; Gonzalez Baron, M; Gruia, G; Joosens, E; Morant, R; Roth, A; Sibaud, D; Van Belle, S; Van Cutsem, E; Van Laethem, JL | 1 |
| Artandi, M; Borner, M; Boussard, B; Carlsson, G; Espana, P; Graeven, U; Ridwelski, K; Rosales, AM; Schmiegel, W; Schölmerich, J | 1 |
| Fujimoto-Ouchi, K; Kato, T; Kikkawa, N; Mishima, H; Nishisho, I; Tanaka, Y; Tsujie, M; Tsujinaka, T; Yanagisawa, M | 1 |
| Bernardeschi, P; Cantore, M; Fiorentini, G; Guadagni, S; Rossi, S | 1 |
| Arnold, CN; Blum, HE | 1 |
| Aparicio, J; Balcells, M; Bosch, C; Busquier, I; Campos, JM; Galán, A; Garcerá, S; Llorca, C; López-Tendero, P; Maestu, I; Vicent, JM | 1 |
| Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C | 1 |
| Venook, A | 1 |
| Altundag, K; Altundag, O; Gundeslioglu, O; Gunduz, M; Silay, YS; Yigitbasi, OG | 1 |
| Alexander, HR; Bartlett, DL; Beresneva, T; Helsabeck, C; Libutti, SK; Pingpank, JF | 1 |
| Poston, GJ | 1 |
| Hurwitz, H | 1 |
| Aravantinos, G; Bacoyiannis, C; Bamias, A; Basdanis, G; Chalkidou, S; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Kalfarentzos, F; Kalofonos, HP; Karina, M; Kosmidis, P; Koutras, A; Papakostas, P; Pectasides, D; Samantas, E; Samelis, GF; Skarlos, D | 1 |
| Bardelli, A; Benvenuti, S; Di Nicolantonio, F; Gambacorta, M; Marrapese, G; Moroni, M; Sartore-Bianchi, A; Siena, S; Veronese, S | 1 |
| Kallinowski, B | 1 |
| Galle, PR; Moehler, M; Teufel, A | 1 |
| Cordon-Cardo, C; Drobnjak, M; Gonen, M; Hummer, A; Kemeny, N; Motwani, M; Schwartz, GK; Shah, MA | 1 |
| Fisher, GA; Wakelee, H | 1 |
| Alfonso, PG; Castañon, C; Cerezuela, P; Cruz, JJ; González, E; López-Mateos, Y; Méndez, M; Pujol, E | 1 |
| Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML | 1 |
| Cunningham, D; Starling, N | 1 |
| Douillard, JY | 2 |
| Brouwers, JR; Coenen, JL; de Graaf, JC; Idzinga, FS; Jansman, FG; Sleijfer, DT; Smit, WM | 1 |
| Brener, J; Chaitchik, S; Czerniak, A; Hayat, H; Schachter, P; Shimonov, M | 1 |
| Agamah, E; Desai, AA; Kindler, HL; Mani, S; Ratain, MJ; Taber, D; Vokes, EE; Wade-Oliver, K | 1 |
| Jäger, D; Knuth, A; Pestalozzi, BC | 1 |
| Abad, A; Antón, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gil, S; Maestu, I; Marcuello, E; Masutti, B; Maurel, J; Navarro, M; Sastre, J; Valladares, M; Vicent, JM | 1 |
| Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I | 1 |
| Fernandez, FG; Goodwin, JW; Hawkins, WG; Linehan, DC; Ritter, J; Strasberg, SM | 1 |
| Borsellino, N; Cartenì, G; Colucci, G; Gebbia, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Manzione, L; Paoletti, G; Pezzella, G; Romito, S | 1 |
| Asmar, L; Boehm, KA; Cartwright, T; Encarnacion, C; Lopez, T; Vukelja, SJ | 1 |
| Wu, WQ; Yu, BM | 1 |
| David, A; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N | 1 |
| Bakker, JM; Falk, S; Groenewegen, G; Kerr, DJ; Maughan, T; Nortier, JW; Punt, CJ; Rea, DW; Richel, DJ; Semiond, D; Smit, JM; Steven, N; Ten Bokkel Huinink, WW | 1 |
| Agostara, B; Borsellino, N; Brunetti, C; Carrozza, F; Cartenì, G; Caruso, M; Chiarenza, M; Colucci, G; Cordio, S; Cramarossa, A; Di Bisceglie, M; Di Seri, M; Durini, E; Filippelli, G; Fortunato, S; Gebbia, N; Gebbia, V; Giuliani, F; Guida, T; Leonardi, V; Lopez, M; Lorusso, V; Maiello, E; Mancarella, S; Manzione, L; Misino, A; Montemurro, S; Nettis, G; Paoletti, G; Pezzella, G; Pisconti, S; Romito, S; Rosati, G; Valdesi, M; Valerio, MR | 1 |
| Anak, O; Bokemeyer, C; El-Serafi, M; Frickhofen, N; Fuchs, R; Genicot, B; Köhne, CH; Langenbuch, T; Lorenz, M; Lutz, MP; Mergenthaler, HG; Müller, L; Nordlinger, B; Reichardt, P; Rougier, P; Rückle-Lanz, H; van Cutsem, E; Vanhoefer, U; Voigtmann, R; Wils, J | 1 |
| Blanke, CD | 1 |
| Cai, SR; Church, RD; Culverhouse, R; Garbow, JR; McLeod, HL; Shannon, WD; Zhang, W | 1 |
| Aggarwal, S; Chu, E | 1 |
| Arnold, D; Schmoll, HJ | 1 |
| Colucci, G; Giuliani, F; Maiello, E; Mangia, A; Montemurro, S; Paradiso, A; Simone, G; Xu, JM; Zhu, BD | 1 |
| Allen, WL; Johnston, PG | 1 |
| Beale, P; Clarke, S; Liddell, S; Noney, L; Rivory, LP; Tobin, PJ | 1 |
| Blumgart, L; D'Angelica, M; DeMatteo, R; Fong, Y; Gönen, M; Jarnagin, W; Kemeny, N; Leonard, G; Morse, M; Paty, P; Schwartz, L | 1 |
| André, T; Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Kornprobst, M; Larsen, AK; Louvet, C; Raymond, E; Tournigand, C | 1 |
| Mulder, NH | 1 |
| Barni, S; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Gasparini, G; Graziano, F; Labianca, R; Scartozzi, M; Sobrero, A; Zaniboni, A | 1 |
| Abenhardt, W; Ballo, H; Behrens, R; Behringer, D; Boeck, HP; Braumann, D; Geer, T; Greinwald, R; Karthaus, M; Kindler, M; Kleeberg, U; Messmann, H; Schimke, J; Steinmetz, T | 1 |
| Baek, JH; Bang, SM; Cho, EK; Han, SH; Lee, JH; Oh, JH; Park, SH; Shin, DB; Sung, JY | 1 |
| Leong, LA; Rosales, J | 1 |
| Aoki, A; Hamada, A; Ito, K; Saito, H; Sasaki, Y; Terazaki, H; Yokoo, K | 1 |
| Hirose, K; Nishimura, M; Sawada, T | 1 |
| Bonnay, M; Delbaldo, C; Dieras, V; Faivre, S; Kovar, A; Laurence, V; Mueser, M; Nolting, A; Pierga, JY; Raymond, E; Vedovato, JC | 1 |
| Bendardaf, R; Elzagheid, A; Lamlum, H; Pyrhönen, S; Ristamäki, R | 1 |
| Caricato, M; Coppola, R; Di Seri, M; La Cesa, A; Rocci, L; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B | 1 |
| Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J | 1 |
| Chong, G; Cunningham, D; Dickson, JL; Hill, ME; Norman, AR; Oates, J; Price, TJ; Rao, S; Tebbutt, N | 1 |
| Tyagi, P | 1 |
| Chung, KY; Flombaum, C; Saltz, L; Schrag, D | 1 |
| Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA | 1 |
| Chan, AT; Ho, WM; King, A; Koh, J; Lai, P; Leow, CK; Lim, R; Ma, B; Mok, T; Wong, YY; Yeo, W | 1 |
| Anderson, KS; Ansén, S; Bohlen, H; Diehl, V; Geisen, C; Gracien, E; Jurkiewicz, E; Nadler, LM; Schmidt, M; Weihrauch, MR; Wittig, B; Wolf, J; Xia, Z | 1 |
| Aiba, M; Kamoshita, N; Makita, F; Morishita, Y; Nagashima, T; Ohwada, S; Takeyoshi, I; Tokiniwa, H | 1 |
| Adróver Cebrián, E; Alonso López, C; Alvarez Gallego, J; Arroyo Yustos, M; Barceló Galíndez, R; García Palomo, A; García-Girón, C; León Carbonero, A; Méndez Ureña, M | 1 |
| Abbruzzese, JL; Eng, C | 1 |
| Brahmandam, M; Cantor, M; Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kinsella, K; Kulke, MH; Loda, M; Meyerhardt, JA; Michelini, AL; Namgyal, C; Ogino, S; Ryan, DP | 1 |
| Abbruzzese, JL; Chang, DZ | 1 |
| Abali, H; Budakoglu, B; Oksüzoglu, B; Uncu, D; Yildirim, N; Zengin, N | 1 |
| Fuchs, CS; Goldberg, RM; Hillner, BE; Sargent, DJ; Schrag, D | 1 |
| Hayashi, Y; Ishida, H; Nakada, H; Ohsawa, T; Okada, N; Shirakawa, K; Yokoyama, M | 1 |
| Aparicio, J; Díaz, R; Gironés, R; Molina, J; Montalar, J; Palomar, L; Segura, A | 1 |
| Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S | 1 |
| Biason, P; Buonadonna, A; Cattarossi, G; Cecchin, E; Colussi, A; Corona, G; Frustaci, S; Masier, S; Toffoli, G | 1 |
| Allen, W; Galligan, L; Johnston, PG; Longley, DB; McDermott, U; Wilson, T | 1 |
| Chu, KW; Epstein, RJ; Liang, RH; Mok, MY; Yau, TC | 1 |
| Laurent-Puig, P; Lièvre, A | 2 |
| Graeven, U; Verbeek, W | 1 |
| Fung, A; Viale, PH; Zitella, L | 1 |
| Akiyama, T; Hirabayashi, Y; Hirai, T; Ikeda, M; Iki, K; Kubozoe, T; Matsumoto, H; Sadahira, Y; Tsunoda, T; Urakami, A; Yamamura, M; Yamashita, K | 1 |
| Gamucci, T; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Morabito, A; Sarmiento, R; Torino, F; Vitale, S | 1 |
| Dercksen, W; Giaccone, G; Noordhuis, P; Peters, GJ; Pinedo, HM; Smid, K; Smorenburg, CH; van Groeningen, CJ; van Riel, AM | 1 |
| Rosati, G | 1 |
| Castañón, C; Castro, J; Escudero, P; Feliu, J; González, E; González-Barón, M; Juárez, F; Lizón, J; López-Gómez, L; Mel, JR; Pelegrín, A; Ruiz, M; Salud, A | 1 |
| Fukunaga, H; Ikeda, M; Ikenaga, M; Monden, M; Ohue, M; Sekimoto, M; Seshimo, I; Takayama, O; Yamamoto, H; Yasui, M | 1 |
| Jensen, BV; Pfeiffer, P | 1 |
| Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L | 1 |
| Baltesgard, L; Ehrsson, H; Fokstuen, T; Glimelius, B; Mortensen, JP; Pfeiffer, P; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, KM; Wallin, I; Øgreid, D | 1 |
| Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS | 1 |
| Hurwitz, H; Kabbinavar, F | 1 |
| Folprecht, G; Köhne, CH; Lutz, MP; Nolting, A; Pollert, P; Schöffski, P; Seufferlein, T | 1 |
| Aizawa, M; Ishibashi, K; Itagaki, H; Katsube, T; Kobayashi, R; Naritaka, Y; Ogawa, K; Yokomizo, H; Yoshimatsu, K | 1 |
| Hamada, H; Katsuki, Y; Takada, J; Tsuji, Y | 1 |
| Amano, M; Fujita, M; Hayashida, H; Higaki, N; Itani, Y; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M | 1 |
| Kitamura, M; Noda, K; Shiba, Y; Umekita, N | 1 |
| Berry, S; Billingsley, K; Croitoru, M; Gallinger, S; Krishnamurthi, S; Mackay, HJ; Pond, GR; Siu, LL; Smith, A; Swanson, PE; Yeung, R | 1 |
| Dimou, E; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Xynotroulas, JP | 1 |
| Alonso, M; Balcells, M; Barceló, R; Castañón, C; Centelles, M; GarcíaGirón, C; López Vivanco, G; Navalón, M; Ramos, M; Rivera, F | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Milaki, G; Pallis, A; Souglakos, J; Xenidis, N | 1 |
| Berg, K; Hammond, LA; Izbicka, E; Kuhn, J; Mita, MM; Ochoa, L; Patnaik, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Yeh, IT | 1 |
| Chiritescu, G; Cripps, C; Fisher, B; Goel, R; Jonker, D; Kocha, W; Lister, D; Malpage, A; Maroun, JA; Seymour, L; Vincent, M | 1 |
| Hladíková, J; Kubácková, K; Kubala, E; Linke, Z; Pipková, R; Prausová, J | 1 |
| Grothey, A; Kim, GP | 1 |
| Ishiguro, A; Munakata, M; Saitoh, S; Sakata, Y; Shitara, K | 1 |
| Becker, K; Hochster, H; Hong, S; John, W; Kettner, E; Kroning, H; Lordick, F; Macdonald, J; Ramanathan, RK; Schmoll, HJ | 1 |
| Aparicio, J; Balcells, M; Busquier, I; Campos, JM; Fernandez-Martos, C; Llorca, C; Maestu, I; Perez-Enguix, D; Vincent, JM | 1 |
| Gill, S; Ho, C; Ng, K; O'Reilly, S | 1 |
| Blanke, CD; Goldberg, RM; Hollis, DR; Lenz, HJ; Niedzwiecki, D; Sutherland, S; Taylor, JR; Venook, AP | 1 |
| Grothey, A; Sargent, D | 1 |
| Abdalla, EK; Vauthey, JN | 1 |
| Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M | 1 |
| Anthoney, DA; Jagdev, S; Seymour, MT; Vasudev, NS | 1 |
| Bhatnagar, P; Levine, E; Saunders, MP; Swindell, R; Valle, JW; Young, E | 1 |
| Eguchi, T; Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Tanaka, K; Toiyama, Y; Yoshiyama, S | 1 |
| Hoff, PM; Varadhachary, GR | 1 |
| Marshall, J | 1 |
| Lepere, C; Rougier, P | 1 |
| Barette, M; Bleiberg, H; Cardoso, F; Galdon, MG; Gallez, J; Hendlisz, A; Larsimont, D; Nagy, N; Paesmans, M; Personeni, N; Van Laethem, JL | 1 |
| Aderka, D; Davidson, T; Goshen, E; Zwas, ST | 1 |
| Abbruzzese, JL; Bogaard, K; Hoff, PM; Waldrum, S; Wolff, RA | 1 |
| Bisonni, R; Leon, A; Lippe, P; Lombardo, M; Marcucci, F; Massacesi, C; Mattioli, R; Pilone, A; Rocchi, MB; Terrazzino, S | 1 |
| Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E | 1 |
| Bracco-Nolin, CH; Chaigneau, L; Huchet, B; Legat-Fagnoni, C; Limat, S; Pivot, X; Stein, U; Woronoff-Lemsi, MC | 1 |
| Goyle, S; Maraveyas, A | 1 |
| de Gramont, A; Tournigand, C | 1 |
| Buxhofer-Ausch, V; Hinterberger, W; Hinterberger-Fischer, M | 1 |
| Battistoni, F; Di Cuonzo, G; Gavasci, M; Gebbia, N; Rocci, L; Russo, A; Santini, D; Silletta, M; Tonini, G; Vincenzi, B | 1 |
| Beomonte Zobel, B; Coppola, R; Rabitti, C; Santini, D; Tonini, G; Trodella, L; Vincenzi, B | 1 |
| Androulakis, N; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalykaki, A; Kouroussis, Ch; Mavroudis, D; Polyzos, A; Samonis, G; Souglakos, J; Syrigos, K; Tsousis, S; Vamvakas, L; Ziras, N | 1 |
| Bogdanow, M; Gorschlüter, M; Lamberti, C; Lundin, S; Sauerbruch, T; Schmidt-Wolf, IG | 1 |
| Kulka, J; Pintér, T; Sipocz, I | 1 |
| Auber, M; Cai, C; Kiefer, G; Matin, K; Patel, H; Potter, D; Ramanathan, RK; Schmotzer, A; Stoller, R; Zamboni, W | 1 |
| Bartlett, DW; Cheng, J; Davis, ME; Heidel, JD; Hollister, B; Hwang, J; Schluep, T | 1 |
| André, T; Aparicio, T; de Gramont, A; Flesch, M; Hebbar, M; Lledo, G; Louvet, C; Mabro, M; Tournigand, C; Varette, C | 1 |
| Biasco, G; Brandi, G; Derenzini, E; Ercolani, G; Grazi, G; Pantaleo, MA; Ravaioli, M | 1 |
| Chowbay, B; Jada, SR; Wan Teck, DL | 1 |
| Bhattacharya, A; Cao, S; Durrani, FA; Fakih, M | 1 |
| Cannita, K; Cianci, G; De Galitiis, F; De Tursi, M; Di Rocco, ZC; Ficorella, C; Iacobelli, S; Marchetti, P; Morelli, MF; Morese, R; Porzio, G; Ricevuto, E; Tinari, N | 1 |
| Abbruzzese, JL; Bogaard, KR; Dutta, A; Eng, C; Hoff, PM; Jones, D; Lin, E; Wolff, RA; Xiong, H | 1 |
| Berlin, JD; Cropp, GF; Donnelly, E; Fleischer, AC; Hande, KR; Hannah, AL; Lockhart, AC; Rothenberg, ML; Schaaf, LJ; Schumaker, RD | 1 |
| Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H | 1 |
| András, C; Farczádi, E; Szántó, J | 1 |
| Santini, D; Tonini, G; Vincenzi, B | 1 |
| André, T; Artru, P; de Gramont, A; Flesch, M; Landi, B; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Plantade, A | 1 |
| Agostara, B; Barone, C; Bordonaro, R; Borsellino, N; Capasso, E; Del Prete, S; Ferraù, F; Gebbia, V; Leonardi, V; Maiello, E; Stinco, S; Tralongo, P; Verderame, F | 1 |
| Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F | 1 |
| Crews, KR | 1 |
| Boukovinas, I; Christofillakis, C; Georgoulias, V; Potamianou, A; Syrigos, K; Tselepatiotis, E; Tsousis, S; Varthalitis, I; Ziras, N | 1 |
| Akazai, Y; Kimura, H; Nitta, Y | 1 |
| Chu, E; Vokes, EE | 1 |
| Beaven, AW; Goldberg, RM | 1 |
| Allen, WL; Coyle, VM; Johnston, PG | 1 |
| Colucci, G; Di Renzo, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Mallamaci, R; Pezzella, G; Romito, S | 1 |
| Chen, JZ; Liao, WJ; Luo, RC; Zheng, H | 1 |
| Goker, E; Karabulut, B; Korkut, M; Sanli, UA; Uslu, R | 1 |
| Allegrini, G; Andreuccetti, M; Barbara, C; Brunetti, IM; Bursi, S; Cerri, E; Cupini, S; Falcone, A; Loupakis, F; Marcucci, L; Masi, G; Murr, R; Ricci, S | 1 |
| Assenat, E; Duffour, J; Ychou, M | 1 |
| Kovacic, P | 1 |
| Eng, C; Shalan, N | 1 |
| Biason, P; Boccalon, M; Bonura, S; Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Pangher, V; Errante, D; Frustaci, S; Gaion, F; Galligioni, E; Giusto, M; Medici, M; Pasetto, LM; Pessa, S; Russo, A; Sandri, P; Toffoli, G | 1 |
| Goto, A | 2 |
| Iwamoto, S; Yoshioka, K | 1 |
| Boku, N; Yamazaki, K; Yoshino, T | 1 |
| Aulds, S; Clarke, S; Crawford, M; Eyers, T; Gallagher, J; Lee, S; Rivory, L; Seale, JP; Solomon, M; Tobin, P | 1 |
| Meropol, NJ | 1 |
| Alberts, S; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK | 1 |
| Aranda, E; Bandres, E; De la Haba, J; Garcia, F; García-Foncillas, J; Gómez, A; Huarriz, M; Morales, R; Romero, RZ | 1 |
| Afchain, P; André, T; de Gramont, A; Segura, C | 1 |
| Akkermans-Vogelaar, JM; Antonini, NF; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Punt, CJ; Rodenburg, CJ; Vreugdenhil, G; Wals, J | 1 |
| Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ | 1 |
| Danenberg, KD; Fazzone, W; Gordon, M; Iqbal, S; Lenz, HJ; Rhodes, KE; Schultheis, AM; Sherrod, AE; Vallböhmer, D; Yang, DY; Zhang, W | 1 |
| Eguchi, T; Shirao, K | 1 |
| Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S | 1 |
| Kamiyama, G; Kusano, M; Nakao, K; Narita, K; Oonaka, T; Suzuki, N; Tsunoda, A; Watanabe, M; Yamazaki, K | 1 |
| Biedrzycki, BA | 1 |
| Cattan, S; Desauw, C; Hebbar, M; Pruvot, FR; Romano, O; Triboulet, JP; Wacrenier, A | 1 |
| Adames, V; Chen, J; Fritzky, L; Higgins, B; Kolinsky, K; Linn, M; Mehta, N; Rashed, M; Smith, M; Wheeldon, E | 1 |
| Casaretti, R; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Massidda, B; Palmeri, S; Putzu, C; Sandomenico, C | 1 |
| Andria, M; Dhami, M; Diasio, RB; Godfrey, T; Gold, PJ; Kovatich, AJ; Lund, KA; Meropol, NJ; Mitchell, E; Schwarting, R | 1 |
| Andre, T; Bleiberg, H; de Gramont, A; Goldberg, RM; Green, E; Rothenberg, ML; Sargent, DJ; Tabah-Fisch, I; Tournigand, C | 1 |
| Creemers, GJ; de Bruijn, P; de Jong, FA; de Jonge, MJ; Eskens, FA; Janssen, JT; Kehrer, DF; Mathijssen, RH; Planting, AS; Ruit, JB; Sparreboom, A; van der Gaast, A; van Schaik, RH; Verweij, J | 1 |
| Chari, RS; Helton, WS; Marsh, RD | 1 |
| Bartlett, DL; Berlin, J; Lauwers, GY; Messersmith, WA; Petrelli, NJ; Venook, AP | 1 |
| Fuchs, C; Hoff, PM; Mitchell, EP | 1 |
| Arai, Y; Aramaki, T; Inaba, Y; Matsueda, K; Sato, Y; Seki, H; Takeuchi, Y; Yamaura, H | 1 |
| Adams, DH; Nutt, T | 1 |
| Catalano, RB; O'Dwyer, PJ | 1 |
| Hamada, A; Masa, K; Saito, H; Sasaki, Y; Terazaki, H; Watanabe, H; Yokoo, K | 1 |
| Aparicio, J; Díaz, R; Giménez, A; Gómez-Codina, J; Molina, J; Palomar, L; Ponce, J; Segura, A | 1 |
| Beale, PJ; Childs, A; Clarke, SJ; Read, JA; Smith, N; Volker, DH | 1 |
| Guputa, M; Reddy, GK; Tyagi, P | 1 |
| Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX | 1 |
| Azarnia, N; Cohn, AL; Gold, P; Khambata-Ford, S; Lenz, HJ; Mauro, DJ; Mayer, RJ; Mirtsching, B; Pippas, AW; Rowinsky, EK; Stella, P; Tsuchihashi, Z; Van Cutsem, E | 1 |
| Andres, A; Audard, V; Brezault, C; Chaussade, S; Dousset, B; Giostra, E; Majno, PE; Mentha, G; Roth, AD; Rubbia-Brandt, L; Sartoretti, P; Soubrane, O; Terris, B | 1 |
| Cattral, MS; Chan, EK; Dixon, E; Gallinger, S; Grant, DR; Greig, PD; Sahajpal, A; Taylor, BR; Vollmer, CM; Wei, A | 1 |
| Abdalla, EK; Charnsangavej, C; Donadon, M; Loyer, EM; Vauthey, JN | 1 |
| Hahn, KK; Kolesar, JM; Wolff, JJ | 1 |
| Cai, X; Guo, YW; Lin, F; Sun, YJ; Tang, LN; Tang, XC; Yao, Y; Zhang, W; Zhao, H | 1 |
| Ahn, JB; Cho, BC; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Roh, WJ; Yoo, NC | 1 |
| Bettegowda, C; Cheong, I; Diaz, LA; Huang, X; Kinzler, KW; Vogelstein, B; Zhou, S | 1 |
| Bressole, F; Chalbos, P; Debrigode, C; Desseigne, F; Duffour, J; Gourgou, S; Mineur, L; Pinguet, F; Poujol, S; Ychou, M | 1 |
| Norum, J | 1 |
| Andreadis, C; Gennatas, C; Michalaki, V; Mouratidou, D; Pafiti, A; Papaxoinis, G; Tsavaris, N | 1 |
| Fuchs, CS; Goldberg, RM; Hurwitz, HI | 1 |
| Wang, JW; Zhou, ZT | 1 |
| Geng, M; Ji, YB; Jiang, JS; Li, H; Lou, GY; Ma, T; Xi, WQ; Xia, HQ; YeE, ZB | 1 |
| Barone, C; Basso, M; Cassano, A; D'Argento, E; Di Leonardo, G; Landriscina, M; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N | 1 |
| Borojevic, N; Kecmanovic, D; Kezic, I; Micev, MT; Milicevic, M; Popov, IP; Radosevic-Jelic, Lj; Tomasevic, Z | 1 |
| Carnahan, MA; Grinstaff, MW; Griset, AP; Kroll, DJ; Manikumar, G; Morgan, MT; Nakanishi, Y; Oberlies, NH; Wani, MC; Wathier, M | 1 |
| Innocenti, F; Ratain, MJ | 1 |
| Ikami, I; Ishiguro, A; Kasai, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Sakuraba, H; Shitara, K | 1 |
| Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J | 1 |
| Aphinives, P; Bhudhisawasdi, V; Sae-seow, O; Uttaravichien, T | 1 |
| Aoyagi, Y; Haku, K; Hayama, T; Matsuda, K; Mimura, T; Nakamura, K; Nozawa, K; Oomi, T; Watanabe, T; Yamada, H | 1 |
| Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Wilson, G | 1 |
| Gyôrffy, B; Tegze, B; Tulassay, Z | 1 |
| Clark, JW; D'Amato, F; Dancey, J; Earle, CC; Eder, JP; Enzinger, PC; Fuchs, CS; Kinsella, K; Mayer, RJ; Meyerhardt, JA; Michelini, A; Ogino, S; Ryan, DP; Stewart, CF; Supko, JG; Zhu, AX | 1 |
| Botwood, N; Chau, I; Cunningham, D; Hickish, T; Higgins, L; Massey, A; Osborne, R; Swaisland, A | 1 |
| Cunningham, D; Starling, N; Tilden, D; White, J | 1 |
| Aitini, E; Bajetta, E; Barone, C; Buzzoni, R; Di Bartolomeo, M; Ferrario, E; Iop, A; Isa, L; Jacobelli, S; Lo Vullo, S; Mariani, L; Pinotti, G; Recaldin, E; Zilembo, N | 1 |
| Abad, A; Catot, S; Cirauqui, B; Manzano, JL; Martinez-Balibrea, E; Martinez-Cardus, A; Moran, T; Taron, M | 1 |
| Guan, ZZ | 1 |
| Adena, M; Damianovich, D; Tebbutt, NC | 1 |
| Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF | 1 |
| Dranitsaris, G; Shah, A; Spirovski, B; Vincent, M | 1 |
| Bareil, C; Bascoul-Mollevi, C; Bibeau, F; Chalbos, P; Conseiller, E; Copois, V; Del Rio, M; Fraslon, C; Granci, V; Kramar, A; Leblanc, B; Martineau, P; Molina, F; Pau, B; Salvetat, N; Ychou, M | 1 |
| Kuboki, Y; Mizunuma, N | 1 |
| Li, J | 1 |
| Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kulke, MH; Loda, M; Meyerhardt, JA; Ogino, S; Ryan, DP; Wolpin, BM | 1 |
| Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Pallis, A; Souglakos, J; Vardakis, N | 1 |
| Komatsu, N; Makuuchi, H; Matsui, N; Mukai, M; Nakamura, M; Nakasaki, H; Ninomiya, H; Sato, S; Wakui, K | 2 |
| Battistoni, F; Dicuonzo, G; Gavasci, M; Gebbia, N; Rocci, L; Rosaria, VM; Russo, A; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Cha, HJ; Choi, DH; Ha, JS; Kim, GY; Lee, BJ; Lee, WH; Park, JH; Park, JW; Song, JK | 1 |
| Arnold, D; Graeven, U; Heuer, T; Nusch, A; Porschen, R; Reinacher-Schick, A; Schmiegel, W | 1 |
| Gil Delgado, M; Khayat, D; Spano, JP | 1 |
| El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM | 1 |
| Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S | 1 |
| Doi, K; Kudo, K; Matsuo, A; Ogata, K; Ohchi, T; Ootao, R | 1 |
| Gordon, M; Lenz, HJ; Zhang, W | 1 |
| Iinuma, N; Ishizone, S; Koide, N; Maruta, F; Miyagawa, S; Nakayama, J; Yanagisawa, Y | 1 |
| Ardito, F; Barone, C; Cassano, A; Giovannini, I; Giuliante, F; Nuzzo, G; Pozzo, C; Vellone, M | 1 |
| Saltz, L | 2 |
| Hatate, K; Ihara, A; Kokuba, Y; Nakamura, T; Onosato, W; Ozawa, H; Sato, T; Watanabe, M | 1 |
| Chiba, H; Honda, K; Kondo, H; Makino, K; Mizushima, T; Ohura, K; Sumiyoshi, T; Tamura, F; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N | 1 |
| Takahashi, K | 1 |
| Ilson, DH; Krol, G; Ku, GY | 1 |
| Allegrini, G; Andreuccetti, M; Barbara, C; Benedetti, G; Brunetti, I; Chiara, S; Cortesi, E; Crinò, L; Evangelista, W; Falcone, A; Fanchini, L; Fioretto, L; Granetto, C; Masi, G; Orlandini, C; Pfanner, E; Picone, V; Porcile, G; Ricci, S; Vitello, S | 1 |
| Bellott, R; Bonnet, J; Charasson, V; Colotte, M; Klein, K; Laurand, A; Le Morvan, V; Robert, J; Smith, D; Zanger, UM | 1 |
| Adoniou, E; Bacoyiannis, C; Felekouras, E; Gryniatsos, J; Kosmas, C; Papadoniou, N; Papalambros, E; Papastratis, G; Polyzos, A; Sigala, F; Skopelitis, H; Tsavaris, N; Zacharakis, M; Zografos, G | 1 |
| Gotoh, M; Hoshino, Y; Terashima, M | 1 |
| Côté, JF; Diebold, MD; Kirzin, S; Kramar, A; Laurent-Puig, P; Mosnier, JF; Selves, J; Soubeyran, I; Thirouard, AS; Ychou, M | 1 |
| Amado, RG; Berlin, J; Chan, D; Hecht, JR; Hu, E; Malik, I; Posey, J; Tchekmedyian, S; Yang, L | 1 |
| Grothey, A; Marshall, JL | 1 |
| Alessandroni, P; Andreoni, F; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Ficarelli, R; Fontana, A; Giustini, L; Graziano, F; Lippe, P; Loupakis, F; Magnani, M; Maltese, P; Mari, D; Menichetti, ET; Pizzagalli, F; Ruzzo, A; Santini, D; Schiavon, G; Testa, E; Tonini, G | 1 |
| Ames, MM; Erlichman, C; Goetz, MP; Krook, JE; McWilliams, RR; Morlan, BW; Rowland, KM; Salim, M | 1 |
| Alberts, SR; Ashley, AC; Campbell, ME; Findlay, BP; Fuchs, CS; Goldberg, RM; Grothey, A; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK | 1 |
| Iversen, A; Jensen, BV; Nielsen, D; Pfeiffer, P; Vejlø, C; Yilmaz, M | 1 |
| Ahmad, A; Bilchik, AJ; Chen, SL | 1 |
| Bearz, A; Berretta, M; Berretta, S; De Ruvo, N; Di Benedetto, F; Drigo, A; Martellotta, F; Simonelli, C; Spina, M; Tirelli, U; Zanet, E | 1 |
| Kawamura, Y; Konishi, F | 1 |
| Beauvillain, L; Bihannic, R; Bousquet, A; Burnat, P; Ceppa, F; Cremades, S; Fontan, E | 1 |
| Chowbay, B; Goh, BC; Jada, SR; Lee, SC; Lim, R; Shu, X; Wong, CI; Zhou, Q | 1 |
| Sargent, D; Schmoll, HJ | 1 |
| Antonini, NF; Creemers, GM; Dalesio, O; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Loosveld, OJ; Mol, L; Punt, CJ; Rodenburg, CJ; Sinnige, HA; Slee, PHTJ; Tesselaar, ME; van Bochove, A; Vreugdenhil, G; Wals, J; Werter, MJ | 1 |
| Ferry, DR; Griffiths, GO; Gwyther, SJ; James, R; Ledermann, JA; Maraveyas, A; Maughan, TS; Meade, AM; Parmar, MK; Seymour, MT; Shepherd, S; Smith, DB; Stephens, RJ; Thompson, L; Topham, C | 1 |
| Elias, D; Goere, D; Pocard, M | 1 |
| Folprecht, G; Köhne, CH; Lutz, MP | 1 |
| Artru, P; Bennouna, J; Bugat, R; Delord, JP; Desseigne, F; Douillard, JY; Faroux, R; François, E; Husseini, F; Naman, H; Perrier, H; Piedbois, P; Smith, D | 1 |
| Gu, J; Yao, YF | 1 |
| Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ | 1 |
| Abrahantes, JC; André, T; Burzykowski, T; Buyse, M; Carola, E; Cervantes, A; Chirivella, I; de Gramont, A; Etienne, PL; Figer, A; Flesch, M; Lledo, G; Louvet, C; Mineur, L; Perez-Staub, N; Quinaux, E; Rivera, F; Tabah-Fisch, I; Tournigand, C | 1 |
| Aso, M; Higashi, H; Imamura, S; Kakeji, Y; Katoh, H; Maehara, S; Maehara, Y; Makino, I; Saeki, H; Tanaka, J | 1 |
| Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT | 1 |
| Lagarde, C; Lebrun-Ly, V; Peyronnet, P; Saint-Marcoux, F; Tubiana-Mathieu, N; Vénat-Bouvet, L | 1 |
| Amado, RG; Berlin, J; Hecht, JR; Malik, I; Meropol, NJ; Navale, L; Patnaik, A; Tchekmedyian, S; Venook, A | 1 |
| Fakih, MG; Ross, ME; Starostik, P | 1 |
| Klek, S; Kulig, J; Popiela, T; Richter, P | 1 |
| Alberts, SR; Delaunoit, T; Dy, GK; Findlay, BP; Fuchs, CS; Goldberg, RM; Green, EM; Krook, JE; Morton, RF; Pitot, HC; Pockaj, BA; Ramanathan, RK; Sargent, DJ; Sticca, RP; Williamson, SK | 1 |
| Takiuchi, H | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P | 1 |
| Bendardaf, R; Korkeila, E; Lamlum, H; Pyrhönen, S; Ristamäki, R; Syrjänen, K | 2 |
| Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T | 1 |
| Fukunaga, M; Furukawa, H; Gotoh, M; Ishida, H; Ishihara, R; Narahara, H; Okamura, S; Takiuchi, H; Tomita, N; Uedo, N | 1 |
| Bearzi, I; Berardi, R; Biscotti, T; Cascinu, S; Catalano, V; Falcone, A; Labianca, R; Loupakis, F; Mandolesi, A; Pierantoni, C; Quadri, A; Scartozzi, M; Zaniboni, A; Zorzi, F | 1 |
| Bexon, A; Diamandidis, D; Eckhardt, SG; Javle, M; Justice, GR; Keiser, W; Lee, FC; Liebmann, JE; Lin, E; Patt, YZ; Salvatore, JR | 1 |
| Morris-Stiff, G; Tan, YM; Vauthey, JN | 1 |
| Cai, RG; Chen, SS; Chu, DT; Wu, F; Zhang, HG | 1 |
| Adenis, A; Bécouarn, Y; Boucher, E; Cany, L; Cvitkovic, F; Jacob, JH; Montoto-Grillot, C; Senesse, P; Thézenas, S; Ychou, M | 1 |
| Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S | 1 |
| Oestreicher, P | 1 |
| Bachelot, T; Biron, P; Blay, JY; Brantus, JF; Confavreux, C; Ghesquière, H; Guastalla, JP; Ray-Coquard, I; Rustam, F; Saba, C; Sebban, C | 1 |
| Chen, HX; Gonen, M; Hochster, HS; Hoff, PM; Hollywood, EM; Kemeny, NE; Kindler, HL; Lenz, HJ; Morse, M; Quinones, M; Saltz, LB; Wadler, S | 1 |
| Astone, A; Barone, C; Basso, M; Cassano, A; D'Argento, E; Giuliante, F; Nuzzo, G; Pozzo, C; Schinzari, G; Trigila, N | 1 |
| Delpero, JR; Desseigne, F; Guimbaud, R; Kramar, A; Mitry, E; Nordlinger, B; Portier, G; Quénet, F; Rivoire, M; Viret, F; Ychou, M | 1 |
| Allal, AS; Andres, A; Gervaz, P; Giostra, E; Majno, PE; Mentha, G; Morel, P; Roth, AD; Rubbia-Brandt, L; Terraz, S | 1 |
| Carroll, C; Jones, R; Paisley, S; Tappenden, P | 1 |
| Berglund, A; Dahl, O; Glimelius, B; Ogreid, D; Sørbye, H; Tveit, KM; Wanderås, EH; Wentzel-Larsen, T | 1 |
| Chang, HM; Kang, YK; Kim, MK; Kim, TW; Koo, DH; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ | 1 |
| Brandsma, D; De Jong, FA; Hamberg, P; Sleijfer, S; Verweij, J | 1 |
| Adam, R; Aloia, T; Azoulay, D; Bouchahda, M; Bralet, MP; Castagne, V; Castaing, D; de Haas, RJ; Ducreux, M; Lévi, F; Machover, D; Paule, B; Wicherts, DA | 1 |
| Barrueco, J; Fuchs, CS; Ganju, V; Jeffery, M; Marshall, J; Mitchell, E; Richards, D; Schulz, J; Soufi-Mahjoubi, R; Wang, B; Wierzbicki, R | 1 |
| Akiyama, S; Gotoh, H; Gotoh, Y; Nakayama, H; Takami, H | 1 |
| Abad, A; Alonso, V; Antón, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Manzano, JL; Marcuello, E; Martinez-Villacampa, M; Massuti, B; Rivera, F; Tabernero, J; Vega, ME; Yuste, AL | 1 |
| Capanu, M; Gallagher, DJ; Kemeny, N; Raggio, G | 1 |
| Meric, JB | 1 |
| Biesmans, B; De Hertogh, G; De Roock, W; De Schutter, J; Humblet, Y; Janssens, M; Peeters, M; Personeni, N; Piessevaux, H; Tejpar, S; Van Cutsem, E; Van Laethem, JL | 1 |
| Fischbach, W; Flieger, D; Hainke, S; Keller, R; Klassert, C; Kleinschmidt, R | 1 |
| Kusano, M; Nakao, K; Narita, K; Suzuki, N; Tsunoda, A; Watanabe, M; Yamazaki, K; Yasuda, N | 1 |
| Audisio, RA; Bruce, C; Köhne, CH | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Sukthomya, V; Tonusin, A | 1 |
| Inaba, Y; Muro, K; Najima, M; Nishiofuku, H; Sato, Y; Shimamoto, H; Ura, T; Yamaura, H | 1 |
| Carroll, MW; Chikoti, P; Drury, N; Griffiths, R; Harrop, R; Hawkins, RE; Kingsman, SM; Naylor, S; Redchenko, I; Shingler, W; Steven, N | 1 |
| Ahn, JB; Cha, SH; Choi, JS; Kim, H; Kim, KS; Kim, NK; Min, BS; Roh, JK | 1 |
| Komatsu, Y | 1 |
| Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ | 1 |
| Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY | 1 |
| Carandina, I; Guarino, S; Lelli, G; Modonesi, C; Pedriali, M; Urbini, B | 1 |
| Hori, S; Hyodo, I; Iguchi, H; Imamine, S; Kajiwara, T; Kataoka, J; Moriwaki, T; Nasu, J; Nishina, T | 1 |
| Hentrich, M; Hoffmann, U; Lutz, L; Reitmeier, M; Scheidt, B; Schiel, X | 1 |
| Au, GK; Chan, RT; Choi, CK; Ho, JW; Law, WL; Lui, L; Siu, S; Tung, SY | 1 |
| Bendell, JC; Clary, BM; Gan, TJ; Hill, SE; Hurwitz, HI; Morse, MA; Reddy, SK | 1 |
| Bachellier, P; Casnedi, S; Chenard-Neu, MP; Dufour, P; Jaeck, D; Nakano, H; Oussoultzoglou, E; Rosso, E | 1 |
| Bramhall, SR; Buckels, JA; Coldham, CA; Hubscher, SG; Mayer, AD; Mehta, NN; Mirza, DF; Ravikumar, R; Wigmore, SJ | 1 |
| Aegerter, P; Afchain, P; André, T; Bachet, JB; Bouchahda, M; Fermanian, C; Landi, B; Levi, F; Lièvre, A; Louvet, C; Mitry, E; Rougier, P | 1 |
| Abbas, R; Andreu, J; Baselga, J; Casado, E; Cortes-Funes, H; Folprecht, G; Köhne, CH; Lejeune, C; Marimón, I; Paz-Ares, L; Quinn, S; Rojo, F; Salazar, R; Tabernero, J; Ubbelohde, U; Zacharchuk, C | 1 |
| Goldberg, RM; Grothey, A; Hedrick, EE; Hurwitz, HI; Mass, RD; Ramanathan, RK; Sargent, DJ; Sarkar, S; Suzuki, S | 1 |
| Hamaguchi, T; Kano, Y; Kato, K; Koizumi, F; Matsumura, Y; Nakajima, TE; Shimada, Y; Shirao, K; Yamada, Y; Yasunaga, M | 1 |
| Balteskard, L; Braendengen, M; Sørbye, H | 1 |
| Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K | 1 |
| Funahashi, K; Ishii, J; Kaneko, H; Koike, J; Otsuka, Y; Tamura, A; Teramoto, T; Tsuchiya, M; Watanabe, M; Yamazaki, K | 1 |
| Bascoul-Mollevi, C; Bec, N; Conseiller, E; Copois, V; Del Rio, M; Denis, V; Fraslon, C; Gongora, C; Larroque, C; Martineau, P; Molina, F; Robert, B; Vié, N | 1 |
| Ariad, S; Gluzman, A; Lavrenkov, K; Man, S; Mermershtain, W; Rubinov, K | 1 |
| Barrueco, J; Fuchs, CS; Marshall, J | 1 |
| Chung, ST; Czuczman, PR; Lewis, AL; Tang, Y | 1 |
| Macdonald, JS; Mahtani, RL | 1 |
| Berger, MR; Boleij, A; Eyol, E; Lewis, AL; Taylor, RR | 1 |
| Tang, X; Wang, G; Wang, Z; Wu, H; Wu, Z; Zhu, D | 1 |
| Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E | 1 |
| Allegrini, G; Bursi, S; Falcone, A; Fontana, A; Loupakis, F; Masi, G; Petrini, I; Ricci, S; Vasile, E | 1 |
| Bergsland, E; Berlin, JD; Lockhart, AC; Rosen, L; Rothenberg, M; Venook, A | 1 |
| Caliendo, V; Ciorba, A; Ciuffreda, L; Clerico, M; Evangelista, W; Facilissimo, I; Fanchini, L; Macripò, G; Milanesi, E; Paris, M; Racca, P; Ritorto, G; Volpatto, R | 1 |
| Bjerregaard, J; Jensen, B; Nielsen, D; Pfeiffer, P; Qvortrup, C; Yilmaz, M | 1 |
| Balteskard, L; Berglund, A; Fokstuen, T; Ogreid, D; Pfeiffer, P; Ploen, J; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, K; Yilmaz, M | 1 |
| Barone, C; Kemeny, NE; Pozzo, C | 1 |
| Chen, PM; Chen, WS; Chiou, TJ; Jiang, JK; Lin, JK; Lin, TC; Liu, CY; Liu, JH; Wang, HS; Wang, WS | 1 |
| Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Yasuda, S | 1 |
| Cervantes, A; Pfeiffer, P; Tabernero, J | 1 |
| Cunningham, D; Jackson, C | 2 |
| Cordoba-Rodriguez, R; Fuchs, C; Giusti, RM; Hughes, M; Keegan, P; Koti, K; Men, AY; Pazdur, R; Pilaro, AM; Rothmann, M; Shastri, K; Weiss, KD; Zhao, H | 1 |
| Bazin, IS; Biakhov, MY; Blatter, J; Goldstein, D; Gorbounova, VA; Granov, DA; Hossain, AM; Kaiser, C; Ma, D; Underhill, C | 1 |
| Altes, A; Baiget, M; Culverhouse, R; Hoskins, JM; Marcuello, E; Marsh, S; Maxwell, T; McLeod, HL; Paré, L; Van Booven, DJ | 1 |
| Greenberger, LM; Horak, ID; Kraft, P; Longley, C; Malaby, J; Mehlig, M; Sapra, P; Zhao, H | 1 |
| Fukuda, H; Hirokawa, S; Nagata, T; Sawada, S; Tazawa, K; Tsukada, K; Uotani, H; Yamagishi, F | 1 |
| Owzar, K | 1 |
| Andreoni, F; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Floriani, I; Fontana, A; Giustini, L; Graziano, F; Humar, B; Loupakis, F; Magnani, M; Maltese, P; Masi, G; Rulli, E; Ruzzo, A; Santini, D; Schiavon, G; Tonini, G; Torresi, U | 1 |
| Douillard, JY; Folprecht, G; Hecker, H; Köhne, CH; Maughan, TS; Mitry, E; Rougier, P; Saltz, L; Schubert, U; Seymour, MT; Stephens, RJ; Van Cutsem, E | 1 |
| Cohen, DJ; Hochster, HS | 1 |
| Allegrini, G; Barletta, MT; Bocci, G; Cerri, E; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Fioravanti, A; Kerbel, RS; Loupakis, F; Masi, G; Orlandi, P | 1 |
| Akagi, Y; Fukushima, T; Ishibashi, N; Mori, S; Murakami, H; Ogata, Y; Shirouzu, K; Ushijima, M | 1 |
| Borg, C; Chaigneau, L; Demarchi, MF; Legat, C; Limat, S; Nguyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Viel, E | 1 |
| Abubakr, YA; Borg, C; Burris, HA; Eng, C; Fehrenbacher, L; Kisker, O; Kopit, J; Kröning, H; Langer, C; Lenz, HJ; Luppi, G; Lutz, MP; Maurel, J; Middleton, G; Prausova, J; Scheithauer, W; Sobrero, AF; Steinhauer, EU; Vega-Villegas, ME; Zubel, A | 1 |
| Andre, T; Bachet, JB; Bouchahda, M; Domont, J; Karaboué, A; Landi, B; Levi, F; Lledo, G; Macarulla, T; Rougier, P; Spano, JP; Tabernero, J | 1 |
| Bueter, M; Fein, M; Gasser, M; Illert, B; Meyer, D; Reimer, P; Thalheimer, A; Thiede, A; Waaga-Gasser, AM | 1 |
| Adenis, A; Bouché, O; Conroy, T; Deligny, N; Di Fioré, F; Fournier, C; Fournier, P; Gasnault, L; Giraud, C; Hebbar, M; Joly, JP; Maes, P; Michel, P; Péreira, R; Rad, E | 1 |
| Fricker, J | 1 |
| Hatate, K; Ihara, A; Ikeda, A; Nakamura, T; Onosato, W; Ozawa, H; Sato, T; Watanabe, M; Yamanashi, T | 1 |
| Allegrini, G; Bocci, G; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Fanelli, G; Fioravanti, A; Kerbel, RS; Naccarato, AG; Orlandi, P; Viacava, P | 1 |
| Folprecht, G; Goldberg, RM; Köhne, CH; Mitry, E; Rougier, P | 1 |
| D'Angelica, MI; Fong, Y; Jarnagin, WR; Kemeny, NE; Munoz, JA; Raggio, G; Schwartz, LH; White, RR | 1 |
| Endo, T; Hasegawa, H; Ishii, Y; Kitagawa, Y; Kubota, T; Ochiai, H; Okabayashi, K | 1 |
| Eggington, S; Hind, D; Ryan, A; Sutcliffe, P; Tappenden, P; Tumur, I | 1 |
| Asaka, M; Doi, T; Fuse, N; Hamamoto, Y; Minashi, K; Muto, M; Ohtsu, A; Tahara, M; Yano, T; Yoshida, S | 1 |
| Kos, M; Mrhar, A; Obradovic, M | 1 |
| Atiq, OT; Dragovich, T; Hochster, H; Kozuch, PS; Lenz, HJ; O'Neil, BH; Pipas, JM; Rocha-Lima, CM; Ryan, DP | 1 |
| Di Fiore, F | 1 |
| Mayer, RJ; Wolpin, BM | 1 |
| Argon, A; Aykan, NF; Basaran, M; Gumus, M; Guney, N; Saglam, S; Sakar, B; Tenekeci, AN; Ustaoglu, MA; Ustuner, Z | 1 |
| Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS | 1 |
| Ban, W; LA, L; Rao, JJ; Wu, SG | 1 |
| Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP | 1 |
| Chang, HM; Kang, BW; Kang, YK; Kim, JC; Kim, JH; Kim, TW; Lee, JL; Lee, JS; Ryu, MH; Yu, CS | 1 |
| Hecht, JR | 1 |
| Heinemann, V; Moosmann, N | 1 |
| Duffy, A; Fong, Y; Huitzil-Melendez, FD; O'Reilly, EM; Shia, J | 1 |
| Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL | 1 |
| Armand, JP; Bugat, R; Canal, P; Chatelut, E; Gay, C; Gonçalvès, E; Lokiec, F; Mathieu-Boué, A; Roché, H | 1 |
| Ohtsu, A; Ono, K; Saijo, N; Sasaki, Y; Shimada, Y | 1 |
| Aiba, K; Dobashi, N; Funakoshi, S; Hirano, A; Kamada, M; Kuraishi, Y; Mizunuma, N; Ohno, N; Sano, M; Sugimoto, Y | 1 |
| Futatsuki, K; Kambe, M; Nakao, I; Ogawa, N; Sakata, Y; Shimada, Y; Taguchi, T; Wakui, A; Yoshino, M | 1 |
| Hidaka, K; Hirohashi, Y; Hisatsugu, T; Kohno, K; Kuwano, M; Sato, S | 1 |
| Creemers, GJ; Dirix, LY; Gamucci, T; Hudson, I; Schöffski, P; Vallentin, S; Verweij, J; Wanders, J | 1 |
| Rowe, PM | 1 |
| Bugat, R; Rougier, P | 1 |
| Bleiberg, H | 3 |
| Beijnen, JH; Creemers, GJ; Davies, BE; de Boer-Dennert, M; Maes, RA; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ; Verweij, J | 1 |
| Burris, HA; Eckardt, JR; Eckhardt, SG; Elfring, GL; Hilsenbeck, SG; Kuhn, JG; Nelson, J; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Schaaf, LJ; Smith, LS; Thurman, AM; Von Hoff, DD; Weiss, GR | 1 |
| Creemers, GJ; de Boer-Dennert, M; Gerrits, CJ; Harteveld, M; Hudson, I; Loos, W; Planting, AS; Schellens, JH; Stoter, G; van Beurden, VM; van der Burg, ME; Verweij, J | 1 |
| Adenis, A; Brunet, R; Bugat, R; Canal, P; Dezeuze, A; Douillard, JY; Gay, C; Herait, P; Lokiec, F; Mathieu-Boue, A | 1 |
| Markham, A; Wiseman, LR | 1 |
| Kojima, S; Oyamada, H; Ueno, Y; Wang, DS | 1 |
| Cunningham, D | 2 |
| Bleiberg, H; Cvitkovic, E | 1 |
| Pitot, H; Rougier, P; Shimada, Y | 1 |
| Khayat, D; Saltz, L; Shimada, Y | 1 |
| Anderson, S; Beidler, D; Belliveau, D; Burtness, BA; Cheng, YC; Fedele, J; Flynn, SD; Murren, JR; Pizzorno, G; Tocino, I; Zelterman, D | 1 |
| Armand, JP; Couteau, C; Terret, C | 1 |
| Misset, JL | 1 |
| Abbruzzese, JL; Arbuck, SG; Ballard, WP; Bradof, JE; Diaz-Canton, E; Graham, S; Pazdur, R; Winn, R | 1 |
| Ghosh, C; Goldberg, RM; Kirschling, RJ; Knost, JA; Levitt, R; Mailliard, JA; O'Connell, MJ; Pitot, HC; Rubin, J; Schroeder, G; Wender, DB; Windschitl, HE | 1 |
| O'Reilly, S; Rowinsky, EK | 1 |
| Berkery, R; Harrison, J; Kelsen, DP; Kemeny, NE; Saltz, LB; Tong, W | 1 |
| Creemers, GJ | 1 |
| Henja, MH; Kornek, GV; Raderer, M; Scheithauer, W; Valencak, J | 1 |
| Astoul, C; Ollitrault, N; Salvat, D | 1 |
| Eisenhauer, EA; Feld, R; Firby, PS; Goldberg, RA; Manzo, J; Michael, M; Moore, MJ; Oza, AM; Siu, LL; Thiessen, JJ; Wainman, N | 1 |
| Bugat, R; Canal, P; Guichard, S; Hennebelle, I | 1 |
| Berg, D | 2 |
| Choe, YH; Conover, CD; Gilbert, C; Greenwald, RB; Hsue, M; Lee, C; Martinez, A; Pendri, A; Wu, D; Xia, J | 1 |
| Rowinsky, EK; Siu, LL | 1 |
| Bulusu, VR | 1 |
| Black, JD; Cao, S; Rustum, YM; Troutt, AB | 1 |
| Bastian, G; Bonnay, M; Cote, C; Cvitkovic, E; Hagipantelli, R; Herait, P; Mahjoubi, M; Mignard, D; Misset, JL; Saliba, F; Vassal, G | 1 |
| Pazdur, R | 2 |
| Pitot, HC | 1 |
| Erlichman, C; Goldberg, RM | 1 |
| Michael, M; Moore, MJ | 1 |
| Conover, CD; Gilbert, CW; Greenwald, RB; Pendri, A; Shum, KL | 1 |
| Meyer, W; Nemunaitis, J; Ognoskie, N; Singh, A; Tong, A | 1 |
| Henderson, CA | 1 |
| Danenberg, K; Danenberg, PV; Groshen, S; Leichman, CG; Leichman, L; Lenz, HJ; Metzger, R; Salonga, D; Schwartz, EL; Wadler, S | 1 |
| Beijnen, JH; Bult, A; Herben, VM; Hillebrand, MJ; ten Bokkel Huinink, WW; van Gijn, R | 1 |
| Awad, L; Cunningham, D; Heikkila, R; Herait, P; Hickish, TF; Jacques, C; James, RD; Johannesen, TB; Punt, CJ; Pyrhönen, S; Starkhammar, H; Topham, CA | 1 |
| Awad, L; Bajetta, E; Bleiberg, H; Herait, P; Jacques, C; Labianca, R; Morant, R; Navarro, M; Niederle, N; Possinger, K; Rougier, P; Van Cutsem, E; Wils, J | 1 |
| Barone, C; Cognetti, F; Cote, C; Dirix, L; Filez, L; Garufi, C; Gruia, G; Humblet, Y; Pozzo, C; Starkhammar, H; Terzoli, E; Van Cutsem, E | 1 |
| Cersosimo, RJ | 1 |
| Armand, JP; Boige, V; Raymond, E | 1 |
| Peeters, M; Van Cutsem, E | 1 |
| Ducreux, M; Mitry, E; Rougier, P | 1 |
| André, T; de Gramond, A; Ducreux, M; Gil-Delgado, M; Khayat, D; Ychou, M | 1 |
| Depisch, D; Haider, K; Hejna, M; Kornek, GV; Kwasny, W; Raderer, M; Scheithauer, W; Valencak, J; Weinländer, G | 1 |
| Achterrath, W; Harstrick, A; Köhne, CH; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H | 1 |
| Cox, JV; DeVore, RF; Elfring, GL; Geyer, CE; Hainsworth, JD; Macdonald, JS; Miller, LL; Mohrland, JS; Pazdur, R; Rivkin, SE; Rothenberg, ML; Sandbach, J; Von Hoff, DD; Wolf, DL | 1 |
| Alexopoulos, CG; Blanc, C; Bleiberg, H; Blijham, GH; Cholet, P; Cote, C; Cunningham, D; Dirix, L; Fillet, G; Hérait, P; Levi, F; Panagos, G; Punt, CJ; Symann, M; Ten Bokkel Huinink, WW; Unger, C; Van Cutsem, E; Van Groeningen, C; Vannetzel, JM; Wils, J | 1 |
| Cunningham, D; Glimelius, B | 1 |
| Blijham, GH; Van Cutsem, E | 1 |
| Erlichman, C; Goldberg, RM; O'Connell, MJ; Pitot, HC | 1 |
| Li, N; Ou, Q; Shen, B; Wang, H; Yu, B; Zhang, H; Zheng, M | 1 |
| Stucky-Marshall, L | 1 |
| Miller, M | 1 |
| Allegrini, G; Antonuzzo, A; Brunetti, I; Cianci, C; Conte, P; Falcone, A; Galli, C; Lencioni, M; Masi, G; Pfanner, E | 1 |
| Dörr, T; Kemmeries, G; Petrasch, S | 1 |
| Twelves, C | 1 |
| Brouwer, E; de Boer-Dennert, MM; de Bruijn, P; de Jonge, MJ; Planting, AS; Sparreboom, A; Stoter, G; van der Burg, ME; Vernillet, L; Verweij, J | 1 |
| Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Comis, S; De Vita, F; Faranda, A; Gravina, A; Orditura, M; Petrillo, A | 1 |
| Angerstein, C; Becker, H; Becker, W; Béhé, M; Behr, TM; Blumenthal, RD; Fayyazi, A; Goldenberg, DM; Hiddemann, W; Liersch, T; Ringe, B; Salib, AL; Sharkey, RM; Wörmann, B | 1 |
| Blanke, CD; Rothenberg, ML | 1 |
| Bekradda, M; Cvitkovic, E | 1 |
| Androulakis, N; Aravantinos, G; Bafaloukos, D; Florou, S; Fountzilas, G; Georgoulias, V; Kosmidis, P; Sgouros, I; Skarlos, DV | 1 |
| Van Cutsem, E | 1 |
| André, T; Carola, E; Couteau, C; de Gramont, A; Gilles-Amar, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F | 1 |
| Boisdron-Celle, M; Boulanger, N; Gamelin, E | 1 |
| Hickish, T; Iveson, TJ; Schmitt, C; Van Cutsem, E | 1 |
| Bras-Gonçalves, RA; Dutrillaux, B; Laurent-Puig, P; Poupon, MF; Rosty, C; Soulié, P | 1 |
| Kobayashi, T; Maeda, Y; Okamoto, R; Omuro, Y; Sasaki, T; Takeda, N | 1 |
| Alakl, M; Awad, L; Carmichael, J; Cunningham, D; Douillard, JY; Gruia, G; Iveson, T; James, RD; Jandik, P; Karasek, P; Navarro, M; Roth, AD; Rougier, P | 1 |
| Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C | 1 |
| Adenis, A; Burki, F; Douillard, JY; Dufour, P; Marty, M; Mignard, D; Mousseau, M; Rougier, P; Wendling, JL; Ychou, M | 1 |
| Ohtsu, A | 1 |
| Endo, W; Kurihara, M; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Yamazaki, T | 1 |
| Schallhorn, A | 1 |
| Baldwin, AS; Cusack, JC; Liu, R | 1 |
| Adjei, AA; Alberts, SA; Burch, PA; Elfring, G; Erlichman, C; Goldberg, RM; Miller, LL; Pitot, HC; Reid, JM; Rubin, J; Schaaf, LJ; Skaff, PA; Sloan, JA | 1 |
| Jelic, S; Nikolic-Tomasevic, Z; Popov, I; Radosavljevic, D | 1 |
| Blijham, G; Jolain, B; Rougier, P; Schmitt, C; Van Cutsem, E | 1 |
| Furuhata, T; Hata, F; Hirata, K; Kawasaki, H; Matsunaga, T; Nakagawa, N; Sasaki, K; Shibata, K; Takasaka, H; Yabana, T; Yasojima, T | 1 |
| Henney, JE | 1 |
| Cao, S; Rustum, YM | 1 |
| Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Nakashima, H; Okamura, T; Toh, Y | 1 |
| Awad, L; Bleiberg, H; Bugat, R; Culine, S; Droz, JP; Freyer, G; Herait, P; Marty, M; Mignard, D; Rougier, P; Trillet-Lenoir, V | 1 |
| Broadwater, R; Govindarajan, R; Hauer-Jensen, M; Heaton, KM; Lang, NP; Zeitlin, A | 1 |
| Fujioka, M; Hashimoto, D; Idezuki, Y; Inokuma, S; Ishida, H; Ishizuka, N; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Okita, H; Suzuki, T; Takahama, T; Takeuchi, I; Yamada, H; Yokoyama, M | 1 |
| Balatoni, G; Farczádi, E; Izsó, J; Kofi, AP; Kristó, K; Lohinszky, J; Pintér, T; Szántó, J | 1 |
| Gamucci, T; Hanauske, A; Heinrich, B; Kaye, S; Paridaens, R; Pavlidis, N; Roelvink, M; Schellens, JH; Sessa, C; Verweij, J; Wanders, J | 1 |
| Cattel, F; Messori, A; Trippoli, S; Vaiani, M | 1 |
| de Bruijn, P; de Jonge, MJ; Kehrer, DF; Sparreboom, A; Verweij, J; Yamamoto, W | 1 |
| Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB | 1 |
| Mayer, RJ | 1 |
| Graeven, U; Schmiegel, W | 1 |
| Ledermann, JA; Napier, MP | 1 |
| Borsellino, N; Cigolari, S; Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Paoletti, G; Pedicini, T | 1 |
| Goldberg, RM; Hatfield, AK; Knost, JA; Krook, JE; Kugler, J; Mahoney, MR; Pitot, HC; Sargent, DJ | 1 |
| Hoff, PM; Pazdur, R; Royce, ME | 1 |
| Cunningham, D; Sumpter, K | 1 |
| Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC | 1 |
| Hill, M; Price, T | 1 |
| Hegewisch-Becker, S; Hossfeld, DK; Lipp, R; Schilling, G | 1 |
| Avallone, A; Biglietto, M; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lena, M; De Lucia, L; De Vita, F; Farris, A; Ianniello, GP; Leo, SS; Lorusso, V; Mancarella, S | 1 |
| Bjarnason, GA; Madarnas, Y; Shorter, AM; Webster, P | 1 |
| Cunningham, D; Waters, J | 1 |
| Maeda, Y; Sasaki, T | 1 |
| Jirajarus, M; Ratanatharathorn, V; Sirachainan, E; Sirilerttrakul, S | 1 |
| Alakl, M; Awad, L; Douillard, JY; Elfring, GL; Gruia, G; Locker, PK; Miller, LL; Pirotta, N; Saltz, LB | 1 |
| Pelley, RJ | 1 |
| Messori, A; Trippoli, S; Vaiani, M | 1 |
| Erlichman, C; Goldberg, RM; O'Connell, MJ | 1 |
| Pestalozzi, BC | 1 |
| Ducreux, M; Pignon, JP | 1 |
| Saijo, N | 1 |
| Dwivedy, S; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, ME; Zukowski, TH | 1 |
| Berlin, J | 1 |
| Bregman, D; Manalo, J; Mani, S | 1 |
| Govindarajan, R | 2 |
| Achterrath, W; Cao, S; Harstrick, A; Rustum, YM; Seeber, S; Vanhoefer, U | 1 |
| Adam, R; Bismuth, H; Castaing, D; Coeffic, D; Durrani, AK; Gil-Delgado, MA; Guinet, F; Khayat, D | 1 |
| Balcells, M; Casal-Rubio, J; Castellanos, J; Constenla, M; Díz, P; Fírvida, JL; Irigoyen, A; Rodríguez, R; Valladares-Ayerbes, M; Vázquez-Estévez, S | 1 |
| Aschelter, AM; Comis, S; D'Attino, RM; Dogliotti, L; Garufi, C; Nisticó, C; Perrone, M; Pugliese, P; Tampellini, M; Terzoli, E | 1 |
| Avallone, A; Biglietto, M; Casaretti, R; Comella, G; Comella, P; De Cataldis, G; De Lucia, L; Di Lullo, L; Maiorino, L; Rivellini, F | 1 |
| Kirichenko, AV; Rich, TA | 1 |
| Cunningham, D; James, RD | 1 |
| Abendroth, K; Adams, J; Baldwin, AS; Cusack, JC; Elliott, PJ; Houston, M; Liu, R | 1 |
| Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, A; Koukourakis, M; Kouroussis, C; Mavroudis, D; Romanos, J; Souglakos, J; Vardakis, N | 1 |
| Antoine, EC; Bastian, G; Gil-Delgado, M; Khayat, D; Nizri, D | 1 |
| Prescott, LM | 1 |
| Koda, T; Kurihara, M; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Yamazaki, T | 1 |
| Ganser, A; Reinke, F; Schlichting, C; Schöffski, P; van Gennip, AH; van Kuilenburg, AB; Volk, J | 1 |
| Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H | 1 |
| Bokemeyer, C; Honecker, F; Kolb, G; Wedding, U | 1 |
| Krieger, G | 1 |
| Louvet, C | 1 |
| Traynor, K | 1 |
| Niedzwiecki, D; O'Connell, MJ; Sargent, DJ; Schilsky, RL | 1 |
| Ledermann, JA; Leonard, P; Seymour, M | 1 |
| Aoki, T; Hirai, K; Kawahara, H; Kuroda, H; Ono, M; Sato, K; Suzuki, T | 1 |
| Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E | 1 |
| Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ | 1 |
| Grivicich, I; Mans, DR; Peters, GJ; Schwartsmann, G | 1 |
| Aguado, M; Fallik, D; Jacob, S; Praz, F | 1 |
| Armand, JP; Becouarn, Y; Ducreux, M; Fizazi, K; Seitz, JF | 1 |
| Guillou, PJ; Guthrie, JA; O'Riordain, DS; Ride, E; Sarela, AI; Seymour, MT | 1 |
| Cunningham, D; Maroun, J; Van Cutsem, E; Vanhoefer, U | 1 |
| Saitoh, S; Sakata, Y | 1 |
| Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H | 1 |
| Colussi, C; Franchitto, A; Palitti, F; Pichierri, P; Piergentili, R | 1 |
| Amaya, K; Miwa, K; Nishijima, K; Nishimura, G; Sasaki, S; Shimizu, K; Tani, T; Terada, I | 1 |
| Reimer, P; Rückle-Lanz, H | 1 |
| Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M | 1 |
| Ratain, MJ | 1 |
| de Jonge, MJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Stoter, G; Verweij, J | 1 |
| Brugger, S; Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schneeweiss, B; Schüll, B; Ulrich-Pur, H | 1 |
| Adler, G; Lutz, MP | 1 |
| Douillard, JY; Köhne, CH; Van Cutsem, E | 1 |
| Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kandilis, K; Kouroussis, C; Mavroudis, D; Sarra, E; Souglakos, J; Vamvakas, L; Ziras, N | 1 |
| Gall, H; Giaccone, G; Gruia, G; Kedde, MA; Leisink, JM; Pinedo, HM; van der Vijgh, WJ; van Groeningen, CJ; van Riel, JM | 1 |
| Bleiberg, H; Di Leo, A | 1 |
| Fletcher, L | 1 |
| Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J | 1 |
| Boige, V; Ducreux, M; Taïeb, J | 1 |
| Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Wagman, LD | 1 |
| Bilchik, AJ; Chawla, SP; Chung, M; Foshag, LJ; Litvak, DA; Morton, DL; Ramming, KP; Tsioulias, GJ; Wood, TF | 1 |
| Cohen, Y; Lavrenkov, K; Man, S; Mermershtain, W | 1 |
| Hacker, U; Heinemann, V; Schalhorn, A; Stemmler, J; Weise, A | 1 |
| Adlard, JW; Quirke, P; Richman, SD; Seymour, MT | 1 |
| Holen, KD; Saltz, LB | 1 |
| Agostini, C; Charasson, V; Montaudon, D; Pavillard, V; Richard, S; Robert, J | 1 |
| Adank, S; Beijnen, JH; Botma, HJ; Ganser, A; Herr, A; Rosing, H; Schöffski, P; Van den Brande, J; Vermorken, JB; Volk, J; Wanders, J | 1 |
| Blandizzi, C; Colucci, R; Danesi, R; De Paolis, B; Del Tacca, M; Di Paolo, A; Falcone, A | 1 |
| Fietkau, R; Klautke, G | 1 |
| Giacchetti, S | 1 |
| Bansback, N; Hummel, S; Lloyd Jones, M; Orr, B; Seymour, M | 1 |
| Delioukina, ML; Hecht, JR; Parson, M; Prager, D; Rosen, LS; Rosen, P | 1 |
| Bassi, R; Ellis, LM; Hicklin, DJ; Hooper, AT; Prewett, MC; Waksal, HW | 1 |
| Barbarot, V; Bennouna, J; Douillard, JY | 1 |
| Kerr, DJ | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Sekido, Y; Shimokata, K | 1 |
| Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N | 1 |
| Manzione, L; Reggiardo, G; Rosati, G; Rossi, A | 1 |
| Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Crucitta, E; De Lucia, L; De Vita, F; Del Prete, S; Lorusso, V; Orditura, M; Palmeri, S | 1 |
| Cunningham, D; Falk, S; Jackson, D | 1 |
| de Bruijn, P; Loos, WJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Verweij, J | 1 |
| Abbruzzese, JL; Anzai, H; Frost, P | 1 |
| Veyrac, M | 1 |
421 review(s) available for camptothecin and Colorectal Cancer
| Article | Year |
|---|---|
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Febrile Neutropenia; Female; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds | 2021 |
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2022 |
Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Placenta Growth Factor; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2022 |
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Leucovorin; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic | 2022 |
A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms | 2022 |
Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin | 2022 |
The efficacy of irinotecan supplementation for colorectal cancer: A meta-analysis of randomized controlled studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dietary Supplements; Fluorouracil; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic | 2022 |
A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Placenta Growth Factor; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms | 2023 |
Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Prospective Studies; Rectal Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor D | 2023 |
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Withholding Treatment | 2020 |
The actual management of colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Electroporation; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Liver Transplantation; Margins of Excision; Microwaves; Organoplatinum Compounds; Prognosis; Radiofrequency Ablation; Reoperation | 2020 |
Controversies in the treatment of RAS wild-type metastatic colorectal cancer.
Topics: Advisory Committees; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colon, Ascending; Colon, Transverse; Colonic Neoplasms; Colorectal Neoplasms; Consensus; Delphi Technique; ErbB Receptors; Fluorouracil; Genes, ras; Genotype; Humans; Leucovorin; Liquid Biopsy; Maintenance Chemotherapy; Organoplatinum Compounds; Proto-Oncogene Proteins B-raf; Retreatment | 2021 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.
Topics: Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Substitution; Fluorouracil; Genes, ras; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Organoplatinum Compounds; Proto-Oncogene Proteins B-raf; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2021 |
Up-to-date role of aflibercept in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2021 |
[FOLFIRI plus Ramucirumab Treatment for Metastatic Colorectal Cancer-Narrative Review of Real-World Evidence in Japan].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Japan; Leucovorin; Neoplasm Metastasis; Ramucirumab | 2021 |
Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; British Columbia; Camptothecin; Cohort Studies; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Retrospective Studies | 2022 |
FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2017 |
Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2017 |
Oral versus intravenous fluoropyrimidines for colorectal cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Palliative Care; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Tegafur; Uracil | 2017 |
Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Network Meta-Analysis; Organoplatinum Compounds; Software; Survival Analysis; Treatment Outcome | 2018 |
The paradigm of tumor shrinkage and rapid liver remnant hypertrophy for conversion of initially unresectable colorectal liver metastasis: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Carcinoma; Colon, Sigmoid; Colonoscopy; Colorectal Neoplasms; Embolization, Therapeutic; Female; Fluorouracil; Hepatectomy; Humans; Hypertrophy; Laparoscopy; Leucovorin; Ligation; Liver; Liver Neoplasms; Liver Regeneration; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Portal Vein; Prognosis; Treatment Outcome; Vascular Surgical Procedures | 2017 |
Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: A systematic review.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Epidemiologic Methods; Humans; Injections, Intra-Arterial; Irinotecan; Liver Neoplasms; Microspheres | 2017 |
Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Camptothecin; Colorectal Neoplasms; Humans; Immunohistochemistry; Irinotecan | 2017 |
Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2017 |
Efficacy and safety of FOLFIRI and biotherapy versus FOLFIRI alone for metastatic colorectal cancer patients: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis | 2017 |
[Metastatic colorectal cancer: To stop or not to stop?]
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Maintenance Chemotherapy; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Withholding Treatment | 2018 |
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2018 |
Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Retrospective Studies | 2018 |
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Databases, Factual; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neutropenia; Organoplatinum Compounds; Proportional Hazards Models; Risk; Survival Rate; Treatment Outcome | 2018 |
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Progression-Free Survival; Randomized Controlled Trials as Topic; Signal Transduction | 2019 |
FOLFOXIRI plus biologics in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2019 |
Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Odds Ratio; Polymorphism, Single Nucleotide; Treatment Outcome; White People | 2013 |
Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.
Topics: Aged; Alleles; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Female; Genetic Association Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Single Nucleotide; Risk Factors; White People | 2014 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
The evolving role of oxaliplatin in the management of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2003 |
Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Hospitalization; Humans; Irinotecan; Molecular Targeted Therapy; Multidrug Resistance-Associated Protein 2; Severity of Illness Index; Topoisomerase I Inhibitors | 2013 |
Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Neutropenia; Pharmacogenetics | 2012 |
FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Treatment Outcome | 2013 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; ErbB Receptors; Humans; Irinotecan; Mutation; Neoplasm Metastasis; Prodrugs; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2013 |
Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Carriers; Humans; Irinotecan; Liver Neoplasms; Quality of Life; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
[Relationship between UGT1A and irinotecan-related toxicity].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Single Nucleotide | 2013 |
Methods of overcoming treatment resistance in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Rectum | 2014 |
Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate; Treatment Outcome | 2014 |
Effects of MTHFR genetic polymorphisms on toxicity and clinical response of irinotecan-based chemotherapy in patients with colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Humans; Irinotecan; Methylenetetrahydrofolate Reductase (NADPH2); Polymorphism, Genetic | 2014 |
Sequencing of treatment in metastatic colorectal cancer: where to fit the target.
Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Panitumumab; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2014 |
Place of hepatic intra-arterial chemotherapy in the treatment of colorectal liver metastases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Treatment Outcome | 2014 |
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
Topics: Alanine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Databases, Factual; ErbB Receptors; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; PubMed; Pyridines; Retreatment; Salvage Therapy; Treatment Failure; Triazines | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplasms; Diarrhea; Disease Models, Animal; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Inflammation; Intestinal Mucosa; Irinotecan; Mucositis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin | 2014 |
Role of cetuximab in first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Ligands; Liver Neoplasms; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaloacetates; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Randomized Controlled Trials as Topic; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retreatment; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiotoxicity; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Liver; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2014 |
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; France; Gastrointestinal Neoplasms; Genotype; Gilbert Disease; Glucuronosyltransferase; Humans; Irinotecan; Pharmacovigilance; Phenotype; Polymorphism, Genetic; Treatment Outcome; United States; White People | 2014 |
Efficacy of S-1 in colorectal cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colon; Colorectal Neoplasms; Drug Combinations; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rectum; Tegafur | 2014 |
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenotype; Precision Medicine; Treatment Outcome | 2014 |
Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Vascular Endothelial Growth Factor A | 2014 |
Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Publication Bias | 2015 |
The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Fluorouracil; Health Care Costs; Humans; Kaplan-Meier Estimate; Leucovorin; Models, Economic; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2015 |
Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2015 |
MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; MicroRNAs; Organoplatinum Compounds; Oxaliplatin | 2015 |
[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2015 |
Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate; Treatment Outcome | 2015 |
Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Female; Fluorouracil; Humans; Irinotecan; Jaw Diseases; Middle Aged; Osteonecrosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tomography, X-Ray Computed | 2016 |
Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; DNA; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Maintenance Chemotherapy; Organoplatinum Compounds; Oxaliplatin; Quality of Life | 2016 |
Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2015 |
Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quality-Adjusted Life Years; Treatment Outcome; United States | 2016 |
Current and advancing treatments for metastatic colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Combinations; ErbB Receptors; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Pyrrolidines; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Therapies, Investigational; Thymine; Trifluridine; Uracil; Vascular Endothelial Growth Factor A | 2016 |
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Dosage Calculations; Genotype; Humans; Irinotecan; Neoplasm Metastasis; Treatment Outcome | 2015 |
Maintenance strategy in metastatic colorectal cancer: A systematic review.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Disease-Free Survival; Drug Administration Schedule; Evidence-Based Medicine; Female; Humans; Irinotecan; Maintenance Chemotherapy; Male; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Organoplatinum Compounds; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 2016 |
Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Leucovorin; Maintenance Chemotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Organoplatinum Compounds | 2016 |
Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases.
Topics: Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Liver; Liver Neoplasms; Neoadjuvant Therapy | 2016 |
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Nausea; Neutropenia; Quality of Life; Randomized Controlled Trials as Topic | 2016 |
Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genes, ras; Humans; Leucovorin; Maintenance Chemotherapy; Mutation; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pharmacokinetics; Proto-Oncogene Proteins B-raf | 2016 |
The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Humans; Irinotecan; Neoplasm Metastasis; Ramucirumab; Survival Rate; Treatment Outcome | 2016 |
Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; DNA Repair; DNA-Binding Proteins; Endonucleases; Fluorouracil; Genetic Markers; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pharmacogenomic Testing; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Xeroderma Pigmentosum Group D Protein | 2016 |
Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.
Topics: Administration, Metronomic; Alkylating Agents; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Forecasting; Humans; Immunity, Cellular; Pyrimidines; Randomized Controlled Trials as Topic; Tubulin Modulators | 2016 |
Liver Metastases in Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; ErbB Receptors; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Organoplatinum Compounds | 2016 |
Unresectable liver metastases in colorectal cancer: review of current strategies.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Management; Embolization, Therapeutic; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 2016 |
Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Treatment Outcome | 2016 |
The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Panitumumab; Prognosis; Survival Rate; Treatment Outcome | 2016 |
Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization; Colorectal Neoplasms; Drug Carriers; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2017 |
Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Humans; Irinotecan; Liver Neoplasms | 2017 |
Second-line systemic therapy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis; Randomized Controlled Trials as Topic; Risk Factors | 2008 |
Drug-eluting particles for interventional pharmacology.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Colorectal Neoplasms; Doxorubicin; Drug Carriers; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Microspheres | 2007 |
[Current therapeutic options for liver metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Catheter Ablation; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery; Floxuridine; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Neoplasm Staging; Prognosis; Survival Rate; Time Factors | 2008 |
Regional chemotherapy for liver-limited metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Mitomycin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2008 |
Irinotecan toxicity.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; ErbB Receptors; Genetic Predisposition to Disease; Humans; Irinotecan; Neutropenia | 2007 |
Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Liver | 2006 |
Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Irinotecan; Metabolic Networks and Pathways; Models, Biological; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Risk Assessment | 2008 |
Irinotecan in the treatment of elderly patients with advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Female; Health Services for the Aged; Humans; Irinotecan; Male | 2008 |
Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Neoplasm Metastasis; Panitumumab | 2008 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Glass; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Microspheres; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Yttrium Radioisotopes | 2009 |
[Colorectal carcinoma--primary treatment in case of advanced metastization].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Leucovorin; Organoplatinum Compounds; Primary Health Care; Treatment Outcome | 2008 |
Pharmacogenomics of tamoxifen and irinotecan therapies.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP2D6; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; Polymorphism, Genetic; Tamoxifen; Treatment Outcome | 2008 |
[New perspectives in predicting response to chemotherapy in colorectal cancer].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA Repair; Drug Monitoring; ErbB Receptors; Genes, Tumor Suppressor; Humans; Irinotecan; Neoplasm Proteins; Oncogenes; Organoplatinum Compounds; Oxaliplatin; Prognosis; Protein Kinase Inhibitors | 2008 |
Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Fatty Liver; Floxuridine; Fluorouracil; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Leucovorin; Liver; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Risk Factors | 2009 |
Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
Topics: Camptothecin; Colorectal Neoplasms; Genetic Predisposition to Disease; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasm Metastasis; Polymorphism, Single Nucleotide | 2009 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2008 |
Treatment of colorectal liver metastases: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2009 |
Does celecoxib have a role in the treatment of patients with colorectal cancer?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides | 2009 |
Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Irinotecan; Microsatellite Repeats; Mutation; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2009 |
Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Metastasis; Palliative Care | 2009 |
The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Eruptions; Evidence-Based Medicine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Risk Factors | 2009 |
The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Europe; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Liver Neoplasms; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasm Metastasis; Treatment Outcome | 2009 |
[Colorectal cancers: prognostic and predictive factors of response to treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Chromosome Deletion; Chromosomes, Human, Pair 18; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Panitumumab; Prognosis | 2009 |
Second-line chemotherapy in advanced and metastatic CRC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate | 2009 |
What's new in ... colorectal cancer. Meaningful progress in therapy options.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2009 |
A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mismatch Repair; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prognosis; Treatment Outcome | 2009 |
Genetic prognostic and predictive markers in colorectal cancer.
Topics: beta Catenin; Biomarkers, Tumor; Camptothecin; Capecitabine; Chromosomes, Human, Pair 18; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression Profiling; Genes, APC; Genes, p53; Genomic Instability; Humans; Irinotecan; Microsatellite Instability; Mutation; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
[Chemotherapy of elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Comorbidity; Cooperative Behavior; Decision Making; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Life Expectancy; Organoplatinum Compounds; Oxaliplatin; Patient Care Team | 2009 |
Irinotecan therapy and molecular targets in colorectal cancer: a systemic review.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colorectal Neoplasms; Humans; Irinotecan; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2009 |
A novel K-ras mutation in colorectal cancer. A case report and literature review.
Topics: Adenocarcinoma, Mucinous; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Tumor Suppressor Protein p53 | 2009 |
Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2009 |
KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Genes, MCC; Humans; Leucovorin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2010 |
Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2009 |
UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
Topics: Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers, Pharmacological; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Genotype; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Models, Biological; Neoplasm Metastasis; Polymorphism, Genetic; Precision Medicine; Racial Groups | 2009 |
Chemotherapy, which drugs and when.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; ErbB Receptors; Humans; Irinotecan; Neoplasm Metastasis; Vascular Endothelial Growth Factor A | 2004 |
[The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Precision Medicine; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2009 |
Treatment of metastatic colorectal cancer in the elderly.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Comorbidity; Drug Delivery Systems; Female; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2009 |
Palliative treatment of unresectable metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care | 2010 |
The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; ErbB Receptors; Genetic Markers; Humans; Irinotecan; Mutation; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Vascular Endothelial Growth Factor A | 2010 |
A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2011 |
[Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fatty Liver; Hepatic Veno-Occlusive Disease; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2010 |
Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Oxaloacetates; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Surgical therapies in metastatic colorectal cancer with a potential for cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Hyperthermia, Induced; Infusions, Parenteral; Leucovorin; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Peritoneal Neoplasms; Pneumonectomy | 2011 |
Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Spheroids, Cellular; Survival Rate; Treatment Outcome | 2010 |
[Transition of chemotherapy for metastatic colorectal cancer and recent advances].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Survival Rate | 2010 |
Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Meta-Analysis as Topic; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2010 |
[Recent developments of pharmacogenomics in the treatment of colorectal cancers].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Drug Screening Assays, Antitumor; ErbB Receptors; Fluorouracil; Genotype; Glutathione Transferase; Humans; Irinotecan; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenotype; Signal Transduction | 2010 |
Consequences of chemotherapy on resection of colorectal liver metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Delivery Systems; Fatty Liver; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Liver Neoplasms; Liver Regeneration; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Prognosis; Survival Rate; Tomography, X-Ray Computed | 2010 |
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2010 |
Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Vitamin B Complex | 2010 |
Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Risk Factors; Treatment Outcome | 2011 |
Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Capecitabine-based chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2011 |
Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2011 |
Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Drug Approval; Europe; Fluorouracil; Humans; Irinotecan; Leucovorin; Mutation; Organoplatinum Compounds; United States; United States Food and Drug Administration | 2010 |
Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Prodrugs; Radiotherapy, Adjuvant | 2010 |
Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2010 |
Chemotherapy of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2010 |
Adjuvant treatment of colon cancer: what is next?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds | 2011 |
Cetuximab in the treatment of patients with colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Evidence-Based Medicine; Humans; Irinotecan; Mutation; Precision Medicine; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Logistic Models; Middle Aged; Multivariate Analysis; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Stomatitis; Survival Analysis; Treatment Outcome | 2011 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Research Design; Treatment Outcome | 2011 |
Common side effects and interactions of colorectal cancer therapeutic agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Complementary Therapies; Deoxycytidine; Drug Interactions; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2011 |
Evolution of systemic therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2011 |
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Polymorphism, Genetic; Precision Medicine | 2011 |
DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; DNA Copy Number Variations; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Leucovorin; Pemetrexed; Treatment Outcome | 2011 |
Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Humans; Irinotecan; Topoisomerase I Inhibitors | 2011 |
Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycin; Mutation; Organoplatinum Compounds; Oxaloacetates; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Vascular Endothelial Growth Factor A | 2012 |
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fluorouracil; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Precision Medicine | 2011 |
Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; France; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2011 |
[Neoadjuvant therapy concepts for liver metastases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Prognosis; Randomized Controlled Trials as Topic | 2011 |
Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2012 |
Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Genetic | 2012 |
[Chemotherapy for advanced colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin | 2011 |
[A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2011 |
[Treatment with CPT-11 based on the UGT1A1 genetic polymorphism].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic | 2011 |
A preclinical and clinical review of aflibercept for the management of cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2012 |
Delivery methods of camptothecin and its hydrosoluble analogue irinotecan for treatment of colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan | 2012 |
Treatment with unfunded drugs in oncology: the impact of access programmes and clinical trials.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Compassionate Use Trials; Cost Sharing; Drug Industry; ErbB Receptors; Female; Health Services Accessibility; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Pyridines; Randomized Controlled Trials as Topic; Survival Analysis | 2012 |
Chemotherapy and molecular-targeted treatment for unresectable hepatic metastases: a Japanese perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Molecular Targeted Therapy; Organoplatinum Compounds; Survival Rate | 2012 |
Cetuximab in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Liver Neoplasms; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2012 |
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2012 |
DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.
Topics: Biomarkers; Camptothecin; Colorectal Neoplasms; DNA Repair; DNA Repair Enzymes; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Irinotecan; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Randomized Controlled Trials as Topic | 2012 |
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Codon; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Mutation; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; ras Proteins; Treatment Outcome | 2012 |
Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Transcriptome; Vascular Endothelial Growth Factor A | 2012 |
Colorectal liver metastases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Treatment Outcome | 2013 |
Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Fluorouracil; Gene Expression Regulation, Neoplastic; Guidelines as Topic; Humans; Leucovorin; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2012 |
Splice isoforms as therapeutic targets for colorectal cancer.
Topics: Alternative Splicing; Camptothecin; Colorectal Neoplasms; Cyclin D1; Dihydrouracil Dehydrogenase (NADP); Glucuronosyltransferase; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Pregnane X Receptor; Protein Isoforms; Receptors, Steroid; Survivin; Vascular Endothelial Growth Factor A | 2012 |
Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Meta-Analysis as Topic; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Randomized Controlled Trials as Topic | 2013 |
Oncological management of unresectable liver metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Neoplasm Staging; Organoplatinum Compounds; Panitumumab; Time Factors | 2012 |
FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Retrospective Studies; Treatment Outcome | 2013 |
Therapeutic advances in the management of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Methotrexate; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2001 |
Chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2002 |
Targeting vascular endothelial growth factor in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Endothelial Growth Factors; Female; Fluorouracil; Humans; Indoles; Irinotecan; Leucovorin; Male; Neovascularization, Pathologic; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2002 |
The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2002 |
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Drug Hypersensitivity; Drug Interactions; Gemcitabine; Head and Neck Neoplasms; Humans; Irinotecan; Pancreatic Neoplasms | 2002 |
Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2001 |
Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2001 |
Review of the role of CPT-11 in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2001 |
Advances in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Uracil | 2001 |
Adjuvant therapy of colon cancer: a review.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Levamisole; Neoplasm Staging | 2002 |
Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2001 |
Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate | 2002 |
Current status of capecitabine in the treatment of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Risk Factors; Stomatitis; Survival; Treatment Outcome | 2002 |
The role of pemetrexed in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Folic Acid Antagonists; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Thymidylate Synthase | 2002 |
The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2003 |
[Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a review].
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Levamisole; Palliative Care; Quality-Adjusted Life Years; Quinazolines; Thiophenes | 2003 |
Palliative treatment of patients with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Palliative Care; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Treatment Outcome; Uracil | 2003 |
[Chemotherapy for colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Time Factors | 2003 |
Irinotecan: promising activity in the treatment of malignant glioma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Glioma; Humans; Irinotecan; United States | 2003 |
Optimal use of the combination of irinotecan and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan | 2003 |
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Survival Rate; Treatment Outcome | 2003 |
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Drug Administration Schedule; Enzyme Inhibitors; Flavonoids; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Isoenzymes; Leucovorin; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin; Piperidines; Prostaglandin-Endoperoxide Synthases; Quinazolines; Thiophenes; Treatment Outcome | 2003 |
Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Neoplasm Staging; Neovascularization, Pathologic; Predictive Value of Tests; Prognosis; Survival Analysis | 2003 |
Current treatments and future perspectives in colorectal and gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Tailoring chemotherapy in advanced colorectal cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Helicases; DNA Repair; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Fluorouracil; Glucuronosyltransferase; Glutathione Transferase; Humans; Irinotecan; Platinum Compounds; Proteins; Thymidylate Synthase; Transcription Factors; Xeroderma Pigmentosum Group D Protein | 2003 |
Campto effective and flexible chemotherapy for advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index | 2003 |
Colorectal cancer: integrating oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome | 2003 |
Current and ongoing trials with irinotecan in the United States.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Pyrazoles; Sulfonamides | 2003 |
Alternative schedules with irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin | 2003 |
Induction therapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2003 |
Review article: colorectal cancer chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Floxuridine; Fluorouracil; Forecasting; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Quinazolines; Thiophenes | 2003 |
[Controversy of treatment for advanced colorectal cancer--intermedisine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Tegafur | 2003 |
Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2003 |
Pharmacology of intraperitoneal CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Parenteral; Irinotecan; Male; Maximum Tolerated Dose; Risk Assessment; Sensitivity and Specificity | 2003 |
Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis | 2003 |
[Polymorphism in colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genetic Predisposition to Disease; Humans; Irinotecan; Life Style; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Neoplasm Invasiveness; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Prodrugs; Prognosis; Risk Factors | 2003 |
[Application and problems in hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Interleukin-2; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy | 2003 |
[Home chemotherapy and outpatient treatment for metastatic colorectal cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Female; Fluorouracil; Home Care Services; Humans; Infusions, Intravenous; Irinotecan; Levamisole; Liver Neoplasms; Middle Aged; Quality of Life | 2003 |
[5-fluorouracil and leucovorin therapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; United States | 2003 |
[Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Prognosis; United States | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Pyridines; Tegafur; United States; Uracil | 2003 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Nausea; Stomatitis; Thrombocytopenia; Vomiting | 2003 |
[Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2003 |
[Guidance and informed consent in colon cancer therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colorectal Neoplasms; Fluorouracil; Humans; Informed Consent; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Neoplasm Recurrence, Local | 2003 |
[Treatment of metastatic liver carcinoma: chemotherapy and immunotherapy].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms | 2003 |
Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Immunotherapy; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2003 |
[Chemotherapy for colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Tegafur; Uracil | 2003 |
Development of new agents for the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2003 |
[Novel molecular approaches in the therapy of advanced colorectal carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Neoplasm Staging; Neovascularization, Pathologic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2003 |
First-line treatment strategies to improve survival in patients with advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2004 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2003 |
The role of new agents in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2004 |
Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Europe; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Survival Analysis; Survival Rate; United States | 2004 |
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2004 |
[Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2004 |
Systemic treatment of advanced colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Treatment Outcome | 2004 |
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Survival Rate; Treatment Outcome | 2004 |
Current approaches to first-line treatment of advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2004 |
Current status of second-line therapy for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Therapy, Combination; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Salvage Therapy | 2004 |
Progress in the development of novel treatments for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2004 |
Current strategies in previously untreated advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2004 |
Current status of adjuvant therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Europe; Fluorouracil; Humans; Leucovorin; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; United States | 2004 |
[New therapy options in colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Treatment Outcome | 2004 |
Developments in combination chemotherapy for colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2004 |
Integration of novel agents in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Delivery Systems; ErbB Receptors; Humans; Irinotecan; Vascular Endothelial Growth Factor A | 2004 |
Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2004 |
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Enzyme Inhibitors; Glucuronidase; Glucuronides; Glucuronosyltransferase; Humans; Intestines; Irinotecan; Loperamide; Topoisomerase I Inhibitors | 2004 |
New options and old dilemmas in the treatment of patients with advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Humans; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Signal Transduction | 2004 |
Evidence-based update of chemotherapy options for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Receptors, Vascular Endothelial Growth Factor | 2004 |
[Advances in palliative and adjuvant chemotherapy of colon cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Tegafur; Uracil | 2004 |
Current perspectives in the treatment of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2004 |
Which drug combination for colorectal cancer?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2004 |
[Colorectal cancer: current treatment options].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; DNA Mutational Analysis; Fluorouracil; Humans; Irinotecan; Mass Screening; Organoplatinum Compounds; Oxaliplatin; Risk; Survival Rate | 2004 |
[Recent results of irinotecan therapy in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Survival Analysis; Treatment Outcome | 2004 |
Pemetrexed in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Folic Acid Antagonists; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Thymidylate Synthase | 2004 |
[Second-line chemotherapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Quality of Life; Survival Rate; Tegafur; Uracil | 2005 |
Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2004 |
Systemic therapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Prodrugs; Pyridines | 2005 |
Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs | 2005 |
Adjuvant therapy of colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2005 |
Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2005 |
Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genes, p53; Genes, ras; Genomic Instability; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Thymidylate Synthase | 2005 |
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2005 |
[Colon cancer: molecular markers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; DNA Repair; DNA, Neoplasm; Feces; Fluorouracil; Genes, ras; Genes, Tumor Suppressor; Genetic Markers; Humans; Irinotecan; Microsatellite Repeats; Mutation; Oncogenes; Polymerase Chain Reaction; Prognosis; Prospective Studies; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Critical evaluation of current treatments in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Medical Oncology; Neoplasm Metastasis; Vascular Endothelial Growth Factors | 2005 |
The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Quinazolines; Thiophenes; United Kingdom | 2005 |
New combinations in metastatic colorectal cancer: what are our expectations?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2005 |
Benefit-risk assessment of irinotecan in advanced colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index | 2005 |
Indications and effect on survival of standard chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prodrugs | 2005 |
New chemotherapeutic strategies in colorectal cancer.
Topics: Administration, Oral; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs | 2005 |
Cetuximab in previously treated colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Salvage Therapy | 2005 |
Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2005 |
Current therapies for advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2005 |
(Neo-)adjuvant treatments in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2005 |
Role of genomic markers in colorectal cancer treatment.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Irinotecan; Oncogenes; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests | 2005 |
[Chemotherapy of patients with colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Incidence; Irinotecan; Leucovorin; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis | 2005 |
Cetuximab therapy and symptomatic hypomagnesemia.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Fatigue; Humans; Hypocalcemia; Incidence; Irinotecan; Magnesium; Magnesium Deficiency; Male; Severity of Illness Index | 2005 |
The treatment of colorectal carcinoma: standard chemotherapy and beyond.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Drug Delivery Systems; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2004 |
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2005 |
[Molecular biology in clinical cancer research: the example of digestive cancers].
Topics: Adenocarcinoma; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomedical Research; Camptothecin; Chromosomal Instability; Chromosomes, Human, 16-18; Chromosomes, Human, 21-22 and Y; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 8; Clinical Trials as Topic; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; DNA, Neoplasm; Fluorouracil; Forecasting; Genes, Tumor Suppressor; Genetic Markers; Humans; Immunohistochemistry; Irinotecan; Molecular Biology; Multivariate Analysis; Mutation; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenotype; Prognosis; Stomach Neoplasms | 2005 |
[Which role do new therapeutic options play in palliative care of colorectal cancer?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Irinotecan; Palliative Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cause of Death; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Costs; Drug Hypersensitivity; Drug Industry; Female; Fluorouracil; Humans; Irinotecan; Male; Medical Assistance; Nausea; Neoplasm Staging; Nurse's Role; Oncology Nursing; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Patient Education as Topic; Treatment Outcome; United States; Vomiting | 2005 |
Metastatic colorectal cancer: is there one standard approach?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Vitamin B Complex | 2005 |
[Drug therapy of patients with metastatic colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Prognosis; Survival Rate | 2005 |
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Pyrimidines; Treatment Outcome | 2005 |
Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome | 2005 |
[Recent progress of chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival Rate | 2005 |
Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2005 |
The role of bevacizumab as first-line therapy for colon cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic | 2005 |
Second-line treatment of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Randomized Controlled Trials as Topic; Risk Factors | 2005 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Uracil; Vitamin B Complex | 2005 |
Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cryosurgery; Decision Trees; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prognosis; Risk Factors; Treatment Failure; Treatment Outcome | 2006 |
Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2006 |
[The modern treatment of colorectal cancer. Present and future].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Immunologic Factors; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2006 |
Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Protein-Tyrosine Kinases | 2006 |
Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; History, 20th Century; History, 21st Century; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Randomized Controlled Trials as Topic | 2006 |
Predicting the outcome of chemotherapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Treatment Outcome | 2006 |
[Irinotecan for the treatment of metastatic colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Folic Acid; Humans; Irinotecan; Maximum Tolerated Dose; Multicenter Studies as Topic; Pharmacogenetics | 2006 |
Biological agents versus chemotherapy in the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Oxonic Acid; Survival Rate; Tegafur | 2006 |
[IFL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Rate | 2006 |
[Adjuvant treatment of colorectal cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Tegafur; Uracil | 2006 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leukopenia; Neutropenia; Oxonic Acid; Survival Rate; Tegafur | 2006 |
[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neutropenia; Oxonic Acid; Remission Induction; Survival Rate; Tegafur | 2006 |
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Irinotecan in the treatment of colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis | 2006 |
[Hepatic arterial infusion chemotherapy for liver metastases from digestive cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Oxonic Acid; Tegafur | 2006 |
Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics | 2006 |
Pharmacogenetics and irinotecan therapy.
Topics: Antineoplastic Agents; Bilirubin; Biomarkers; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Drug Labeling; Genetic Predisposition to Disease; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Polymorphism, Genetic; Practice Guidelines as Topic; Risk Assessment | 2006 |
The role of targeted therapy in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Epidermal Growth Factor; Humans; Irinotecan; Neovascularization, Pathologic; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
[Present status and prospect of irinotecan application in adjuvant therapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Postoperative Care; Treatment Outcome | 2006 |
[Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cancer Vaccines; Carcinoma; Cetuximab; Colorectal Neoplasms; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fluorouracil; Humans; Hungary; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2006 |
[Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
Topics: Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Survival Analysis | 2006 |
[Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Neoplasm Staging; Panitumumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Cetuximab plus irinotecan in refractory colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chronic Disease; Colorectal Neoplasms; Humans; Irinotecan | 2007 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis | 2008 |
Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Panitumumab | 2006 |
[Surgery and chemotherapy for colorectal cancer: current status and perspective].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colonoscopy; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Lymph Node Excision; Organoplatinum Compounds; Quality of Life; Radiotherapy Dosage; Randomized Controlled Trials as Topic | 2007 |
Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Treatment Outcome | 2007 |
[Pre-operative chemotherapy for patients with hepatic metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Survival Analysis | 2007 |
[Cetuximab].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Approval; Drug Eruptions; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Mice | 2007 |
Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fatty Liver; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2008 |
[Are antiangiogenic antibodies universal for solid tumor?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fluorouracil; Humans; Hypertension; Kidney Neoplasms; Leucovorin; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2007 |
The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis | 2007 |
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
Topics: Adult; Antiemetics; Antineoplastic Agents, Phytogenic; Ataxia; Camptothecin; Capecitabine; Central Nervous System; Colorectal Neoplasms; Cytotoxins; Deoxycytidine; Dexamethasone; Dysarthria; Female; Fluorouracil; Granisetron; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Sarcoma, Small Cell; Serotonin Antagonists; Topoisomerase I Inhibitors | 2008 |
[Angiogenesis targeting in gastro-intestinal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2007 |
Treatment of advanced colorectal cancer in the elderly.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colectomy; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Stents | 2007 |
[Progress of chemotherapy in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Organoplatinum Compounds | 2007 |
[Palliative chemotherapy and radiotherapy for metastatic colorectal cancer].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life; Survival Rate | 2008 |
[Predictive factors of response to anti-EGFR treatments in colorectal cancer].
Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Cyclin D1; Drug Eruptions; Drug Resistance, Neoplasm; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Gene Dosage; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Mutation; Neoplasm Proteins; Panitumumab; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Vascular Endothelial Growth Factor A | 2008 |
Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Humans; Irinotecan; Treatment Outcome | 2008 |
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2008 |
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Sulfonamides | 2008 |
Advances in neoadjuvant therapy for colorectal cancer with liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2008 |
Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Irinotecan; Time Factors | 2008 |
Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Vascular Endothelial Growth Factor A | 2008 |
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Confounding Factors, Epidemiologic; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Vascular Endothelial Growth Factor A | 2007 |
Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biological Therapy; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Protein-Tyrosine Kinases; Signal Transduction; Vascular Endothelial Growth Factor A | 2007 |
A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; ErbB Receptors; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Treatment Failure; Vascular Endothelial Growth Factor A | 2007 |
[Antibody treatment in colorectal cancer--what the surgeon needs to know].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Panitumumab; Phthalazines; Pyridines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A; Vitamin B Complex | 2008 |
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Treatment Outcome | 2008 |
Systemic treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Treatment Outcome | 2008 |
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2008 |
CPT-11: an original spectrum of clinical activity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Topoisomerase I Inhibitors | 1996 |
CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors | 1996 |
Role of chemotherapy for advanced colorectal cancer: new opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 1996 |
[Recent advance in chemotherapy for advanced colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Quinazolines; Remission Induction; Thiophenes; Thymidylate Synthase | 1996 |
Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; Europe; Humans; In Vitro Techniques; Irinotecan; Japan; Tissue Distribution; Treatment Outcome; United States | 1996 |
Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan | 1996 |
Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Middle Aged; Neutropenia | 1996 |
Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 1996 |
CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan | 1996 |
CPT-11: the European clinical development.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Humans; Irinotecan; Lung Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | 1996 |
Experimental chemotherapeutic agents for the treatment of colorectal carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drugs, Investigational; Enzyme Inhibitors; Female; Fluorouracil; Humans; Irinotecan; Male; Metalloendopeptidases; Platinum Compounds; Thymidylate Synthase; Topoisomerase I Inhibitors | 1997 |
Topotecan in advanced colorectal cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Staging; Topoisomerase I Inhibitors; Topotecan | 1997 |
Continuing the fight against advanced colorectal cancer: new and future treatment options.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors | 1998 |
Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Gastrointestinal Diseases; Humans; Irinotecan; Neutropenia; Patient Care Planning; Topoisomerase I Inhibitors | 1998 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil | 1998 |
Irinotecan in the first-line treatment of colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Humans; Irinotecan | 1998 |
Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; North America | 1998 |
Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Salvage Therapy | 1998 |
Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Cryosurgery; Embolization, Therapeutic; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Arterial; Injections, Intralesional; Irinotecan; Liver Neoplasms; Topoisomerase I Inhibitors; Treatment Failure; Trimetrexate | 1998 |
Efficacy and toxicity of irinotecan in patients with colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Humans; Irinotecan; Neoplasm Metastasis; Salvage Therapy; Topoisomerase I Inhibitors | 1998 |
Irinotecan: a new antineoplastic agent for the management of colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia | 1998 |
[Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Hepatic Artery; Humans; Inactivation, Metabolic; Injections, Intra-Arterial; Injections, Intravenous; Irinotecan; Neoplasm Proteins; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors | 1998 |
[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Europe; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Palliative Care; Remission Induction; Salvage Therapy; Topoisomerase I Inhibitors; Treatment Outcome; United States | 1998 |
[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Irinotecan in combination for colon cancer].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Europe; Fluorouracil; Irinotecan; Japan; Leucovorin; Mitomycin; Neoplasm Metastasis; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors; Treatment Outcome; United States | 1998 |
Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Palliative Care; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors | 1999 |
New agents in gastrointestinal malignancies: Part 1: Irinotecan in clinical practice.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis; Oncology Nursing; Pancreatic Neoplasms | 1999 |
CPT-11 in gastrointestinal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Humans; Irinotecan; Pancreatic Neoplasms; Stomach Neoplasms | 1999 |
Topoisomerase I inhibitors in the treatment of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 1999 |
Oxaliplatin: a new therapeutic option in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 1999 |
[Pharmacokinetic monitoring].
Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug Monitoring; Etoposide; Fluorouracil; Humans; Irinotecan; Liver; Paclitaxel; Topotecan | 2000 |
[New combination therapies for gastrointestinal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Docetaxel; Fluorouracil; Humans; Irinotecan; Leucovorin; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Analysis; Taxoids | 2000 |
[Adjuvant chemotherapy for colorectal carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2000 |
[State of the treatment for gastrointestinal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Doxorubicin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Mitomycin; Stomach Neoplasms | 2000 |
[Colon carcinoma. Consensus of therapeutic strategies].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Leucovorin; Lymphatic Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs | 2000 |
Novel chemotherapeutic agents in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Thymidylate Synthase | 2000 |
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?
Topics: Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunotherapy; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes | 2000 |
Current treatment options for advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2000 |
Combination chemotherapy and colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2000 |
Colorectal cancer chemotherapy: irinotecan.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors | 2000 |
The role of irinotecan in colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Patient Selection; Topoisomerase I Inhibitors; Treatment Outcome | 1999 |
The changing face of chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Thymidylate Synthase; Topoisomerase I Inhibitors | 2001 |
[Progress in chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxonic Acid; Pyridines; Tegafur | 2000 |
Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Gastrointestinal Neoplasms; Humans; Irinotecan; Lung Neoplasms | 2001 |
Determinants of prognosis and response to therapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxidoreductases; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase | 2001 |
Oxaliplatin: a new agent for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Approval; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome; United States; United States Food and Drug Administration | 2001 |
Preclinical and clinical trials of topoisomerase inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors | 2000 |
Colorectal cancer: chemotherapy treatment overview.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome; Uracil | 2000 |
Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2000 |
Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2000 |
Second-line therapy in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2000 |
Novel combinations with oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2000 |
Efficacy of oxaliplatin in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Treatment Outcome | 2000 |
Irinotecan in the treatment of colorectal cancer: clinical overview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis; Treatment Outcome | 2001 |
Camptothecin schedule and timing of administration with irradiation.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Humans; Radiation-Sensitizing Agents; Time Factors | 2001 |
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Pyrimidines; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
[New chemotherapies for colorectal cancer treatment].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2001 |
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms | 2001 |
Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2001 |
[Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2001 |
Optimizing the use of irinotecan in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Quality of Life; Retrospective Studies; Survival Analysis; Treatment Outcome | 2001 |
[Standard therapy of CPT-11 for colorectal cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin | 2001 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
[Chemotherapy of colorectal carcinoma].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Folic Acid; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Survival Analysis; Treatment Outcome | 2001 |
[The new chemotherapy of colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Postoperative Care; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Time Factors | 2002 |
Prediction of the response of colorectal cancer to systemic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Survival Rate; Treatment Outcome | 2002 |
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Trimetrexate; Uracil | 2001 |
A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; England; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thiophenes; Treatment Outcome; Wales | 2001 |
Update on European adjuvant trials with irinotecan for colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Europe; Humans; Irinotecan; Survival Rate; Treatment Outcome | 2002 |
Irinotecan/thalidomide in metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Thalidomide | 2002 |
Capecitabine/irinotecan combination regimens in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan | 2002 |
854 trial(s) available for camptothecin and Colorectal Cancer
| Article | Year |
|---|---|
A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPA
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; GTP Phosphohydrolases; Humans; Leucovorin; Male; Membrane Proteins; Middle Aged; Palliative Care; Precision Medicine; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptor, ErbB-2 | 2022 |
Machine Learning Application in a Phase I Clinical Trial Allows for the Identification of Clinical-Biomolecular Markers Significantly Associated With Toxicity.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Leucovorin; Machine Learning; Male; Maximum Tolerated Dose; Retrospective Studies | 2022 |
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2022 |
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 2022 |
Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Proto-Oncogene Proteins B-raf; Vemurafenib | 2022 |
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neutropenia; Rectal Neoplasms; Retrospective Studies | 2023 |
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan | 2022 |
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms; Retrospective Studies | 2022 |
Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Germ Cells; Humans; Leucovorin; Rectal Neoplasms | 2022 |
Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell-Free Nucleic Acids; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Mutation; Panitumumab; Proto-Oncogene Proteins B-raf; Rectal Neoplasms | 2022 |
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circulating Tumor DNA; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Leucovorin; Panitumumab; Proto-Oncogene Proteins B-raf; Rectal Neoplasms | 2022 |
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms | 2022 |
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic; Rectal Neoplasms | 2022 |
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Rectal Neoplasms; Retrospective Studies | 2023 |
Triplet (FOLFOXIRI) Versus Doublet (FOLFOX or FOLFIRI) Regimen as First Line Treatment in Metastatic Colorectal Carcinoma, a Prospective Phase II, Randomized Controlled Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Prospective Studies | 2022 |
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2023 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms | 2023 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Middle Aged; Rectal Neoplasms; Retrospective Studies | 2022 |
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Prognosis; Rectal Neoplasms | 2023 |
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms; Transcriptome | 2023 |
Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Vascular Endothelial Growth Factor A | 2023 |
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Panitumumab; Rectal Neoplasms | 2023 |
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Prospective Studies; Proto-Oncogene Proteins B-raf; Rectal Neoplasms | 2023 |
Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms | 2023 |
Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Middle Aged; Oxaliplatin; Rectal Neoplasms; Tocotrienols; Young Adult | 2023 |
A randomized controlled, open-label early phase II trial comparing incidence of FOLFIRI.3-induced diarrhoea between Hangeshashinto and oral alkalization in Japanese patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Glucuronosyltransferase; Humans; Incidence; Leucovorin; Male; Middle Aged; Young Adult | 2019 |
ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; United Kingdom | 2019 |
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Organoplatinum Compounds; Progression-Free Survival; Sex Characteristics; Treatment Outcome; Vomiting | 2019 |
Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Oxaliplatin; Placenta Growth Factor; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate; Vascular Endothelial Growth Factor A | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Proto-Oncogene Proteins p21(ras); Quality of Life; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2020 |
Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Genotyping Techniques; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Phenylurea Compounds; Precision Medicine; Prodrugs; Progression-Free Survival; Pyridines; Randomized Controlled Trials as Topic; Time Factors; Young Adult | 2019 |
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Clinical Decision-Making; Colon; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Prognosis; Progression-Free Survival; Rectum | 2019 |
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Retrospective Studies; Treatment Outcome | 2020 |
The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Inflammation; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Prognosis; Translational Research, Biomedical | 2020 |
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2020 |
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Bone Neoplasms; Camptothecin; Cell Count; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Microsatellite Instability; Middle Aged; Mutation; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins B-raf; ras Proteins; Risk Assessment; Young Adult | 2020 |
A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Liver; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Perioperative Period; Postoperative Complications; Progression-Free Survival; Prospective Studies; Tomography, X-Ray Computed | 2020 |
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panit
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Panitumumab; Proto-Oncogene Proteins B-raf; ras Proteins; Treatment Outcome | 2020 |
Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Oxonic Acid; Progression-Free Survival; Survival Rate; Tegafur; Young Adult | 2020 |
Immune characterization of metastatic colorectal cancer patients post reovirus administration.
Topics: Adult; Antigen-Presenting Cells; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Camptothecin; Colon; Colorectal Neoplasms; Combined Modality Therapy; Cytokines; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Intestinal Mucosa; Leucovorin; Lymphocyte Activation; Male; Middle Aged; Mutation; Oncolytic Virotherapy; Oncolytic Viruses; Proto-Oncogene Proteins p21(ras); T-Lymphocytes; Treatment Outcome | 2020 |
Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Japan; Leucovorin; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2020 |
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Hypercalciuria; Irinotecan; Leucovorin; Magnesium; Male; Nephrocalcinosis; Prognosis; Renal Tubular Transport, Inborn Errors; Retrospective Studies; Survival Rate | 2020 |
Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Prognosis; Young Adult | 2020 |
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Italy; Leucovorin; Microsatellite Instability; Organoplatinum Compounds; Prospective Studies | 2020 |
Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Polymorphism, Genetic; Proto-Oncogene Proteins p21(ras) | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Mutation; Nivolumab; Organoplatinum Compounds; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Vascular Endothelial Growth Factor A; Young Adult | 2020 |
Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tumor Burden | 2020 |
Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Progression-Free Survival; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2020 |
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Products; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Genome-Wide Association Study; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Risk Assessment; Young Adult | 2021 |
Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Panitumumab; Proto-Oncogene Proteins p21(ras); Retrospective Studies | 2020 |
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prognosis; Progression-Free Survival; Tumor Burden; Young Adult | 2020 |
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Progression-Free Survival; Salvage Therapy; Treatment Outcome | 2021 |
A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome | 2021 |
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Genes, ras; Humans; Intention to Treat Analysis; Leucovorin; Middle Aged; Progression-Free Survival | 2021 |
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Proto-Oncogene Proteins p21(ras); Quality of Life; Retrospective Studies | 2021 |
A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Prospective Studies; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2021 |
Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Proton Pump Inhibitors | 2021 |
[Capecitabine and Oxaliplatin(CAPOX)plus Bevacizumab as Second-Line Chemotherapy for Metastatic Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Oxaliplatin; Treatment Outcome | 2021 |
Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Oxaliplatin; Topoisomerase I Inhibitors | 2021 |
A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Leucovorin; Male; Middle Aged; Panitumumab; Proto-Oncogene Proteins p21(ras) | 2021 |
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Camptothecin; Colorectal Neoplasms; Female; Humans; Immunoconjugates; Italy; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Spain; Trastuzumab | 2021 |
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Fluorouracil; Humans; Hyperthermic Intraperitoneal Chemotherapy; Leucovorin; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Perioperative Period; Peritoneal Neoplasms; Response Evaluation Criteria in Solid Tumors | 2021 |
A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Dietary Supplements; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Pilot Projects; Prospective Studies; Protective Agents; Silymarin; Treatment Outcome; Young Adult | 2021 |
Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Bevacizumab; Camptothecin; Colorectal Neoplasms; Humans; Japan; Leucovorin; Naphthoquinones | 2021 |
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Prognosis; Progression-Free Survival; Topoisomerase I Inhibitors; Treatment Outcome; Young Adult | 2021 |
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Prognosis; Prospective Studies; Retrospective Studies; Risk Factors; Survival Rate; Weight Loss | 2022 |
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Proteins; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Humans; Hypertension; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Protein-Tyrosine Kinases | 2017 |
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Genetic Association Studies; Humans; Insulin Receptor Substrate Proteins; Leucovorin; Male; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Sequence Analysis, DNA; Signal Transduction; Somatomedins; Survival Analysis | 2017 |
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Exons; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Treatment Outcome | 2017 |
Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2017 |
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neuregulin-1; Organoplatinum Compounds; Oxaliplatin; Prognosis; Receptor, ErbB-2; Receptor, ErbB-3; Retrospective Studies | 2017 |
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Prospective Studies; Research Design; Treatment Outcome | 2017 |
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Canada; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genes, ras; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome; United States | 2017 |
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Panitumumab; Spain; Survival Analysis | 2017 |
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2017 |
A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Treatment Outcome | 2017 |
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2018 |
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2017 |
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arylamine N-Acetyltransferase; ATP Binding Cassette Transporter, Subfamily B; Camptothecin; Catecholamine Plasma Membrane Transport Proteins; Cetuximab; Colorectal Neoplasms; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Glucuronosyltransferase; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome; Vitamin K Epoxide Reductases | 2017 |
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Leucovorin; Mutation; Neoplasm Metastasis; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Risk Factors; Time Factors; Treatment Outcome | 2017 |
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; L-Lactate Dehydrogenase; Leucovorin; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2017 |
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liquid Biopsy; Mutation; Neoplasm Metastasis; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2018 |
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Genotype; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; Population Groups; Prognosis; Protein Serine-Threonine Kinases; Survival Rate | 2017 |
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Survival Rate | 2018 |
Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxyuridine; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Rate; Treatment Outcome | 2018 |
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care | 2018 |
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Double-Blind Method; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Progression-Free Survival; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor D | 2018 |
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Lymphocyte Count; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Organoplatinum Compounds; Prognosis; Retrospective Studies | 2018 |
EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Double-Blind Method; Doxycycline; Exanthema; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Patient Compliance; Pharmaceutical Vehicles; Quality of Life; Skin Cream; Vitamin K 1; Young Adult | 2018 |
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Induction Chemotherapy; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome; Young Adult | 2018 |
Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Nodes; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prospective Studies; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Colorectal Neoplasms; Female; Fluorouracil; Glucuronosyltransferase; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Progression-Free Survival | 2018 |
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cohort Studies; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Hypertension; Italy; Leucovorin; Male; Middle Aged; Neutropenia; Progression-Free Survival; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Stomatitis; Surveys and Questionnaires | 2018 |
Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Models, Biological; Neoplasm Staging; Nonlinear Dynamics; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate; Tumor Burden | 2018 |
UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Frequency; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Survival Rate; Young Adult | 2018 |
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2018 |
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quality of Life; Treatment Outcome; Young Adult | 2018 |
Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Height; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colon; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Prognosis; Progression-Free Survival; Prospective Studies; Rectum | 2018 |
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Pyridines | 2018 |
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
Topics: Adult; Aged; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Prospective Studies | 2018 |
Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Leucovorin; MicroRNAs; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Young Adult | 2019 |
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retreatment; Treatment Outcome | 2018 |
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Topics: Adult; Aged; Antibodies; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Biosimilar Pharmaceuticals; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Intention to Treat Analysis; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Progression-Free Survival; Therapeutic Equivalency | 2018 |
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Mutation; Neoplasm Metastasis; Neovascularization, Pathologic; Prognosis; Proto-Oncogene Proteins c-raf; Ramucirumab; ras Proteins; Survival Rate | 2019 |
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Folic Acid; Humans; Irinotecan; Leucovorin; Male | 2019 |
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival | 2019 |
A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds | 2019 |
Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hematologic Diseases; Humans; Leucovorin; Male; Middle Aged; Progression-Free Survival; Ramucirumab; Retrospective Studies; Treatment Outcome | 2019 |
Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Costs; Female; Fluorouracil; France; Health Status; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prospective Studies; Quality of Life; Surveys and Questionnaires | 2019 |
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Fluorouracil; Genotype; GTP Phosphohydrolases; Humans; Leucovorin; Male; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Panitumumab; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate | 2019 |
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Patient Reported Outcome Measures; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Severity of Illness Index; Treatment Outcome; Young Adult | 2019 |
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Panitumumab; Retrospective Studies | 2019 |
Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Cohort Studies; Colorectal Neoplasms; Drug Dosage Calculations; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Middle Aged; Prospective Studies; Survival Analysis | 2019 |
Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cognition Disorders; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Geriatric Assessment; Health Services for the Aged; Humans; Irinotecan; Logistic Models; Male; Multivariate Analysis; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2013 |
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Phenylurea Compounds; Pyridines; Treatment Outcome; Young Adult | 2013 |
An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Inflammation; Leucovorin; Lymphocytes; Male; Neutrophils; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrimidines; Reproducibility of Results | 2013 |
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Genotype; Humans; Insulin-Like Growth Factor Binding Proteins; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Treatment Outcome | 2013 |
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sirolimus; Treatment Outcome | 2013 |
Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Netherlands; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Treatment Outcome | 2013 |
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Injections, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2013 |
Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; DNA; Female; Genotype; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Retrospective Studies | 2013 |
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Survival Rate | 2013 |
Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cetuximab; China; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Research Design; Treatment Outcome | 2013 |
Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cetuximab; Colorectal Neoplasms; Denmark; Digestive System Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Outcome Assessment, Health Care; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Republic of Korea; Young Adult | 2013 |
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; GTP Phosphohydrolases; Humans; Leucovorin; Male; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glutamates; Guanine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis | 2013 |
Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2013 |
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
Topics: Aged; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Panitumumab; Proportional Hazards Models; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Time Factors; Treatment Outcome; United Kingdom | 2013 |
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Prospective Studies; Proto-Oncogene Proteins B-raf; Pyrimidines; Sirolimus; Treatment Outcome | 2013 |
Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study.
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Blotting, Western; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Drug Delivery Systems; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver; Liver Neoplasms; Mass Spectrometry; Microsomes; Neoplasm Proteins; Prospective Studies; Reproducibility of Results | 2013 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Indoles; Irinotecan; Maximum Tolerated Dose; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Hepatic arterial infusion with irinotecan in patients with liver metastases of colorectal cancer: results of an extended phase I study.
Topics: Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intra-Arterial; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Survival Analysis; Tomography, X-Ray Computed | 2013 |
UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Floxuridine; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Interactions; Female; Humans; Irinotecan; Japan; Male; Maximum Tolerated Dose; Middle Aged; Receptor, IGF Type 1; Treatment Outcome | 2013 |
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Calcium-Binding Proteins; Camptothecin; Capecitabine; Colorectal Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; MicroRNAs; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaloacetates; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI(®)) for colorectal liver metastases does not predict tumour destruction or long-term outcome.
Topics: Adult; Aged; Angiography; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Contrast Media; Disease Progression; Drug Delivery Systems; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Camptothecin; Colorectal Neoplasms; Cyclosporine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Odds Ratio; Time Factors; Treatment Outcome; United Kingdom | 2013 |
Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Survival Analysis; Young Adult | 2013 |
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP2A6; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pharmacogenetics; Polymorphism, Genetic; Tegafur | 2013 |
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptothecin; Cohort Studies; Colorectal Neoplasms; Cytochrome P-450 CYP2A6; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Half-Life; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Polymorphism, Genetic; Stomach Neoplasms; Survival Analysis; Tegafur | 2013 |
[Effectiveness of combined systemic and regional chemotherapy in treating patients with metastatic colorectal cancer after extrahepatic progression of the disease].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Disease Progression; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Quinazolines; Thiophenes; Treatment Outcome | 2013 |
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Frequency; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; UDP-Glucuronosyltransferase 1A9 | 2013 |
Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Placebos; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate; Treatment Outcome; Young Adult | 2013 |
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Japan; Leucovorin; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Stomatitis; Survival Analysis | 2013 |
Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Creatinine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Oxaloacetates | 2013 |
Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Polyethylene Glycols; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Young Adult | 2013 |
Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Rectum; Treatment Outcome | 2014 |
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Prognosis; Prospective Studies; Proto-Oncogene Proteins B-raf; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2014 |
SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasm Metastasis; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Pyrimidines; Reduced Folate Carrier Protein; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2013 |
Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Young Adult | 2013 |
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Young Adult | 2013 |
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Young Adult | 2014 |
KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; DNA, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Treatment Outcome | 2013 |
Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Demography; DNA Mutational Analysis; Dose-Response Relationship, Drug; Female; Fluorouracil; Genotype; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Methotrexate; Neoplasm Metastasis; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2013 |
Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA-Binding Proteins; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Glutathione S-Transferase pi; Humans; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Republic of Korea; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2014 |
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Topics: Adiponectin; Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; PPAR gamma; Thiazolidinediones; Treatment Outcome | 2014 |
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Panitumumab; Quality of Life; Skin Diseases; Treatment Outcome | 2014 |
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Middle Aged; Treatment Outcome | 2013 |
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Interactions; Female; Fluorouracil; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome | 2014 |
Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glucuronosyltransferase; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Promoter Regions, Genetic; Prospective Studies; Survival Rate | 2014 |
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib | 2014 |
Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Simvastatin; Treatment Outcome | 2014 |
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Delayed-Action Preparations; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Loperamide; Male; Middle Aged; Octreotide; Quality of Life; Severity of Illness Index; Young Adult | 2014 |
Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Decision-Making; Colorectal Neoplasms; Decision Trees; Disease-Free Survival; DNA Mutational Analysis; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinase; Precision Medicine; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Response Evaluation Criteria in Solid Tumors; Thymidine Phosphorylase; Thymidylate Synthase | 2016 |
The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Proportional Hazards Models; Treatment Outcome | 2014 |
FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: preliminary results of a phase I-II study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies | 2014 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Membrane Glycoproteins; Middle Aged; Young Adult | 2014 |
Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Tumor Burden | 2014 |
Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome | 2014 |
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Treatment Outcome | 2014 |
FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Demography; Disease-Free Survival; Female; Fluorouracil; Genotyping Techniques; Humans; Leucovorin; Male; Multivariate Analysis; Polymorphism, Genetic; Treatment Outcome | 2014 |
Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Panitumumab; Treatment Outcome; Young Adult | 2014 |
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Indoles; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2014 |
Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2013 |
Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Treatment Outcome; Young Adult | 2014 |
miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2014 |
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Republic of Korea; Salvage Therapy; Tegafur; Treatment Outcome; Uracil | 2014 |
Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Female; GTP Phosphohydrolases; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2014 |
A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Gastrins; Humans; Infusions, Intravenous; Injections, Intramuscular; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Vomiting | 2014 |
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Maximum Tolerated Dose; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Pericytes; Predictive Value of Tests; Retrospective Studies; Treatment Outcome | 2015 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Austria; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Germany; Humans; Infusions, Intravenous; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Prognosis; Survival Rate; Treatment Outcome; Young Adult | 2014 |
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Survival Rate; Tegafur | 2015 |
Association between chemotherapy and plasma adipokines in patients with colorectal cancer.
Topics: Adipokines; Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Prognosis; Prospective Studies; Survival; Treatment Outcome | 2014 |
A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Aluminum Silicates; Antineoplastic Agents, Phytogenic; Camptothecin; Clay; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Placebos; Treatment Outcome; Young Adult | 2015 |
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Sulfonamides; Topoisomerase I Inhibitors; Treatment Outcome | 2015 |
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Treatment Outcome; Young Adult | 2014 |
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Integrin alphaV; Irinotecan; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2015 |
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Early Termination of Clinical Trials; Female; Humans; Irinotecan; Male; MAP Kinase Kinase Kinases; Middle Aged; Mutation; Neoplasm Proteins; Pilot Projects; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Analysis; Topoisomerase I Inhibitors | 2015 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds | 2014 |
Genomic landscape of metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atlases as Topic; Camptothecin; Chromosomes, Human, Pair 6; Colorectal Neoplasms; DNA Copy Number Variations; Drug Resistance, Neoplasm; Genes, Neoplasm; Genome, Human; Humans; Irinotecan; Treatment Outcome | 2014 |
Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Evidence-Based Medicine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United Kingdom | 2015 |
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Proportional Hazards Models | 2015 |
A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Republic of Korea; Young Adult | 2015 |
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2015 |
A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; China; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Young Adult | 2015 |
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Treatment Outcome | 2014 |
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2015 |
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2015 |
A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2015 |
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2015 |
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Genetic Testing; GTP Phosphohydrolases; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Membrane Proteins; Middle Aged; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2015 |
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Oligonucleotides; Toll-Like Receptor 9 | 2015 |
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2015 |
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2015 |
Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Italy; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden | 2015 |
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Italy; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Everolimus; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sirolimus | 2015 |
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Middle Aged; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Panitumumab; Young Adult | 2015 |
Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Chemoembolization, Therapeutic; Colorectal Neoplasms; Disease-Free Survival; Drug Delivery Systems; Feasibility Studies; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2015 |
A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Young Adult | 2015 |
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Frequency; GTP Phosphohydrolases; High-Throughput Nucleotide Sequencing; Humans; Leucovorin; Membrane Proteins; Mutation; Organoplatinum Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2015 |
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase | 2015 |
Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Necrosis; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Endostatins; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Recombinant Proteins; Survival Rate | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Ramucirumab | 2015 |
Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin | 2015 |
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate | 2015 |
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2015 |
Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prospective Studies | 2015 |
Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Panitumumab; Treatment Outcome | 2015 |
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Survival Rate | 2015 |
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Drugs, Chinese Herbal; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Quality of Life; Stomatitis; Young Adult | 2015 |
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2015 |
The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intralesional; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2016 |
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fatigue; Female; Fluorouracil; Humans; Hypertension; Leucovorin; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Survival Rate; Thrombosis; Vomiting | 2016 |
Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Ramucirumab | 2015 |
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Hypersensitivity; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2015 |
Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome | 2015 |
Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Proto-Oncogene Proteins p21(ras); Pyrrolidines; Thymine; Trifluridine; Uracil | 2015 |
Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Young Adult | 2015 |
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2015 |
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2015 |
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Genes, ras; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Severity of Illness Index | 2015 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Intention to Treat Analysis; Irinotecan; Italy; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Time Factors; Treatment Outcome | 2015 |
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; Exons; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Panitumumab; Proportional Hazards Models; Proto-Oncogene Proteins B-raf; Retreatment; Survival Analysis; Treatment Outcome | 2015 |
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Health Care Costs; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Quality of Life; Tegafur; Young Adult | 2015 |
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Feasibility Studies; Female; Gene Expression Regulation, Neoplastic; Humans; Hyperglycemia; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor, IGF Type 1; Up-Regulation | 2015 |
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Multivariate Analysis; Proportional Hazards Models; Treatment Outcome | 2016 |
High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic | 2015 |
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Republic of Korea; Simvastatin; Survival Analysis; Treatment Outcome | 2015 |
Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Metastasis; Outcome Assessment, Health Care; Paraffin Embedding; Prognosis; Proportional Hazards Models; Prospective Studies; Proto-Oncogene Proteins p21(ras); Tissue Fixation | 2015 |
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2016 |
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Polymorphism, Genetic; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Sulfonamides | 2016 |
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing A
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Double-Blind Method; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Analysis; Treatment Outcome | 2016 |
High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2016 |
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Retreatment; Sucrose; Treatment Outcome | 2016 |
Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Phenotype; Raltegravir Potassium | 2016 |
Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Radiotherapy Dosage; Treatment Outcome | 2016 |
Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Interleukin-6; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Prognosis; STAT3 Transcription Factor | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Treatment Outcome | 2016 |
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Pyrrolidinones; Quinolines | 2016 |
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Panitumumab; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2016 |
Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Recurrence; Tegafur; Treatment Failure; Treatment Outcome | 2016 |
A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Phthalazines; Piperazines; Treatment Outcome | 2016 |
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Quality of Life | 2016 |
Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Constitutive Androstane Receptor; Drug Interactions; Female; France; Genetic Markers; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Pharmacogenetics; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Xenobiotics | 2016 |
Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bilirubin; Biomarkers, Tumor; Camptothecin; Chi-Square Distribution; China; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Logistic Models; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pharmacogenomic Variants; Phenotype; Predictive Value of Tests; Prospective Studies; ROC Curve; Treatment Outcome; Young Adult | 2016 |
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proportional Hazards Models; Treatment Outcome | 2016 |
Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Combinations; Fatigue; Female; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.
Topics: Adult; Aged; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Eukaryotic Initiation Factor-4E; Female; HCT116 Cells; Humans; Irinotecan; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Oligoribonucleotides; RNA, Messenger | 2016 |
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Exons; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Proto-Oncogene Proteins p21(ras) | 2016 |
Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements.
Topics: Algorithms; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Monitoring; Humans; Irinotecan; Metabolic Clearance Rate; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2016 |
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
Topics: Activating Transcription Factor 6; Antineoplastic Agents; Basic-Leucine Zipper Transcription Factors; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; GTP Phosphohydrolases; Humans; Irinotecan; Membrane Proteins; Mutation; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Research Design | 2016 |
Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Quality of Life; Treatment Outcome | 2016 |
Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Panitumumab; Proto-Oncogene Proteins p21(ras); Survival Rate; Tegafur | 2016 |
Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Chronotherapy; Europe; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2017 |
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2016 |
A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2016 |
PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Disease-Free Survival; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Metastasectomy; Microspheres; Middle Aged; Neoadjuvant Therapy; Treatment Outcome | 2016 |
The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients.
Topics: Activities of Daily Living; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Health Status; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Quality of Life; Retrospective Studies; Surveys and Questionnaires; Survival Analysis | 2016 |
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Ramucirumab | 2016 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Response Evaluation Criteria in Solid Tumors; Tomography, X-Ray Computed | 2016 |
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Exons; Female; Humans; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Irinotecan; Male; Middle Aged; Mutation; Proto-Oncogene Proteins p21(ras); Receptor, IGF Type 1 | 2017 |
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins B-raf; ras Proteins; Retreatment; Treatment Outcome | 2016 |
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Ramucirumab | 2016 |
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate | 2017 |
Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Geriatric Assessment; Humans; Irinotecan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Neoplasm Metastasis; Prospective Studies; Quality of Life; Treatment Outcome | 2017 |
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; GTP Phosphohydrolases; Humans; Leucovorin; Liquid Biopsy; Male; Membrane Proteins; Neoplasm Metastasis; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Analysis; Treatment Outcome | 2017 |
Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins B-raf; Treatment Outcome | 2017 |
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Proto-Oncogene Proteins p21(ras); Remission Induction; Treatment Outcome | 2017 |
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-V
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Febrile Neutropenia; Female; Filgrastim; Fluorouracil; Follow-Up Studies; Humans; Incidence; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Young Adult | 2017 |
Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Panitumumab; Retrospective Studies; Treatment Outcome | 2017 |
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Neoplasm Metastasis; Nitro Compounds; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Pyridines; Survival Rate | 2015 |
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
Topics: Adenocarcinoma; Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemoprevention; Colorectal Neoplasms; Doxycycline; Drug Eruptions; Exanthema; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Ointments; Skin Care; Treatment Outcome; Vitamin K 1 | 2017 |
Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2017 |
High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome | 2008 |
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Analysis | 2008 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2008 |
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fever; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin | 2008 |
A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Time Factors; Treatment Outcome | 2008 |
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies | 2008 |
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Quinazolines | 2008 |
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; T-Lymphocytes; Treatment Outcome; Viral Vaccines | 2008 |
Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Treatment Outcome | 2008 |
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chelating Agents; Colorectal Neoplasms; Copper; Cytokines; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Molybdenum; Neoplasm Metastasis; Pilot Projects | 2009 |
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Spain; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Prospective Studies; Quality of Life; Treatment Outcome | 2008 |
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genotype; Glutathione S-Transferase pi; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Genetic | 2008 |
A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2009 |
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pain Measurement; Survival Analysis; Treatment Outcome | 2008 |
Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Treatment Outcome | 2008 |
Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2008 |
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
[Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Tomography, X-Ray Computed | 2008 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines | 2009 |
A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Rectal Neoplasms; Tegafur | 2009 |
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Genotype; Haplotypes; Humans; Inactivation, Metabolic; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Linkage Disequilibrium; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Metastasis; Polymorphism, Single Nucleotide | 2008 |
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2008 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Mesothelioma; Middle Aged; Mitomycin; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate | 2009 |
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2008 |
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Statistics, Nonparametric; Treatment Outcome | 2008 |
A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Carriers; Female; Fluorouracil; Humans; Hyaluronic Acid; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Survival Analysis; Treatment Outcome | 2009 |
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Placebos; Retrospective Studies; Survival Rate | 2009 |
Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Tegafur; Uracil | 2009 |
[Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neoplasms; Combined Modality Therapy; Drug Combinations; HLA-A Antigens; HLA-A24 Antigen; Humans; Immunotherapy; Irinotecan; Male; Oxonic Acid; Peptides; Tegafur; Tomography, X-Ray Computed | 2008 |
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2009 |
The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Predictive Value of Tests | 2009 |
DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gene Dosage; Humans; Irinotecan; Male; Middle Aged; Predictive Value of Tests; Prognosis | 2009 |
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Tolerance; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies | 2009 |
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Failure; Treatment Outcome | 2009 |
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prospective Studies; Radiopharmaceuticals | 2009 |
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Adenosquamous; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; DNA Methylation; DNA Mismatch Repair; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Incidence; Irinotecan; Male; Microsatellite Instability; Middle Aged; MutL Protein Homolog 1; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Prognosis; Promoter Regions, Genetic; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2009 |
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Simvastatin | 2009 |
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate; Tegafur; Tissue Distribution; Treatment Outcome | 2009 |
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Approval; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Treatment Outcome; United States; United States Food and Drug Administration | 2009 |
A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Immunohistochemistry; Irinotecan; Japan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Pyrimidines | 2009 |
Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Survival Rate; Tegafur; Treatment Outcome; Young Adult | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Female; Fluorouracil; Genes, ras; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Young Adult | 2009 |
[Role of sequential chemotherapy in the treatment of metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Predictive Value of Tests; Prognosis; Prospective Studies; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
Topics: Adult; Aged; Alleles; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Colorectal Neoplasms; Female; Glucuronosyltransferase; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasm Metastasis; Organic Anion Transporters; Polymorphism, Genetic; Prospective Studies; Retrospective Studies | 2007 |
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Vomiting | 2009 |
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Cohort Studies; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate; Treatment Outcome | 2009 |
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Pyrazoles; Sulfonamides; Survival Rate | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Survival Analysis; Treatment Outcome | 2009 |
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Young Adult | 2009 |
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2009 |
A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Treatment Outcome | 2009 |
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Humans; Irinotecan; Multivariate Analysis; Radiography; Regression Analysis; Treatment Outcome | 2009 |
A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Feasibility Studies; Female; Humans; Immunoenzyme Techniques; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Survival Rate; Tegafur; Uracil | 2009 |
Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Capecitabine; Cell Cycle Proteins; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Fluorouracil; Humans; Irinotecan; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Transcription Factors; Tumor Suppressor Proteins | 2009 |
Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Time Factors | 2010 |
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Patient Compliance; Treatment Outcome | 2009 |
[Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate | 2009 |
[Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Time Factors | 2009 |
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Camptothecin; Colorectal Neoplasms; Disease Progression; DNA; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Odds Ratio; Organoplatinum Compounds; Proportional Hazards Models; Risk Assessment; Time Factors; Treatment Outcome; United States; White People; Young Adult | 2009 |
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Australia; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Maximum Tolerated Dose; Microspheres; Middle Aged; Radiopharmaceuticals; Radiotherapy, Adjuvant; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; Yttrium Isotopes | 2009 |
Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Colorectal Neoplasms; Complementarity Determining Regions; Female; Fluorouracil; Genes, T-Cell Receptor beta; Hematuria; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Proteinuria; Receptors, Antigen, T-Cell; T-Lymphocyte Subsets; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
A model of primary culture of colorectal cancer and liver metastasis to predict chemosensitivity.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cell Division; Colorectal Neoplasms; Drug Monitoring; Drug Resistance, Neoplasm; HT29 Cells; Humans; Irinotecan; Ki-67 Antigen; Liver Neoplasms; Polyhydroxyethyl Methacrylate; Radiography; Topoisomerase I Inhibitors | 2011 |
Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Catheterization, Central Venous; Colorectal Neoplasms; Disease Progression; Early Diagnosis; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies; Pulmonary Embolism; Risk Factors; Thrombophilia; Ultrasonography, Doppler; Vena Cava, Superior; Venous Thromboembolism; Young Adult | 2010 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival Analysis; Treatment Outcome | 2010 |
Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome | 2010 |
Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2009 |
[Clinical effects of Hange-shashin-to on combination therapy of S-1/irinotecan against the for patients with metastatic gastric and colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Quality of Life; Stomach Neoplasms; Tegafur | 2009 |
A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2010 |
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Glutathione Transferase; Humans; Irinotecan; Leucovorin; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Predictive Value of Tests; Probability; Survival Analysis; Thymidylate Synthase; Time Factors; Treatment Outcome | 2009 |
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Microsatellite Instability; Mutation; MutL Protein Homolog 1; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Precision Medicine; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Humans; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Prospective Studies; Registries; Treatment Outcome | 2009 |
Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Austria; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Germany; Hepatectomy; Humans; Leucovorin; Linear Models; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Odds Ratio; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Risk Assessment; Time Factors; Tomography, Spiral Computed; Treatment Outcome | 2010 |
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Cytokines; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2010 |
Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Floxuridine; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic | 2010 |
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Maximum Tolerated Dose; Middle Aged; Patient Selection; Phenotype; Polymorphism, Genetic; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; O(6)-Methylguanine-DNA Methyltransferase; Purines; Treatment Outcome | 2010 |
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colorectal Neoplasms; Cytochrome P-450 CYP3A; Drug Dosage Calculations; Female; Humans; Individuality; Irinotecan; Male; Midazolam; Middle Aged; Models, Biological; Neoplasm Metastasis; Phenotype; Precision Medicine; Prodrugs | 2010 |
Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2011 |
Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neutropenia; Retrospective Studies; Survival Rate; Thymidylate Synthase; Treatment Outcome | 2011 |
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
Topics: 3' Untranslated Regions; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; Genotype; Humans; Irinotecan; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Salvage Therapy | 2010 |
Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Kidney Failure, Chronic; Leukopenia; Male; Middle Aged; Rectal Neoplasms; Renal Dialysis; Stomach Neoplasms | 2010 |
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Survival Analysis | 2010 |
Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Survival; Vomiting; Young Adult | 2011 |
Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Longitudinal Studies; Male; Middle Aged; Oxonic Acid; Quality of Life; Surveys and Questionnaires; Tegafur; Time Factors; Treatment Outcome | 2010 |
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Decision Making; Disease Progression; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Research Personnel; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2011 |
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Protocols; Colorectal Neoplasms; Disease-Free Survival; Humans; Irinotecan; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2010 |
Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Carriers; Female; Humans; Hyaluronic Acid; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Risk Factors; Survival; Treatment Outcome | 2011 |
Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Confidence Intervals; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Vitamin B Complex | 2010 |
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Disease Progression; Double-Blind Method; Female; Fever; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Odds Ratio; Organoplatinum Compounds; Polyethylene Glycols; Recombinant Proteins; Risk Factors; Young Adult | 2010 |
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Treatment Outcome | 2010 |
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Chronotherapy; ErbB Receptors; Female; Fluorouracil; Gene Amplification; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Eruptions; Female; Humans; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2010 |
[Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Endostatins; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Recombinant Proteins | 2010 |
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2010 |
Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2011 |
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2010 |
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2010 |
A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Survival; Tegafur; Treatment Outcome | 2010 |
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gene Frequency; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Patient Selection; Polymorphism, Genetic; Survival Analysis; Thymidylate Synthase; Treatment Outcome | 2010 |
[Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Rate | 2010 |
Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Camptothecin; Chemoembolization, Therapeutic; Cholangiocarcinoma; Colorectal Neoplasms; Confidence Intervals; Digestive System Diseases; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Female; Follow-Up Studies; Hematologic Diseases; Humans; Hypertension; Irinotecan; Length of Stay; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Registries; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2010 |
Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Iodized Oil; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2010 |
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prodrugs; Tegafur | 2010 |
Treatment of colorectal cancer with and without bevacizumab: a phase III study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Hypertension; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2010 |
Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; Cytokines; Female; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Lymphocyte Culture Test, Mixed; Male; Middle Aged; T-Lymphocytes; Time Factors; Treatment Outcome | 2012 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Panitumumab; Predictive Value of Tests; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2010 |
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Research Design; Time Factors; Treatment Outcome | 2010 |
Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged | 2011 |
[Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Fatty Liver; Female; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Treatment Outcome | 2010 |
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Genetic; Predictive Value of Tests; Survival Rate; Young Adult | 2010 |
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2010 |
Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; France; Humans; Infusions, Intravenous; Intra-Abdominal Fat; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Tegafur | 2010 |
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Levoleucovorin; Male; Middle Aged; Treatment Outcome | 2011 |
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Proportional Hazards Models; Remission Induction; Sample Size; Treatment Outcome | 2011 |
Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prospective Studies; Survival Rate; Treatment Outcome; Tumor Burden | 2010 |
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tegafur; Treatment Failure | 2012 |
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Indoles; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Pyrroles; Sunitinib | 2011 |
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cinnamates; Colorectal Neoplasms; Cyclohexanes; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epoxy Compounds; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Models, Statistical; Oxaloacetates; Republic of Korea; Sesquiterpenes; Survival Analysis; Treatment Failure | 2012 |
Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Neoplasm Metastasis; Survival Rate; Treatment Outcome | 2010 |
Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colorectal Neoplasms; Endostatins; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prognosis; Receptors, Antigen, T-Cell; Recombinant Proteins; Remission Induction | 2011 |
A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Treatment Outcome | 2011 |
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Genetic Predisposition to Disease; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; Severity of Illness Index; Topoisomerase I Inhibitors; Treatment Outcome | 2011 |
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neovascularization, Pathologic; Organoplatinum Compounds; Pharmacogenetics; Thrombospondin 1; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2011 |
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Female; Genetic Linkage; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Salvage Therapy; Treatment Outcome | 2011 |
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2012 |
Unresectable peritoneal carcinomatosis from colorectal cancer: a single center experience.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2011 |
Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Humans; Irinotecan; Neoplasm Metastasis; Survival Rate; Treatment Outcome | 2011 |
The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dipeptides; Drug Resistance, Neoplasm; Humans; Irinotecan | 2012 |
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Survival Rate; Thrombocytopenia | 2012 |
Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Linear Models; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Vitamin B Complex | 2011 |
Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome | 2011 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Research Design; Treatment Outcome | 2011 |
Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome; Young Adult | 2012 |
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Young Adult | 2011 |
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Skin Diseases; Treatment Outcome | 2011 |
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Retrospective Studies; Vitamin B Complex | 2012 |
Neoadjuvant treatment of colorectal liver metastases is associated with altered contrast enhancement on computed tomography.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Radiographic Image Enhancement; Retrospective Studies; Tomography, X-Ray Computed | 2011 |
Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Contrast Media; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Treatment Outcome | 2012 |
Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia | 2012 |
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Obesity; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
[Chemotherapy in patients with non-resectable colorectal cancer metastases to the liver: systemic or regional?].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Recurrence; Splenic Neoplasms; Treatment Outcome | 2011 |
Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cell Count; Colorectal Neoplasms; Deoxycytidine; Endothelial Cells; Endothelium, Vascular; Female; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Proportional Hazards Models; Treatment Outcome; Tumor Burden | 2012 |
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Genotype; Humans; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Polymorphism, Single Nucleotide; Proportional Hazards Models; Vascular Endothelial Growth Factor A | 2012 |
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Real-Time Polymerase Chain Reaction; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drugs, Chinese Herbal; Female; Fluorouracil; Half-Life; Humans; Irinotecan; Leucovorin; Male; Mice; Middle Aged; Phytotherapy | 2011 |
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Leucovorin; Male; Middle Aged; Models, Statistical; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2011 |
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Neoplasm Metastasis; Quality of Life | 2011 |
Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Tegafur; Treatment Outcome | 2012 |
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2011 |
Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Thymidylate Synthase | 2011 |
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Survival Rate; Young Adult | 2011 |
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Panitumumab | 2012 |
Metabolic activation of irinotecan during intra-arterial chemotherapy of metastatic colorectal cancer.
Topics: Aged; Biotransformation; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Humans; Infusions, Intra-Arterial; Irinotecan; Middle Aged; Neoplasm Metastasis; Time Factors | 2011 |
Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Floxuridine; Follow-Up Studies; Hepatectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2011 |
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Polymerase Chain Reaction; Premedication; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Skin Diseases; Survival Rate; Young Adult | 2011 |
Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2012 |
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2011 |
Immunogenicity of panitumumab in combination chemotherapy clinical trials.
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Hypersensitivity; Humans; Incidence; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Severity of Illness Index | 2011 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Peritoneal Neoplasms; Prospective Studies | 2012 |
FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Treatment Failure; Treatment Outcome | 2012 |
Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study.
Topics: Aged; Aged, 80 and over; Arteries; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prospective Studies; Quality of Life; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Codon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome; Withholding Treatment | 2012 |
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Treatment Outcome | 2012 |
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Rate; Treatment Outcome | 2012 |
Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Vitamin B Complex | 2012 |
First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Exanthema; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Treatment Outcome | 2012 |
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2012 |
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Epidermal Growth Factor; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Thymidylate Synthase | 2012 |
Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Prospective Studies | 2012 |
A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies; Survival Analysis; Treatment Outcome | 2012 |
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypertension; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Severity of Illness Index; Tegafur; Treatment Outcome | 2012 |
A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP2A6; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Polymorphism, Genetic; Tegafur; Treatment Outcome | 2012 |
A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Case-Control Studies; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Dendritic Cells; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gemcitabine; Humans; Immunomodulation; Immunotherapy; Interleukin-2; Irinotecan; Killer Cells, Natural; Male; Middle Aged; Recombinant Proteins; T-Lymphocyte Subsets | 2012 |
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Organoplatinum Compounds; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tissue Distribution | 2013 |
Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2013 |
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Prognosis; Retrospective Studies; Signal Transduction; Skin; Treatment Outcome | 2013 |
Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Republic of Korea | 2012 |
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Piperidines; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Osteopontin; Treatment Outcome | 2012 |
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Eruptions; Female; Humans; Irinotecan; Male; Middle Aged | 2012 |
Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged | 2012 |
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Genes, ras; Germany; Humans; Leucovorin; Mutation; Neoplasm Metastasis | 2012 |
The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds | 2012 |
Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Survival Rate; Treatment Outcome | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Randomized Controlled Trials as Topic | 2012 |
Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Radiography, Interventional; Time Factors; Treatment Outcome | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate; Young Adult | 2012 |
Evaluation of predictive markers for patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; C-Reactive Protein; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Linear Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prealbumin; Predictive Value of Tests; Prognosis; Receptors, Albumin; Sensitivity and Specificity; Serum Amyloid A Protein; Sweden; Tissue Inhibitor of Metalloproteinase-1; Tissue Polypeptide Antigen | 2012 |
Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Prospective Studies; Tegafur; Young Adult | 2012 |
Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2012 |
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Mutation; Panitumumab; Quality of Life; Skin; Skin Diseases; Young Adult | 2012 |
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; GTP Phosphohydrolases; Humans; Irinotecan; Male; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Treatment Outcome | 2013 |
Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Colorectal Neoplasms; Disease Progression; Drug Chronotherapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2013 |
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; ras Proteins; Surveys and Questionnaires; Survival Analysis; Young Adult | 2013 |
Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Preoperative Care; Prognosis; Prospective Studies; Survival Rate | 2013 |
A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pilot Projects; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2012 |
A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
Topics: Administration, Intravenous; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2013 |
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; bcl-2-Associated X Protein; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged | 2013 |
Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Carriers; Europe; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Time Factors; Treatment Outcome | 2013 |
Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2013 |
Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome; Tumor Burden | 2013 |
A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2013 |
Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Camptothecin; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Fas Ligand Protein; fas Receptor; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models | 2013 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Quality of Life; Time Factors; Treatment Outcome; Venous Thrombosis | 2013 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Panitumumab; Prospective Studies; ras Proteins; Time Factors; Treatment Outcome | 2013 |
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Double-Blind Method; Female; Fluorouracil; Humans; International Agencies; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Recombinant Fusion Proteins; Salvage Therapy; Survival Rate; Young Adult | 2013 |
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Topics: 3' Untranslated Regions; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genetic Markers; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; Severity of Illness Index | 2013 |
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; In Vitro Techniques; Leucovorin; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Treatment Outcome; Vomiting | 2013 |
Modulation of irinotecan metabolism by ketoconazole.
Topics: Adult; Aged; Antifungal Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Ketoconazole; Leukocyte Count; Leukocytes; Liver; Male; Middle Aged; Mixed Function Oxygenases; Neutrophils; Prodrugs | 2002 |
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Italy; Leucovorin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Quinazolines; Thiophenes; Treatment Outcome | 2002 |
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Palliative Care; Probability; Prognosis; Quinazolines; Severity of Illness Index; Survival Analysis; Thiophenes; Treatment Outcome | 2002 |
Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Probability; Prognosis; Pyridines; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Outcome | 2002 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Folic Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2002 |
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Analysis; Treatment Outcome | 2002 |
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Quinazolines; Thiophenes | 2002 |
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival; Treatment Outcome | 2002 |
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Rate; Treatment Outcome; Vomiting | 2002 |
Efficacy and tolerability of irinotecan in patients with advanced colorectal cancer in Singapore.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome | 2002 |
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Failure | 2002 |
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Mouth Mucosa; Neoplasm Metastasis; Stomatitis; Treatment Outcome | 2002 |
Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Cryosurgery; Disease-Free Survival; Floxuridine; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Neoplasm Recurrence, Local; Prodrugs; Survival Analysis; Tomography, X-Ray Computed; Topoisomerase I Inhibitors; Treatment Outcome | 2001 |
Oxaliplatin combinations as first-line therapy in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Palliative Care; Probability; Pyridines; Survival Analysis; Treatment Outcome | 2002 |
N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Staging; Organoplatinum Compounds; Palliative Care; Pyridines; Survival Analysis | 2002 |
The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.
Topics: Adult; Aged; Camptothecin; Canada; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Linear Models; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Probability; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome | 2002 |
Irinotecan in 5-fluorouracil-refractory colorectal cancer.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2002 |
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Probability; Survival Analysis; Survival Rate; Treatment Outcome | 2002 |
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Risk Assessment; Survival Analysis; Treatment Outcome | 2002 |
Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Pyridines; Survival Analysis; Treatment Outcome | 2002 |
Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Salvage Therapy; Survival Analysis; Treatment Failure | 2002 |
Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Prospective Studies; Quality of Life; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2003 |
Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2003 |
[Cytoreductive surgery of liver metastasis from colorectal cancer: principles of intra-arterial regional chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Female; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2003 |
Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Palliative Care; Survival Analysis; Topoisomerase I Inhibitors; Treatment Failure | 2003 |
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; United States | 2003 |
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin | 2003 |
Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Hydroxyurea; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2003 |
A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2003 |
Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2003 |
A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome | 2003 |
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Odds Ratio; Probability; Risk Assessment; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2003 |
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Risk Assessment; Survival Analysis; Tegafur; Treatment Outcome; United Kingdom; Uracil | 2003 |
Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma.
Topics: Acrylamides; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Injections, Intravenous; Male; Middle Aged; Polymers; Prodrugs | 2003 |
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dexamethasone; Disease-Free Survival; Female; Floxuridine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Middle Aged; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2003 |
Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged | 2003 |
5-fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimens as first line.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Treatment Outcome | 2003 |
Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2003 |
Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neutropenia | 2003 |
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Rectal Neoplasms; Topoisomerase I Inhibitors | 2003 |
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2003 |
Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug Stability; Glucuronates; Humans; Irinotecan; Neoplasm Metastasis; Reproducibility of Results; Saliva; Sensitivity and Specificity; Spectrometry, Fluorescence | 2003 |
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2003 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2004 |
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Spain; Treatment Outcome; Vomiting | 2003 |
Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors; Treatment Outcome | 2004 |
A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Spain; Survival Analysis; Treatment Outcome | 2003 |
Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-Fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Italy; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2003 |
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2004 |
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Tegafur; Treatment Outcome; Uracil | 2004 |
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis | 2003 |
FDA drug approval summaries: oxaliplatin.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Approval; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Random Allocation; Recurrence; United States; United States Food and Drug Administration | 2004 |
Pilot study of low-dose, divided maximum tolerated dose of CPT-11 in 21 consecutive patients with metastatic colorectal or gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Stomach Neoplasms | 2004 |
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Glucuronides; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Patient Selection; Quinazolines; Thiophenes; Vomiting | 2004 |
Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome | 2004 |
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2004 |
Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Folic Acid; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2004 |
Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2004 |
Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2004 |
A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease Progression; Epothilones; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Treatment Failure | 2004 |
Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2004 |
Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2004 |
Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Survival Analysis | 2004 |
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluorouracil; Gene Expression Profiling; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Multivariate Analysis; Prognosis; Thymidylate Synthase; Treatment Outcome | 2004 |
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Humans; Infusion Pumps; Irinotecan; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2004 |
Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gene Expression; Genes, erbB-1; Head and Neck Neoplasms; Humans; Immunoglobulin G; Irinotecan; Lung Neoplasms; Male; Mice | 2004 |
The toxicity rates of two different regimens of irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Topoisomerase I Inhibitors | 2003 |
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life | 2004 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Shock, Septic; Stomatitis; Survival Rate | 2004 |
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Remission Induction; Treatment Outcome | 2004 |
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Exanthema; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Single-Blind Method; Survival Analysis; Topoisomerase I Inhibitors | 2004 |
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Pharmacogenetics; Polymorphism, Genetic; Promoter Regions, Genetic; Survival Analysis; TATA Box | 2004 |
A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Prospective Studies; Thymidylate Synthase | 2004 |
The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Atropine; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Irinotecan; Male; Middle Aged; Muscarinic Antagonists; Neoplasm Metastasis | 2004 |
First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Survival Rate | 2004 |
A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Stomatitis; Survival Analysis; Survival Rate | 2004 |
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome | 2004 |
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2004 |
Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2004 |
Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neutropenia; Prospective Studies; Safety; Time Factors | 2004 |
Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Prognosis; Survival Rate | 2004 |
Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2004 |
Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2004 |
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Quinazolines; Treatment Outcome | 2004 |
Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Charcoal; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2004 |
Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Interactions; Female; Floxuridine; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, fos; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Up-Regulation | 2004 |
Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome | 2004 |
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2004 |
Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Israel; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Time Factors; Treatment Outcome | 2004 |
Bevacizumab for advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Approval; Fluorouracil; Humans; Leucovorin; Treatment Outcome; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factors | 2004 |
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome | 2005 |
Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prospective Studies; Treatment Outcome | 2005 |
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quality of Life; Treatment Outcome | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Selection; Treatment Outcome | 2005 |
Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gene Frequency; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Polymorphism, Genetic; Prognosis; Prospective Studies; Treatment Outcome; UDP-Glucuronosyltransferase 1A9 | 2005 |
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Placebos; Quality of Life; Safety; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Failure | 2005 |
Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Time Factors; Treatment Outcome | 2005 |
Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Transplantation, Heterologous | 2005 |
First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Irinotecan; Male; Middle Aged; Neutropenia; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome; Vomiting | 2005 |
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2005 |
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
Topics: Aged; Amino Acid Sequence; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials as Topic; Cohort Studies; Colorectal Neoplasms; ErbB Receptors; Female; Gene Dosage; Humans; Irinotecan; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Panitumumab | 2005 |
A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cytoprotection; Dose-Response Relationship, Drug; Humans; Irinotecan; Neoplasm Metastasis | 2005 |
Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Tegafur; Uracil | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Diarrhea; Drug Interactions; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome | 2005 |
Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Interactions; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2005 |
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Cyclosporine; Drug Interactions; Female; Humans; Immunosuppressive Agents; Irinotecan; Male; Middle Aged | 2005 |
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Geriatric Assessment; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Invasiveness; Neoplasm Staging; Probability; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2005 |
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Celecoxib; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis | 2005 |
[Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2005 |
[Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronobiology Phenomena; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged | 2005 |
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged | 2005 |
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2005 |
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Caco-2 Cells; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Enzyme Induction; Female; Flavonoids; Glucuronates; Glucuronosyltransferase; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pilot Projects | 2006 |
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.
Topics: Administration, Oral; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Budesonide; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Topoisomerase I Inhibitors; Treatment Outcome | 2005 |
Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Korea; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Salvage Therapy; Survival Rate; Treatment Failure; Treatment Outcome | 2005 |
Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cetuximab; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged | 2005 |
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Glutamine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Survival Analysis | 2005 |
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; CD3 Complex; CD4 Antigens; CD8 Antigens; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Flow Cytometry; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; HLA-A2 Antigen; Humans; Immunodominant Epitopes; Immunotherapy; Interferon-gamma; Interleukin-2; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Oligopeptides; Prospective Studies; T-Lymphocytes; Treatment Outcome | 2005 |
Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2005 |
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Cell Cycle Proteins; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; DNA Mutational Analysis; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Weight Loss | 2005 |
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Lactones; Middle Aged; Neoplasm Metastasis; Sulfones | 2005 |
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thymidylate Synthase | 2006 |
Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Humans; Irinotecan; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2005 |
Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Topics: Adenocarcinoma; Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; DNA Topoisomerases, Type I; Drug Therapy, Combination; Follow-Up Studies; Humans; Irinotecan; Treatment Outcome | 2005 |
Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2005 |
Clinical usefulness of oral granisetron hydrochloride for alleviation of delayed nausea and vomiting induced by CPT-11.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Granisetron; Humans; Irinotecan; Male; Middle Aged; Nausea; Pilot Projects; Vomiting | 2005 |
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Vomiting | 2005 |
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Failure | 2006 |
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis | 2006 |
A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p27; Disease-Free Survival; DNA, Neoplasm; Female; Fluorouracil; Gastrointestinal Diseases; Hepatectomy; Humans; Irinotecan; Life Tables; Liver Neoplasms; Male; Microsatellite Repeats; Middle Aged; Neoplasm Proteins; Neutropenia; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dexamethasone; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Survival Analysis | 2006 |
Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Time Factors; Treatment Outcome | 2005 |
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Leukocytes, Mononuclear; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oligonucleotides, Antisense; Thionucleotides | 2006 |
A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cohort Studies; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Treatment Outcome | 2006 |
Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dietary Supplements; Dose-Response Relationship, Drug; Female; Fluorouracil; Glutamates; Guanine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Time Factors; Treatment Outcome; Vitamins | 2005 |
FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Feasibility Studies; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prospective Studies; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2005 |
Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Products; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds | 2005 |
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2006 |
A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Treatment Outcome | 2006 |
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon-Nitrogen Ligases; Carcinoma; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Predictive Value of Tests; Promoter Regions, Genetic; Quinazolines; Thiophenes; Thymidylate Synthase; Vomiting | 2006 |
Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Analysis; Treatment Failure; Treatment Outcome | 2006 |
Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Treatment Outcome | 2006 |
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Time Factors | 2006 |
Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome | 2006 |
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Survivors; Tegafur; Treatment Outcome | 2006 |
New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Immunohistochemistry; Infusions, Intravenous; Irinotecan; Vascular Endothelial Growth Factor A | 2006 |
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2006 |
Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2006 |
Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides; Treatment Outcome | 2006 |
[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2006 |
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Prospective Studies; Treatment Outcome | 2006 |
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2006 |
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Netherlands; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2006 |
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2006 |
[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Remission Induction; Tegafur | 2006 |
[Combination chemotherapy with S-1 plus CPT-11 for patients with advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Tegafur; Vomiting, Anticipatory | 2006 |
Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival | 2006 |
Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2006 |
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Logistic Models; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2006 |
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Mass Screening; Middle Aged; Neomycin; Placebos; Stomach Neoplasms | 2006 |
Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Biomarkers; Body Composition; Camptothecin; Colorectal Neoplasms; Cytokines; Dietary Proteins; Dietary Supplements; Eicosapentaenoic Acid; Energy Intake; Female; Fluorouracil; Humans; Inflammation; Irinotecan; Leucovorin; Male; Malnutrition; Middle Aged; Nutritional Status; Nutritional Support; Phospholipids; Quality of Life; Treatment Outcome; Vitamin B Complex | 2007 |
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2006 |
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Exanthema; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Treatment Outcome | 2006 |
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2006 |
Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 2007 |
A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2006 |
Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Proliferation; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Feasibility Studies; Female; Fluorouracil; HT29 Cells; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Treatment Outcome | 2007 |
[Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate | 2006 |
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Treatment Outcome | 2006 |
Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2007 |
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines | 2007 |
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Male; Middle Aged; Mutation; Quinazolines | 2007 |
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Humans; Irinotecan; Neoplasm Metastasis; Salvage Therapy; Survival Analysis | 2007 |
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Tegafur; Uracil | 2007 |
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronates; Humans; Intestinal Mucosa; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Mucositis; Neoplasm Transplantation; Neoplasms, Experimental; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides | 2007 |
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Health Status; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Patient Compliance; Quality of Life; Salvage Therapy; Surveys and Questionnaires; Treatment Outcome | 2007 |
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Sample Size; Survival Rate; Treatment Failure | 2007 |
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Failure | 2008 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis | 2008 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Recurrence; Survival Analysis | 2007 |
Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Patient Compliance | 2007 |
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.
Topics: Aged; Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Promoter Regions, Genetic; Treatment Outcome | 2007 |
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Panitumumab; Vitamin B Complex | 2007 |
Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Treatment Outcome | 2007 |
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2007 |
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis | 2007 |
HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Drug Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Tegafur; Treatment Outcome; Uracil | 2007 |
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2007 |
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Survival Rate; Treatment Outcome | 2007 |
A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Floxuridine; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Rate | 2007 |
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Skin Diseases; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Neoplasm Staging; Palliative Care; Prospective Studies; Survival Rate | 2007 |
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Retrospective Studies; Treatment Outcome | 2007 |
Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost of Illness; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2007 |
Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Tegafur; Uracil | 2007 |
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome | 2007 |
[10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Leucovorin; Male; Middle Aged; Neutropenia; Treatment Outcome | 2007 |
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2007 |
Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Capecitabine; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Irinotecan; Liver Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2007 |
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome | 2007 |
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2008 |
Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2007 |
A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Safety | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Survival Rate; Treatment Outcome | 2007 |
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2008 |
Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antidiarrheals; Camptothecin; Cholestyramine Resin; Colorectal Neoplasms; Diarrhea; Female; Humans; Irinotecan; Levofloxacin; Male; Middle Aged; Ofloxacin; Time Factors | 2007 |
Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2007 |
FOLFIRI chemotherapy for metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival; Time Factors; Treatment Outcome | 2007 |
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Vaccines, DNA | 2008 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Diarrhea; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyrazoles; Shock, Septic; Sulfonamides; Survival Analysis | 2008 |
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Thrombospondins; Vascular Endothelial Growth Factor A | 2007 |
Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate | 2008 |
Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis | 2008 |
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with
Topics: Adult; Aged; Aminoquinolines; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organic Chemicals; Proliferating Cell Nuclear Antigen | 2008 |
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Palliative Care; Survival Analysis | 2008 |
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Diarrhea; Disease-Free Survival; Fluorouracil; Hematologic Diseases; Humans; Leucovorin; Myocardial Ischemia; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Patient Compliance; Prospective Studies; Quality of Life; Radiotherapy, Adjuvant; Survival Analysis | 2008 |
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Sulfonamides | 2008 |
Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation.
Topics: Anti-Infective Agents, Local; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis; Skin Diseases | 2008 |
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronotherapy; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxaloacetates; Treatment Failure; Treatment Outcome | 2008 |
Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Rate; Tegafur; Uracil | 2008 |
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Approval; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Survival Rate; United States; United States Food and Drug Administration | 2008 |
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; gamma-Glutamyl Hydrolase; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Polymorphism, Single Nucleotide; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Tandem Repeat Sequences; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Quality of Life | 2008 |
Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Tegafur; Uracil | 2009 |
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Pyrazines; Survival Rate | 2008 |
Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Maximum Allowable Concentration; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Recombinant Proteins; Salivary Gland Neoplasms; Stomach Neoplasms; Topotecan | 1994 |
Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 1994 |
Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Organ Specificity; Vomiting | 1993 |
Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Topotecan | 1995 |
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
Topics: Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Ovarian Neoplasms; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan | 1996 |
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Topics: Adenocarcinoma; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Irinotecan; Loperamide; Salvage Therapy; Survival Analysis; Treatment Outcome | 1996 |
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Humans; Infusion Pumps; Male; Middle Aged; Topotecan | 1996 |
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged | 1996 |
Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged | 1997 |
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged | 1997 |
9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Thrombocytopenia; Treatment Outcome | 1997 |
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Colloids; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Regression Analysis; Salvage Therapy | 1998 |
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Prospective Studies; Thiorphan | 1998 |
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Probability; Quality of Life; Survival Analysis; Treatment Failure | 1998 |
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quality of Life; Survival Rate | 1998 |
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 1998 |
Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin | 1999 |
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Remission Induction | 1999 |
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Vomiting | 1999 |
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Quality of Life; Treatment Outcome | 1999 |
A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prospective Studies; Quality of Life; Survival Analysis; Topoisomerase I Inhibitors | 1999 |
Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Quality of Life; Survival Analysis; Topoisomerase I Inhibitors; Treatment Failure | 1999 |
Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 1999 |
[Irinotecan in the second-line therapy of metastatic colorectal carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Quality of Life; Time Factors | 1999 |
UFT plus calcium folinate/irinotecan in colorectal cancer.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Humans; Irinotecan; Leucovorin; Tegafur; Topoisomerase I Inhibitors; Treatment Outcome; Uracil | 1999 |
Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.
Topics: Adult; Aged; Camptothecin; Cisplatin; Colorectal Neoplasms; Cross-Over Studies; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Middle Aged; Topoisomerase I Inhibitors | 1999 |
Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prognosis; Severity of Illness Index; Survival Rate; Treatment Outcome | 1999 |
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
Topics: Adult; Aged; Animals; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Radioimmunotherapy | 1999 |
Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Rate; Treatment Outcome | 1999 |
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 1999 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Rate | 2000 |
Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Administration Schedule; Female; Fluorouracil; France; Health Care Costs; Hospital Costs; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Salvage Therapy; Sensitivity and Specificity; Survival Analysis | 2000 |
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Severity of Illness Index; Time Factors; Treatment Outcome | 2000 |
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Topics: Adjuvants, Anesthesia; Adult; Aged; Aged, 80 and over; Antidiarrheals; Antiemetics; Antineoplastic Agents, Phytogenic; Area Under Curve; Atropine; Camptothecin; Colorectal Neoplasms; Dexamethasone; Digestive System; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Follow-Up Studies; Gallbladder Neoplasms; Glucuronates; Humans; Irinotecan; Loperamide; Male; Maximum Tolerated Dose; Middle Aged; Time Factors | 2000 |
Colorectal cancer: dilemmas regarding patient selection and toxicity prediction.
Topics: Adult; Antineoplastic Agents, Phytogenic; Blood Proteins; Camptothecin; Colorectal Neoplasms; Creatinine; Diarrhea; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Patient Selection; Risk Factors; Urea | 2000 |
Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Length of Stay; Neoplasm Metastasis; Prospective Studies; Survival Analysis; Time Factors; Treatment Failure | 1999 |
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Topics: Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Neutropenia; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Factors; Thiorphan | 2000 |
Effect of thalidomide on gastrointestinal toxic effects of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Digestive System; Humans; Irinotecan; Pilot Projects; Thalidomide | 2000 |
[Combination chemotherapy with irinotecan hydrochloride plus carboplatin for patients with advanced or recurrent colorectal cancer--a pilot study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Colorectal Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Survival Analysis | 2000 |
Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mouth Mucosa; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Quality of Life; Stomatitis; Survival Analysis | 2000 |
5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2000 |
A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Time Factors | 2000 |
Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2000 |
UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Tegafur; Treatment Outcome; Uracil | 2000 |
UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Tegafur; Uracil | 2000 |
Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Quinazolines; Thiophenes; Treatment Failure | 2000 |
Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Palliative Care; Prognosis; Prospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome | 2000 |
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2001 |
Irinotecan and thalidomide in metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Thalidomide | 2000 |
Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy | 2001 |
Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2001 |
Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life | 2001 |
Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Topics: Actuarial Analysis; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Salvage Therapy; Survival Analysis; Treatment Failure; Treatment Outcome | 2001 |
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2001 |
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 2001 |
Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin | 2001 |
Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Tegafur; Uracil | 2001 |
Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quinazolines; Survival Rate; Thiophenes | 2002 |
Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Remission Induction; Survival Analysis | 2002 |
Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Glucuronates; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Time Factors | 2002 |
Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Treatment Outcome | 2002 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Quinazolines; Salvage Therapy; Secondary Prevention; Thiophenes; Treatment Outcome | 2002 |
Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; California; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery; Disease-Free Survival; Floxuridine; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Multivariate Analysis; Proportional Hazards Models; Survival Rate | 2002 |
Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Eating; Female; Humans; Male; Middle Aged; Neoplasm Metastasis | 2002 |
Chronotherapy of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronotherapy; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rats | 2002 |
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Pilot Projects | 2002 |
Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Patient Compliance; Quality of Life; Survival Analysis | 2002 |
A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Survival Rate; Treatment Outcome | 2002 |
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2002 |
Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Costs and Cost Analysis; England; Fluorouracil; Humans; Irinotecan; Leucovorin | 2002 |
1320 other study(ies) available for camptothecin and Colorectal Cancer
| Article | Year |
|---|---|
7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Hydrolysis; Inhibitory Concentration 50; Irinotecan; Models, Chemical; Rhodamines; Structure-Activity Relationship; Topotecan | 2009 |
Tumor Vascular Microenvironment of Colorectal Hepatic Metastasis and Chemotherapy Response.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Computed Tomography Angiography; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Survival Analysis; Treatment Outcome; Tumor Microenvironment | 2021 |
Therapeutic efficacy and gastrointestinal biodistribution of polycationic nanoparticles for oral camptothecin delivery in early and late-stage colorectal tumor-bearing animal model.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Colorectal Neoplasms; Cyclodextrins; Drug Delivery Systems; Gastrointestinal Tract; Mice; Models, Animal; Nanoparticles; Neoplasm Metastasis; Polyelectrolytes; Tissue Distribution; Treatment Outcome | 2021 |
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Progression-Free Survival; Pyrimidines; Retrospective Studies; Time Factors | 2021 |
A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins | 2022 |
[A case of pembrolizumab responding to recurrent small bowel mucinous adenocarcinoma with Peutz-Jeghers syndrome].
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Recurrence, Local; Peutz-Jeghers Syndrome | 2021 |
Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2022 |
Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Humans; Saudi Arabia | 2022 |
Treatment of HT29 Human Colorectal Cancer Cell Line with Nanocarrier-Encapsulated Camptothecin Reveals Histone Modifier Genes in the
Topics: Camptothecin; Colorectal Neoplasms; Genes, Neoplasm; Histones; HT29 Cells; Humans; Nanocapsules; Neoplasm Proteins; Wnt Signaling Pathway | 2021 |
p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Atlases as Topic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Crk-Associated Substrate Protein; Epiregulin; Epithelial-Mesenchymal Transition; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Leucovorin; Male; Middle Aged; Molecular Sequence Annotation; Mutation; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins B-raf; RNA, Small Interfering; Signal Transduction; Survival Analysis | 2021 |
Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Treatment Outcome; Young Adult | 2021 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Prospective Studies; Rectal Neoplasms | 2022 |
Assessment of Drug-drug Interaction and Optimization in Capecitabine and Irinotecan Combination Regimen using a Physiologically Based Pharmacokinetic Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboxylesterase; Colorectal Neoplasms; Drug Interactions; Fluorouracil; Irinotecan; Rats | 2022 |
Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Pyridines; Rectal Neoplasms | 2022 |
[A Long-Survival Case of Lower Rectal Cancer with Unresectable Liver Metastases Treated with FOLFOXIRI plus Bevacizumab(BEV)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Neoplasm Recurrence, Local; Organoplatinum Compounds; Rectal Neoplasms | 2021 |
Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2022 |
[Prognostic factors affecting the success of conversion chemotherapy in patients with unresectable liver metastases from initially colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Prognosis; Retrospective Studies | 2022 |
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Comorbidity; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms; Treatment Outcome | 2022 |
Comparison of
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Retrospective Studies | 2022 |
Delayed Diagnosis of Clostridium difficile Colitis in a 48-Year-Old Woman with a Homozygous Mutation of the UGT1A1 Gene While on Chemotherapy for Colorectal Carcinoma.
Topics: Camptothecin; Clostridioides difficile; Colitis; Colorectal Neoplasms; Delayed Diagnosis; Diarrhea; Female; Glucuronosyltransferase; Humans; Middle Aged; Mutation | 2022 |
A silica-based antioxidant nanoparticle for oral delivery of Camptothecin which reduces intestinal side effects while improving drug efficacy for colon cancer treatment.
Topics: Animals; Antioxidants; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Endothelial Cells; Mice; Nanoparticles; Reactive Oxygen Species; Silicon Dioxide | 2022 |
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms | 2022 |
Cases in the management of metastatic colorectal cancer: regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Mutation; Organoplatinum Compounds; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Pyridines | 2021 |
Camptothecin, triptolide, and apoptosis inducer kit have differential effects on mitochondria in colorectal carcinoma cells.
Topics: Apoptosis; Camptothecin; Colorectal Neoplasms; Diterpenes; Epoxy Compounds; Humans; Mitochondria; Phenanthrenes | 2022 |
Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Oxaliplatin; Rectal Neoplasms; Republic of Korea | 2023 |
Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Data Analysis; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2022 |
Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms; Retrospective Studies | 2022 |
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Rectal Neoplasms | 2022 |
Another Signal from DEBIRI.
Topics: Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Humans; Liver Neoplasms | 2022 |
Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms; Retrospective Studies | 2022 |
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Interferons; Leucovorin; Membrane Proteins; Nucleotidyltransferases; Rectal Neoplasms | 2022 |
[Comparative Safety Assessment of Ramucirumab plus FOLFIRI and Bevacizumab plus FOLFIRI in Second- and Later-Line Treatment in Japanese Patients with Metastatic Colorectal Carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Japan; Leucovorin; Neoplasm Metastasis; Ramucirumab | 2022 |
Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis | 2022 |
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Proto-Oncogene Proteins B-raf; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2022 |
Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies | 2022 |
Oral delivery of camptothecin-loaded multifunctional chitosan-based micelles is effective in reduce colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Chitosan; Colorectal Neoplasms; Drug Carriers; Humans; Micelles; Oleic Acid | 2022 |
Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Diseases, Metabolic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neutropenia; Organoplatinum Compounds; Retrospective Studies | 2022 |
Provider imaging practices and outcomes of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Oxaliplatin | 2022 |
Real-world overall survival of patients receiving cetuximab in later lines of treatment for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Rectal Neoplasms; Retrospective Studies | 2022 |
De novo engineering of both an omega-3 fatty acid-derived nanocarrier host and a prodrug guest to potentiate drug efficacy against colorectal malignancies.
Topics: Animals; Camptothecin; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Fatty Acids, Omega-3; Mice; Nanoparticles; Polyethylene Glycols; Prodrugs | 2022 |
Managing life-threatening 5-fluorouracil cardiotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Camptothecin; Cardiotoxicity; Cardiotoxins; Colorectal Neoplasms; Coronary Vasospasm; Diltiazem; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Nitrates | 2022 |
Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; East Asian People; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Product Surveillance, Postmarketing; Receptors, Vascular Endothelial Growth Factor; Rectal Neoplasms | 2023 |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neutropenia; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Rectal Neoplasms | 2023 |
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; G2 Phase Cell Cycle Checkpoints; Humans; Irinotecan | 2022 |
Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival times.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin | 2022 |
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials.
Topics: Bevacizumab; Bone Neoplasms; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Prognosis; Quality of Life | 2022 |
5-fluorouracil with oxaliplatin and/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Anti-tumor effects of P-LPK-CPT, a peptide-camptothecin conjugate, in colorectal cancer.
Topics: Amino Acid Transport System ASC; Camptothecin; Colorectal Neoplasms; Glutamine; Humans; Minor Histocompatibility Antigens; Molecular Docking Simulation; Peptides | 2022 |
Synthesis and biological evaluation of novel SN38-glucose conjugate for colorectal cancer treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Delivery Systems; Humans; Irinotecan | 2023 |
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circulating MicroRNA; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; MicroRNAs; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms | 2023 |
Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Hypertension; Leucovorin; Middle Aged; Neoplasm Metastasis; Recombinant Fusion Proteins; Rectal Neoplasms; Retrospective Studies | 2023 |
[Cases of Advanced Colorectal Cancer with Nephrotic Syndrome after FOLFIRI plus Ramucirumab Administration].
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Nephrotic Syndrome; Proteinuria; Ramucirumab; Sigmoid Neoplasms | 2022 |
[FOLFIRI plus RAM Therapy in Later Line of Unresectable Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Retrospective Studies | 2023 |
Drug-eluting beads loaded with irinotecan to treat synchronous liver-only metastases of colorectal cancer non-responsive to bevacizumab-based chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Treatment Outcome | 2023 |
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Mice; Xenograft Model Antitumor Assays | 2023 |
Synergistic and Antagonistic Antiproliferative Effects of Ribociclib (Lee011) and Irinotecan (SN38) on Colorectal Cancer Cells.
Topics: Apoptosis; Camptothecin; Caspase 8; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Humans; Irinotecan | 2023 |
[Educational Project of Self-Removal of the Intravenous Central Venous Access Port Guided by Patients with Advanced Colorectal Cancer Instructed by a Nurse in the University Hospital].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization, Central Venous; Colorectal Neoplasms; Fluorouracil; Hospitals; Humans; Leucovorin; Retrospective Studies | 2023 |
Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Incidence; Leucovorin; Proteinuria; Ramucirumab; Rectal Neoplasms | 2023 |
Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Radiation-Sensitizing Agents; Treatment Outcome | 2023 |
Design, Synthesis, and Evaluation of Glucose Transporter Inhibitor-SN38 Conjugates for Targeting Colorectal Cancer.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Irinotecan; Mice; Prodrugs; Tissue Distribution; Tumor Microenvironment | 2023 |
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Neoplasm Metastasis; Prognosis; Rectal Neoplasms; Retrospective Studies; Vascular Endothelial Growth Factor A | 2023 |
Prognostic Value of TACE With Irinotecan-loaded Drug-eluting Beads (DEBIRI) in Patients With Liver Metastases from Unresectable Colorectal Cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Male; Prognosis; Topoisomerase I Inhibitors; Treatment Outcome | 2023 |
Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Indonesia; Leucovorin; Oxaliplatin; Rectal Neoplasms | 2023 |
Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Prospective Studies; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms | 2023 |
Caffeine enhances chemosensitivity to irinotecan in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Caffeine; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; DNA; Humans; Irinotecan | 2023 |
FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome | 2023 |
Laparoscopic versus open two-stage hepatectomy for bilobar colorectal liver metastases: A bi-institutional, propensity score-matched study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Hepatectomy; Humans; Kaplan-Meier Estimate; Laparoscopy; Length of Stay; Leucovorin; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Postoperative Complications; Propensity Score; Retrospective Studies | 2019 |
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Broadly Neutralizing Antibodies; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Immunoconjugates; Mice; Receptor, ErbB-3; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cell-Free Nucleic Acids; Circulating Tumor DNA; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Progression-Free Survival; Treatment Outcome | 2019 |
Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Topics: Aged; Alternative Splicing; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Prognosis; Prospective Studies; Protein Isoforms; Retrospective Studies; Survival Rate; Vascular Endothelial Growth Factor A | 2019 |
Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Germ Cells; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Ribosomal Proteins; Survival Rate; Tumor Cells, Cultured | 2019 |
Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Conversion to Open Surgery; Female; Fluorouracil; Hepatectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Treatment Outcome; Tumor Burden | 2019 |
[A Case Altered Consciousness Due to 5-Fluorouracil-Induced Hyperammonemia in a Patient with Recurrent Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Consciousness; Fluorouracil; Humans; Hyperammonemia; Leucovorin; Male; Neoplasm Recurrence, Local | 2019 |
Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Progression-Free Survival; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies | 2020 |
Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Hypertension; Leucovorin; Neoplasm Metastasis; Prognosis; Ramucirumab; Randomized Controlled Trials as Topic; Survival Rate; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies | 2020 |
Cost-effectiveness analysis of selective first-line use of biologics for unresectable
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Products; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Protein Kinase Inhibitors; ras Proteins | 2019 |
FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
Topics: Animals; Apoptosis; Autoantigens; Benzodioxoles; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; China; Colorectal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colorectal Neoplasms; Fluorouracil; Green Fluorescent Proteins; Humans; Leucovorin; Mice; Mice, Nude; Mice, Transgenic; Random Allocation; Trabectedin; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Consensus; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Humans; Leucovorin; Male; Middle Aged; Models, Biological; Molecular Targeted Therapy; Patient Selection; Progression-Free Survival; Randomized Controlled Trials as Topic; Tumor Microenvironment | 2019 |
A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Canada; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Proto-Oncogene Proteins p21(ras); Young Adult | 2019 |
Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.
Topics: Adenomatous Polyposis Coli Protein; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell-Free Nucleic Acids; Circulating Tumor DNA; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liquid Biopsy; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Remission Induction; Tumor Suppressor Protein p53 | 2020 |
Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; China; Colorectal Neoplasms; Cost-Benefit Analysis; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Panitumumab; Quality-Adjusted Life Years | 2020 |
EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
Topics: Acneiform Eruptions; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Image; Camptothecin; Cetuximab; Colorectal Neoplasms; Cross-Sectional Studies; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Paronychia; Protein Kinase Inhibitors; Pruritus; Quality of Life; Skin Diseases; Surveys and Questionnaires | 2020 |
Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; United Kingdom; Uracil | 2020 |
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Multivariate Analysis; Prognosis; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Analysis | 2020 |
Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; China; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2020 |
Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Panitumumab; Progression-Free Survival; Retrospective Studies | 2020 |
Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; DNA Mismatch Repair; Drug Resistance, Neoplasm; Female; Fluorouracil; Hepatectomy; Humans; Immune Checkpoint Inhibitors; Leucovorin; Liver Neoplasms; Microsatellite Instability; Neoadjuvant Therapy; Nivolumab; Organoplatinum Compounds; Treatment Outcome | 2020 |
[A Case of Nephrotic Syndrome Induced by FOLFIRI plus Ramucirumab for Metastatic Descending Colon Cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colon, Descending; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Nephrotic Syndrome; Ramucirumab | 2019 |
[Experience of Using Aflibercept Beta and FOLFIRI Chemotherapy for Metastatic Colorectal Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Vascular Endothelial Growth Factor A | 2019 |
FOLFOXIRI reintroduction in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds | 2020 |
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; China; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Polymorphism, Genetic; Precision Medicine; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2020 |
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Genotyping Techniques; Humans; Intercellular Signaling Peptides and Proteins; Leucovorin; Male; Middle Aged; Mutation; Patient Selection; Polymorphism, Single Nucleotide; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic | 2020 |
Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2020 |
Hepatic metastases resection after cetuximab: are we missing something?
Topics: Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Liver Neoplasms | 2020 |
Cyclodextrin nanoparticle bound oral camptothecin for colorectal cancer: Formulation development and optimization.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Camptothecin; Cell Line; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Drug Carriers; Drug Compounding; Drug Liberation; Humans; Mice; Mucus; Nanoparticles | 2020 |
Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy.
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; HLA-G Antigens; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Models, Molecular; Protein Binding; Protein Conformation; Protein Isoforms; Solubility; Spectrometry, Fluorescence | 2020 |
Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Proto-Oncogene Proteins B-raf; Skin Neoplasms | 2020 |
TRIBE2 results and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds | 2020 |
TRIBE2 results and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds | 2020 |
2020 ASCO Annual Meeting.
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cholangiocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Female; Humans; Immunoconjugates; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Societies, Medical; Trastuzumab; Urinary Bladder Neoplasms | 2020 |
[Three Cases of Augmented Chemotherapy-Induced Peripheral Neuropathy after Changing from mFOLFOX6 to FOLFIRI Therapy in Patients with Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Peripheral Nervous System Diseases | 2020 |
Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Sectional Studies; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrimidines | 2020 |
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Time Factors; Treatment Outcome; Tumor Microenvironment | 2020 |
Impact of preoperative chemotherapy on the histological response of patients with peritoneal metastases from colorectal cancer according to peritoneal regression grading score (PRGS) and TRG.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Fluorouracil; Humans; Hyperthermic Intraperitoneal Chemotherapy; Leucovorin; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Peritoneal Neoplasms; Proportional Hazards Models | 2020 |
Effects of postoperative adjuvant chemotherapy and palliative chemotherapy on the gut microbiome in colorectal cancer.
Topics: Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Gastrointestinal Microbiome; Humans; Leucovorin | 2020 |
Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Leucovorin; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Positron Emission Tomography Computed Tomography; Proto-Oncogene Proteins B-raf; Treatment Outcome | 2020 |
FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Decision-Making; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Metastasectomy; Middle Aged; Organoplatinum Compounds; Patient Selection; Prognosis; Progression-Free Survival; Retrospective Studies; Survival Rate; Young Adult | 2020 |
Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Portal Vein; Pyrazoles; Pyridones; Rectal Neoplasms | 2021 |
Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colitis-Associated Neoplasms; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Progression-Free Survival; Prospective Studies; Retrospective Studies | 2020 |
Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Male; Middle Aged; Oxaliplatin | 2020 |
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Disease Progression; DNA Mutational Analysis; Drug Combinations; Fluorouracil; Humans; Leucovorin; Liquid Biopsy; Male; Middle Aged; Mutation; Phenylurea Compounds; Pyridines; Pyrrolidines; ras Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thymine; Trifluridine | 2020 |
Extrahepatic recurrence rates in patients receiving adjuvant hepatic artery infusion and systemic chemotherapy after complete resection of colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatic Artery; Humans; Incidence; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; United States | 2020 |
The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Repair; Humans; MRE11 Homologue Protein; Topoisomerase I Inhibitors; Triazoles | 2021 |
Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; China; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Quality-Adjusted Life Years | 2020 |
Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Postmenopause; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2020 |
Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; DNA Repair; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Treatment Outcome | 2021 |
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Panitumumab; Propensity Score; Proto-Oncogene Proteins B-raf; Quality of Life | 2021 |
Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Prognosis; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Survival Rate; Vascular Endothelial Growth Factor A | 2021 |
The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Panitumumab; Proto-Oncogene Proteins p21(ras); Survival Analysis | 2021 |
Modulation of Immune Checkpoints by Chemotherapy in Human Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Hepatitis A Virus Cellular Receptor 2; Humans; Irinotecan; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Programmed Cell Death 1 Receptor; Tumor Microenvironment | 2020 |
Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retreatment; Treatment Outcome | 2021 |
Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Phenylurea Compounds; Pyridines | 2020 |
In Reply: Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Phenylurea Compounds; Pyridines | 2020 |
FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS/BRAF Wild-Type Colorectal Cancer: Which "Side" Are You On?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Panitumumab; Proto-Oncogene Proteins B-raf | 2021 |
Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Databases, Factual; Female; Fluorouracil; Humans; Japan; Leucovorin; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Time Factors; Treatment Outcome | 2021 |
Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Delivery Systems; Esterases; Irinotecan; Nanoparticles; Prodrugs | 2021 |
Self-assembly delivery system based on small-molecule camptothecin prodrug for treatment of colorectal carcinoma.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Delivery Systems; Humans; Mice; Nanoparticles; Prodrugs | 2021 |
Conversion therapy in patients with colorectal liver metastases.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Logistic Models; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Retrospective Studies | 2021 |
Repurposing of camptothecin: An esterase-activatable prodrug delivered by a self-emulsifying formulation that improves efficacy in colorectal cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Repositioning; Esterases; Mice; Prodrugs | 2021 |
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Consensus; Fluorouracil; Humans; Leucovorin; Prognosis | 2021 |
Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Calcium; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Sodium | 2021 |
Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Saskatchewan | 2022 |
Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Retrospective Studies | 2021 |
Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer.
Topics: Biomarkers; Camptothecin; Colorectal Neoplasms; Humans; Immunoconjugates; Trastuzumab | 2021 |
Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2021 |
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prognosis | 2021 |
[Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplasms; Consensus; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2021 |
Optimal Allocation of Chemotherapy Schemes for Metastatic Colon Cancer in Colombia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colombia; Colonic Neoplasms; Colorectal Neoplasms; Humans | 2021 |
Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Indonesia; Leucovorin; Markov Chains; Neoplasm Metastasis; Organoplatinum Compounds; Quality-Adjusted Life Years | 2021 |
[Establishment of a Needle-Removal Method Considering Anticancer Drug Exposure after Continuous Administration of Fluorouracil Using an Infusion Pump].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Infusion Pumps; Japan; Leucovorin; Organoplatinum Compounds | 2021 |
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Treatment Outcome | 2021 |
Antitumor Mechanism of Hydroxycamptothecin via the Metabolic Perturbation of Ribonucleotide and Deoxyribonucleotide in Human Colorectal Carcinoma Cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Survival; Colorectal Neoplasms; DNA; DNA Damage; HCT116 Cells; Humans; Irinotecan; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Ribonucleotides | 2021 |
Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity | 2017 |
Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug Monitoring; Glucuronides; Humans; Irinotecan; Precision Medicine; Reproducibility of Results; Tandem Mass Spectrometry | 2018 |
Bacterial Metabolism Affects the C. elegans Response to Cancer Chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Caenorhabditis elegans; Camptothecin; Colorectal Neoplasms; Comamonas; Deoxyuridine; Diet; Escherichia coli; Fluorouracil; Gastrointestinal Microbiome; Humans; Models, Animal; Pyrimidine Nucleosides | 2017 |
Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Azacitidine; Caco-2 Cells; Camptothecin; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; DNA Methylation; DNA Repair; Gene Expression; Gene Expression Profiling; HCT116 Cells; Humans; Irinotecan; Long Interspersed Nucleotide Elements; Mice; Mice, Inbred NOD; Mice, SCID | 2017 |
MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells.
Topics: Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; HEK293 Cells; HT29 Cells; Humans; Irinotecan; Lentivirus; Leukocytes, Mononuclear; MicroRNAs; T-Lymphocytes, Regulatory; Transfection | 2017 |
Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Genetic Predisposition to Disease; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide | 2017 |
The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Hypoxia; Cell Survival; Colorectal Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Screening Assays, Antitumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Glycogen Synthase Kinase 3 beta; HT29 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inhibitory Concentration 50; Irinotecan; MAP Kinase Signaling System; Piperazines; Protein Stability; Proto-Oncogene Proteins c-akt; Pyridines | 2017 |
An evolving function of DNA-containing exosomes in chemotherapy-induced immune response.
Topics: Animals; Camptothecin; Colorectal Neoplasms; Diarrhea; DNA; Exosomes; Humans; Irinotecan; Models, Biological | 2017 |
Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Predictive Value of Tests; Randomized Controlled Trials as Topic; RNA, Messenger; Toll-Like Receptor 7 | 2017 |
[Chemotherapy for colorectal cancer: Pragmatic assessment of prescription changes and relative dose intensity].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Substitution; Female; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2017 |
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Methylation; DNA Mutational Analysis; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gene Dosage; Genes, erbB-1; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf; Retreatment; Retrospective Studies; Survival Rate | 2017 |
Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Models, Biological; Molecular Structure | 2017 |
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Topics: Adult; Aged; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged | 2017 |
Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; HSP27 Heat-Shock Proteins; Humans; Irinotecan; Janus Kinase 2; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Signal Transduction; STAT3 Transcription Factor; Tyrphostins | 2017 |
Interstitial lung disease following FOLFOX + FOLFIRI and bevacizumab therapy associated with leucovorin: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Lung Diseases, Interstitial; Male; Neutropenia; Organoplatinum Compounds; Tomography, X-Ray Computed | 2018 |
Photothermal, Targeting, Theranostic Near-Infrared Nanoagent with SN38 against Colorectal Cancer for Chemothermal Therapy.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Humans; Indoles; Irinotecan; Nanoparticles; Phototherapy; Theranostic Nanomedicine | 2017 |
Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clarithromycin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies | 2017 |
Preoperative bevacizumab and volumetric recovery after resection of colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Liver Regeneration; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2017 |
Irinotecan-induced muscle twitching from a possible drug interaction: A case report.
Topics: Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP3A; Drug Interactions; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Spasm | 2018 |
Small-molecule CB002 restores p53 pathway signaling and represses colorectal cancer cell growth.
Topics: Aniline Compounds; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Fluorouracil; Humans; Purines; Signal Transduction; Tumor Protein p73; Tumor Suppressor Protein p53 | 2017 |
Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer.
Topics: Camptothecin; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Genes, Neoplasm; HCT116 Cells; Humans; Irinotecan; Kaplan-Meier Estimate; MAP Kinase Signaling System; Protein Interaction Maps; Signal Transduction; Up-Regulation | 2017 |
Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fasciitis, Necrotizing; Fatal Outcome; Fluorouracil; Fournier Gangrene; Humans; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2017 |
Therapeutic response assessment using 3D ultrasound for hepatic metastasis from colorectal cancer: Application of a personalized, 3D-printed tumor model using CT images.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Imaging, Three-Dimensional; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome; Tumor Burden; Ultrasonography | 2017 |
TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.
Topics: Arabinonucleosides; BRCA2 Protein; Camptothecin; Colorectal Neoplasms; Cytarabine; Cytosine; DNA Breaks, Single-Stranded; DNA Damage; DNA Repair; DNA Replication; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Phosphoric Diester Hydrolases; Poly (ADP-Ribose) Polymerase-1 | 2017 |
Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Mice, Inbred NOD; Mice, SCID; Organoplatinum Compounds; Oxaliplatin; Xenograft Model Antitumor Assays; Zebrafish | 2017 |
Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Malnutrition; Middle Aged; Nutritional Status; Organoplatinum Compounds; Prognosis; Serum Albumin; Treatment Outcome | 2017 |
FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Treatment Outcome | 2017 |
Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Retreatment; Retrospective Studies; Treatment Outcome | 2018 |
Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prognosis; Treatment Outcome | 2017 |
Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Health Services Accessibility; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Registries; Retrospective Studies; Saskatchewan; Survival Rate; Travel | 2017 |
First-line treatment in metastatic colorectal cancer: Important or crucial?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Organoplatinum Compounds | 2017 |
Impressive Suppression of Colon Cancer Growth by Triple Combination SN38/EF24/Melatonin: "Oncogenic"
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylidene Compounds; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Hydrogen Peroxide; Irinotecan; Magnetic Resonance Imaging; Male; Melatonin; Mice, Inbred BALB C; Mice, Nude; Oncogenes; Oxidative Stress; Piperidones; Reactive Oxygen Species; Signal Transduction; Superoxides; Time Factors; Tumor Burden | 2017 |
How to Assess Drug Resistance in Cancer Stem Cells.
Topics: Animals; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplastic Stem Cells | 2018 |
Estimation of the future remnant liver function is a better tool to predict post-hepatectomy liver failure than platelet-based liver scores.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Glycine; Hepatectomy; Humans; Imino Acids; Irinotecan; Liver Failure; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Organotechnetium Compounds; Oxaliplatin; Platelet Function Tests; Predictive Value of Tests; Radiopharmaceuticals; Treatment Outcome | 2017 |
Early small bowel perforation due to aflibercept.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Intestinal Perforation; Intestine, Small; Leucovorin; Liver Neoplasms; Middle Aged; Pancreaticoduodenectomy; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2017 |
Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Organoplatinum Compounds; Panitumumab; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor, ErbB-2; Receptor, ErbB-3; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Wnt Signaling Pathway | 2017 |
Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Proto-Oncogene Proteins B-raf; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Panitumumab; Retreatment; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Panitumumab; Prognosis; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Retrospective Studies; Treatment Outcome | 2018 |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Nucleus; Cell Survival; Cetuximab; Colorectal Neoplasms; Curcumin; Dasatinib; Drug Resistance, Neoplasm; Fatty Acids, Unsaturated; Female; Fluorouracil; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Leucovorin; Male; Middle Aged; Molecular Chaperones; Molecular Targeted Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Protein Inhibitors of Activated STAT; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib | 2017 |
Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Leucovorin; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2017 |
Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Intra-Abdominal Fat; Leucovorin; Male; Middle Aged; Obesity; Organoplatinum Compounds; Retrospective Studies; Young Adult | 2018 |
The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
Topics: Caco-2 Cells; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genotype; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Methylenetetrahydrofolate Reductase (NADPH2); Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Thymidylate Synthase | 2017 |
Silencing Artemis Enhances Colorectal Cancer Cell Sensitivity to DNA-Damaging Agents.
Topics: Bleomycin; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; DNA End-Joining Repair; DNA-Binding Proteins; Endonucleases; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Nuclear Proteins; Radiation Tolerance; Radiation, Ionizing; Treatment Outcome | 2018 |
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Cost-Benefit Analysis; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Models, Economic; Organoplatinum Compounds; Panitumumab; Proto-Oncogene Proteins p21(ras); Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis | 2018 |
Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer.
Topics: Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2018 |
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; GTP Phosphohydrolases; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Mutation; Neoplasm Metastasis; Panitumumab; Prognosis; Proto-Oncogene Proteins p21(ras); Survival Rate | 2018 |
Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cohort Studies; Colectomy; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Margins of Excision; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Radiotherapy; Response Evaluation Criteria in Solid Tumors; Survival Rate; Treatment Outcome | 2018 |
Correlation between CT morphologic appearance and histologic findings in colorectal liver metastasis after preoperative chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Contrast Media; Female; Fluorouracil; Humans; Iohexol; Iopamidol; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Preoperative Care; Tomography, X-Ray Computed | 2018 |
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
Topics: Activin Receptors, Type II; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colon; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Italy; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Progression-Free Survival; Prospective Studies; RNA, Messenger | 2018 |
Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture.
Topics: Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Hedgehog Proteins; Humans; Hyaluronan Receptors; Irinotecan; Neoplastic Stem Cells; Organoids; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins c-myc; Pyridines; Pyrimidines; trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride; Zinc Finger Protein GLI1 | 2018 |
Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Palliative Care; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2018 |
Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Ethiodized Oil; Female; Gemcitabine; Humans; Hyperthermia, Induced; Irinotecan; Laser Therapy; Liver Neoplasms; Male; Microwaves; Middle Aged; Mitomycin; Neoadjuvant Therapy; Palliative Care; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2018 |
How should BRAF V600E-mutated colorectal cancer be treated?
Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Survival Analysis | 2018 |
Ultrasound Triggered Conversion of Porphyrin/Camptothecin-Fluoroxyuridine Triad Microbubbles into Nanoparticles Overcomes Multidrug Resistance in Colorectal Cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HT29 Cells; Humans; Microbubbles; Nanoparticles; Optical Imaging; Particle Size; Photosensitizing Agents; Porphyrins; Surface Properties; Ultrasonography | 2018 |
Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Genetic Markers; Genetic Testing; Health Care Costs; Humans; Leucovorin; Precision Medicine; Quality-Adjusted Life Years; Treatment Outcome | 2018 |
Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Datasets as Topic; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Progression-Free Survival; Registries | 2018 |
Potential therapeutic targets for growth arrest of colorectal cancer cells exposed to PTHrP.
Topics: Animals; Apoptosis; Caco-2 Cells; Camptothecin; Carcinogenesis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclin D1; Drug Resistance, Neoplasm; HCT116 Cells; Humans; MAP Kinase Signaling System; Mice, Nude; Models, Biological; Molecular Targeted Therapy; Parathyroid Hormone-Related Protein; Phosphorylation; Protein Kinase C-alpha; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2018 |
A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo.
Topics: A549 Cells; ADAM17 Protein; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Fluorouracil; HeLa Cells; Hep G2 Cells; Humans; Irinotecan; MCF-7 Cells; Receptors, Notch; Signal Transduction | 2018 |
Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; DNA Damage; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Irinotecan; Proto-Oncogene Proteins pp60(c-src); Radiation-Sensitizing Agents; Signal Transduction; Tumor Suppressor Protein p53 | 2018 |
A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Febrile Neutropenia; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Leucovorin; Leukopenia; Male; Middle Aged; Organoplatinum Compounds; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2019 |
Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
Topics: Aminopyridines; Animals; Benzimidazoles; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; HT29 Cells; Humans; Irinotecan; MAP Kinase Kinase 1; Mice; Molecular Targeted Therapy; Morpholines; Protein Kinase Inhibitors; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo.
Topics: Animals; Apoptosis; Binding Sites; Camptothecin; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Computer-Aided Design; DNA Topoisomerases, Type I; Drug Design; Female; HCT116 Cells; HT29 Cells; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Molecular Structure; Protein Binding; Structure-Activity Relationship; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2018 |
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; ras Proteins | 2018 |
Chemoembolization in Conjunction with Bevacizumab: Preliminary Results.
Topics: Administration, Intravenous; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Humans; Irinotecan; Italy; Liver Neoplasms; Male; Middle Aged; Preliminary Data; Prospective Studies; Quality of Life; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
A novel microfluidic liposomal formulation for the delivery of the SN-38 camptothecin: characterization and in vitro assessment of its cytotoxic effect on two tumor cell lines.
Topics: Caco-2 Cells; Camptothecin; Cell Cycle; Cell Death; Cell Survival; Chemistry, Pharmaceutical; Colorectal Neoplasms; Flow Cytometry; Freeze Drying; HeLa Cells; Humans; Irinotecan; L-Lactate Dehydrogenase; Liposomes; Microfluidics; Suspensions; Topoisomerase I Inhibitors | 2018 |
[Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Panitumumab; Retrospective Studies; Stomatitis | 2018 |
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; GPI-Linked Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Receptors, Purinergic P1; Survival Rate | 2019 |
A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Irinotecan; Lactams, Macrocyclic; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A | 2019 |
Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Metastasis; Prospective Studies; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2018 |
Laparoscopic repair of bevacizumab-induced vesicovaginal fistula in metastatic colon cancer - a video vignette.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cecal Neoplasms; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Hysterectomy; Laparoscopy; Leucovorin; Middle Aged; Peritoneal Neoplasms; Salpingo-oophorectomy; Vesicovaginal Fistula | 2019 |
Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colorectal Neoplasms; Cornea; Dry Eye Syndromes; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies; Protein Kinase Inhibitors | 2018 |
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Progression-Free Survival; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Time Factors; Up-Regulation | 2019 |
[The inhibition of angiogenic pathway in second line treatment of metastatic colorectal cancer.]
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2018 |
Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Glucuronates; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Organoplatinum Compounds | 2019 |
Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplasms; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genotyping Techniques; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Neutropenia | 2019 |
Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Differentiation; Colon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Macrophages; Middle Aged; Neuroendocrine Cells; Oxaliplatin; Prognosis; Progression-Free Survival; Prospective Studies; Rectum | 2019 |
Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Europe; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Panitumumab; Prospective Studies; ras Proteins | 2019 |
Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Early Diagnosis; Early Medical Intervention; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Male; Panitumumab; Radiography, Thoracic; Tomography, X-Ray Computed | 2019 |
The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Progression-Free Survival | 2019 |
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Remission Induction | 2019 |
Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Muscle, Skeletal; Muscular Atrophy; Organoplatinum Compounds; Panitumumab; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2019 |
Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Ramucirumab; Retrospective Studies | 2019 |
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Female; HCT116 Cells; HT29 Cells; Humans; Immunoconjugates; Mice; Mice, Inbred BALB C; Mice, Nude; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2019 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Computational Biology; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Radiographic Image Interpretation, Computer-Assisted; Response Evaluation Criteria in Solid Tumors; Survival Rate; Tomography, X-Ray Computed | 2020 |
Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Forecasting; Glucuronates; Humans; Irinotecan; Leucovorin; Leukopenia; Machine Learning; Male; Middle Aged; Models, Biological; Neutropenia; Oxaliplatin; Topoisomerase I Inhibitors | 2019 |
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nomograms; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model.
Topics: Adenomatous Polyposis Coli Protein; Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; DNA Damage; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Knockout; NF-kappa B; Signal Transduction; Vimentin | 2019 |
Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Factors; Sarcopenia; Survival Analysis | 2019 |
Nomogram predicted disease free survival for colorectal liver metastasis patients with preoperative chemotherapy followed by hepatic resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Carcinoma; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Lymph Nodes; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Nomograms; Organoplatinum Compounds; Oxaloacetates; Prognosis; Retrospective Studies; Survival Rate; Tumor Burden | 2019 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Fluorouracil; Hepatectomy; Humans; Hyperthermia, Induced; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies | 2019 |
Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Histocytochemistry; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome | 2013 |
Camptothecine encapsulated composite drug delivery system for colorectal peritoneal carcinomatosis therapy: biodegradable microsphere in thermosensitive hydrogel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Female; Hydrogels; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Microspheres; Peritoneal Neoplasms | 2013 |
Aflibercept.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Placenta Growth Factor; Pregnancy Proteins; Protein Binding; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B | 2013 |
Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; CD3 Complex; Cetuximab; Colorectal Neoplasms; Cytokines; Female; Fluorouracil; Humans; Leucovorin; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Phenotype; T-Lymphocytes, Regulatory | 2013 |
Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2013 |
[Panitumumab-induced trichomegaly].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Eyelashes; Female; Fluorouracil; Hair Diseases; Humans; Leucovorin; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Panitumumab | 2013 |
Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2013 |
Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Death; Diarrhea; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Leukopenia; Logistic Models; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Sex Factors; Skin Neoplasms; Stomach Neoplasms; Thrombocytopenia | 2013 |
A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Survival; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Mice, SCID; Microscopy, Confocal; Neoplasm Transplantation; Random Allocation; Real-Time Polymerase Chain Reaction; Spheroids, Cellular; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Comet Assay; DNA Damage; Female; Fluorouracil; HCT116 Cells; Histones; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Poly(ADP-ribose) Polymerase Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.
Topics: Antineoplastic Agents; Camptothecin; Cell Cycle; Colorectal Neoplasms; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; HCT116 Cells; Humans; Irinotecan; Microsatellite Instability; S Phase | 2013 |
High-dose FOLFIRI, surgery, and radiofrequency ablation for patients with unresectable liver metastases from colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Prospective Studies; Vomiting; Young Adult | 2013 |
Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Female; Glucuronates; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic | 2014 |
Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Combinations; Female; Fluorouracil; HT29 Cells; Humans; Irinotecan; Liposomes; Male; Mice; Tumor Burden | 2013 |
Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Organoplatinum Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
[Changes of lymphocyte subsets before and after chemotherapy in colorectal carcinoma patients].
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Lymphocyte Subsets; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2013 |
Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2013 |
KRAS mutations in patients with colorectal cancer as detected by high-resolution melting analysis and direct sequencing.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; Follow-Up Studies; Freezing; Humans; Irinotecan; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate | 2013 |
Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Longitudinal Studies; Male; Models, Biological; Randomized Controlled Trials as Topic; Regression Analysis; Treatment Outcome; Tumor Burden | 2013 |
Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Drug Carriers; Female; Humans; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Polymers; Prospective Studies; Salvage Therapy; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Retrospective Studies | 2013 |
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Case-Control Studies; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Retrospective Studies | 2013 |
How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins p21(ras) | 2013 |
EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Structure, Tertiary | 2013 |
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Will PICCOLO affect metastatic colorectal cancer therapy?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colectomy; Colorectal Neoplasms; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tegafur; Treatment Outcome | 2013 |
Establishment of a human colorectal cancer cell line P6C with stem cell properties and resistance to chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Design; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Hyaluronan Receptors; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Neoplastic Stem Cells; Xenograft Model Antitumor Assays | 2013 |
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2013 |
FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Mutation; Neoplasm Metastasis; Precision Medicine; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver; Liver Neoplasms; Organoplatinum Compounds | 2013 |
[Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Irinotecan; Ligands; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2014 |
Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies.
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Glasgow Outcome Scale; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2013 |
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Gene Expression; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Retrospective Studies; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
[Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 2013 |
[Efficacy and safety of cetuximab+irinotecan for unresectable advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Recurrence; Retrospective Studies | 2013 |
Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; China; Colorectal Neoplasms; Female; Follow-Up Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Tissue Distribution | 2013 |
Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Demography; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Postoperative Care; Recurrence; Survival Analysis; Treatment Outcome | 2013 |
Targeting colorectal cancer cells with single-walled carbon nanotubes conjugated to anticancer agent SN-38 and EGFR antibody.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Delayed-Action Preparations; Drug Carriers; ErbB Receptors; HCT116 Cells; HT29 Cells; Humans; Immunoconjugates; Irinotecan; Microscopy, Confocal; Nanotubes, Carbon | 2013 |
Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan.
Topics: Amphiregulin; Base Sequence; Biomarkers; Camptothecin; Colorectal Neoplasms; DNA Primers; ErbB Receptors; Female; Humans; Irinotecan; Male; Neoplasm Metastasis; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction | 2014 |
Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Mice; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Oligonucleotides; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2013 |
[Analysis of therapeutic effect and prognosis in patients with metastatic colorectal cancer and different K-ras status].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Genes, ras; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate | 2013 |
Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Young Adult | 2014 |
A postmarketing surveillance study on erbitux (cetuximab) in patients with metastatic colorectal cancer refractory to irinotecan-containing treatment.
Topics: Aged; Antibodies, Monoclonal, Humanized; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Product Surveillance, Postmarketing; Treatment Failure; Treatment Outcome | 2013 |
Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genetic Variation; Genotype; Humans; Irinotecan; Leucovorin; Linkage Disequilibrium; Liver-Specific Organic Anion Transporter 1; Neoplasm Metastasis; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Treatment Outcome | 2013 |
Prognostic significance of visible cardiophrenic angle lymph nodes in the presence of peritoneal metastases from colorectal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Digestive System Surgical Procedures; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Lymph Nodes; Male; Mediastinum; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Predictive Value of Tests; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fatty Liver; Female; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Liver Neoplasms; Male; Neoplasm Invasiveness; Neoplasm Micrometastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome | 2013 |
[Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Approval; Europe; Fluorouracil; Humans; Leucovorin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2013 |
Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Fluorouracil; Humans; Leucovorin; Multicenter Studies as Topic; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Placenta Growth Factor; Pregnancy Proteins; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Salvage Therapy; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2013 |
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leukocyte Common Antigens; Male; Middle Aged; Neutrophils; Prognosis; Programmed Cell Death 1 Receptor; Prospective Studies; Toll-Like Receptor 4 | 2013 |
Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Treatment Outcome | 2013 |
ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.
Topics: Antineoplastic Agents, Phytogenic; ATP Citrate (pro-S)-Lyase; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression; Gene Knockdown Techniques; HT29 Cells; Humans; Irinotecan; Models, Biological; Proto-Oncogene Proteins c-akt; RNA Interference | 2013 |
Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Spain; Time Factors; Treatment Outcome | 2014 |
P7 peptides targeting bFGF sensitize colorectal cancer cells to CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; HT29 Cells; Humans; Irinotecan; Keratin-8; Peptide Fragments; Proto-Oncogene Proteins c-akt; Ribonucleotide Reductases | 2014 |
Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11).
Topics: Animals; Camptothecin; Colorectal Neoplasms; Gene Expression Regulation, Neoplastic; Glucuronic Acid; Glucuronosyltransferase; Histological Techniques; Immunoblotting; Intestinal Mucosa; Irinotecan; Liver; Male; Mice; Mice, Knockout; Microscopy, Confocal; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; DNA-Binding Proteins; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Irinotecan; MRE11 Homologue Protein; Mutation; Phthalazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Real-Time Polymerase Chain Reaction | 2014 |
Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Colectomy; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2013 |
A small cog in a big wheel: PIK3CA mutations in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases | 2013 |
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2014 |
Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Treatment Outcome | 2014 |
Impact of stereotactic body radiotherapy on colorectal cancer with distant metastases.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Organoplatinum Compounds; Radiosurgery; Treatment Outcome | 2014 |
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Substitution; Fluorouracil; Heart Diseases; Humans; Irinotecan; Middle Aged; Quinazolines; Thiophenes | 2014 |
Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; France; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Treatment Outcome; Young Adult | 2014 |
[Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Folic Acid; Hepatectomy; Hospitals, General; Humans; Irinotecan; Kaplan-Meier Estimate; Length of Stay; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Operative Time; Organoplatinum Compounds; Oxaliplatin; Surgery Department, Hospital; Treatment Outcome | 2013 |
Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Topics: Abdominal Abscess; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Digestive System Fistula; Female; Fluorouracil; Hematoma; Humans; Hyperthermia, Induced; Length of Stay; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Peritoneal Neoplasms; Wound Healing | 2014 |
Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genotype; Humans; Leucovorin; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Proteins; Organoplatinum Compounds; Oxaloacetates; Pharmacogenetics; Polymorphism, Single Nucleotide; Recurrence; Retrospective Studies | 2014 |
Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Growth Processes; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Random Allocation; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2014 |
Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2014 |
[Efficacy and tolerance of maintenance therapy in patients with incurable advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2013 |
Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Cohort Studies; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Irinotecan; Male; Mesothelioma; Middle Aged; Mitomycin; Neoplasms, Multiple Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Pseudomyxoma Peritonei; Quality of Life; Stomach Neoplasms; Treatment Outcome | 2014 |
Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed | 2014 |
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2014 |
Proteomic analysis identifies proteins associated with curcumin-enhancing efficacy of irinotecan-induced apoptosis of colorectal cancer LOVO cell.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Curcumin; Humans; Irinotecan; Proteomics; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Regulation and expression of aberrant methylation on irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Colorectal Neoplasms; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Glucuronidase; Glucuronosyltransferase; Humans; Irinotecan; Promoter Regions, Genetic; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 2014 |
Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Monitoring; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Precision Medicine; Retrospective Studies | 2014 |
Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinote
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prognosis; Vitamin B Complex | 2014 |
FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Republic of Korea; Retrospective Studies; Survival Analysis | 2014 |
Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prednisolone; Prognosis; Radiography, Thoracic; Retrospective Studies | 2014 |
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Gene Frequency; Genetic Variation; Genotype; HLA Antigens; HLA-B Antigens; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Receptors, KIR; Receptors, KIR3DL1; Treatment Outcome | 2014 |
Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2014 |
Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Comorbidity; Disease-Free Survival; Female; Health Status; Humans; Irinotecan; Male; Middle Aged | 2014 |
Pharmacokinetically guided dose adjustment of 5-FU-A critical element toward personalized medicine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Monitoring; Humans; Male | 2014 |
The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Retrospective Studies | 2014 |
Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cancer Care Facilities; Cetuximab; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Databases, Factual; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; United States | 2014 |
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Introns; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2014 |
A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Health Status; Humans; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; ras Proteins; Sample Size; Severity of Illness Index; Skin; Surveys and Questionnaires | 2014 |
Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Contrast Media; Female; Follow-Up Studies; Gadolinium DTPA; Hepatectomy; Humans; Intraoperative Care; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2014 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Blood Transfusion; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Gallbladder Neoplasms; Humans; Hyperthermia, Induced; Intraoperative Care; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Stomach Neoplasms; Survival Rate; Tertiary Care Centers | 2014 |
Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations.
Topics: Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy; Drug-Eluting Stents; Humans; Injections, Intra-Arterial; Internationality; Irinotecan; Liver Neoplasms; Practice Guidelines as Topic | 2014 |
Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Databases, Factual; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2014 |
Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Treatment Outcome | 2014 |
Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Prospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Sorafenib inhibits ABCG2 and overcomes irinotecan resistance--letter.
Topics: Animals; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Humans; Neoplasm Proteins; Niacinamide; Phenylurea Compounds | 2014 |
Sorafenib inhibits ABCG2 and overcomes irinotecan resistance--response.
Topics: Animals; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Humans; Neoplasm Proteins; Niacinamide; Phenylurea Compounds | 2014 |
Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Female; Humans; Male; Proto-Oncogene Proteins; ras Proteins | 2014 |
Response to comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Female; Humans; Male; Proto-Oncogene Proteins; ras Proteins | 2014 |
Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Digestive System Surgical Procedures; Female; Fluorouracil; Humans; Intestinal Obstruction; Intestinal Perforation; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Factors | 2014 |
FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Leucovorin; Liver Neoplasms; Male; Middle Aged | 2014 |
Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2014 |
Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Rectum; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Salvage Therapy; Survival Rate | 2014 |
Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Body Composition; Body Mass Index; Camptothecin; Cetuximab; Colorectal Neoplasms; Cross-Sectional Studies; Female; Humans; Intra-Abdominal Fat; Irinotecan; Male; Middle Aged; Muscle, Skeletal; Neoplasm Metastasis; Nutrition Assessment; Prospective Studies; Sarcopenia; Young Adult | 2014 |
A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2014 |
Prognostic factors for metastatic colorectal cancer after first-line chemotherapy with FOLFOX-4 or FOLFIRI regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hemoglobins; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Odds Ratio; Organoplatinum Compounds; Prognosis; Retrospective Studies | 2014 |
A case report--treatment of metastatic colorectal cancer in a patient on hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Kidney Failure, Chronic; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Renal Dialysis | 2014 |
Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Combined Modality Therapy; Drug Synergism; Humans; Irinotecan; Microscopy, Electron, Scanning; Mutation; Oncolytic Virotherapy; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rats; Reoviridae; Tumor Cells, Cultured | 2014 |
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Survival Rate | 2014 |
Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Administration Schedule; ErbB Receptors; Female; GTP Phosphohydrolases; Humans; Immunohistochemistry; In Situ Hybridization; Irinotecan; Male; Membrane Proteins; Mutation; Panitumumab; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Retrospective Studies; Treatment Outcome | 2014 |
The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies | 2014 |
Autophagy inhibition switches low-dose camptothecin-induced premature senescence to apoptosis in human colorectal cancer cells.
Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Autophagy; Camptothecin; Cell Line, Tumor; Cellular Senescence; Chloroquine; Class III Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Lysosomes; Neoplasm Proteins; Osmolar Concentration; Signal Transduction; Tumor Suppressor Protein p53 | 2014 |
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Enzyme Activation; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Prognosis | 2014 |
Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response--a retrospective stu
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Treatment Outcome | 2014 |
CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Fluorouracil; GTP Phosphohydrolases; High-Throughput Nucleotide Sequencing; Humans; Leucovorin; Membrane Proteins; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Sequence Analysis, DNA; Tumor Suppressor Protein p53 | 2014 |
RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.
Topics: Biomarkers, Tumor; Caco-2 Cells; Camptothecin; Colorectal Neoplasms; Computational Biology; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Profiling; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Precision Medicine; Real-Time Polymerase Chain Reaction; Reproducibility of Results; RNA, Neoplasm; Sequence Analysis, RNA; Topoisomerase I Inhibitors | 2014 |
Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; NF-kappaB-Inducing Kinase; Oligopeptides; Protein Serine-Threonine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2014 |
FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2014 |
Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Survival Rate | 2014 |
Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Camptothecin; Canada; Colorectal Neoplasms; Diarrhea; Drug Screening Assays, Antitumor; Europe; Female; Fluorouracil; Humans; Immunologic Factors; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prevalence; Quality of Life; Risk Assessment; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; United States | 2014 |
Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Community Health Services; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United States; Young Adult | 2014 |
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Metastasectomy; Microsatellite Instability; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Peritoneal Neoplasms; Proto-Oncogene Proteins B-raf; Survival Rate | 2014 |
Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2014 |
A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Cyclobutanes; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis | 2014 |
Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Duodenal Neoplasms; Female; Humans; Hyperthermia, Induced; Ileal Neoplasms; Infusions, Parenteral; Intestine, Small; Irinotecan; Jejunal Neoplasms; Male; Metastasectomy; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Peritoneal Lavage; Peritoneal Neoplasms; Peritoneum; Retrospective Studies; Treatment Outcome | 2014 |
Cetuximab or bevacizumab in metastatic colorectal cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male | 2014 |
Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Nuclear Proteins; RNA, Small Interfering; Topoisomerase Inhibitors; Transfection | 2014 |
Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nutrition Assessment; Nutritional Status; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2015 |
[The efficacy and safety of FOLFIRI or combined FOLFIRI and bevacizumab treatment as second-line chemotherapy for metastatic colorectal cancer patients aged 75 years and older].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Retrospective Studies | 2014 |
Gastrointestinal cancer: FOLFIRI plus cetuximab--preferred first-line treatment for mCRC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Male | 2014 |
[Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Markov Chains; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2014 |
UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2014 |
A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Analysis; Treatment Outcome | 2014 |
Fatal outcome of posterior "reversible" encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Staging; Posterior Leukoencephalopathy Syndrome | 2014 |
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Inflammation; Irinotecan; Kaplan-Meier Estimate; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Retrospective Studies; ROC Curve | 2014 |
Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; China; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome; Young Adult | 2014 |
A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes.
Topics: Aged; Algorithms; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Female; Genetic Variation; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide | 2014 |
Gene signatures of drug resistance predict patient survival in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Survival Rate | 2015 |
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Camptothecin; Carboxylesterase; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Thymidylate Synthase; Treatment Outcome | 2014 |
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Focal Adhesion Kinase 1; Hepatectomy; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins pp60(c-src); Survival Analysis; Treatment Outcome | 2014 |
Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Differentiation; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Mice; Myeloid Cells; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
Influence of UGT1A1 gene methylation level in colorectal cancer cells on the sensitivity of the chemotherapy drug CPT-11.
Topics: Antineoplastic Agents; Camptothecin; Carboxylesterase; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; HCT116 Cells; HT29 Cells; Humans; Irinotecan; RNA, Small Interfering; Transfection | 2014 |
Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Treatment Outcome | 2014 |
Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Compounding; Drug Synergism; Humans; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Nitrophenols; Piperazines; Sulfonamides; Thrombocytopenia | 2014 |
Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Young Adult | 2015 |
Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI.
Topics: Animals; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Monitoring; Female; Humans; Irinotecan; Male; Mice; Mice, Inbred C57BL; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution | 2015 |
Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Camptothecin; Case-Control Studies; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorescent Antibody Technique; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Male; Matrix Metalloproteinase 7; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Syndecan-1; Tumor Cells, Cultured | 2014 |
CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate | 2015 |
Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Neoplasm Recurrence, Local; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Failure | 2014 |
Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer: A Pilot Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neutropenia; Organoplatinum Compounds; Pilot Projects; Proto-Oncogene Proteins p21(ras); Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Salvage Therapy; Survival Rate | 2017 |
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome; Tumor Burden | 2015 |
The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Irinotecan; Israel; Male; Metastasectomy; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2015 |
Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Irinotecan; Male; Middle Aged; Morbidity; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Retrospective Studies; Young Adult | 2014 |
Gastrointestinal cancer: FOLFOXIRI-improving outcomes of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Male; Neoplasm Metastasis | 2014 |
Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2014 |
Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2015 |
FOLFIRI with cetuximab or bevacizumab: FIRE-3.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Male | 2014 |
FOLFIRI with cetuximab or bevacizumab: FIRE-3.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Male | 2014 |
FOLFIRI with cetuximab or bevacizumab: FIRE-3.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Male | 2014 |
FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Male | 2014 |
FOLFOXIRI and bevacizumab in metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds | 2014 |
Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Carriers; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Liver; Liver Neoplasms; Male; Microspheres; Middle Aged | 2014 |
DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Survival; Chromosomal Proteins, Non-Histone; Colorectal Neoplasms; Down-Regulation; Female; Gene Expression; Gene Knockdown Techniques; Humans; Irinotecan; Male; Middle Aged; Oncogene Proteins; Phenotype; Poly-ADP-Ribose Binding Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2014 |
Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan.
Topics: Biocatalysis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Phosphoric Diester Hydrolases; RNA, Messenger | 2015 |
Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Transformation, Neoplastic; Cellular Senescence; Colorectal Neoplasms; Drug Resistance, Neoplasm; Flow Cytometry; Heterografts; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection | 2015 |
Mcl-1 and tumor cell persistence.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cellular Senescence; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Male; Myeloid Cell Leukemia Sequence 1 Protein | 2015 |
FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Male; Neoplasm Metastasis | 2015 |
FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Male; Neoplasm Metastasis | 2015 |
FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Male; Neoplasm Metastasis | 2015 |
TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tissue Inhibitor of Metalloproteinase-1 | 2015 |
Always look at the bright side of drugs?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors | 2015 |
OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Polymorphism, Single Nucleotide; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Protein Tyrosine Phosphatases, Non-Receptor; Protein-Tyrosine Kinases | 2015 |
Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds | 2015 |
FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Induction Chemotherapy; Leucovorin; Neoplasm Metastasis; Randomized Controlled Trials as Topic | 2015 |
A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Panitumumab | 2015 |
Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a case of real "pan-thrombosis".
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Collateral Circulation; Colorectal Neoplasms; Disease Progression; Enoxaparin; Fatal Outcome; Female; Fibrinolytic Agents; Fluorouracil; Humans; Leucovorin; Middle Aged; Superior Vena Cava Syndrome; Tomography, X-Ray Computed; Venous Thromboembolism | 2015 |
Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organoplatinum Compounds; Outcome and Process Assessment, Health Care; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Tumor Burden; United Kingdom | 2015 |
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Panitumumab; Prognosis; Prospective Studies; Proto-Oncogene Proteins B-raf; ras Proteins | 2015 |
Hypersensitivity and tumor lysis syndrome associated with cetuximab treatment: should we be afraid?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Neoplasms; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Hypersensitivity; Emergency Treatment; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome; Tumor Lysis Syndrome | 2015 |
Senescence versus apoptosis in chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cellular Senescence; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Male; Myeloid Cell Leukemia Sequence 1 Protein | 2015 |
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Mice; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays | 2015 |
Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.
Topics: Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Models, Biological; Organoplatinum Compounds; Oxaliplatin | 2015 |
Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Protein Biosynthesis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines | 2016 |
A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Canada; Colorectal Neoplasms; Female; Genetic Testing; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide | 2015 |
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Leucovorin; Male; MicroRNAs; Middle Aged; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Prospective Studies | 2015 |
CCR 20th Anniversary commentary: in search of cetuximab's first indication-combination therapy with irinotecan in colorectal cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; History, 20th Century; History, 21st Century; Humans; Irinotecan; Medical Oncology | 2015 |
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; DNA; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2015 |
Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Prognosis; Retreatment; Retrospective Studies; Survival Rate; Turkey | 2015 |
The rapidly escalating cost of treating colorectal cancer in Australia.
Topics: Aged, 80 and over; Antineoplastic Agents; Australia; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Female; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2016 |
Second-line therapy for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Male; Organoplatinum Compounds | 2015 |
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
Topics: Aged; Alleles; Asian People; Bilirubin; Camptothecin; Colorectal Neoplasms; Female; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Neutrophils; Nomograms; Prospective Studies | 2015 |
Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Diffusion Magnetic Resonance Imaging; Dipeptides; Female; Humans; Immunoenzyme Techniques; Indoles; Irinotecan; Lymphatic Metastasis; Mice; Mice, Nude; Necrosis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2015 |
UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Colorectal Neoplasms; Female; Gene Expression; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Male; Middle Aged; Prognosis; Ubiquitin-Conjugating Enzymes | 2016 |
FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzodioxoles; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Indolizines; Irinotecan; Lung Neoplasms; Mice, SCID; Neoplasm Proteins; Topoisomerase Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 Enzyme System; Disease-Free Survival; Female; Fluorouracil; Gene Frequency; Genotype; Humans; Leucovorin; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies | 2015 |
Gastrointestinal cancer: RAISE in second-line options for mCRC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Male; Organoplatinum Compounds | 2015 |
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Exons; Female; GTP Phosphohydrolases; Humans; In Situ Hybridization, Fluorescence; Insulin-Like Growth Factor I; Irinotecan; Male; Membrane Proteins; Middle Aged; Phosphatidylinositol 3-Kinases; Prospective Studies; Proto-Oncogene Proteins p21(ras); Receptor, ErbB-3; Treatment Outcome | 2015 |
Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cetuximab; China; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins p21(ras); Survival Analysis; Treatment Outcome | 2015 |
Fasting protects against the side effects of irinotecan but preserves its anti-tumor effect in Apc15lox mutant mice.
Topics: Adenomatous Polyposis Coli Protein; Animals; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Fasting; G2 Phase Cell Cycle Checkpoints; Irinotecan; Mice; Mice, Inbred C57BL; Mice, Knockout; S Phase Cell Cycle Checkpoints; Topoisomerase I Inhibitors | 2015 |
Colorectal cancer: to stack or sequence therapy?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Sequence Analysis, DNA; Treatment Outcome | 2015 |
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Down-Regulation; Female; Fluorouracil; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Predictive Value of Tests; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; HCT116 Cells; Heat-Shock Proteins; Humans; Irinotecan; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Transcriptome | 2015 |
The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Digestive System Surgical Procedures; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2015 |
The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
Topics: Amino Acid Transport System X-AG; Antineoplastic Agents; Aspartic Acid; Camptothecin; Cell Death; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Copper; Drug Resistance, Neoplasm; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 3; Gene Expression; Gene Knockdown Techniques; Glutathione; HCT116 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Protein Transport; Tumor Suppressor Protein p53 | 2015 |
[Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Retrospective Studies | 2015 |
The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.
Topics: Alu Elements; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; SOX Transcription Factors | 2015 |
Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cells, Cultured; Chlorocebus aethiops; Colorectal Neoplasms; Combined Modality Therapy; Drug Synergism; Female; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Organoplatinum Compounds; Oxaliplatin; Vaccinia virus | 2015 |
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Diphenylamine; Drug Synergism; ErbB Receptors; Female; Humans; Irinotecan; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Phosphatidylinositol 3-Kinases; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Czech Republic; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Treatment Outcome | 2015 |
Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.
Topics: Antineoplastic Agents; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Hyaluronan Receptors; Irinotecan; Neoplastic Stem Cells; Organoplatinum Compounds; Oxaliplatin; Protein Isoforms; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Triazines; Wnt Signaling Pathway | 2015 |
Successful Desensitization Protocol for Hypersensitivity Reaction Caused by Irinotecan in a Patient With Metastatic Colorectal Cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Irinotecan; Neoplasm Metastasis | 2015 |
Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Spain | 2015 |
[The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Incidence; Irinotecan; Leucovorin; Male; Middle Aged; Polymorphism, Genetic; Thrombocytopenia | 2015 |
Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Culture Media, Conditioned; Drug Resistance, Neoplasm; Enzyme Activation; Fibroblasts; HCT116 Cells; Hepatocyte Growth Factor; HT29 Cells; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Proto-Oncogene Proteins c-met | 2015 |
The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Follow-Up Studies; Genotype; Germany; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Insurance, Health; Irinotecan; Leucovorin; Neoplasm Staging; Prognosis; Quality of Life; Quality-Adjusted Life Years; Survival Rate | 2016 |
Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Comet Assay; Disease Progression; DNA Damage; DNA Repair; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Genetic; Repetitive Sequences, Nucleic Acid; Topoisomerase I Inhibitors; Treatment Outcome | 2015 |
[Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Treatment Outcome | 2015 |
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Function Tests; Male; Middle Aged; Retrospective Studies | 2015 |
Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Drug Carriers; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Middle Aged; Organoplatinum Compounds; Prospective Studies; Remission Induction | 2015 |
Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Role of Raf-kinase inhibitor protein in colorectal cancer and its regulation by hydroxycamptothecine.
Topics: Apoptosis; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Lymph Nodes; Lymphatic Metastasis; MAP Kinase Signaling System; Phosphatidylethanolamine Binding Protein | 2015 |
Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gene Frequency; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Polymorphism, Single Nucleotide; Proteolysis; Treatment Outcome; Ubiquitin-Conjugating Enzymes; Ubiquitination | 2015 |
[Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2015 |
Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Ramucirumab; Randomized Controlled Trials as Topic; United States | 2015 |
Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Taiwan; Treatment Outcome | 2015 |
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
Topics: Adult; Aged; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Epiregulin; Female; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Proportional Hazards Models; Proto-Oncogene Proteins B-raf; RNA, Messenger | 2016 |
Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Drug Synergism; Gene Knockdown Techniques; Genes, p53; Humans; Irinotecan; Neoplasm Proteins; Nitrofurans; Nuclear Proteins; Piperazines; Proteolysis; Proto-Oncogene Mas; Recombinant Fusion Proteins; RNA, Small Interfering; Signal Transduction; Tumor Protein p73; Tumor Stem Cell Assay; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Metastasectomy; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate | 2016 |
[Occurrence, intratumoral heterogeneity, prognostic and predictive potential of microsatellite instability following surgical resection of primary colorectal carcinomas and corresponding liver metastases].
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Mismatch Repair; Female; Fluorouracil; Genetic Markers; Humans; Irinotecan; Liver Neoplasms; Male; Microsatellite Instability; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Predictive Value of Tests; Prognosis; Survival Analysis | 2015 |
Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Colorectal Neoplasms; Feces; Glucuronates; Glucuronidase; Glucuronosyltransferase; Humans; Irinotecan; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Necrosis Factor-alpha | 2015 |
ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Genetic Markers; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies | 2015 |
SN-38 active loading in poly(lactic-co-glycolic acid) nanoparticles and assessment of their anticancer properties on COLO-205 human colon adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lactic Acid; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2015 |
Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Irinotecan; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; RNA, Messenger | 2015 |
Aberrant Apoptotic Response of Colorectal Cancer Cells to Novel Nucleoside Analogues.
Topics: Annexin A5; Apoptosis; Caco-2 Cells; Camptothecin; Caspase 3; Caspase 8; Cell Line, Tumor; Colorectal Neoplasms; HT29 Cells; Humans; Membrane Potential, Mitochondrial; Mitochondria; Nucleosides | 2015 |
MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Irinotecan; Male; MicroRNAs; Multicenter Studies as Topic; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2015 |
Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glycoproteins; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Peptides; Polymorphism, Genetic; Prognosis; Survival Rate | 2015 |
Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2015 |
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Cluster Analysis; Colorectal Neoplasms; Female; Gene Expression; Gene Expression Profiling; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Nuclear Proteins; Proto-Oncogene Proteins B-raf; ras Proteins; Transcription Factors; Treatment Outcome | 2015 |
Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colitis, Microscopic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2015 |
Synergistic Combination Chemotherapy of Camptothecin and Floxuridine through Self-Assembly of Amphiphilic Drug-Drug Conjugate.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colon; Colorectal Neoplasms; Drug Synergism; Floxuridine; Humans; Nanoparticles; Rectum; Tissue Distribution | 2015 |
Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell lines.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Promoter Regions, Genetic | 2016 |
Loss of Nek11 Prevents G2/M Arrest and Promotes Cell Death in HCT116 Colorectal Cancer Cells Exposed to Therapeutic DNA Damaging Agents.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Death; Cell Survival; Colorectal Neoplasms; DNA Damage; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; Humans; Irinotecan; M Phase Cell Cycle Checkpoints; NIMA-Related Kinases; Protein Kinases; RNA Interference | 2015 |
Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Gas Chromatography-Mass Spectrometry; Humans; Immunoassay; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate | 2015 |
Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Models, Genetic; Oligonucleotide Array Sequence Analysis; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Signal Transduction | 2015 |
Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Survival Rate | 2016 |
Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circadian Rhythm; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Treatment Outcome | 2015 |
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Computer Simulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Genes, ras; Humans; Immune System; Irinotecan; Lymphocytes; Models, Theoretical; Mutation; ras Proteins; Stochastic Processes | 2016 |
Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diffusion Magnetic Resonance Imaging; Early Detection of Cancer; Female; Fluorouracil; Humans; Image Processing, Computer-Assisted; Leucovorin; Liver Neoplasms; Male; Middle Aged; Motion; Neoplasm Metastasis; Perfusion; ROC Curve; Spleen; Tomography, X-Ray Computed; Whole Body Imaging | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
5-Fluorouracil enteric-coated nanoparticles for improved apoptotic activity and therapeutic index in treating colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Delayed-Action Preparations; Fluorouracil; Gastric Emptying; HCT116 Cells; Humans; Irinotecan; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Tissue Distribution | 2016 |
A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Codon; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Panitumumab; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Treatment Outcome | 2016 |
Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Female; Fluorouracil; gamma-Glutamyl Hydrolase; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peptide Synthases; Prognosis; RNA, Messenger; Tetrahydrofolate Dehydrogenase; Thymidine Phosphorylase | 2016 |
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Body Fluids; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Prospective Studies; Risk Factors | 2016 |
Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Drug Delivery Systems; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome; United States | 2016 |
BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?
Topics: Adult; Aged; Aged, 80 and over; Australia; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Genetic Testing; Humans; Irinotecan; Leucovorin; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins B-raf; Treatment Outcome; Young Adult | 2016 |
Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Costs; Fees, Medical; Female; Financing, Personal; Health Care Costs; Hospital Charges; Humans; Irinotecan; Japan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2016 |
A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Panitumumab; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Metastasectomy; Microsatellite Instability; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Singapore | 2015 |
Bevacizumab safety in Japanese patients with colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Heart Failure; Hemorrhage; Humans; Hypertension; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Product Surveillance, Postmarketing; Proteinuria; Risk Factors | 2016 |
Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Disease Progression; Female; HCT116 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; Irinotecan; Male; Middle Aged; Phosphorylation; Retinoblastoma Protein; Retrospective Studies; RNA, Small Interfering | 2016 |
Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Camptothecin; Colorectal Neoplasms; Female; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Risk; Thailand | 2016 |
Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dexamethasone; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Young Adult | 2016 |
Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proto-Oncogene Proteins p21(ras); Retrospective Studies | 2016 |
A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colon; Colorectal Neoplasms; Dextrans; Drug Carriers; Drug Delivery Systems; Female; Humans; Irinotecan; Magnetite Nanoparticles; Methacrylates; Mice, Inbred BALB C; Mice, Nude; Micelles; Polyesters; Polyethylene Glycols; Rectum; RNA, Small Interfering; RNAi Therapeutics; Theranostic Nanomedicine; Vascular Endothelial Growth Factor A | 2016 |
Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cohort Studies; Colectomy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Prognosis; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Survival Rate | 2015 |
Irinotecan-induced dysarthria: A case report and review of the literature.
Topics: Adult; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Dysarthria; Female; Humans; Irinotecan | 2017 |
Gastrointestinal cancer: PICCOLO--changing the tune of anti-EGFR therapy.
Topics: Amphiregulin; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; EGF Family of Proteins; Epiregulin; Humans; Irinotecan; Molecular Targeted Therapy; Panitumumab; RNA, Messenger | 2016 |
MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Grading; Neoplasm Metastasis; Pilot Projects; Prognosis; Survival Analysis | 2016 |
Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Decision-Making; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Leucovorin; Quality-Adjusted Life Years | 2016 |
Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Safety | 2016 |
Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2016 |
Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Doxorubicin; Embolization, Therapeutic; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Retrospective Studies; Yttrium Radioisotopes | 2016 |
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Axin Protein; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Middle Aged; Tankyrases; Xenograft Model Antitumor Assays | 2016 |
Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies | 2016 |
Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Female; Fucose; Humans; Immunochemistry; Irinotecan; Lectins; Liposomes; Male; Mice; Middle Aged; Nanoparticles; Neoplasm Transplantation; Proteins | 2016 |
Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Long Term Adverse Effects; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2016 |
Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Survival Rate | 2016 |
Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neoplasms, Second Primary; Urologic Neoplasms | 2016 |
WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; CpG Islands; DNA Methylation; Gene Expression; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Werner Syndrome Helicase | 2016 |
Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome; Turkey | 2016 |
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calreticulin; Camptothecin; Cell Death; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Dendritic Cells; Disease Models, Animal; Endoplasmic Reticulum Stress; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Leucovorin; Mice; Panitumumab; Phagocytosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Sulfonamides; Unfolded Protein Response; Vemurafenib; X-Box Binding Protein 1 | 2016 |
Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
A Novel Computational Tool for Mining Real-Life Data: Application in the Metastatic Colorectal Cancer Care Setting.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Combined Modality Therapy; Computational Biology; Data Mining; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Retrospective Studies; Treatment Outcome | 2016 |
[KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; France; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis | 2016 |
A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Transforming Growth Factor beta; Young Adult | 2016 |
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Proto-Oncogene Proteins p21(ras); Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2016 |
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Genotype; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Polymorphism, Single Nucleotide; Retreatment; Toll-Like Receptor 1; Treatment Outcome | 2016 |
Incompatibility between irinotecan and fluorouracil injections.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Incompatibility; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan | 2016 |
[Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; Colorectal Neoplasms; Dexamethasone; Female; Fluorouracil; Granisetron; Humans; Leucovorin; Male; Morpholines; Organoplatinum Compounds; Vomiting | 2016 |
UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Cachexia; Camptothecin; Cell Line; Colorectal Neoplasms; Flavonoids; Fluorouracil; Humans; Leucovorin; Male; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mice; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle Fatigue; Muscle, Skeletal; Muscular Atrophy; Myoblasts; Myostatin; Organoplatinum Compounds; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Up-Regulation | 2016 |
UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; DNA Damage; Drug Synergism; HCT116 Cells; Humans; Irinotecan; Mice; Neoplastic Stem Cells; Protein Kinase Inhibitors; Signal Transduction; Staurosporine; Xenograft Model Antitumor Assays | 2016 |
Knockdown of NDRG1 promote epithelial-mesenchymal transition of colorectal cancer via NF-κB signaling.
Topics: Adult; Aged; Camptothecin; Cell Cycle Proteins; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Female; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; NF-kappa B; Signal Transduction; Vimentin | 2016 |
Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles.
Topics: AC133 Antigen; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; HCT116 Cells; HT29 Cells; Humans; Immunotoxins; Irinotecan; Mice; Mice, Nude; Molecular Targeted Therapy; Nanoparticles; Neoplastic Stem Cells; Random Allocation; Xenograft Model Antitumor Assays | 2016 |
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
Topics: Administration, Intravenous; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Camptothecin; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Operative Time; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Sarcopenia | 2016 |
Early Experience with 70-150 μm Irinotecan Drug-eluting Beads (M1-DEBIRI) for the Treatment of Unresectable Hepatic Colorectal Metastases.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Delayed-Action Preparations; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Retrospective Studies; Treatment Outcome | 2016 |
Hepatic Arterial Infusion of Polyethylene Glycol Drug-eluting Beads for Primary and Metastatic Liver Cancer Therapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Cholangiocarcinoma; Colorectal Neoplasms; Delayed-Action Preparations; Disease-Free Survival; Doxorubicin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Polyethylene Glycols; Retrospective Studies; Treatment Outcome | 2016 |
Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Retrospective Studies | 2016 |
Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bevacizumab; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Palliative Care; Pregnancy; Survival Rate; Tegafur; Tumor Suppressor Protein p53 | 2016 |
Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Comorbidity; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2016 |
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; GTP Phosphohydrolases; Humans; Irinotecan; Male; Membrane Proteins; Middle Aged; Mutation; Neoplasms, Unknown Primary; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras) | 2016 |
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Azepines; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Female; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrimidines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colorectal Neoplasms; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2017 |
Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colon; Colorectal Neoplasms; Drug Delivery Systems; Female; HCT116 Cells; Humans; Irinotecan; Liposomes; Mice, Inbred BALB C; Organoplatinum Compounds; Oxaliplatin; Rectum | 2016 |
CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; CpG Islands; Disease-Free Survival; Female; Genes, erbB-1; Humans; Irinotecan; Japan; Male; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pharmacogenomic Testing; Proto-Oncogene Proteins B-raf; ras Proteins; Statistics as Topic; Treatment Outcome | 2016 |
Primary cultures of human colon cancer as a model to study cancer stem cells.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Mice; Neoplastic Stem Cells; Octamer Transcription Factor-3; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Drug Resistance in Colorectal Cancer Cell Lines is Partially Associated with Aneuploidy Status in Light of Profiling Gene Expression.
Topics: Aneuploidy; Camptothecin; Cell Line, Tumor; Chromosomes, Human, Pair 14; Colorectal Neoplasms; Drug Resistance; Gene Dosage; Gene Expression Profiling; HCT116 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2016 |
Robotic-Assisted Placement of an Hepatic Artery Infusion Pump and Catheter for Regional Chemotherapy of the Liver.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Robotic Surgical Procedures; Vascular Surgical Procedures | 2016 |
FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Retrospective Studies | 2016 |
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Fluorouracil; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2016 |
Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Case-Control Studies; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gamma Rays; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Quality of Life; Stents; Survival Analysis | 2016 |
Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carbocyanines; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Female; Fucose; Humans; Immunohistochemistry; Irinotecan; Liposomes; Male; Mannose; Mice; Middle Aged; Nanoparticles; Neoplasm Transplantation; Proteins | 2016 |
Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bilirubin; Bone Neoplasms; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2017 |
Bevacizumab in colorectal cancer: it should have worked.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Organoplatinum Compounds | 2016 |
Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C-Reactive Protein; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Lymphocyte Count; Male; Middle Aged; Neutrophils; Platelet Count; Prognosis; Retrospective Studies; Serum Albumin; Treatment Outcome; Turkey; Young Adult | 2017 |
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Spain; Survival Rate | 2017 |
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Male; Mice; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Sulfonamides; Survival Analysis; Treatment Outcome; Vemurafenib; Xenograft Model Antitumor Assays | 2016 |
Gap junction composed of connexin43 modulates 5‑fluorouracil, oxaliplatin and irinotecan resistance on colorectal cancers.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Connexin 43; Drug Resistance, Neoplasm; Fluorouracil; Gap Junctions; Gene Knockdown Techniques; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2016 |
Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.
Topics: Amphiregulin; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Panitumumab; Proportional Hazards Models; Proto-Oncogene Proteins B-raf; ras Proteins; Retrospective Studies | 2016 |
Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; MicroRNAs; Organoplatinum Compounds; Oxaliplatin; RNA, Neoplasm; Signal Transduction; Stress, Physiological | 2016 |
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Eruptions; Erlotinib Hydrochloride; Fluorouracil; Folliculitis; Humans; Irinotecan; Lung Neoplasms; Male | 2017 |
[Difference analysis of chemotherapy efficacy among different primary tumor sites in metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Colon, Transverse; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectum; Retrospective Studies | 2016 |
Unusual case of hyperpigmentation secondary to irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Drug Eruptions; Female; Humans; Hyperpigmentation; Irinotecan; Middle Aged; Mouth Mucosa; Nails; Neoplasm Recurrence, Local | 2016 |
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Gene Dosage; Genes, ras; High-Throughput Nucleotide Sequencing; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Panitumumab; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf | 2017 |
RhoA regulates resistance to irinotecan by regulating membrane transporter and apoptosis signaling in colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Membrane Transport Proteins; Proto-Oncogene Proteins c-bcl-2; rhoA GTP-Binding Protein; Signal Transduction | 2016 |
SIRT6 interacts with TRF2 and promotes its degradation in response to DNA damage.
Topics: Acetylation; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Colorectal Neoplasms; DNA Damage; Humans; Immunohistochemistry; Models, Molecular; Poly(ADP-ribose) Polymerases; Protein Binding; Protein Conformation; Protein Stability; Proteolysis; Recombinant Fusion Proteins; Sirtuins; Substrate Specificity; Telomeric Repeat Binding Protein 2; Ubiquitination | 2017 |
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Phenylurea Compounds; Pyridines; Retreatment; Treatment Outcome | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Prospective Studies; Young Adult | 2017 |
[Aflibercept: focus on tolerability.]
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2016 |
Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Liberation; HT29 Cells; Humans; Male; Matrix Metalloproteinase 2; Mice, Inbred BALB C; Nanoparticles; Niacinamide; Phenylurea Compounds; Photoacoustic Techniques; Rats, Sprague-Dawley; Sorafenib; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Female; Gene Amplification; Genes, p53; Humans; Irinotecan; Male; Middle Aged; Mutation; ras Proteins | 2017 |
Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Products; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Female; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Quality-Adjusted Life Years; Texas | 2017 |
Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Survival Rate | 2017 |
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Chemoradiotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fluorouracil; Gene Amplification; High-Throughput Nucleotide Sequencing; Humans; Laparoscopy; Leucovorin; Liver Neoplasms; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Off-Label Use; Palliative Care; Proto-Oncogene Proteins c-myc; Receptor, ErbB-2; Tomography, X-Ray Computed; Trastuzumab; Tumor Suppressor Protein p53; Ultrasonography | 2017 |
Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Colorectal Neoplasms; Delayed-Action Preparations; Dendrimers; Female; Irinotecan; Mice; Mice, Nude; Oxazoles; Rats, Wistar; Rectum | 2017 |
Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies | 2017 |
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Neoplasm Staging; Patient Care Management; Pharmacogenomic Testing; Pharmacogenomic Variants; Retrospective Studies; Topoisomerase I Inhibitors | 2017 |
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; CD3 Complex; CD56 Antigen; CD8 Antigens; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Inflammation; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2017 |
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Gene Dosage; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2017 |
FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Organoplatinum Compounds | 2017 |
Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Quality of Life; ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2017 |
CQ synergistically sensitizes human colorectal cancer cells to SN-38/CPT-11 through lysosomal and mitochondrial apoptotic pathway via p53-ROS cross-talk.
Topics: Animals; Apoptosis; Autophagy; Camptothecin; Cell Line, Tumor; Cell Survival; Chloroquine; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lysosomes; Mice; Mitochondria; Reactive Oxygen Species; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
Drug Combo Beats Vemurafenib Alone for Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Indoles; Irinotecan; Mutation; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; Vemurafenib | 2017 |
Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies | 2017 |
Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan.
Topics: Acetylation; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Breaks, Double-Stranded; DNA Repair; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histones; Humans; Irinotecan; Models, Biological; Phosphoric Diester Hydrolases; Topoisomerase I Inhibitors | 2017 |
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Glucuronosyltransferase; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome; Vomiting | 2017 |
Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Exons; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2017 |
Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; France; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Prospective Studies; Survival Rate | 2017 |
Correlation of Ultrasound Shear Wave Elastography with Pathological Analysis in a Xenografic Tumour Model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Elastic Modulus; Elasticity Imaging Techniques; Humans; Irinotecan; Mice, Nude; Random Allocation; Treatment Outcome; Tumor Burden; Ultrasonic Waves; Xenograft Model Antitumor Assays | 2017 |
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prognosis; Survival Rate; Transcriptome; Treatment Outcome | 2017 |
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
Management and survival trends in advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2008 |
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Exons; Female; Gene Dosage; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Polymorphism, Genetic; Protein Structure, Tertiary; Retrospective Studies; Treatment Outcome | 2008 |
Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.
Topics: Aldehyde Dehydrogenase; Animals; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Cyclophosphamide; Humans; Irinotecan; Mice; Neoplastic Stem Cells | 2008 |
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Magnesium; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2008 |
Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Camptothecin; Colorectal Neoplasms; Fluorouracil; HIV Infections; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2008 |
The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: outcome study in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Skin; Skin Diseases; Weight Loss | 2008 |
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-X Protein; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; ErbB Receptors; fas Receptor; Fluorouracil; Humans; Irinotecan; Myeloid Cell Leukemia Sequence 1 Protein; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2008 |
Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Humans; Immunohistochemistry; Irinotecan; Mutation; Panitumumab; Proto-Oncogene Proteins; ras Proteins | 2008 |
Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biological Transport; Camptothecin; Cell Line, Tumor; Cell Survival; Cetuximab; Colorectal Neoplasms; Drug Interactions; Fluorodeoxyglucose F18; Fluorouracil; Glucose; Hexokinase; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Radiopharmaceuticals | 2008 |
Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Mice; Middle Aged; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin | 2008 |
Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Therapy; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Survival Analysis; Treatment Outcome | 2008 |
Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2008 |
[Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Constipation; Diarrhea; Female; Fluorouracil; Health Surveys; Humans; Leucovorin; Male; Middle Aged; Pamphlets | 2008 |
KRAS status predicts response to cetuximab for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA, Neoplasm; Fluorouracil; Gene Frequency; Humans; Leucovorin; Mutation; Patient Selection; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2008 |
New lessons from "old" chemotherapy in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pyrimidines | 2008 |
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pleural Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Irinotecan; Italy; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Models, Statistical; Placebos; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Rate | 2008 |
Clinical determinants of response to irinotecan-based therapy derived from cell line models.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gene Expression Profiling; HCT116 Cells; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Topoisomerase I Inhibitors | 2008 |
Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Salvage Therapy; Tomography, X-Ray Computed | 2008 |
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines.
Topics: Acid Anhydride Hydrolases; Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Cytotoxins; DNA Repair Enzymes; DNA-Binding Proteins; Humans; Irinotecan; Microsatellite Instability; MRE11 Homologue Protein; MutL Protein Homolog 1; Nuclear Proteins | 2008 |
Effects of nutritional support in patients with colorectal cancer during chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Body Mass Index; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Nutritional Status; Nutritional Support; Quality of Life; Retrospective Studies; Weight Loss | 2008 |
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Morbidity; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
[Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Prescriptions; ErbB Receptors; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2008 |
[The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Cyclin D1; Dihydrouracil Dehydrogenase (NADP); Epidermal Growth Factor; Fluorouracil; Glucuronosyltransferase; Glutathione Transferase; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Thymidylate Synthase | 2008 |
Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Immunosuppressive Agents; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Prodrugs; Retrospective Studies; Survival Rate; Treatment Outcome; Vitamin B Complex | 2008 |
Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2009 |
[Report from the 44th Congress of the American Society of Clinical Oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Mass Screening; Medical Oncology; Neoplasms; Organoplatinum Compounds; Societies, Medical | 2008 |
Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
Topics: Apoptosis; bcl-X Protein; Biphenyl Compounds; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Humans; Irinotecan; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2008 |
Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Palliative Care; Prospective Studies; Survival Rate; Tomography, Spiral Computed | 2009 |
A dilemma in geriatric oncology: malignant bowel obstruction in an 81-year-old man.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Intestinal Obstruction; Irinotecan; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2008 |
Recurrent disease four years after surgery and adjuvant chemotherapy.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Organoplatinum Compounds | 2008 |
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Retrospective Studies; Survival Rate | 2009 |
[Third-line treatment of intermittent hepatic arterial infusion for unresectable liver metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2008 |
[The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Leucovorin; Male; Matrix Metalloproteinase 7; Middle Aged; Organoplatinum Compounds | 2009 |
Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer: a retrospective study of case analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure | 2009 |
Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
Topics: Camptothecin; Colorectal Neoplasms; Genetic Predisposition to Disease; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Models, Biological; Neoplasm Metastasis; Neutropenia | 2009 |
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Mutation; Polymorphism, Genetic; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Retrospective Studies; Survival Analysis | 2009 |
Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Chemoembolization, Therapeutic; Colorectal Neoplasms; Doxorubicin; Female; Irinotecan; Mice; Mice, Inbred BALB C; Mitoxantrone; Peritoneal Neoplasms | 2009 |
The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Patient Selection; Polymorphism, Single Nucleotide; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Organoplatinum Compounds; Pyridines; Regression Analysis; Tumor Cells, Cultured | 2009 |
Irinotecan in cancer patients with end-stage renal failure.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Glucuronates; Humans; Irinotecan; Kidney Failure, Chronic; Male; Middle Aged; Palliative Care; Renal Dialysis | 2009 |
A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Markov Chains; Models, Econometric; Neoplasm Staging; Organoplatinum Compounds; Quality of Life; Quality-Adjusted Life Years; Sensitivity and Specificity; Treatment Outcome | 2009 |
TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genotype; HSP90 Heat-Shock Proteins; HT29 Cells; Humans; Irinotecan; Male; Middle Aged; Mitochondria; Organoplatinum Compounds; Oxaliplatin; Peptide Fragments; Phenotype; RNA, Messenger; Transfection; Up-Regulation | 2009 |
Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Liver; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pneumonectomy; Treatment Outcome | 2009 |
The CAIRO and FOCUS studies: which lesson is to be learned?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2009 |
[The optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disposable Equipment; Drug Dosage Calculations; Fluorouracil; Home Care Services; Humans; Infusion Pumps; Infusions, Intravenous; Leucovorin; Organoplatinum Compounds; Solutions; Time Factors | 2009 |
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Microsatellite Instability; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2009 |
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Interactions; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan | 2009 |
[Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Quality of Life; Surveys and Questionnaires; Taste Disorders | 2009 |
Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2009 |
Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Female; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Phytic Acid | 2009 |
Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dimerization; Drug Therapy, Combination; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Nude; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2009 |
Irinogenetics: how many stars are there in the sky?
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Genetic Predisposition to Disease; Glucuronosyltransferase; Hepatocyte Nuclear Factor 1-alpha; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neutropenia; Organic Anion Transporters; Patient Selection; Phenotype; Polymorphism, Genetic; Risk Assessment; Risk Factors; Treatment Outcome | 2009 |
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Genetic Predisposition to Disease; Glucuronides; Glucuronosyltransferase; Hepatocyte Nuclear Factor 1-alpha; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Multivariate Analysis; Neutropenia; Organic Anion Transporters; Patient Selection; Phenotype; Polymorphism, Genetic; Risk Assessment; Risk Factors; Treatment Outcome | 2009 |
Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Hypertrophy; Leucovorin; Ligation; Liver; Liver Circulation; Liver Neoplasms; Liver Regeneration; Male; Middle Aged; Organoplatinum Compounds; Portal Vein; Preoperative Care; Prospective Studies; Young Adult | 2009 |
UGT1A and irinotecan toxicity: keeping it in the family.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Glucuronosyltransferase; Humans; Irinotecan | 2009 |
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Glucuronosyltransferase; Haplotypes; Humans; Leucovorin; Linkage Disequilibrium; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Treatment Outcome; UDP-Glucuronosyltransferase 1A9 | 2009 |
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Immunohistochemistry; Irinotecan; Italy; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Mutation; Patient Selection; Phosphorylation; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Retrospective Studies; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Ciprofloxacin; Colorectal Neoplasms; Diarrhea; Female; Immunity, Mucosal; Intestinal Mucosa; Irinotecan; Lymphatic Metastasis; Neoplasm Transplantation; Rats; Rats, Inbred F344; Spleen; Survival Analysis | 2009 |
Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyrimidines; Retrospective Studies; Tegafur | 2009 |
Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
Topics: Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Camptothecin; Cell Cycle Proteins; Checkpoint Kinase 1; Colorectal Neoplasms; DNA Damage; DNA Replication; DNA-Binding Proteins; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Enzyme Inhibitors; Female; HCT116 Cells; Histones; Humans; Protein Kinases; Protein Serine-Threonine Kinases; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Topoisomerase I Inhibitors; Tumor Suppressor Proteins; Up-Regulation | 2009 |
Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Prodrugs; Tegafur | 2009 |
UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Diarrhea; DNA; DNA, Neoplasm; Ethnicity; Female; Gastrointestinal Tract; Genetic Variation; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Young Adult | 2009 |
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Irinotecan; Orotate Phosphoribosyltransferase; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2009 |
Perforating dermatosis in a patient receiving bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Skin Diseases; Treatment Outcome | 2009 |
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dexamethasone; Female; Floxuridine; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Mastectomy, Segmental; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.
Topics: Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Decision Trees; Genetic Testing; Genetic Variation; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Neoplasm Metastasis; Neutropenia; Quality of Life | 2009 |
[Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Palliative Care | 2009 |
Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
Topics: 14-3-3 Proteins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Azacitidine; Camptothecin; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; DNA Damage; DNA Methylation; DNA Topoisomerases, Type I; Drug Therapy, Combination; Epigenesis, Genetic; Humans; Irinotecan; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2009 |
[Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Survival Rate | 2009 |
Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk; Smoking; Treatment Outcome | 2009 |
[Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Organoplatinum Compounds; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Treatment Outcome | 2009 |
Cetuximab, chemotherapy and KRAS status in mCRC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Mutation; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Chi-Square Distribution; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Female; Humans; Immunohistochemistry; Irinotecan; Logistic Models; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Survival Rate | 2009 |
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Codon; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
[Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Leucovorin; Male; Polymorphism, Genetic | 2009 |
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cause of Death; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Monitoring; Fluorouracil; Humans; Irinotecan; Middle Aged; Multicenter Studies as Topic; Netherlands; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2010 |
Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; CA-19-9 Antigen; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Health Status Indicators; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Predictive Value of Tests; Retrospective Studies; Serum Albumin; Survival Analysis; Treatment Outcome | 2009 |
Efficacy of 5-FU/LV plus CPT-11 as first-line adjuvant chemotherapy for stage IIIa colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging | 2009 |
Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome; Vitamin B Complex | 2009 |
Radioembolization of liver metastases in patients with colorectal cancer: a nonsurgical treatment with combined modality potential.
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Maximum Tolerated Dose; Microspheres; Radiopharmaceuticals; Radiotherapy, Adjuvant; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; Yttrium Isotopes | 2009 |
Metastatic colorectal cancer: is surgery necessary?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Research Design; Retrospective Studies; SEER Program; Unnecessary Procedures | 2009 |
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Odds Ratio; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line; Cell Proliferation; Colorectal Neoplasms; Drug Administration Schedule; Endothelial Cells; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Male; Mice; Microvessels; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Vascular Endothelial Growth Factor A | 2009 |
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Injections, Intraperitoneal; Irinotecan; Leucovorin; Mice; Mice, Nude; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; In Situ Hybridization, Fluorescence; Irinotecan; Male; Middle Aged; Mutation; ras Proteins; Retrospective Studies; Treatment Failure | 2009 |
Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Treatment Outcome | 2009 |
Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Predictive Value of Tests | 2009 |
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pneumonectomy; Survival Rate; Treatment Outcome | 2009 |
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Gene Expression; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Ligands; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; RNA, Messenger; Survival Analysis | 2009 |
The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Skin | 2009 |
Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pilot Projects; Sirolimus; Treatment Outcome | 2009 |
Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Retrospective Studies | 2009 |
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Male; Middle Aged; Thymidylate Synthase; Treatment Outcome; Young Adult | 2009 |
Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonoscopy; Colorectal Neoplasms; Cost Savings; Cost-Benefit Analysis; Drug Costs; Female; Fluorouracil; Humans; Incidence; Leucovorin; Male; Mass Screening; Middle Aged; Neoplasm Staging; Occult Blood; Organoplatinum Compounds; SEER Program; Selection Bias; Sigmoidoscopy; Survival Rate; United States | 2009 |
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Retrospective Studies; Young Adult | 2009 |
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.
Topics: Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Gene Frequency; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Quality of Life; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Humans; Irinotecan; Mice; Mice, Nude; Piperidines; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
The impact of new treatment options for advanced colorectal cancer on routine care: results of a retrospective analysis of 206 consecutive patients treated in a community-based oncology group practice in Germany.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Retrospective Studies; Survival Analysis; Vitamin B Complex | 2010 |
UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Retrospective Studies | 2009 |
The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Young Adult | 2010 |
MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate; Treatment Outcome | 2010 |
The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Repair; DNA-Binding Proteins; Female; Follow-Up Studies; Genetic Predisposition to Disease; Genotype; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prospective Studies; Survival Analysis; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2010 |
Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; ErbB Receptors; Genes, ras; Genetic Testing; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Oxaliplatin; Precision Medicine; Protein Kinase Inhibitors; ras Proteins; Signal Transduction; Treatment Outcome | 2009 |
Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.
Topics: Acute Coronary Syndrome; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2009 |
Irinotecan and mismatch repair deficiency.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Carcinoma; Colorectal Neoplasms; DNA Mismatch Repair; DNA Repair-Deficiency Disorders; Drug Resistance, Neoplasm; Humans; Irinotecan; Liver Neoplasms; Postoperative Period; Prognosis | 2010 |
Improved first-line chemotherapy: a better chance for surgery?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Patient Selection; Time Factors; Treatment Outcome | 2010 |
PTEN status in advanced colorectal cancer treated with cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Follow-Up Studies; Gene Deletion; Gene Dosage; Gene Expression Profiling; Humans; Irinotecan; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Salvage Therapy; Signal Transduction; Treatment Outcome | 2010 |
CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Islands; DNA Methylation; Drug Combinations; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Silencing; Humans; Irinotecan; Male; Membrane Proteins; Middle Aged; Oxonic Acid; Proto-Oncogene Proteins; Tegafur | 2010 |
Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Time Factors; Treatment Failure | 2010 |
Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2010 |
Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression.
Topics: alpha-Crystallin B Chain; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Humans; Immunohistochemistry; Irinotecan; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor C | 2010 |
Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Random Allocation; Treatment Outcome; Vitamin B Complex | 2010 |
Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Genetic Variation; Humans; In Vitro Techniques; Irinotecan; Liver Neoplasms; Loss of Heterozygosity; Polyhydroxyethyl Methacrylate; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors | 2010 |
[Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Genes, ras; Humans; Irinotecan; Panitumumab | 2009 |
[The prognosis of patients with an allergic reaction in the treatment of mFOLFOX6 therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Hypersensitivity; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Prognosis | 2009 |
[Results of neo-adjuvant chemotherapy by FOLFOX and FOLFIRI for colorectal liver metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds | 2009 |
[Intermittent hepatic arterial infusion with systemic chemotherapy for metastatic colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Hepatic Artery; Humans; Infusions, Intra-Arterial; Injections, Intravenous; Irinotecan; Liver Neoplasms; Middle Aged | 2009 |
[A curative resection with the combination of portal vein branch embolization and systemic chemotherapy in a patient with synchronous multiple and bilobar colorectal liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Embolization, Therapeutic; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Portal Vein | 2009 |
Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
[Validation study of KRAS mutation in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Genes, ras; Genetic Predisposition to Disease; Genetic Testing; Humans; Leucovorin; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Pathology, Molecular; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2009 |
Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; ErbB Receptors; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Vascular Endothelial Growth Factor A | 2010 |
[Evaluation of bevacizumab for advanced colorectal cancer].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds | 2010 |
[Pulmonary embolism during palliative chemotherapy including cetuximab for metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Palliative Care; Pulmonary Embolism | 2010 |
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Immunoenzyme Techniques; Insulin-Like Growth Factor I; Irinotecan; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate | 2010 |
Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Costs and Cost Analysis; Drug Administration Schedule; Fluorouracil; Humans; Japan; Leucovorin; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2010 |
Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Medicare; Neoplasm Metastasis; Retrospective Studies; SEER Program; Treatment Outcome; United States | 2009 |
Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication.
Topics: Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Histamine H1 Antagonists; Humans; Hypersensitivity; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Premedication; Retreatment | 2010 |
Secreted protein acidic and rich in cysteine-induced cellular senescence in colorectal cancers in response to irinotecan is mediated by P53.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cellular Senescence; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; DNA Damage; Humans; Irinotecan; Mice; Osteonectin; Tumor Suppressor Protein p53 | 2010 |
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Exanthema; Fluorouracil; Folliculitis; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Panitumumab; Tomography, X-Ray Computed | 2010 |
Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
Topics: Camptothecin; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Irinotecan; Pregnane X Receptor; Receptors, Steroid; Rifampin; RNA, Messenger; RNA, Small Interfering; Transfection | 2010 |
[Prognostic analysis of patients with liver metastases from colorectal cancer treated with different modes of therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Retrospective Studies; Survival Rate; Young Adult | 2010 |
Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.
Topics: Aneurysm; Angiogenesis Inhibitors; Angiomyolipoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kidney Neoplasms; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasms, Second Primary; Tomography, X-Ray Computed | 2010 |
Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Mutation; Panitumumab; Predictive Value of Tests; Proto-Oncogene Proteins B-raf; Treatment Outcome | 2010 |
Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Blotting, Western; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Disease Progression; DNA-Binding Proteins; Female; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Irinotecan; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tissue Array Analysis; Topoisomerase I Inhibitors; Treatment Outcome; Tumor Cells, Cultured | 2010 |
[Optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients (2nd report)-influence of temperature on outflow speed of the medicinal solution].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disposable Equipment; Fluorouracil; Humans; Infusion Pumps; Infusions, Intravenous; Leucovorin; Organoplatinum Compounds; Regression Analysis; Solutions; Temperature; Time Factors; Viscosity | 2010 |
[Prognostic factors and survival of metastatic colorectal cancer in the Sousse University Hospital (Tunisia): comparative study of two treatment period of 200 patients].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tunisia; Young Adult | 2010 |
Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Competence; Colorectal Neoplasms; Dermatology; Drug Eruptions; Humans; Irinotecan; Medical Oncology; Middle Aged; Neoplasm Metastasis; Observer Variation; Pilot Projects | 2010 |
Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Fatty Liver; Female; Humans; Irinotecan; Liver Circulation; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2010 |
Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Indocyanine Green; Irinotecan; Leucovorin; Liver; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Recovery of Function; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fibrin Fibrinogen Degradation Products; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Sensitivity and Specificity; Sepsis; Venous Thromboembolism | 2010 |
[Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hospitals, General; Hospitals, Public; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study.
Topics: Adult; Aged; Alabama; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chi-Square Distribution; Colorectal Neoplasms; Czech Republic; Female; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Kentucky; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Proportional Hazards Models; Prospective Studies; Registries; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Quebec; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Clubbing and hypertrophic osteoarthropathy in two patients taking long-term bevacizumab for metastatic colorectal cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Osteoarthropathy, Secondary Hypertrophic; Treatment Outcome | 2011 |
Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2010 |
Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer.
Topics: Adenocarcinoma; Adenoma, Villous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Gastrectomy; Humans; Leucovorin; Liver Neoplasms; Male; Neoplasm Staging; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2011 |
Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Gene Frequency; Genotype; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Panitumumab; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Skin; Treatment Outcome | 2010 |
[Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Salvage Therapy; Survival Rate | 2010 |
p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-Associated Death Protein; Camptothecin; Caspase 8; Cell Adhesion; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Humans; p21-Activated Kinases; Phosphorylation; Plasmids; Poly(ADP-ribose) Polymerases; Signal Transduction; Transfection | 2010 |
Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Incidence; Intestinal Diseases; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Postoperative Complications; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Genotype; Humans; Irinotecan; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Retrospective Studies; Treatment Outcome | 2011 |
Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Costs and Cost Analysis; Disease-Free Survival; Dose-Response Relationship, Drug; Fee Schedules; Fluorouracil; Japan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome | 2010 |
Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Compassionate Use Trials; Denmark; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrroles; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Sunitinib; Treatment Outcome | 2010 |
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Treatment Failure | 2011 |
Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cetuximab; Colorectal Neoplasms; Cross-Over Studies; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies | 2010 |
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Glucuronosyltransferase; Health Surveys; Humans; Irinotecan; Mitomycin; Neutropenia; Organoplatinum Compounds; Pyridines; Risk Factors; State Medicine; United Kingdom | 2010 |
Effects of methimazole on the elimination of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Antithyroid Agents; Camptothecin; Colorectal Neoplasms; Drug Interactions; Glucuronides; Glucuronosyltransferase; Graves Disease; Humans; Irinotecan; Male; Methimazole; Middle Aged | 2011 |
When more is worse in clinical research and clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomedical Research; Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis; Panitumumab; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Reproducibility of Results | 2010 |
Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS).
Topics: Acetonitriles; Camptothecin; Chromatography, Liquid; Colorectal Neoplasms; Drugs, Chinese Herbal; Formates; Humans; Irinotecan; Tandem Mass Spectrometry | 2010 |
Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Retrospective Studies | 2010 |
Glycolytic flux occurs in Drosophila melanogaster recovering from camptothecin treatment.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carrier Proteins; Cell Division; Colorectal Neoplasms; Drosophila melanogaster; Drosophila Proteins; Drug-Related Side Effects and Adverse Reactions; Female; Genital Neoplasms, Female; Glycolysis; Humans; Proteomics; Pyruvates; Recovery of Function; Tumor Suppressor Protein p53 | 2010 |
Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cohort Studies; Colorectal Neoplasms; Drug Delivery Systems; Feasibility Studies; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
[mRNA quantification. The next challenge in routine diagnostics].
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Molecular Diagnostic Techniques; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; RNA, Messenger; Survival Rate; Thymidylate Synthase | 2010 |
Dietary glycine protects from chemotherapy-induced hepatotoxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Dietary Supplements; Drug-Related Side Effects and Adverse Reactions; Fatty Liver; Female; Fluorouracil; Glycine; Immunohistochemistry; Irinotecan; Kupffer Cells; Leucovorin; Liver; Microcirculation; Neoadjuvant Therapy; Nitric Oxide Synthase Type II; Organoplatinum Compounds; Oxaliplatin; Phagocytosis; Rats; Rats, Sprague-Dawley; Transaminases | 2011 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
Outcomes in the management of obstructive unresectable stage IV colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Colostomy; Comorbidity; Emergencies; Female; Fluorouracil; Humans; Intestinal Obstruction; Kaplan-Meier Estimate; Length of Stay; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Palliative Care; Quality of Life; Retrospective Studies; Stents; Treatment Outcome | 2010 |
Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Carcinoembryonic Antigen; Colorectal Neoplasms; Dendritic Cells; Female; Fluorouracil; Leucovorin; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory | 2010 |
EGFR antibodies in colorectal cancer: where do they belong?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Leucovorin; Multicenter Studies as Topic; Mutation; Organoplatinum Compounds; Panitumumab; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; ras Proteins | 2010 |
Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Genotype; Humans; Irinotecan; Neoplasm Metastasis; Pharmacogenetics; Survival Analysis; Time Factors; Vascular Endothelial Growth Factor A | 2010 |
A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Drug Tolerance; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Rectal Neoplasms; Retrospective Studies; Safety; Spain; Treatment Outcome | 2010 |
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genetic Association Studies; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Japan; Leucovorin; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prodrugs; Retrospective Studies; Survival Analysis; Topoisomerase I Inhibitors | 2011 |
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Research Design; Survival Rate; Tomography, X-Ray Computed | 2010 |
Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Focal Nodular Hyperplasia; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2011 |
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Blood Cell Count; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Creatinine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Hemoglobins; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Patient Selection | 2010 |
Guesstimates are not good enough for determining what is happening in routine care.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Glucuronosyltransferase; Humans; Irinotecan | 2010 |
[Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Organoplatinum Compounds; Patient Care Team; Treatment Outcome | 2010 |
[Two cases of colorectal cancer presenting with periodic, transient elevation of serum iron after chemotherapy including irinotecan].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Iron; Transferrin | 2010 |
Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Irinotecan; Male; Matrix Metalloproteinase 7; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Incidence; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nasal Septum; Nose Diseases; Organoplatinum Compounds; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Colorectal Neoplasms; Dendrimers; Humans; Irinotecan | 2011 |
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Genotype; Humans; Irinotecan; Kaplan-Meier Estimate; Magnesium; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2011 |
Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Camptothecin; Cohort Studies; Colorectal Neoplasms; Drug Combinations; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Failure | 2011 |
Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Palliative Care; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Professional Practice; Standard of Care; Treatment Outcome; Young Adult | 2011 |
Effect of kaempferol on lipid peroxidation and antioxidant status in 1,2-dimethyl hydrazine induced colorectal carcinoma in rats.
Topics: 1,2-Dimethylhydrazine; Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Camptothecin; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Irinotecan; Kaempferols; Lipid Peroxidation; Male; Rats; Rats, Wistar; Species Specificity | 2011 |
Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Germany; Health Status Indicators; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Peritoneal Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Pharmacogenetics; Polymorphism, Single Nucleotide; Predictive Value of Tests; Proportional Hazards Models; Radiography; Vascular Endothelial Growth Factor A | 2011 |
Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Calcium-Binding Proteins; Camptothecin; Cell Separation; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Irinotecan; Membrane Proteins; Mice; Mice, SCID; Mutation; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2011 |
Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Female; Fluorouracil; Humans; Indocyanine Green; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Survival Rate; Treatment Outcome | 2011 |
RECQL5 is an important determinant for camptothecin tolerance in human colorectal cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Gene Knockout Techniques; HCT116 Cells; Humans; Mice, Inbred BALB C; Mice, Nude; RecQ Helicases; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Genes, ras; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Mutation; Prognosis; Receptor, ErbB-3; Retrospective Studies; Treatment Outcome | 2011 |
[Our experience of the treatment with cetuximab for unresectable advanced colorectal cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged | 2010 |
[Prehepatectomy chemotherapy using hepatic artery infusion plus systemic chemotherapy for liver metastases from colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds | 2010 |
[The efficacy of cetuximab for metastatic colorectal cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Rectal Neoplasms; Sigmoid Neoplasms | 2010 |
[Hepatic resection after systemic chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Hepatectomy; Humans; Irinotecan; Length of Stay; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Tegafur; Uracil | 2010 |
[A case of unresectable multiple hepatic metastases from colorectal cancer successfully treated with IRIS (S-1, CPT-11) therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Oxonic Acid; Tegafur; Tumor Burden | 2010 |
[Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Parenteral; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Salvage Therapy | 2010 |
Changing management and survival in patients with stage IV colorectal cancer.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antineoplastic Agents; Australia; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Colostomy; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Proportional Hazards Models; Pyrimidines; Radiotherapy, Adjuvant; Survival Rate | 2011 |
Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bevacizumab; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Platelet Count; Radiography; Retrospective Studies; Splenomegaly | 2011 |
Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Microspheres; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2011 |
Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Genotype; Glucuronosyltransferase; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Pharmacogenetics; Pilot Projects; Polymerase Chain Reaction; Survival Rate; Thymidylate Synthase; Treatment Outcome; Young Adult | 2011 |
R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neutropenia; Polymorphism, Genetic | 2011 |
Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Epistaxis; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Hypertension; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Proteinuria; Retrospective Studies; Tegafur; Thrombosis; Treatment Outcome | 2011 |
Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Japan; Leucovorin; Lung Diseases, Interstitial; Male; Medical Records Systems, Computerized; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Pulmonary Fibrosis; Retrospective Studies; Severity of Illness Index; Smoking; Tomography, X-Ray Computed | 2011 |
Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Diarrhea; Feasibility Studies; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2011 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Child; Child, Preschool; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infant; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Hepatic arterial infusion chemotherapy prior to standard systemic chemotherapy in patients with highly advanced unresectable liver metastases from colorectal cancer: a report of three patients.
Topics: Angiography; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization; Colorectal Neoplasms; Combined Modality Therapy; Embolization, Therapeutic; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds | 2011 |
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Japan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Retrospective Studies | 2011 |
Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies | 2011 |
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Irinotecan-cetuximab-bevacizumab as a salvage treatment in heavily pretreated metastatic colorectal cancer patients: a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Salvage Therapy | 2011 |
CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis.
Topics: Abdominal Wall; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Hyaluronan Receptors; Hyaluronic Acid; Inhibitory Concentration 50; Injections, Intraperitoneal; Irinotecan; Male; Neoplasm Transplantation; Peritoneal Neoplasms; Random Allocation; Rats; Rats, Inbred Strains | 2011 |
Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Decision Trees; Fluorouracil; Genetic Testing; Genotype; Glucuronosyltransferase; Granulocyte Colony-Stimulating Factor; Humans; Leucovorin; Models, Economic; Neutropenia; Polymorphism, Genetic; Severity of Illness Index | 2010 |
Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; DNA Methylation; Female; Genes, erbB-1; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Promoter Regions, Genetic; Treatment Outcome | 2011 |
Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
Topics: Adenocarcinoma; Anastomotic Leak; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Organoplatinum Compounds; Surgical Wound Dehiscence | 2011 |
In vitro cytotoxic effect of ethanol extract prepared from sporophyll of Undaria pinnatifida on human colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Colorectal Neoplasms; Culture Media; Ethanol; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Plant Extracts; Seaweed; Undaria; Xanthophylls | 2012 |
Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2011 |
Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Risk; Survival Analysis; Vitamin B Complex | 2011 |
Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Activity of aspirin analogues and vanillin in a human colorectal cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; Aspirin; Benzaldehydes; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Humans; Inhibitory Concentration 50; Irinotecan | 2011 |
New Topoisomerase I mutations are associated with resistance to camptothecin.
Topics: Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Cell Cycle; Cell Line, Tumor; Clone Cells; Colorectal Neoplasms; DNA Breaks, Double-Stranded; DNA Replication; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; HCT116 Cells; Humans; Mutation; Protein Structure, Secondary; Topoisomerase I Inhibitors | 2011 |
Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Delivery Systems; Fluorouracil; Follow-Up Studies; Genes, ras; Germany; Humans; Leucovorin; Liver Neoplasms; Models, Economic; Models, Statistical; Organoplatinum Compounds; Survival Rate | 2011 |
Comparative proteomic analysis of irinotecan-sensitive colorectal carcinoma cell line and its chemoresistant counterpart.
Topics: Actin Depolymerizing Factors; Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Image Processing, Computer-Assisted; Irinotecan; Molecular Sequence Data; Neoplasm Proteins; Phosphopyruvate Hydratase; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2011 |
Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2011 |
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Middle Aged; Models, Statistical; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factors | 2011 |
The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Statistics as Topic | 2011 |
Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Research Design | 2011 |
Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Epidermal Growth Factor; Female; Humans; Irinotecan; Keratitis; Lung Neoplasms; Ophthalmic Solutions | 2011 |
Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression; Humans; Leucovorin; Male; Microarray Analysis; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Thymidylate Synthase; Tissue Inhibitor of Metalloproteinase-3; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Gene Dosage; Genes, erbB-1; Genes, ras; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins B-raf; Xenograft Model Antitumor Assays | 2011 |
Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Humans; Mice; Models, Molecular; Nanoparticles; Silicon Dioxide; Surface Properties; Tissue Distribution | 2011 |
Cetuximab after bevacizumab in metastatic colorectal cancer: is it the best sequence?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Genes, ras; Humans; Irinotecan; Kaplan-Meier Estimate; Neoplasm Metastasis; Organoplatinum Compounds; Proportional Hazards Models; Pyridines; Treatment Failure; Vascular Endothelial Growth Factor A | 2011 |
Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Treatment Outcome | 2011 |
Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Treatment Outcome | 2011 |
[Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Quality of Life; Surveys and Questionnaires; Tegafur | 2011 |
Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Neoplasm Seeding; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prospective Studies; Second-Look Surgery; Tumor Burden; Young Adult | 2011 |
Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
[Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Blood Pressure; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Forecasting; Humans; Hypertension; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
[Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Salvage Therapy | 2011 |
Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; National Cancer Institute (U.S.); Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Reference Standards; United States | 2012 |
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Organoplatinum Compounds; Quinazolines; Thyroid Neoplasms; Transcriptional Activation; Treatment Failure; Treatment Outcome | 2011 |
Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Japan; Leucovorin; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Patient Selection | 2011 |
Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Comorbidity; Drug Approval; Female; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2011 |
Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Incidence; Infusions, Intravenous; Irinotecan; Japan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Patient Selection; Polymorphism, Genetic; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Surveys and Questionnaires; Thrombocytopenia | 2011 |
Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Body Surface Area; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Precision Medicine | 2011 |
Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
Topics: Aged; Alleles; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Female; Gastrointestinal Diseases; Genetic Predisposition to Disease; Genotype; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide | 2011 |
Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathepsins; Cell Line, Tumor; Colon; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; Gene Expression; Humans; Irinotecan; Mice; Mice, Nude; Neovascularization, Pathologic; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost Savings; Cost-Benefit Analysis; ErbB Receptors; Fluorouracil; Genetic Testing; Germany; Humans; Irinotecan; Leucovorin; Markov Chains; Monte Carlo Method; Mutation; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United States | 2012 |
Sequential chemotherapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Organoplatinum Compounds | 2011 |
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
Novel activity of acriflavine against colorectal cancer tumor cells.
Topics: Acriflavine; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Female; Fluorouracil; High-Throughput Screening Assays; Humans; Irinotecan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2011 |
[Cetuximab-associated skin ulceration in patient with metastatic colorectal cancer: a case report].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Lymphatic Metastasis; Skin Ulcer; Tomography, X-Ray Computed | 2011 |
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Fluorouracil; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polycomb Repressive Complex 2; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Transcription Factors; Treatment Outcome | 2012 |
Preparation of camptothecin-loaded PCEC microspheres for the treatment of colorectal peritoneal carcinomatosis and tumor growth in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug Carriers; Mice; Microscopy, Electron, Scanning; Microspheres; Particle Size; Peritoneal Neoplasms; Polymers | 2011 |
Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Premedication; Survival Rate | 2012 |
Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Administration Routes; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2011 |
Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dexamethasone; Drug Therapy, Combination; Female; Humans; Incidence; Irinotecan; Male; Middle Aged; Nausea; Prospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2011 |
Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Choline Kinase; Choline-Phosphate Cytidylyltransferase; Colorectal Neoplasms; Female; Flavonoids; HCT116 Cells; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Mice; Phosphorus Isotopes; Piperidines; Protons; Saccharomyces cerevisiae; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
Looking through the vascular normalization window: timing antiangiogenic treatment and chemotherapy with (99m)Tc-annexin A5.
Topics: Animals; Annexin A5; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Irinotecan; Neovascularization, Pathologic; Organotechnetium Compounds; Tomography, Emission-Computed, Single-Photon | 2011 |
A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Ribonucleoproteins, Small Nuclear; RNA Interference; RNA, Small Interfering; Systems Biology | 2012 |
[Induced nausea and vomiting induced by mFOLFOX6 and FOLFIRI with advanced colorectal cancer: a retrospective survey].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Forecasting; Humans; Leucovorin; Logistic Models; Male; Middle Aged; Nausea; Organoplatinum Compounds; Retrospective Studies; Risk Factors; Sex Factors; Vomiting | 2011 |
Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab.
Topics: 3' Untranslated Regions; 5' Untranslated Regions; Alleles; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Creatinine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Fluorouracil; Genetic Association Studies; Glycine Hydroxymethyltransferase; Homocysteine; Humans; Hypertension; INDEL Mutation; Leucovorin; Methylenetetrahydrofolate Reductase (NADPH2); Polymorphism, Genetic; Prognosis; Thymidylate Synthase; Treatment Outcome | 2012 |
(99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
Topics: Actins; Angiopoietin-1; Animals; Annexin A5; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Camptothecin; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cell Transformation, Neoplastic; Colorectal Neoplasms; Female; Irinotecan; Mice; Microvessels; Neovascularization, Pathologic; Organotechnetium Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Tomography, Emission-Computed, Single-Photon; Transcription, Genetic; Tumor Burden; Vascular Endothelial Growth Factor A | 2011 |
Peri-operative chemotherapy for resectable colorectal liver metastasis: does timing of systemic therapy matter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Matched-Pair Analysis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Propensity Score; Young Adult | 2012 |
Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; DNA Repair; Fluorouracil; Genetic Engineering; Humans; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Time Factors | 2012 |
Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts.
Topics: Animals; Annexin A2; Antineoplastic Agents; Apoptosis; Calpain; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; I-kappa B Proteins; Irinotecan; Mice; Mice, Inbred Strains; Mice, Nude; Neoplasm Transplantation; NF-kappa B; Pyrimidines; S100 Proteins; Transfection; Xenograft Model Antitumor Assays | 2012 |
The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization, Central Venous; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2012 |
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gene Dosage; Humans; Insulin-Like Growth Factor I; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; NF-kappa B; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor, ErbB-3; Retrospective Studies; Treatment Outcome | 2012 |
Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, SCID; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Europe; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Treatment Outcome; Young Adult | 2012 |
TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity.
Topics: Camptothecin; Cell Death; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Statistics, Nonparametric | 2012 |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Blotting, Western; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Death, Sudden; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged | 2012 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Doxorubicin; Etoposide; Floxuridine; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomic Instability; Humans; Irinotecan; Metaphase; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Protein Array Analysis; Reproducibility of Results; Tegafur; Tissue Array Analysis; Tumor Cells, Cultured; Up-Regulation; Uracil | 2012 |
In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Chromatography, Supercritical Fluid; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Compounding; Humans; Mice; Mice, Inbred BALB C; Nanotechnology; Solvents; Technology, Pharmaceutical; Topoisomerase I Inhibitors; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: 3' Flanking Region; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Dosage; Genetic Association Studies; Glucuronosyltransferase; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Retrospective Studies; Survival Analysis | 2012 |
Treatment results of peritonectomy combined with perioperative chemotherapy for colorectal cancer-patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pelvic Exenteration; Peritoneal Neoplasms; Young Adult | 2011 |
Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2012 |
Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Drug Synergism; Etoposide; Flow Cytometry; Fluorouracil; Humans; Inhibitor of Apoptosis Proteins; Male; Prostatic Neoplasms; Quercetin; Survivin; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2012 |
[Importance and practice of UGT1A1 polymorphisms].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic | 2011 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2011 |
[Safety and efficacy of FOLFOX and FOLFIRI in elderly patients with colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds | 2011 |
Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2012 |
Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Comorbidity; Female; Humans; Intestinal Perforation; Irinotecan; Kaplan-Meier Estimate; Male; Medicare; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stroke; Survival Rate; United States | 2012 |
Viewing metastatic colorectal cancer as a curable chronic disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Bevacizumab; Camptothecin; Cetuximab; Chronic Disease; Colorectal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Metastasectomy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Recurrence; Reoperation; Survival Rate | 2012 |
Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chi-Square Distribution; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Ultrasonography | 2012 |
The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Markov Chains; Organoplatinum Compounds; Oxaliplatin; Prognosis; Quality-Adjusted Life Years; Risk Factors; State Medicine; Survival Analysis; United Kingdom | 2012 |
Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Indoles; Irinotecan; Mutation; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Purines; ras Proteins; TOR Serine-Threonine Kinases; Transcription Factors | 2012 |
Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG | 2012 |
Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2012 |
Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Mice; Mice, Nude; Microarray Analysis; Sulfonamides; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Fluorouracil; Genotype; Humans; Leucovorin; Middle Aged; Polycomb Repressive Complex 2; Polymorphism, Single Nucleotide; Prognosis; Risk Assessment; Survival Analysis; Transcription Factors | 2012 |
What is a safe future liver remnant size in patients undergoing major hepatectomy for colorectal liver metastases and treated by intensive preoperative chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Preoperative Care; Prognosis; Survival Rate | 2012 |
SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Division; Cell Hypoxia; Colorectal Neoplasms; Drug Resistance, Neoplasm; Flow Cytometry; Fluorouracil; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2012 |
Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Indocyanine Green; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Prognosis; Risk Factors; Survival Rate | 2012 |
Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Republic of Korea; Retrospective Studies; Treatment Outcome | 2012 |
Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Receptors, Androgen; RNA Interference; RNA, Small Interfering; Sex Characteristics; Steroid 17-alpha-Hydroxylase; Treatment Outcome; Tubulin | 2012 |
Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 9; Caspases; Colorectal Neoplasms; Drug Synergism; G1 Phase; Ginsenosides; HCT116 Cells; Humans; Irinotecan; Panax; Phytotherapy; Plant Extracts | 2012 |
Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Retrospective Studies | 2012 |
Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fibrosis; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Mucins; Multivariate Analysis; Necrosis; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prognosis; Retrospective Studies; Single-Blind Method | 2012 |
Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; England; Female; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Proportional Hazards Models; Reoperation; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2012 |
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Phosphorylation; Proto-Oncogene Proteins c-akt; Treatment Outcome | 2012 |
Effects of depletion of dihydropyrimidine dehydrogenase on focus formation and RPA phosphorylation.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Damage; Humans; Phosphorylation; Radiation Dosage; Radiation Tolerance; Replication Protein A | 2012 |
ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer.
Topics: Aldehyde Dehydrogenase; Amyloid Precursor Protein Secretases; Animals; Camptothecin; Colorectal Neoplasms; Female; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Mice; Mice, Nude; Receptor, Notch1; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chi-Square Distribution; Colorectal Neoplasms; Cryosurgery; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Proportional Hazards Models; Retrospective Studies; Tumor Burden; Young Adult | 2012 |
The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic | 2012 |
N-glycan biosynthesis inhibitors induce in vitro anticancer activity in colorectal cancer cells.
Topics: Blotting, Western; Caco-2 Cells; Camptothecin; Cell Movement; Cell Survival; Cisplatin; Colorectal Neoplasms; Flow Cytometry; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Polysaccharides; Swainsonine; Tunicamycin | 2012 |
Central venous port system-related complications in outpatient chemotherapy for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Catheterization, Central Venous; Catheters, Indwelling; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Outpatients | 2012 |
Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Colorectal Neoplasms; Contraindications; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Tumor Burden | 2012 |
Combined portal vein embolization and preoperative chemotherapy prior to liver resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Blood Loss, Surgical; Blood Volume; Camptothecin; Carcinoma; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Embolization, Therapeutic; Female; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Length of Stay; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Operative Time; Organoplatinum Compounds; Oxaliplatin; Portal Vein; Retrospective Studies; Statistics, Nonparametric | 2012 |
Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
Complete calcification of colorectal liver metastases on imaging after chemotherapy does not indicate sterilization of disease.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Tomography, Spiral Computed; Treatment Outcome; Ultrasonography | 2012 |
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Databases, Factual; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Mitogen-Activated Protein Kinases; Reproducibility of Results; Signal Transduction; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2012 |
3D superhydrophobic electrospun meshes as reinforcement materials for sustained local drug delivery against colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Delivery Systems; Glycerol; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Monoglycerides; Polyesters; Stearates | 2012 |
Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation Disorders; Blood Coagulation Tests; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Thrombelastography | 2012 |
Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Chemokine CCL22; Cohort Studies; Colorectal Neoplasms; Epidermal Growth Factor; Female; Humans; Interleukins; Irinotecan; Male; Middle Aged | 2012 |
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
Bradycardia associated with drug-eluting beads loaded with irinotecan (DEBIRI) infusion for colorectal liver metastases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bradycardia; Camptothecin; Colorectal Neoplasms; Cone-Beam Computed Tomography; Drug Delivery Systems; Electrocardiography; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2013 |
Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Retrospective Studies; Treatment Outcome | 2012 |
Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Products; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cohort Studies; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Hyperthermia, Induced; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Peritoneal Neoplasms; Retrospective Studies; Treatment Outcome; United States | 2013 |
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.
Topics: Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Mice; Microsatellite Instability; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rats; Xenograft Model Antitumor Assays | 2012 |
First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI).
Topics: Aged; Aged, 80 and over; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Drug Delivery Systems; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2012 |
Enhanced chemosensitivity to CPT-11 in colorectal carcinoma xenografts by small hairpin RNA interference targeting PLK1.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA Interference; Xenograft Model Antitumor Assays | 2012 |
Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Antigens, CD; Antigens, Neoplasm; Apoptosis; Biomarkers, Tumor; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Flow Cytometry; Glycoproteins; Humans; Hyaluronan Receptors; Isoenzymes; Neoplastic Stem Cells; Peptides; Retinal Dehydrogenase | 2012 |
Irinotecan induces senescence and apoptosis in colonic cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma; Cellular Senescence; Colon; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; DNA Damage; Fibroblasts; Gene Expression Regulation; Gene Knockdown Techniques; HCT116 Cells; Humans; Irinotecan; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Signal Transduction; Tumor Suppressor Protein p53 | 2012 |
[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Isoquinolines; Leucovorin; Male; Middle Aged; Nausea; Organoplatinum Compounds; Palonosetron; Quinuclidines; Retrospective Studies; Vomiting | 2012 |
K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins B-raf | 2012 |
In vivo real-time imaging of chemotherapy response on the liver metastatic tumor microenvironment using multiphoton microscopy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Green Fluorescent Proteins; HT29 Cells; Humans; Leucovorin; Liver; Liver Neoplasms; Luminescent Proteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microscopy, Confocal; Neoplasm Transplantation; Organoplatinum Compounds; Red Fluorescent Protein; Transplantation, Heterologous; Tumor Microenvironment | 2012 |
Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Female; Fluorouracil; Hospitalization; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Office Visits; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Palliative Care; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Retrospective Studies; Scandinavian and Nordic Countries; Sweden | 2012 |
The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2013 |
A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Periodontitis; Prednisone; Retrospective Studies; Treatment Outcome; Vindesine | 2013 |
Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Device Approval; Drug Approval; Fluorouracil; Genetic Testing; Humans; Leucovorin; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United States; United States Food and Drug Administration | 2012 |
Colorectal cancer targeted Irinotecan-Assam Bora rice starch based microspheres: a mechanistic, pharmacokinetic and biochemical investigation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Colon; Colorectal Neoplasms; Emulsions; Gastrointestinal Tract; Irinotecan; Liver; Male; Microspheres; Oryza; Rats; Solvents; Starch; Time Factors; Tissue Distribution | 2013 |
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Outcome; Young Adult | 2012 |
First description of an uterine perforation potentially imputable to treatment with bevacizumab.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Fatal Outcome; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Tomography, X-Ray Computed; Uterine Perforation | 2012 |
Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Retrospective Studies; Risk Factors; Treatment Outcome | 2013 |
Clinical outcome of up-front surgery in patients with asymptomatic, incurable synchronous peritoneal carcinomatosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Humans; Intestinal Obstruction; Irinotecan; Male; Middle Aged; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cetuximab; Colorectal Neoplasms; Epidermal Growth Factor; Female; Humans; Irinotecan; Japan; Male; Middle Aged; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Analysis | 2012 |
Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Signal Transduction; STAT3 Transcription Factor; Survival Rate | 2013 |
A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Irinotecan; Liver Neoplasms; Logistic Models; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Propensity Score; Proportional Hazards Models; Registries; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells.
Topics: Adenocarcinoma; Adult; Antimutagenic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Damage; DNA Repair; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Lung Neoplasms; Lymphocytes; Melatonin; Young Adult | 2013 |
Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Topoisomerases, Type I; DNA-Binding Proteins; Drug Combinations; Endonucleases; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Leucovorin; Male; Middle Aged; National Cancer Institute (U.S.); Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Real-Time Polymerase Chain Reaction; Retrospective Studies; RNA, Messenger; Tegafur; United States; Up-Regulation | 2012 |
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Topics: Alleles; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Codon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Frequency; Humans; Irinotecan; Leucovorin; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; ras Proteins; Retrospective Studies; Survival Analysis | 2013 |
Hepatic arterial infusion of irinotecan, 5-Fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate | 2012 |
Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; HCT116 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Peritoneal Neoplasms; Serum Albumin, Bovine; Solubility; Xenograft Model Antitumor Assays | 2013 |
Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; China; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Thymidylate Synthase; Treatment Outcome | 2012 |
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Survival Rate | 2013 |
[Predictive value of Köhne's index on the efficacy of FOLFIRI regimen in the treatment of unresectable liver metastatsis of colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Retrospective Studies | 2012 |
Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; SEER Program | 2013 |
Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retreatment; Young Adult | 2013 |
Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Retrospective Studies | 2013 |
New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides | 2002 |
ERBITUX as a single agent and in combination in colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2002 |
Another NICE mess.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Legislation, Drug; Organizational Policy; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; State Medicine; United Kingdom | 2002 |
Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Nuclear Proteins; Oligonucleotides, Antisense; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Survival Rate; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Carboxylic Ester Hydrolases; Cloning, Molecular; Colorectal Neoplasms; DNA, Complementary; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Gene Library; Humans; Hydrolysis; Irinotecan; Isoelectric Focusing; Kinetics; Protein Isoforms; Time Factors; Transfection; Tumor Cells, Cultured | 2002 |
Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quinazolines; Thiophenes; Treatment Failure | 2002 |
[Gastrointestinal toxicity caused by irinotecan in the case of preexistent passage problems].
Topics: Abdominal Pain; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fever; Humans; Intestinal Obstruction; Irinotecan; Leukopenia; Middle Aged; Stents | 2002 |
25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2001 |
Perspectives in colorectal cancer meeting. Miami, Florida. September 28-29, 2001.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Guanylate Cyclase; Humans; Irinotecan; Microsatellite Repeats; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Receptors, Enterotoxin; Receptors, Guanylate Cyclase-Coupled; Receptors, Peptide | 2001 |
Capecitabine combinations in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2001 |
Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Retrospective Studies; Survival Analysis; United States; United States Food and Drug Administration | 2002 |
Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Product Surveillance, Postmarketing; Survival Analysis; United States; United States Food and Drug Administration | 2002 |
Lessons learned from the Saltz and Mayo Clinic regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration | 2002 |
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2002 |
Systemic chemotherapy for metastatic colorectal cancer: reasons to combine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2002 |
Erbitux trial flawed from the beginning, committee finds.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Approval; Drug Synergism; Humans; Irinotecan; Research Design; Treatment Outcome; United States; United States Food and Drug Administration | 2002 |
Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Europe; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2002 |
[Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Outpatients; Oxonic Acid; Paclitaxel; Pyridines; Retrospective Studies; Stomach Neoplasms; Tegafur | 2002 |
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Fluorouracil; Follow-Up Studies; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Life Tables; Lymphokines; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Nitrates; Nitric Oxide; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Rectal Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2003 |
Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Ceramides; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fumonisins; Glucosylceramides; Humans; Irinotecan; Morpholines; Protein Kinase C; Sphingolipids; Sphingosine; Tumor Cells, Cultured | 2003 |
Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Retrospective Studies; Salvage Therapy; Time Factors | 2002 |
Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Camptothecin; Cell Division; Colorectal Neoplasms; Cyclin D1; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytoskeletal Proteins; Dinoprostone; Drug Synergism; Endothelial Growth Factors; Fluorouracil; Intercellular Signaling Peptides and Proteins; Interleukin-10; Interleukin-12; Irinotecan; Isoenzymes; Lactones; Liver Neoplasms, Experimental; Lymphokines; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Prostaglandin-Endoperoxide Synthases; Sulfones; Trans-Activators; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Hepatic artery infusion for liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
[Optimal dosing schedule in combination therapy with irinotecan and doxifluridine in a human colorectal cancer xenograft model].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Floxuridine; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation | 2003 |
Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.
Topics: Antidiarrheals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drugs, Chinese Herbal; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Aphidicolin; Apoptosis; Camptothecin; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; DNA Topoisomerases, Type I; DNA-Binding Proteins; E2F Transcription Factors; E2F1 Transcription Factor; Genes, p53; Genetic Therapy; Genetic Vectors; Humans; Male; Mice; Mice, Inbred BALB C; Topoisomerase I Inhibitors; Transcription Factors | 2003 |
[A case of metastatic liver tumor of colorectal cancer responding to low-dose CPT-11 chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2003 |
Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bacitracin; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Neomycin | 2003 |
[The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Cisplatin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Stomach Neoplasms | 2003 |
Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Topics: Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; beta-Galactosidase; Camptothecin; Cell Cycle; Cell Division; Cell Line, Tumor; Cellular Senescence; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Fluorescent Dyes; Genes, p53; Humans; Immunoblotting; Irinotecan; Oligonucleotides, Antisense; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Time Factors; Topoisomerase I Inhibitors | 2003 |
Chemotherapy with irinothecan, 5-fluorouracil and folinic acid in the first-line management of advanced colorectal carcinoma: retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2003 |
Intestinal permeability in colorectal cancer patients treated by raltitrexed or irinotecan.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Intestinal Mucosa; Irinotecan; Male; Middle Aged; Permeability; Quinazolines; Thiophenes | 2003 |
Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Nail Diseases; Nails | 2003 |
Validation of the role of angiogenesis as a chemotherapeutic target.
Topics: Adaptation, Physiological; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Fluorouracil; Humans; Irinotecan; Leucovorin; Neovascularization, Pathologic; Randomized Controlled Trials as Topic; Survival Analysis; Wound Healing | 2003 |
Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Endothelial Growth Factors; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Lymphokines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis | 2003 |
Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases | 2003 |
Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Base Pair Mismatch; bcl-2-Associated X Protein; Camptothecin; Carrier Proteins; Colorectal Neoplasms; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Exons; Female; Gene Deletion; Genomic Instability; Humans; Irinotecan; Male; Middle Aged; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 2003 |
Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Vomiting | 2003 |
Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Flow Cytometry; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, MHC Class I; Humans; Irinotecan; Mice; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Up-Regulation | 2003 |
Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Approval; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Netherlands; Program Evaluation; Treatment Outcome | 2003 |
Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan | 2003 |
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Topics: Animals; Apoptosis; Camptothecin; Cell Division; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Poly(ADP-ribose) Polymerases; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |
First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Health Care Costs; Hepatic Artery; Humans; Immunosuppressive Agents; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Patient Selection; Treatment Outcome | 2004 |
Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gilbert Disease; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies | 2004 |
Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Ploidies; Predictive Value of Tests; Treatment Outcome | 2004 |
Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Genes, p53; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Tumor Suppressor Protein p53 | 2004 |
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors | 2004 |
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Costs; Humans; Hypoalbuminemia; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Prognosis; Sample Size | 2004 |
Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Survival Analysis; Treatment Outcome | 2004 |
An immediate hemolytic reaction induced by repeated administration of oxaliplatin.
Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antibody Specificity; Antigens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Grouping and Crossmatching; Blood Transfusion; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Disease Progression; Fatal Outcome; Female; Fluorouracil; Humans; Immunoglobulin G; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2004 |
Two new drugs for colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Humans; Irinotecan; Lung Neoplasms; Pancreatic Neoplasms | 2004 |
The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines.
Topics: Base Sequence; Camptothecin; Cell Division; Cell Line, Tumor; Colorectal Neoplasms; Cyclin-Dependent Kinases; Etoposide; Flow Cytometry; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Oligonucleotides | 2004 |
[Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2004 |
[Resection of liver metastasis of colorectal origin following chemotherapy with irinotecan].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Survival Rate | 2004 |
The price tag on progress--chemotherapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Costs; Humans; Irinotecan; Medicare; Neoplasm Metastasis; United States | 2004 |
New treatment options for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Exanthema; Humans; Irinotecan; Research Design; Topoisomerase I Inhibitors | 2004 |
Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2004 |
Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; Enzyme Stability; Female; HeLa Cells; Humans; Mice; Mice, SCID; Plasmids; Xenograft Model Antitumor Assays | 2004 |
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Leukopenia; Liver; Liver Neoplasms; Male; Middle Aged; Neutropenia; Retrospective Studies | 2004 |
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Thymidylate Synthase; Topoisomerase I Inhibitors | 2004 |
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Colorectal Neoplasms; DNA Primers; Female; Fluorouracil; Genetic Vectors; Genotype; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Polymerase Chain Reaction; Polymorphism, Genetic; Risk; Sequence Analysis, DNA | 2004 |
Roles of infusional high-dose 5-fluorouracil with leucovorin in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Taiwan | 2004 |
[Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Pyrimidines; Retrospective Studies; Survival Rate | 2004 |
Cetuximab in colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Costs; Humans; Irinotecan; Quality of Life; Topoisomerase I Inhibitors | 2004 |
Cetuximab in colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Irinotecan; Outcome Assessment, Health Care; Topoisomerase I Inhibitors | 2004 |
Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
Topics: Animals; Camptothecin; Capsules; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; Humans; Injections, Intravenous; Irinotecan; Liposomes; Liver Neoplasms; Male; Mice; Mice, SCID; Survival Analysis; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2004 |
Bevacizumab in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Quality-Adjusted Life Years; Research Design | 2004 |
[Evaluation of bronchial arterial infusion (BAI) for metastatic lung tumor from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Camptothecin; Cisplatin; Colorectal Neoplasms; Disease Progression; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Length of Stay; Lung Neoplasms; Male; Middle Aged | 2004 |
Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Contraindications; Enzyme Inhibitors; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Topoisomerase I Inhibitors | 2004 |
Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2005 |
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2004 |
Effects of camptothecin on double-strand break repair by non-homologous end-joining in DNA mismatch repair-deficient human colorectal cancer cell lines.
Topics: Base Pair Mismatch; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; DNA Repair; Enzyme Inhibitors; Frameshift Mutation; Humans; Recombination, Genetic; Topoisomerase I Inhibitors | 2005 |
Unfavourable expression of pharmacologic markers in mucinous colorectal cancer.
Topics: Adenocarcinoma, Mucinous; Aged; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Primers; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Humans; Irinotecan; Monitoring, Physiologic; Neutropenia; Reproducibility of Results | 2005 |
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Immunohistochemistry; Irinotecan; Male; Medical Records Systems, Computerized; Middle Aged | 2005 |
Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Sodium Bicarbonate; Surveys and Questionnaires | 2004 |
New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice: a single center's experience before and after their introduction.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Evidence-Based Medicine; Female; Humans; Irinotecan; Male; Medical Oncology; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Thiophenes; Treatment Outcome | 2005 |
[Short-term effects of chemotherapy with combination of hydroxycamptothecine and oxaliplatin in the treatment of advanced digestive tract cancers].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Treatment Outcome | 2004 |
Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Fluorouracil; HT29 Cells; Humans; Ibuprofen; Irinotecan; Lactones; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Sulfones; Survival Analysis; Xenograft Model Antitumor Assays | 2005 |
Gene expression profiling of the irinotecan pathway in colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Resistance; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Predictive Value of Tests; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA; Tumor Cells, Cultured | 2005 |
Is there a new drug beyond floxuridine for intra-arterial hepatic chemotherapy in liver metastases from colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dexamethasone; Floxuridine; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms | 2005 |
Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Depression, Chemical; Dietary Supplements; Dinoprostone; Drug Synergism; ErbB Receptors; Humans; Irinotecan; Membrane Proteins; Models, Biological; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Protein Processing, Post-Translational; Selenium; Selenomethionine; Signal Transduction | 2005 |
Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Disease Progression; Female; Humans; Hyperthermia, Induced; Irinotecan; Liver Neoplasms; Male; Melphalan; Middle Aged; Neoplasm Staging; Treatment Failure; Treatment Outcome | 2005 |
Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle Proteins; Colorectal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Irinotecan; Liver Neoplasms; Male; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2005 |
Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronotherapy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Quality of Life | 2005 |
Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
[Systemic therapy for colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Synergism; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
[Improving longevity in advanced intestinal cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Randomized Controlled Trials as Topic | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fatty Liver; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Risk Factors; Topoisomerase I Inhibitors | 2005 |
Whither irinotecan?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Irinotecan; Research Design | 2005 |
A mouse model for developing treatment for secondary liver tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Humans; Immunohistochemistry; Irinotecan; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neoplasm Metastasis; Time Factors | 2005 |
[Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluorouracil; Humans; Irinotecan; Ki-67 Antigen; Male; Middle Aged; Prognosis; Thymidylate Synthase; Treatment Outcome | 2005 |
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Protein Serine-Threonine Kinases; Quinazolines; rho-Associated Kinases; Thymidylate Synthase; Time Factors; Topoisomerase I Inhibitors | 2005 |
[New oncolytic agents and immunomodulators and their application].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2005 |
Chemotherapy for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colorectal Neoplasms; Diarrhea; Humans; Hydrogen-Ion Concentration; Intestines; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2005 |
[Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Female; Floxuridine; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Mitomycin; Peritoneal Neoplasms; Survivors | 2005 |
Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Survival Analysis; Thymidylate Synthase | 2005 |
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronotherapy; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Adjuvant irinotecan regimens in combination with infusional 5-fluorouracil/leucovorin fail to improve outcomes in surgically resected colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate | 2005 |
[Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged | 2005 |
Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis.
Topics: Adenocarcinoma; Camptothecin; Colorectal Neoplasms; Diabetic Nephropathies; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Renal Dialysis; Risk Assessment; Treatment Outcome | 2005 |
[Utilizing synergism].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Synergism; Humans; Irinotecan; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors | 2005 |
[Clinical significant of semiquantificating DNA topoisomerase- I mRNA in colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidylate Synthase | 2005 |
Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Retrospective Studies; Treatment Outcome | 2005 |
Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboxylesterase; Chromatography, High Pressure Liquid; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluorouracil; Humans; Irinotecan; Kinetics; Leucovorin; Leukocytes, Mononuclear; Male; Middle Aged; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2005 |
Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; fas Receptor; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Quinazolines; RNA, Messenger; STAT1 Transcription Factor; Thiophenes; Tumor Suppressor Protein p53; Up-Regulation | 2005 |
Acute presentation of rheumatoid arthritis following cancer chemotherapy using the topoisomerase I inhibitor irinotecan.
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Arthritis, Rheumatoid; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Topoisomerase I Inhibitors | 2005 |
In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Cisplatin; Colorectal Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Leucovorin; Male; Middle Aged; Mitomycin; Taxoids | 2005 |
Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2005 |
[Host immunity in colorectal cancer patients treated with TS-1 plus CPT-11].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Irinotecan; Silicates; Titanium | 2005 |
[Radiofrequency ablation (RFA) in colorectal cancer with hepatic metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Tomography, X-Ray Computed | 2005 |
[Chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2005 |
[A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Neoplasm Recurrence, Local | 2005 |
[Irinotecan in combination with 5-fluorouracil and leucovorin in the treatment of metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged | 2005 |
Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Health Services Accessibility; Humans; Irinotecan; Models, Theoretical; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2005 |
Unresectable hepatic colorectal metastases: need for new surgical strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
Intravenous irinotecan plus oral ciclosporin.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cyclosporine; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged | 2005 |
Irinotecan with bolus and infusional 5-flurouracil and folinic acid for patients with advanced or metastatic colorectal cancer previously treated with 5-flurouracil: a possible alternative to single-agent irinotecan in a 'real-life' setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies | 2005 |
in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Synergism; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-bcl-2 | 2006 |
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Phosphorylation | 2005 |
Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Treatment Outcome | 2005 |
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Tegafur; Thiophenes; Treatment Outcome; Uracil | 2005 |
PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Health Care Costs; Health Services; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Retrospective Studies | 2006 |
[Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2006 |
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagnosis, Differential; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Humans; Interferon-gamma; Irinotecan; Male; Middle Aged; Neovascularization, Pathologic; Prospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
[Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Germany; Guideline Adherence; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Radiotherapy, Adjuvant; Survival Rate | 2006 |
[The results of cetuximab treatment of a patient with multiple pretreated, irinotecan resistant metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Signal Transduction; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
Topics: Animals; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Cyclodextrins; Disease Models, Animal; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Nanotechnology; Pancreatic Neoplasms; Polymers; Sarcoma, Ewing; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Correspondence re: Cecchin et al., Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin Cancer Res 2005;11:6901-7.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboxylesterase; Colorectal Neoplasms; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Isoenzymes; Leukocytes, Mononuclear; Predictive Value of Tests; RNA, Messenger | 2006 |
Individualizing chemotherapeutic treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; United States | 2006 |
[Outpatient based colorectal cancer treatment--the current status, challenges and future outlook].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Home Care Services, Hospital-Based; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Quality of Life | 2006 |
Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate | 2006 |
Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
Topics: Antibodies, Monoclonal; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Survival; Treatment Outcome | 2006 |
Mechanism of central nervous system toxicity by irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Central Nervous System; Colorectal Neoplasms; Electrochemistry; Humans; Irinotecan; Models, Biological | 2006 |
[24 hour infusion of CPT-11/oral UFT/LV].
Topics: Administration, Oral; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Tegafur; Uracil | 2006 |
The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Colorectal Neoplasms; Glucuronidase; Humans; Hydroxyquinolines; Irinotecan; Nitrophenols; Tumor Cells, Cultured | 2006 |
Turning point for colorectal cancer clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2006 |
Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glutathione Transferase; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length | 2006 |
Molecular determinants of irinotecan efficacy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Repair; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Irinotecan; Male; Middle Aged; Peptide Termination Factors; Polymerase Chain Reaction; Predictive Value of Tests; Retrospective Studies; RNA, Messenger; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Case-based discussion for the management of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Monitoring; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Nurse's Role; Oncology Nursing; Organoplatinum Compounds; Patient Care Planning; Practice Guidelines as Topic; Salvage Therapy | 2006 |
Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Transplantation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous | 2007 |
Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Gene Expression Profiling; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2006 |
Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement by Bartlett et al.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2006 |
Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2006 |
[Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Survival Rate | 2006 |
A case report and discussion of cetuximab-induced folliculitis.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clindamycin; Colorectal Neoplasms; ErbB Receptors; Folliculitis; Humans; Irinotecan; Lung Neoplasms; Male; Remission Induction | 2006 |
Effect of S-1 on pharmacokinetics of irinotecan in a patient with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Combinations; Humans; Irinotecan; Middle Aged; Oxonic Acid; Tegafur; Time Factors | 2006 |
Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Treatment Outcome | 2006 |
Highlights from: 42nd Annual Meeting of the American Society of Clinical Oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; United States | 2006 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fibrosis; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2007 |
Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Fatty Liver; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Retrospective Studies; Treatment Outcome | 2007 |
Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fatty Liver; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Portal Vein; Venous Thrombosis | 2006 |
Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2006 |
A bacterial protein enhances the release and efficacy of liposomal cancer drugs.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Bacterial Proteins; Base Sequence; Camptothecin; Cell Line, Tumor; Cloning, Molecular; Clostridium; Colorectal Neoplasms; Doxorubicin; Drug Carriers; Humans; Irinotecan; Lipase; Lipid Bilayers; Liposomes; Mice; Molecular Sequence Data; Mutation; Neoplasm Transplantation; Protein Structure, Tertiary | 2006 |
Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Humans; Irinotecan; Middle Aged; Models, Theoretical; Neoplasm Metastasis; Sensitivity and Specificity | 2006 |
[In vitro chemo-sensitivity MTT assay guided intraperitoneal chemotherapy for malignant ascites].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ascites; Camptothecin; Cell Survival; Colorectal Neoplasms; Docetaxel; Female; Humans; Injections, Intraperitoneal; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured | 2006 |
Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Time Factors | 2006 |
Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro.
Topics: Antineoplastic Agents, Phytogenic; Biocompatible Materials; Biological Transport; Brain Neoplasms; Breast Neoplasms; Camptothecin; Capsules; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Dendrimers; Female; Glioblastoma; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Solubility | 2006 |
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Genotype; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Pharmacogenetics | 2006 |
5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Costs; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate | 2006 |
[A treatment for pulmonary metastases from colorectal cancer by pre-operative CPT-11/5'-DFUR combination therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Floxuridine; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Pneumonectomy | 2006 |
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxa
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Pyrophosphatases; Thymidylate Synthase; X-ray Repair Cross Complementing Protein 1 | 2007 |
Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis.
Topics: Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Camptothecin; Cohort Studies; Colorectal Neoplasms; Databases, Factual; Disease Progression; Drug Resistance, Neoplasm; Drug Utilization; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; National Health Programs; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Practice Patterns, Physicians'; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Sex Distribution; Survival Analysis | 2007 |
Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Assessment; Risk Factors | 2007 |
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Humans; Irinotecan; Leucovorin; Male; Middle Aged | 2007 |
[Chemotherapy for elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Vomiting, Anticipatory | 2007 |
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Islands; DNA Methylation; Female; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Massachusetts; Microsatellite Instability; Middle Aged; Quinazolines; Survival Rate | 2007 |
Sensitivity to CPT-11 and platinum derivatives of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.
Topics: bcl-2-Associated X Protein; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Humans; Immunohistochemistry; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Unknown Primary; Organoplatinum Compounds; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors | 2007 |
Sensitivity to CPT-11 and platinum derivatives of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses.
Topics: bcl-2-Associated X Protein; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Humans; Immunohistochemistry; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Unknown Primary; Organoplatinum Compounds; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors | 2007 |
Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Heat-Shock Proteins; Humans; Immunohistochemistry; Irinotecan; Up-Regulation | 2007 |
[Second-or third-line chemotherapy with CPT-11+TS-1 for 5 cases of metastatic and recurrent colorectal cancer].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Tegafur | 2007 |
Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lewis X Antigen; Male; Middle Aged; Oligosaccharides; Orotate Phosphoribosyltransferase; Prognosis; Sialyl Lewis X Antigen; Survival Rate; Thymidine Phosphorylase; Thymidylate Synthase; Vitamin B Complex | 2007 |
Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Postoperative Complications | 2007 |
Size matters. What can we learn from a small randomized trial?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Interpretation, Statistical; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2007 |
[Outpatient chemotherapy of an advanced or metastatic colorectal cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Critical Pathways; Drug Administration Schedule; Fluorouracil; Humans; Infusion Pumps, Implantable; Leucovorin; Organoplatinum Compounds | 2006 |
[Present status of home therapy cancer patients using an infusor].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Home Care Services; Humans; Infusion Pumps; Infusion Pumps, Implantable; Leucovorin; Organoplatinum Compounds; Risk Management | 2006 |
[The future of chemotherapy at home--from outpatient chemotherapy to chemotherapy at home].
Topics: Ambulatory Care; Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Home Infusion Therapy; Humans; Infusion Pumps, Implantable; Leucovorin; Organoplatinum Compounds; Quality of Life; Risk Management | 2006 |
Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dacarbazine; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Middle Aged; Temozolomide; Treatment Outcome | 2007 |
Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene.
Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Colorectal Neoplasms; DNA; Genotype; Humans; Irinotecan; Liver; Paraffin Embedding; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis | 2008 |
[Comparisons of standard treatments for colorectal cancer between Japan and Western Countries].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans; Japan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Practice Guidelines as Topic; Radiotherapy, Adjuvant; United Kingdom; United States | 2007 |
Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Palliative Care | 2007 |
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Gene Expression Profiling; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies | 2008 |
Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2007 |
Role of repeated hepatectomy in the multimodal treatment of hepatic colorectal metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Reoperation; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2007 |
Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; HIV Infections; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis | 2007 |
[Role of pharmacogenetics in chemotherapy of colorectal cancers].
Topics: Acetylcholinesterase; Antineoplastic Agents; Butyrylcholinesterase; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Humans; Irinotecan; Methylenetetrahydrofolate Reductase (NADPH2); Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Genetic | 2007 |
Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
Topics: Adult; Aged; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; India; Irinotecan; Lung Neoplasms; Malaysia; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Polymorphism, Genetic; Singapore; Urogenital Neoplasms | 2007 |
Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2007 |
Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome | 2007 |
Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Diarrhea; Fluorouracil; Granulomatosis with Polyangiitis; Hemorrhage; Humans; Irinotecan; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis | 2007 |
Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Predictive Value of Tests; Prodrugs; Promoter Regions, Genetic | 2007 |
Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Camptothecin; Colorectal Neoplasms; DNA Repair; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Metastasis; Nuclear Proteins; Treatment Outcome | 2007 |
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Injections, Intravenous; Japan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Retrospective Studies; Survival Analysis; Treatment Outcome; Vomiting | 2007 |
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Eruptions; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; NF-kappa B; Survival Rate | 2007 |
Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Delivery Systems; ErbB Receptors; Evidence-Based Medicine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Nurse's Role; Oncology Nursing; Organoplatinum Compounds; Practice Guidelines as Topic; Vascular Endothelial Growth Factor A | 2007 |
Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Prospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2007 |
Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Mismatch Repair; Europe; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Microsatellite Instability; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Staging; Nuclear Proteins; Thymidylate Synthase; Treatment Outcome | 2008 |
Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diabetes Mellitus, Type 1; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Renal Dialysis; Treatment Outcome | 2007 |
Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2007 |
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Mutation; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Tomography, X-Ray Computed | 2008 |
Central venous access port-related complications in outpatient chemotherapy for colorectal cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization, Central Venous; Colorectal Neoplasms; Female; Fluorouracil; Humans; Incidence; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome | 2007 |
Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome | 2007 |
The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies | 2007 |
[Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Tumor Lysis Syndrome | 2008 |
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Female; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Morbidity; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prodrugs; Treatment Outcome; United States; Vascular Endothelial Growth Factor A | 2008 |
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Length of Stay; Leucovorin; Liver; Liver Neoplasms; Logistic Models; Male; Middle Aged; Morbidity; Organoplatinum Compounds; Preoperative Care; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome | 2008 |
Cetuximab efficacy in patients treated routinely in university hospitals.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; France; Hospitals, University; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Registries | 2007 |
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis | 2008 |
Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Synergism; Fluorouracil; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Polymers; Transplantation, Heterologous | 2008 |
[Transarterial chemoembolization with irinotecan (CPT-11) and degradable starch microspheres (DSM) in patients with liver metastases from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Middle Aged; Neoplasm Staging; Starch; Survival Rate | 2007 |
Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Transaminases; Tumor Cells, Cultured | 2008 |
Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Retrospective Studies; Survival Analysis | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic; Survival Rate | 2008 |
Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Drug Stability; Humans; Hydrogels; Hydrogen-Ion Concentration; Irinotecan; Kinetics; Lactones; Liver Neoplasms; Microspheres; Models, Chemical; Particle Size; Solubility | 2008 |
Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; beta-Galactosidase; Blotting, Western; Camptothecin; Cell Proliferation; Chemoembolization, Therapeutic; Colorectal Neoplasms; Doxorubicin; Drug Delivery Systems; Irinotecan; Liver Neoplasms; Male; Microspheres; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Prodrugs; Rats | 2008 |
Carboxylesterase 2 is downregulated in colorectal cancer following progression of the disease.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Blotting, Western; Camptothecin; Carboxylesterase; Colorectal Neoplasms; Disease Progression; Down-Regulation; Humans; Immunoglobulin G; Irinotecan; Mice; Neoplasm Staging; Topoisomerase I Inhibitors | 2008 |
Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Failure; Treatment Outcome | 2008 |
UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Retrospective Studies | 2008 |
Irinotecan pharmacogenetics: influence of pharmacodynamic genes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Retrospective Studies | 2008 |
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Models, Biological; Neoplasms; Pancreatic Neoplasms; Polyethylene Glycols; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
[A successfully resected case of colorectal cancer with multiple liver metastases treated with FOLFIRI after failure of mFOLFOX6].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colonoscopy; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2008 |
Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Data Interpretation, Statistical; ErbB Receptors; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Irinotecan; Polymorphism, Genetic; Research Design; Salvage Therapy | 2008 |
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genetic Markers; Haplotypes; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Salvage Therapy; Signal Transduction | 2008 |
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Thrombospondin 1; Vascular Endothelial Growth Factor A | 2008 |
Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Tegafur; Uracil | 2007 |
A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate | 2008 |
Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Deoxycytidine; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Randomized Controlled Trials as Topic; Vomiting | 2008 |
Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Clinical Trials as Topic; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Irinotecan; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Registries; Retrospective Studies; Treatment Outcome | 2008 |
Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Immunoenzyme Techniques; Irinotecan; Male; Middle Aged; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |
Sequential vs combination colorectal cancer therapy sparks debate.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2008 |
Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Japan; Neoplasm Recurrence, Local; Survival Rate; Topoisomerase I Inhibitors | 2008 |
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Immunoenzyme Techniques; Immunohistochemistry; Indoles; Irinotecan; Male; Mice; Mice, Nude; Microcirculation; Pyrroles; Thrombospondin 1; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2008 |
Chemotherapy in elderly patients with colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Geriatric Assessment; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2008 |
Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dexamethasone; Female; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Time Factors; Treatment Outcome | 2008 |
Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Retrospective Studies | 2008 |
Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer.
Topics: Camptothecin; Cohort Studies; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Genotype; Glucuronosyltransferase; Humans; Irinotecan | 2008 |
[Non-resectable metastases from colorectal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Eruptions; ErbB Receptors; Female; Fluorouracil; Humans; Hypertension; Leucovorin; Middle Aged; Neoplasm Metastasis; Treatment Failure | 2008 |
XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Pilot Projects; Randomized Controlled Trials as Topic | 2007 |
[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Case-Control Studies; China; Colorectal Neoplasms; Diarrhea; Fluorouracil; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Young Adult | 2007 |
[Hydrocamptothecin promotes the mRNA expression of Wnt signaling inhibitor DKK-1].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Flow Cytometry; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Wnt Proteins | 2008 |
Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2009 |
Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; ErbB Receptors; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2008 |
Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Treatment Outcome | 2008 |
Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine.
Topics: Antineoplastic Agents, Phytogenic; Bile; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged | 1995 |
[Antitumor effect of SN-38, active form of CPT-11, on human colorectal cancer cell line].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA, Superhelical; Drug Screening Assays, Antitumor; Humans; Irinotecan; Tumor Cells, Cultured | 1994 |
Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Hot Temperature; Humans; Neoplasm Proteins; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vincristine | 1995 |
Camptothecins: new enthusiasm for an old drug.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Topoisomerase I Inhibitors | 1996 |
Irinotecan shown to be effective against colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Humans; Irinotecan; Treatment Outcome | 1996 |
Enhancement of the antitumor effect of gamma-ray irradiation in combination with camptothecin against human colorectal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality Therapy; Gamma Rays; Humans; Iodine Radioisotopes; Mice; Mice, Nude; Neoplasm Transplantation; Radioimmunotherapy; Transplantation, Heterologous | 1996 |
Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cyclophosphamide; DNA Fragmentation; DNA, Neoplasm; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Topotecan | 1997 |
Irinotecan for metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Costs and Cost Analysis; Drug Therapy; Humans; Irinotecan | 1997 |
[Chemotherapy of advanced colorectal cancers after failure of a treatment with fluoropyrimidine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Thymidylate Synthase; Treatment Failure | 1997 |
Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Topics: Abdominal Pain; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atropine; Blood Pressure; Camptothecin; Cholinergic Fibers; Colorectal Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Parasympatholytics; Salivation; Topoisomerase I Inhibitors | 1998 |
[Derivatives of camptothecin. A new class of antineoplastic agents].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Ovarian Neoplasms; Topotecan | 1997 |
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Enzyme Inhibitors; Fluorouracil; HT29 Cells; Humans; Irinotecan; S Phase; Thymidylate Synthase; Topoisomerase I Inhibitors | 1998 |
Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Transport; Camptothecin; Colorectal Neoplasms; Humans; Leukemia P388; Magnetic Resonance Spectroscopy; Mice; Neoplasm Transplantation; Rats; Spectrometry, Mass, Fast Atom Bombardment; Tumor Cells, Cultured | 1998 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Etoposide; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Risk Assessment | 1998 |
Irinotecan and 5-fluorouracil in colorectal cancer: time for a pause?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; DNA, Neoplasm; Drug Synergism; Fluorouracil; Humans; Irinotecan; Treatment Outcome | 1998 |
Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Colorectal Neoplasms; Diarrhea; Disease Models, Animal; Drug Interactions; Duodenum; Female; Interleukin-15; Intestinal Mucosa; Irinotecan; Paraffin Embedding; Rats; Rats, Inbred F344 | 1998 |
Irinotecan: toward clinical end points in drug development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Randomized Controlled Trials as Topic | 1998 |
US pivotal studies of irinotecan in colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; United States | 1998 |
Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Male; Outcome Assessment, Health Care; Palliative Care; Prostatic Neoplasms; Quality of Life; Research Design | 1998 |
Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Carriers; Glycine; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Neoplasm Transplantation; Polyethylene Glycols; Prodrugs; Tissue Distribution; Tritium | 1998 |
Improved survival in patients with advanced colorectal carcinoma failing 5-fluorouracil who received irinotecan hydrochloride and have high intratumor C-fos expression.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Male; Middle Aged; Prognosis; Proto-Oncogene Proteins c-fos; Survival Analysis; Treatment Failure | 1998 |
Managing the side effects of chemotherapy for colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drugs, Investigational; Fluorouracil; Humans; Irinotecan; Patient Care Team; Quality of Life | 1998 |
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; RNA, Messenger; Thymidine Phosphorylase; Thymidylate Synthase | 1998 |
Irinotecan may extend survival in people with metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 1998 |
High-performance liquid chromatographic analysis of the investigational anticancer drug 9-aminocamptothecin, as the lactone form and as the total of the lactone and the hydroxycarboxylate forms, in micro-volumes of human plasma.
Topics: Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug Stability; Humans; Lactones; Reproducibility of Results | 1998 |
Irinotecan for colorectal cancer: a small step forward.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Survival Rate; Topoisomerase I Inhibitors | 1998 |
Optimum doses of irinotecan.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Humans; Irinotecan; Topoisomerase I Inhibitors | 1999 |
The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Genes, p53; Humans; Male; Middle Aged; Mutation; Retrospective Studies | 1999 |
Second line therapies move to the forefront in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 1999 |
Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Analysis; Treatment Outcome | 1999 |
Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.
Topics: Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Cell Division; Colorectal Neoplasms; DNA Primers; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Microsatellite Repeats; Mutation; Phenotype; Tumor Suppressor Protein p53 | 2000 |
Recent advances in colorectal chemotherapy: oral fluorinated pyrimidines, oxaliplatin and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2000 |
New drugs for colorectal cancer based on Japanese experience.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Approval; Humans; Irinotecan; Japan; Organoplatinum Compounds; Oxaliplatin | 2000 |
[Absence of cross resistance between an irinotecan plus cisplatin combination and raltitrexed (ZD1694) in two patients with advanced colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Resistance; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Middle Aged; Quinazolines; Thiophenes; Thymidylate Synthase | 2000 |
Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation.
Topics: Adenoviridae; Animals; Apoptosis; Breast Neoplasms; Camptothecin; Cell Nucleus; Colorectal Neoplasms; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Female; Humans; I-kappa B Proteins; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Mice; Mice, Nude; NF-kappa B; NF-KappaB Inhibitor alpha; Time Factors; Transgenes; Tumor Cells, Cultured | 2000 |
FDA approves irinotecan as first-line therapy for colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Quality of Life; Surveys and Questionnaires; Topoisomerase I Inhibitors; United States; United States Food and Drug Administration | 2000 |
[Weekly low-dose CPT-11 and HCFU for advanced colorectal cancer on an outpatient treatment basis].
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Lymph Node Excision; Lymphatic Metastasis | 2000 |
From the Food and Drug Administration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fetal Monitoring; Humans; Irinotecan; Oximetry; United States; United States Food and Drug Administration | 2000 |
Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Irinotecan; Kinetics; Maximum Tolerated Dose; Neoplasm Transplantation; Rats; Rats, Inbred F344; Time Factors | 2000 |
[Irinotecan--experience with second-line treatment in advanced colorectal cancer] .
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Genes, MDR; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Topoisomerase I Inhibitors; Treatment Failure; Treatment Outcome | 2000 |
Cost-effectiveness of irinotecan in advanced colorectal cancer.
Topics: Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Humans; Irinotecan; Survival Analysis | 2000 |
Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biotransformation; Caco-2 Cells; Camptothecin; Carboxylic Ester Hydrolases; Colorectal Neoplasms; Feces; Female; Glucuronidase; Half-Life; Humans; Irinotecan; Male; Middle Aged; Oxidation-Reduction | 2000 |
Moving beyond fluorouracil for colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia | 2000 |
Irinotecan-associated pulmonary toxicity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Middle Aged | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis; Value of Life | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Quality of Life | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Interpretation, Statistical; Fluorouracil; Humans; Irinotecan; Leucovorin; Quality of Life | 2001 |
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Camptothecin; Colorectal Neoplasms; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multienzyme Complexes; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged | 2001 |
The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin | 2001 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine | 1995 |
Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2001 |
Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxidoreductases; Quinazolines; Thiophenes | 2001 |
[Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?].
Topics: Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Geriatric Assessment; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant | 2001 |
[Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2001 |
Researchers urge caution with standard regimen for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2001 |
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis | 2001 |
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis | 2001 |
[Usefulness of chemotherapy with CPT-11 in clinic for three colorectal cancer in terminal stage].
Topics: Ambulatory Care; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Terminal Care | 2001 |
The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Base Pair Mismatch; Camptothecin; Carrier Proteins; Cell Cycle; Colorectal Neoplasms; DNA Repair; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Multiple; Enzyme Inhibitors; Etoposide; Humans; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Proto-Oncogene Proteins; Retrospective Studies; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer.
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Intestinal Obstruction; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis; Tomography, X-Ray Computed | 2001 |
Hypersensitivity to camptothecin in MSH2 deficient cells is correlated with a role for MSH2 protein in recombinational repair.
Topics: Animals; Antineoplastic Agents, Phytogenic; Base Pair Mismatch; Camptothecin; Cell Cycle; Cell Survival; Chromosome Aberrations; Colorectal Neoplasms; DNA Damage; DNA Repair; DNA Replication; DNA-Binding Proteins; Drug Hypersensitivity; Flow Cytometry; Mice; Mice, Knockout; MutS Homolog 2 Protein; Proto-Oncogene Proteins; Rad51 Recombinase; Sister Chromatid Exchange; Tumor Cells, Cultured | 2001 |
[Four cases of multiple liver metastasis of colorectal cancer treated with hepatic resection after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2001 |
Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; France; Humans; Leucovorin; Treatment Outcome | 2001 |
Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Body Surface Area; Camptothecin; Colorectal Neoplasms; Diarrhea; Glucuronosyltransferase; Humans; Irinotecan | 2002 |
Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Body Constitution; Body Surface Area; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Irinotecan; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Multivariate Analysis; Netherlands; Retrospective Studies | 2002 |
Toxicity of irinotecan in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin | 2001 |
Nothing succeeds like failure.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Industry; Humans; Irinotecan | 2002 |
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiovascular Diseases; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Syndrome; Thrombosis | 2002 |
ImClone BLA is declined.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Industry; Humans; Irinotecan; United States; United States Food and Drug Administration | 2002 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
Fighting wars, winning battles.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery; Disease-Free Survival; Floxuridine; Humans; Irinotecan; Liver Neoplasms | 2002 |
Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Patient Compliance; Retrospective Studies | 2002 |
Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Irinotecan; Kidney Failure, Chronic; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Renal Dialysis | 2002 |
Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Catalysis; Colorectal Neoplasms; DNA Topoisomerases, Type I; HT29 Cells; Humans; Irinotecan; Neoplasm Proteins; Tumor Cells, Cultured | 2002 |
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role.
Topics: Acetylcholinesterase; Adenocarcinoma; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Camptothecin; Cholinergic Agents; Cholinesterase Inhibitors; Colorectal Neoplasms; Confidence Intervals; Female; Humans; Irinotecan; Male; Middle Aged; Physostigmine | 2002 |
[Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate | 2002 |
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Colorectal Neoplasms; Drug Therapy, Combination; ErbB Receptors; Female; HT29 Cells; Humans; Irinotecan; Ki-67 Antigen; Mice; Mice, Nude; Neoplasm Transplantation; Platelet Endothelial Cell Adhesion Molecule-1; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients.
Topics: Adult; Aged; Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasms; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length | 2002 |
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Prodrugs; Random Allocation; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Azacitidine; Camptothecin; Colorectal Neoplasms; Decitabine; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Lethal Dose 50; Methylation; Mice; Mice, Inbred BALB C; Topotecan; Tumor Cells, Cultured | 1992 |
[Colorectal carcinogenesis, tumor progression and chemoresistance].
Topics: Camptothecin; Cell Transformation, Neoplastic; Colorectal Neoplasms; Drug Resistance; Fluorouracil; Growth Inhibitors; Humans; Methotrexate; Tumor Cells, Cultured | 1990 |